{"2e9cf2cb177ce62bf867f3261c6b29c4d704ff86": [["OVERVIEWThe respiratory tract is continually exposed to a range of micro organisms that normal immune responses generally prevent from causing infection.", [["respiratory tract", "ANATOMY", 12, 29], ["infection", "DISEASE", 143, 152], ["respiratory tract", "ORGANISM_SUBDIVISION", 12, 29], ["The respiratory tract", "PROBLEM", 8, 29], ["infection", "PROBLEM", 143, 152], ["respiratory tract", "ANATOMY", 12, 29], ["immune responses", "OBSERVATION", 95, 111], ["infection", "OBSERVATION", 143, 152]]], ["Hence, it is not surprising that patients with significantly impaired immunity frequently develop lung infections.", [["lung", "ANATOMY", 98, 102], ["impaired immunity", "DISEASE", 61, 78], ["lung infections", "DISEASE", 98, 113], ["patients", "ORGANISM", 33, 41], ["lung", "ORGAN", 98, 102], ["patients", "SPECIES", 33, 41], ["lung infections", "PROBLEM", 98, 113], ["lung", "ANATOMY", 98, 102], ["infections", "OBSERVATION", 103, 113]]], ["Immunodeficient patients also frequently have several other risk factors that contribute to an increased risk for development of pneumonia, including lowlevel microaspi ration of oropharyngeal contents, mucosal damage caused by cytotoxic therapy, underlying lung damage, and poor nutrition.", [["oropharyngeal", "ANATOMY", 179, 192], ["mucosal", "ANATOMY", 203, 210], ["lung", "ANATOMY", 258, 262], ["pneumonia", "DISEASE", 129, 138], ["mucosal damage", "DISEASE", 203, 217], ["lung damage", "DISEASE", 258, 269], ["patients", "ORGANISM", 16, 24], ["oropharyngeal", "ORGANISM_SUBDIVISION", 179, 192], ["mucosal", "TISSUE", 203, 210], ["lung", "ORGAN", 258, 262], ["patients", "SPECIES", 16, 24], ["several other risk factors", "PROBLEM", 46, 72], ["an increased risk", "PROBLEM", 92, 109], ["pneumonia", "PROBLEM", 129, 138], ["lowlevel microaspi ration", "TREATMENT", 150, 175], ["oropharyngeal contents", "PROBLEM", 179, 201], ["mucosal damage", "PROBLEM", 203, 217], ["cytotoxic therapy", "TREATMENT", 228, 245], ["underlying lung damage", "PROBLEM", 247, 269], ["pneumonia", "OBSERVATION", 129, 138], ["oropharyngeal contents", "ANATOMY", 179, 201], ["mucosal", "ANATOMY", 203, 210], ["damage", "OBSERVATION", 211, 217], ["cytotoxic therapy", "OBSERVATION", 228, 245], ["lung", "ANATOMY", 258, 262], ["damage", "OBSERVATION", 263, 269], ["poor nutrition", "OBSERVATION", 275, 289]]], ["As a consequence, lung infections are a common and frequently serious complication in patients with significant impairment of the immune system.", [["lung", "ANATOMY", 18, 22], ["immune system", "ANATOMY", 130, 143], ["lung infections", "DISEASE", 18, 33], ["impairment of the immune system", "DISEASE", 112, 143], ["lung", "ORGAN", 18, 22], ["patients", "ORGANISM", 86, 94], ["immune system", "ANATOMICAL_SYSTEM", 130, 143], ["patients", "SPECIES", 86, 94], ["lung infections", "PROBLEM", 18, 33], ["frequently serious complication", "PROBLEM", 51, 82], ["significant impairment of the immune system", "PROBLEM", 100, 143], ["lung", "ANATOMY", 18, 22], ["infections", "OBSERVATION", 23, 33], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["impairment", "OBSERVATION", 112, 122], ["immune system", "OBSERVATION", 130, 143]]], ["Pulmonary infiltrates occur in 25% of patients with neutropenia developing after chemotherapy, and up to 5% of patients undergoing hematopoietic stem cell trans plantation (HSCT) will die as a result of pneumonia.", [["Pulmonary infiltrates", "ANATOMY", 0, 21], ["hematopoietic stem cell", "ANATOMY", 131, 154], ["Pulmonary infiltrates", "DISEASE", 0, 21], ["neutropenia", "DISEASE", 52, 63], ["pneumonia", "DISEASE", 203, 212], ["Pulmonary", "PATHOLOGICAL_FORMATION", 0, 9], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 111, 119], ["hematopoietic stem cell", "CELL", 131, 154], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 111, 119], ["Pulmonary infiltrates", "PROBLEM", 0, 21], ["neutropenia", "PROBLEM", 52, 63], ["chemotherapy", "TREATMENT", 81, 93], ["hematopoietic stem cell trans plantation", "TREATMENT", 131, 171], ["pneumonia", "PROBLEM", 203, 212], ["infiltrates", "OBSERVATION", 10, 21], ["25%", "OBSERVATION_MODIFIER", 31, 34], ["neutropenia", "OBSERVATION", 52, 63], ["hematopoietic stem cell", "OBSERVATION", 131, 154], ["pneumonia", "OBSERVATION", 203, 212]]], ["The range of potential pathogens causing lung infections in immunocom promised patients is much broader than for the usual patho gens causing communityacquired pneumonia and includes organisms such as Aspergillus fumigatus and human cytomega lovirus (CMV); the diagnosis of infections due to these microbes can be difficult, and the required therapies frequently are toxic.", [["lung", "ANATOMY", 41, 45], ["lung infections", "DISEASE", 41, 56], ["pneumonia", "DISEASE", 160, 169], ["Aspergillus fumigatus", "DISEASE", 201, 222], ["infections", "DISEASE", 274, 284], ["lung", "ORGAN", 41, 45], ["patients", "ORGANISM", 79, 87], ["Aspergillus fumigatus", "ORGANISM", 201, 222], ["human", "ORGANISM", 227, 232], ["cytomega lovirus", "ORGANISM", 233, 249], ["CMV", "ORGANISM", 251, 254], ["patients", "SPECIES", 79, 87], ["Aspergillus fumigatus", "SPECIES", 201, 222], ["human", "SPECIES", 227, 232], ["Aspergillus fumigatus", "SPECIES", 201, 222], ["human cytomega lovirus", "SPECIES", 227, 249], ["CMV", "SPECIES", 251, 254], ["potential pathogens", "PROBLEM", 13, 32], ["lung infections", "PROBLEM", 41, 56], ["the usual patho gens", "PROBLEM", 113, 133], ["communityacquired pneumonia", "PROBLEM", 142, 169], ["organisms", "PROBLEM", 183, 192], ["Aspergillus fumigatus", "PROBLEM", 201, 222], ["human cytomega lovirus", "PROBLEM", 227, 249], ["CMV", "PROBLEM", 251, 254], ["infections", "PROBLEM", 274, 284], ["these microbes", "PROBLEM", 292, 306], ["therapies", "TREATMENT", 342, 351], ["toxic", "PROBLEM", 367, 372], ["range", "OBSERVATION_MODIFIER", 4, 9], ["pathogens", "OBSERVATION_MODIFIER", 23, 32], ["lung", "ANATOMY", 41, 45], ["infections", "OBSERVATION", 46, 56], ["pneumonia", "OBSERVATION", 160, 169], ["Aspergillus fumigatus", "OBSERVATION", 201, 222], ["infections", "OBSERVATION", 274, 284]]], ["The large number of potential pathogens and the background disease together make management of lung infection in immu nocompromised patients considerably more complex, and the use of invasive diagnostic tests such as bronchoscopy frequently is necessary.", [["lung", "ANATOMY", 95, 99], ["lung infection", "DISEASE", 95, 109], ["lung", "ORGAN", 95, 99], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["potential pathogens", "PROBLEM", 20, 39], ["the background disease", "PROBLEM", 44, 66], ["lung infection", "PROBLEM", 95, 109], ["invasive diagnostic tests", "TEST", 183, 208], ["bronchoscopy", "TREATMENT", 217, 229], ["large", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["potential", "OBSERVATION_MODIFIER", 20, 29], ["pathogens", "OBSERVATION", 30, 39], ["lung", "ANATOMY", 95, 99], ["infection", "OBSERVATION", 100, 109]]], ["This chapter focuses on the common causative pathogens and the clinical approach to pulmonary infections in patients who have been severely immunocompromised by chemotherapy, organ transplantation, or hematologic disease (Box 28-1) but not human immunodeficiency virus (HIV) in fection (discussed in Chapter 29).", [["pulmonary", "ANATOMY", 84, 93], ["organ", "ANATOMY", 175, 180], ["hematologic", "ANATOMY", 201, 212], ["pulmonary infections", "DISEASE", 84, 104], ["hematologic disease", "DISEASE", 201, 220], ["human immunodeficiency virus (HIV) in fection", "DISEASE", 240, 285], ["pulmonary", "ORGAN", 84, 93], ["patients", "ORGANISM", 108, 116], ["organ", "ORGAN", 175, 180], ["human immunodeficiency virus", "ORGANISM", 240, 268], ["patients", "SPECIES", 108, 116], ["human", "SPECIES", 240, 245], ["immunodeficiency virus", "SPECIES", 246, 268], ["human immunodeficiency virus", "SPECIES", 240, 268], ["HIV", "SPECIES", 270, 273], ["the common causative pathogens", "PROBLEM", 24, 54], ["pulmonary infections", "PROBLEM", 84, 104], ["severely immunocompromised", "PROBLEM", 131, 157], ["chemotherapy", "TREATMENT", 161, 173], ["organ transplantation", "TREATMENT", 175, 196], ["hematologic disease", "PROBLEM", 201, 220], ["Box", "TEST", 222, 225], ["human immunodeficiency virus", "PROBLEM", 240, 268], ["pathogens", "OBSERVATION", 45, 54], ["pulmonary", "ANATOMY", 84, 93], ["infections", "OBSERVATION", 94, 104], ["severely", "OBSERVATION_MODIFIER", 131, 139], ["immunocompromised", "OBSERVATION", 140, 157]]], ["Pneumonia in patients with milder degrees of immunosuppression due to myeloma, low dose cytotoxic therapy, or diseasemodifying agents adminis tered for rheumatologic conditions generally should be managed as community or hospitalacquired pneumonia, but with rec ognition that the disease could be due to various opportunistic pathogens, as discussed in this chapter.GENERAL PRINCIPLES OF THE CLINICAL APPROACHPotential pathogens causing lung infection in the immunocom promised patient are listed in Table 28 -1.", [["myeloma", "ANATOMY", 70, 77], ["lung", "ANATOMY", 437, 441], ["Pneumonia", "DISEASE", 0, 9], ["immunosuppression", "DISEASE", 45, 62], ["myeloma", "DISEASE", 70, 77], ["pneumonia", "DISEASE", 238, 247], ["lung infection", "DISEASE", 437, 451], ["patients", "ORGANISM", 13, 21], ["myeloma", "CANCER", 70, 77], ["lung", "ORGAN", 437, 441], ["patient", "ORGANISM", 478, 485], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 478, 485], ["Pneumonia", "PROBLEM", 0, 9], ["immunosuppression", "TREATMENT", 45, 62], ["myeloma", "PROBLEM", 70, 77], ["low dose cytotoxic therapy", "TREATMENT", 79, 105], ["diseasemodifying agents", "TREATMENT", 110, 133], ["rheumatologic conditions", "PROBLEM", 152, 176], ["hospitalacquired pneumonia", "PROBLEM", 221, 247], ["the disease", "PROBLEM", 276, 287], ["various opportunistic pathogens", "PROBLEM", 304, 335], ["THE CLINICAL APPROACHPotential pathogens", "PROBLEM", 388, 428], ["lung infection", "PROBLEM", 437, 451], ["milder degrees", "OBSERVATION_MODIFIER", 27, 41], ["immunosuppression", "OBSERVATION", 45, 62], ["myeloma", "OBSERVATION", 70, 77], ["pneumonia", "OBSERVATION", 238, 247], ["disease", "OBSERVATION", 280, 287], ["opportunistic", "OBSERVATION_MODIFIER", 312, 325], ["pathogens", "OBSERVATION", 326, 335], ["lung", "ANATOMY", 437, 441], ["infection", "OBSERVATION", 442, 451]]], ["Empirical therapy that is active against all these possible pathogens is not feasible, especially given the potential toxicity of some treatments.", [["toxicity", "DISEASE", 118, 126], ["Empirical therapy", "TREATMENT", 0, 17], ["pathogens", "PROBLEM", 60, 69], ["some treatments", "TREATMENT", 130, 145]]], ["Hence, the challenge in managing these patients is to (1) reduce the scope of the differential diagnosis to include the most likely problems and thus allow relatively targeted empirical therapy and (2) identify when and which type of invasive diagnostic test(s) should be used to provide the most useful data.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["empirical therapy", "TREATMENT", 176, 193], ["invasive diagnostic test", "TEST", 234, 258]]], ["The likely potential causative pathogens can be defined by ascer taining the following:GENERAL PRINCIPLES OF THE CLINICAL APPROACH\u2022 The clinical and radiologic presentation \u2022 The speed of onset of the infection \u2022 The type, duration, and severity of the patient's immune defect \u2022 Positive results on microbiologic studies \u2022 Associated factors of importance, including any recent local infective epidemics and the patient's prophylaxis regimen, ethnic background, and travel historyGENERAL PRINCIPLES OF THE CLINICAL APPROACHThe exact type of immune defect is determined by a com bination of the disease and the treatment received and, fortu nately, can generally be predicted ( Table 28 -2).", [["infection", "DISEASE", 201, 210], ["patient", "ORGANISM", 253, 260], ["patient", "ORGANISM", 412, 419], ["patient", "SPECIES", 253, 260], ["patient", "SPECIES", 412, 419], ["potential causative pathogens", "PROBLEM", 11, 40], ["the infection", "PROBLEM", 197, 210], ["the patient's immune defect", "PROBLEM", 249, 276], ["microbiologic studies", "TEST", 299, 320], ["any recent local infective epidemics", "PROBLEM", 367, 403], ["the patient's prophylaxis regimen", "TREATMENT", 408, 441], ["immune defect", "PROBLEM", 541, 554], ["the disease", "PROBLEM", 590, 601], ["the treatment", "TREATMENT", 606, 619], ["likely potential", "UNCERTAINTY", 4, 20], ["causative", "OBSERVATION_MODIFIER", 21, 30], ["pathogens", "OBSERVATION", 31, 40], ["infection", "OBSERVATION", 201, 210], ["immune defect", "OBSERVATION", 541, 554], ["disease", "OBSERVATION", 594, 601]]], ["The three main categories of immune defect are absolute or functional neutro penia, defects in cellmediated immunity, and deficiencies in antibody responses (a clinically less severely affected category).", [["immune defect", "PROBLEM", 29, 42], ["functional neutro penia", "PROBLEM", 59, 82], ["defects in cellmediated immunity", "PROBLEM", 84, 116], ["deficiencies in antibody responses", "PROBLEM", 122, 156], ["three", "OBSERVATION_MODIFIER", 4, 9], ["main", "OBSERVATION_MODIFIER", 10, 14], ["immune defect", "OBSERVATION", 29, 42], ["absolute", "OBSERVATION_MODIFIER", 47, 55], ["neutro penia", "OBSERVATION", 70, 82], ["cellmediated immunity", "OBSERVATION", 95, 116]]], ["Each is associated with a particular range of pathogens (see Table 282 ).", [["pathogens", "PROBLEM", 46, 55], ["pathogens", "OBSERVATION", 46, 55]]], ["Patients with neutropenia are mainly at risk for infection with extracellular pathogens such as pyogenic bacte ria and filamentous fungi.", [["extracellular", "ANATOMY", 64, 77], ["neutropenia", "DISEASE", 14, 25], ["infection", "DISEASE", 49, 58], ["Patients", "ORGANISM", 0, 8], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["Patients", "SPECIES", 0, 8], ["neutropenia", "PROBLEM", 14, 25], ["infection", "PROBLEM", 49, 58], ["extracellular pathogens", "PROBLEM", 64, 87], ["pyogenic bacte ria", "PROBLEM", 96, 114], ["filamentous fungi", "PROBLEM", 119, 136], ["neutropenia", "OBSERVATION", 14, 25], ["infection", "OBSERVATION", 49, 58], ["pathogens", "OBSERVATION", 78, 87], ["pyogenic", "OBSERVATION_MODIFIER", 96, 104], ["filamentous fungi", "OBSERVATION", 119, 136]]], ["Defects in cellmediated immunity tend to predispose affected patients to development of infec tions with intracellular pathogens such as viruses and myco bacteria, as well as some unusual extracellular infections such as Pneumocystis pneumonia (PCP).", [["intracellular", "ANATOMY", 105, 118], ["extracellular", "ANATOMY", 188, 201], ["extracellular infections", "DISEASE", 188, 212], ["Pneumocystis pneumonia", "DISEASE", 221, 243], ["PCP", "DISEASE", 245, 248], ["patients", "ORGANISM", 61, 69], ["infec", "ORGANISM", 88, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 118], ["myco bacteria", "ORGANISM", 149, 162], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["patients", "SPECIES", 61, 69], ["Pneumocystis pneumonia", "SPECIES", 221, 243], ["Defects in cellmediated immunity", "PROBLEM", 0, 32], ["infec tions", "PROBLEM", 88, 99], ["intracellular pathogens", "PROBLEM", 105, 128], ["viruses", "PROBLEM", 137, 144], ["myco bacteria", "PROBLEM", 149, 162], ["some unusual extracellular infections", "PROBLEM", 175, 212], ["Pneumocystis pneumonia", "PROBLEM", 221, 243], ["unusual", "OBSERVATION_MODIFIER", 180, 187], ["extracellular", "OBSERVATION_MODIFIER", 188, 201], ["infections", "OBSERVATION", 202, 212], ["Pneumocystis", "OBSERVATION_MODIFIER", 221, 233], ["pneumonia", "OBSERVATION", 234, 243]]], ["Deficiencies in antibody responses result in a high incidence of infections due to encap sulated bacteria such as Streptococcus pneumoniae and to her pesviruses.", [["infections", "DISEASE", 65, 75], ["Streptococcus pneumoniae", "DISEASE", 114, 138], ["Streptococcus pneumoniae", "ORGANISM", 114, 138], ["Streptococcus pneumoniae", "SPECIES", 114, 138], ["Streptococcus pneumoniae", "SPECIES", 114, 138], ["Deficiencies in antibody responses", "PROBLEM", 0, 34], ["infections", "PROBLEM", 65, 75], ["encap sulated bacteria", "PROBLEM", 83, 105], ["Streptococcus pneumoniae", "PROBLEM", 114, 138], ["her pesviruses", "PROBLEM", 146, 160], ["antibody responses", "OBSERVATION", 16, 34], ["infections", "OBSERVATION", 65, 75], ["Streptococcus pneumoniae", "OBSERVATION", 114, 138]]], ["Individual patients may have a combination of these immune defects; for example, lymphoma can cause impairment of cellmediated immunity that can be combined with neutro penia if the patient receives chemotherapy.GENERAL PRINCIPLES OF THE CLINICAL APPROACHHSCT, especially for allograft recipients, is particularly asso ciated with lung complications, including infections with a daunting range of pathogens.", [["lymphoma", "ANATOMY", 81, 89], ["allograft", "ANATOMY", 276, 285], ["lung", "ANATOMY", 331, 335], ["immune defects", "DISEASE", 52, 66], ["lymphoma", "DISEASE", 81, 89], ["impairment of cellmediated immunity", "DISEASE", 100, 135], ["lung complications", "DISEASE", 331, 349], ["infections", "DISEASE", 361, 371], ["patients", "ORGANISM", 11, 19], ["lymphoma", "CANCER", 81, 89], ["patient", "ORGANISM", 182, 189], ["lung", "ORGAN", 331, 335], ["patients", "SPECIES", 11, 19], ["patient", "SPECIES", 182, 189], ["these immune defects", "PROBLEM", 46, 66], ["lymphoma", "PROBLEM", 81, 89], ["impairment of cellmediated immunity", "PROBLEM", 100, 135], ["neutro penia", "PROBLEM", 162, 174], ["chemotherapy", "TREATMENT", 199, 211], ["allograft recipients", "TREATMENT", 276, 296], ["lung complications", "PROBLEM", 331, 349], ["infections", "PROBLEM", 361, 371], ["pathogens", "PROBLEM", 397, 406], ["immune defects", "OBSERVATION", 52, 66], ["lymphoma", "OBSERVATION", 81, 89], ["lung", "ANATOMY", 331, 335], ["complications", "OBSERVATION", 336, 349], ["infections", "OBSERVATION", 361, 371]]], ["The immune defects associated with HSCT depend on the conditioning regimen and type of graft, and evolve with time.", [["graft", "ANATOMY", 87, 92], ["immune defects", "DISEASE", 4, 18], ["graft", "TISSUE", 87, 92], ["The immune defects", "PROBLEM", 0, 18], ["HSCT", "TREATMENT", 35, 39], ["the conditioning regimen", "TREATMENT", 50, 74], ["type of graft", "TREATMENT", 79, 92], ["immune defects", "OBSERVATION", 4, 18], ["graft", "OBSERVATION", 87, 92]]], ["In phase I, the preengraftment phase (15 to 45 days after transplantation), prolonged neutro penia and breaks in the mucocutaneous barrier increase the risk of bacterial and fungal infections.", [["mucocutaneous barrier", "ANATOMY", 117, 138], ["bacterial and fungal infections", "DISEASE", 160, 191], ["the preengraftment phase", "TEST", 12, 36], ["transplantation", "TREATMENT", 58, 73], ["prolonged neutro penia", "TREATMENT", 76, 98], ["the mucocutaneous barrier", "TREATMENT", 113, 138], ["bacterial and fungal infections", "PROBLEM", 160, 191], ["mucocutaneous barrier", "OBSERVATION", 117, 138], ["bacterial", "OBSERVATION_MODIFIER", 160, 169], ["fungal infections", "OBSERVATION", 174, 191]]], ["Herpes simplex virus reactivation also can occur during this phase.", [["Herpes simplex virus reactivation", "DISEASE", 0, 33], ["Herpes simplex virus", "ORGANISM", 0, 20], ["Herpes simplex virus", "SPECIES", 0, 20], ["Herpes simplex virus", "SPECIES", 0, 20], ["Herpes simplex virus reactivation", "PROBLEM", 0, 33], ["simplex virus reactivation", "OBSERVATION", 7, 33]]], ["In phase II, the immediate postengraftment phase at around 30 to 100 days after transplantation, infections relate primarily to impaired cellmediated immunity and include those due to herpesviruses (particularly CMV) and PCP unless the patient is given pro phylaxis.", [["infections", "DISEASE", 97, 107], ["impaired cellmediated immunity", "DISEASE", 128, 158], ["herpesviruses", "DISEASE", 184, 197], ["PCP", "DISEASE", 221, 224], ["herpesviruses", "ORGANISM", 184, 197], ["CMV", "ORGANISM", 212, 215], ["patient", "ORGANISM", 236, 243], ["patient", "SPECIES", 236, 243], ["CMV", "SPECIES", 212, 215], ["transplantation", "TREATMENT", 80, 95], ["infections", "PROBLEM", 97, 107], ["impaired cellmediated immunity", "PROBLEM", 128, 158], ["herpesviruses", "PROBLEM", 184, 197], ["pro phylaxis", "TREATMENT", 253, 265], ["infections", "OBSERVATION", 97, 107]]], ["During phase III, the late phase (beyond 100 days), common pathogens again include herpesviruses, but there is also a marked increased incidence of infection with encapsu lated bacteria such as S. pneumoniae, perhaps relating to impaired humoral immunity.", [["herpesviruses", "DISEASE", 83, 96], ["infection", "DISEASE", 148, 157], ["impaired humoral immunity", "DISEASE", 229, 254], ["S. pneumoniae", "ORGANISM", 194, 207], ["S. pneumoniae", "SPECIES", 194, 207], ["S. pneumoniae", "SPECIES", 194, 207], ["common pathogens", "PROBLEM", 52, 68], ["herpesviruses", "PROBLEM", 83, 96], ["a marked increased incidence of infection", "PROBLEM", 116, 157], ["encapsu lated bacteria", "PROBLEM", 163, 185], ["S. pneumoniae", "PROBLEM", 194, 207], ["impaired humoral immunity", "PROBLEM", 229, 254], ["late phase", "OBSERVATION_MODIFIER", 22, 32], ["herpesviruses", "OBSERVATION", 83, 96], ["marked", "OBSERVATION_MODIFIER", 118, 124], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["incidence", "OBSERVATION_MODIFIER", 135, 144], ["infection", "OBSERVATION", 148, 157], ["pneumoniae", "OBSERVATION", 197, 207], ["impaired", "OBSERVATION_MODIFIER", 229, 237], ["humoral immunity", "OBSERVATION", 238, 254]]], ["Graftversushost disease also is associated with ongoing susceptibility to Aspergillus during phases II and III.", [["Graftversushost disease", "DISEASE", 0, 23], ["Graftversushost disease", "PROBLEM", 0, 23], ["ongoing susceptibility to Aspergillus", "PROBLEM", 48, 85], ["disease", "OBSERVATION", 16, 23], ["associated with", "UNCERTAINTY", 32, 47], ["Aspergillus", "OBSERVATION", 74, 85]]], ["For recipients of nonmyeloablative hemato poietic stem cell transplants, substantial differences may be observed during phase I, but susceptibility to infections during phases II and III is about the same.", [["hemato poietic stem cell", "ANATOMY", 35, 59], ["infections", "DISEASE", 151, 161], ["hemato poietic stem cell", "CELL", 35, 59], ["nonmyeloablative hemato poietic stem cell transplants", "TREATMENT", 18, 71], ["susceptibility to infections", "PROBLEM", 133, 161], ["nonmyeloablative hemato", "OBSERVATION", 18, 41], ["poietic stem cell transplants", "OBSERVATION", 42, 71], ["infections", "OBSERVATION", 151, 161]]], ["The risk of disease from communityacquired respiratory viruses is elevated in all three phases.GENERAL PRINCIPLES OF THE CLINICAL APPROACHBy combining the clinical pattern of presentation with knowledge of the patient's immune defect, a differential diag nosis of likely pathogens can be suggested.", [["respiratory viruses", "DISEASE", 43, 62], ["immune defect", "DISEASE", 220, 233], ["patient", "ORGANISM", 210, 217], ["patient", "SPECIES", 210, 217], ["disease", "PROBLEM", 12, 19], ["communityacquired respiratory viruses", "PROBLEM", 25, 62], ["the patient's immune defect", "PROBLEM", 206, 233], ["pathogens", "PROBLEM", 271, 280], ["disease", "OBSERVATION", 12, 19], ["respiratory viruses", "OBSERVATION", 43, 62], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["immune defect", "OBSERVATION", 220, 233]]], ["For example, infec tions developing rapidly over 1 to 3 days with a marked rise in serum inflammatory markers such as Creactive protein (CRP), pronounced fever, and focal radiologic changes are very likely to be due to infection with pyogenic bacteria.", [["infec tions", "ANATOMY", 13, 24], ["serum", "ANATOMY", 83, 88], ["fever", "DISEASE", 154, 159], ["infection", "DISEASE", 219, 228], ["infec tions", "ORGANISM", 13, 24], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["Creactive protein", "GENE_OR_GENE_PRODUCT", 118, 135], ["CRP", "GENE_OR_GENE_PRODUCT", 137, 140], ["serum inflammatory markers", "PROTEIN", 83, 109], ["Creactive protein", "PROTEIN", 118, 135], ["CRP", "PROTEIN", 137, 140], ["infec tions", "PROBLEM", 13, 24], ["a marked rise in serum inflammatory markers", "PROBLEM", 66, 109], ["Creactive protein", "TEST", 118, 135], ["CRP", "TEST", 137, 140], ["pronounced fever", "PROBLEM", 143, 159], ["focal radiologic changes", "PROBLEM", 165, 189], ["infection", "PROBLEM", 219, 228], ["pyogenic bacteria", "PROBLEM", 234, 251], ["rapidly", "OBSERVATION_MODIFIER", 36, 43], ["marked", "OBSERVATION_MODIFIER", 68, 74], ["rise", "OBSERVATION_MODIFIER", 75, 79], ["serum inflammatory", "OBSERVATION_MODIFIER", 83, 101], ["pronounced", "OBSERVATION_MODIFIER", 143, 153], ["fever", "OBSERVATION", 154, 159], ["focal", "OBSERVATION_MODIFIER", 165, 170], ["very likely to be due to", "UNCERTAINTY", 194, 218], ["infection", "OBSERVATION", 219, 228], ["pyogenic", "OBSERVATION_MODIFIER", 234, 242], ["bacteria", "OBSERVATION", 243, 251]]], ["In a patient with a defect in cellmediated immunity, however, widespread ground glass infiltrations in both lungs developing over several days could represent CMV pneumonitis or PCP.", [["lungs", "ANATOMY", 108, 113], ["pneumonitis", "DISEASE", 163, 174], ["PCP", "DISEASE", 178, 181], ["PCP", "CHEMICAL", 178, 181], ["patient", "ORGANISM", 5, 12], ["lungs", "ORGAN", 108, 113], ["CMV", "ORGANISM", 159, 162], ["patient", "SPECIES", 5, 12], ["a defect in cellmediated immunity", "PROBLEM", 18, 51], ["widespread ground glass infiltrations in both lungs", "PROBLEM", 62, 113], ["CMV pneumonitis", "PROBLEM", 159, 174], ["PCP", "PROBLEM", 178, 181], ["defect", "OBSERVATION", 20, 26], ["widespread", "OBSERVATION_MODIFIER", 62, 72], ["ground glass infiltrations", "OBSERVATION", 73, 99], ["both", "ANATOMY_MODIFIER", 103, 107], ["lungs", "ANATOMY", 108, 113], ["could represent", "UNCERTAINTY", 143, 158], ["CMV pneumonitis", "OBSERVATION", 159, 174]]], ["In general, the more severe and prolonged the immune defect, the greater the range of possible causative pathogens and the less typical the clinical presentation for a particular pathogen, prompting the need for early invasive investigation if the initial therapy is failing to effect improvement.", [["prolonged the immune defect", "PROBLEM", 32, 59], ["causative pathogens", "PROBLEM", 95, 114], ["a particular pathogen", "PROBLEM", 166, 187], ["early invasive investigation", "TEST", 212, 240], ["the initial therapy", "TREATMENT", 244, 263], ["more severe", "OBSERVATION_MODIFIER", 16, 27], ["immune defect", "OBSERVATION", 46, 59], ["possible", "UNCERTAINTY", 86, 94], ["causative", "OBSERVATION_MODIFIER", 95, 104], ["pathogens", "OBSERVATION", 105, 114]]], ["Furthermore the character of the disease can be dictated by the severity of the immune defect.", [["the disease", "PROBLEM", 29, 40], ["the immune defect", "PROBLEM", 76, 93], ["disease", "OBSERVATION", 33, 40], ["immune defect", "OBSERVATION", 80, 93]]], ["For example, infections due to filamentous fungi such as Aspergillus progress faster with increasing severity of neutropenia, but may regress and become more focal when the neutrophil count recovers.", [["neutrophil", "ANATOMY", 173, 183], ["infections", "DISEASE", 13, 23], ["neutropenia", "DISEASE", 113, 124], ["neutrophil", "CELL", 173, 183], ["infections", "PROBLEM", 13, 23], ["filamentous fungi", "PROBLEM", 31, 48], ["Aspergillus", "PROBLEM", 57, 68], ["neutropenia", "PROBLEM", 113, 124], ["the neutrophil count", "TEST", 169, 189], ["infections", "OBSERVATION", 13, 23], ["filamentous fungi", "OBSERVATION", 31, 48], ["increasing", "OBSERVATION_MODIFIER", 90, 100], ["severity", "OBSERVATION_MODIFIER", 101, 109], ["neutropenia", "OBSERVATION", 113, 124], ["focal", "OBSERVATION_MODIFIER", 158, 163], ["neutrophil count", "OBSERVATION", 173, 189]]], ["Table 28 -3 shows the common conditions that should be considered for different presentations of lung com plications in immunocompromised patients.", [["lung", "ANATOMY", 97, 101], ["lung com plications", "DISEASE", 97, 116], ["lung", "ORGAN", 97, 101], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["lung com plications", "TREATMENT", 97, 116], ["lung", "ANATOMY", 97, 101]]], ["Many patients will be found to have dual pathologic processes, either involving two separate pathogens or with simultaneous noninfective (fluid overload being the most common) and infective prob lems, which will be responsible for separate elements of the clinical picture.GENERAL PRINCIPLES OF THE CLINICAL APPROACHPrevious results of microbiologic tests need to be reviewed, because these may provide a strong indication of the cause of the present lung infection.", [["fluid", "ANATOMY", 138, 143], ["lung", "ANATOMY", 451, 455], ["fluid overload", "DISEASE", 138, 152], ["lung infection", "DISEASE", 451, 465], ["patients", "ORGANISM", 5, 13], ["lung", "ORGAN", 451, 455], ["patients", "SPECIES", 5, 13], ["dual pathologic processes", "PROBLEM", 36, 61], ["two separate pathogens", "PROBLEM", 80, 102], ["simultaneous noninfective (fluid overload", "PROBLEM", 111, 152], ["infective prob lems", "PROBLEM", 180, 199], ["microbiologic tests", "TEST", 336, 355], ["the present lung infection", "PROBLEM", 439, 465], ["pathologic", "OBSERVATION", 41, 51], ["fluid overload", "OBSERVATION", 138, 152], ["infective", "OBSERVATION_MODIFIER", 180, 189], ["lung", "ANATOMY", 451, 455], ["infection", "OBSERVATION", 456, 465]]], ["For instance, infected indwelling *As defined in this chapter.GENERAL PRINCIPLES OF THE CLINICAL APPROACHLymphoma/leukemia Hematopoietic stem cell transplantation (HSCT) Aplastic anemia Solid organ transplantation Other causes of neutropenia (fewer than 1500 cells/mL) Inherited disorders of immune function (e.g., chronic granulomatous disease, recent chemotherapy) High-dose corticosteroid treatment (greater than 30 mg prednisolone for 21 days or longer) Treatment with immunosuppressive therapy (e.g., tacrolimus, cyclosporine) Treatment with cytotoxic therapy (e.g., cyclophosphamide, mycophenolate) Other important factors that need to be taken into account include the patient's present antibiotic prophylaxis regimen, travel history, and ethnic background.", [["APPROACHLymphoma/leukemia Hematopoietic stem cell", "ANATOMY", 97, 146], ["organ", "ANATOMY", 192, 197], ["cells", "ANATOMY", 259, 264], ["granulomatous", "ANATOMY", 323, 336], ["APPROACHLymphoma/leukemia", "DISEASE", 97, 122], ["anemia", "DISEASE", 179, 185], ["neutropenia", "DISEASE", 230, 241], ["disorders of immune function", "DISEASE", 279, 307], ["chronic granulomatous disease", "DISEASE", 315, 344], ["prednisolone", "CHEMICAL", 422, 434], ["tacrolimus", "CHEMICAL", 506, 516], ["cyclosporine", "CHEMICAL", 518, 530], ["cyclophosphamide", "CHEMICAL", 572, 588], ["mycophenolate", "CHEMICAL", 590, 603], ["prednisolone", "CHEMICAL", 422, 434], ["tacrolimus", "CHEMICAL", 506, 516], ["cyclosporine", "CHEMICAL", 518, 530], ["cyclophosphamide", "CHEMICAL", 572, 588], ["mycophenolate)", "CHEMICAL", 590, 604], ["APPROACHLymphoma/leukemia Hematopoietic stem cell", "CELL", 97, 146], ["organ", "ORGAN", 192, 197], ["prednisolone", "SIMPLE_CHEMICAL", 422, 434], ["tacrolimus", "SIMPLE_CHEMICAL", 506, 516], ["cyclosporine", "SIMPLE_CHEMICAL", 518, 530], ["cyclophosphamide", "SIMPLE_CHEMICAL", 572, 588], ["mycophenolate", "SIMPLE_CHEMICAL", 590, 603], ["patient", "ORGANISM", 676, 683], ["patient", "SPECIES", 676, 683], ["infected indwelling", "TREATMENT", 14, 33], ["THE CLINICAL APPROACHLymphoma", "PROBLEM", 84, 113], ["leukemia", "PROBLEM", 114, 122], ["Hematopoietic stem cell transplantation", "TREATMENT", 123, 162], ["Aplastic anemia", "PROBLEM", 170, 185], ["Solid organ transplantation", "TREATMENT", 186, 213], ["neutropenia", "PROBLEM", 230, 241], ["Inherited disorders", "PROBLEM", 269, 288], ["immune function", "PROBLEM", 292, 307], ["chronic granulomatous disease", "PROBLEM", 315, 344], ["recent chemotherapy", "TREATMENT", 346, 365], ["High-dose corticosteroid treatment", "TREATMENT", 367, 401], ["prednisolone", "TREATMENT", 422, 434], ["immunosuppressive therapy", "TREATMENT", 473, 498], ["tacrolimus", "TREATMENT", 506, 516], ["cyclosporine", "TREATMENT", 518, 530], ["cytotoxic therapy", "TREATMENT", 547, 564], ["cyclophosphamide", "TREATMENT", 572, 588], ["mycophenolate", "TREATMENT", 590, 603], ["present antibiotic prophylaxis regimen", "TREATMENT", 686, 724], ["infected", "OBSERVATION_MODIFIER", 14, 22], ["indwelling", "OBSERVATION", 23, 33], ["leukemia Hematopoietic stem cell transplantation", "OBSERVATION", 114, 162], ["neutropenia", "OBSERVATION", 230, 241], ["immune function", "OBSERVATION", 292, 307], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["granulomatous", "OBSERVATION", 323, 336]]], ["A patient compliant with cotrimoxazole prophylaxis will rarely develop PCP, and flu conazole prophylaxis predisposes to nonalbicans Candida infection.", [["cotrimoxazole", "CHEMICAL", 25, 38], ["PCP", "DISEASE", 71, 74], ["flu conazole", "CHEMICAL", 80, 92], ["nonalbicans Candida infection", "DISEASE", 120, 149], ["cotrimoxazole", "CHEMICAL", 25, 38], ["PCP", "CHEMICAL", 71, 74], ["conazole", "CHEMICAL", 84, 92], ["patient", "ORGANISM", 2, 9], ["cotrimoxazole", "SIMPLE_CHEMICAL", 25, 38], ["flu conazole", "SIMPLE_CHEMICAL", 80, 92], ["nonalbicans Candida", "ORGANISM", 120, 139], ["patient", "SPECIES", 2, 9], ["cotrimoxazole prophylaxis", "TREATMENT", 25, 50], ["PCP", "PROBLEM", 71, 74], ["flu conazole prophylaxis", "TREATMENT", 80, 104], ["nonalbicans Candida infection", "PROBLEM", 120, 149], ["Candida infection", "OBSERVATION", 132, 149]]], ["Patients with certain ethnic backgrounds or a perti nent travel history are more at risk of TB, endemic mycoses such as histoplasmosis, or parasitic diseases such as dissemi nated strongyloidiasis.", [["TB", "DISEASE", 92, 94], ["mycoses", "DISEASE", 104, 111], ["histoplasmosis", "DISEASE", 120, 134], ["parasitic diseases", "DISEASE", 139, 157], ["strongyloidiasis", "DISEASE", 180, 196], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["certain ethnic backgrounds", "PROBLEM", 14, 40], ["TB", "PROBLEM", 92, 94], ["endemic mycoses", "PROBLEM", 96, 111], ["histoplasmosis", "PROBLEM", 120, 134], ["parasitic diseases", "PROBLEM", 139, 157], ["dissemi nated strongyloidiasis", "PROBLEM", 166, 196], ["TB", "OBSERVATION", 92, 94], ["endemic", "OBSERVATION_MODIFIER", 96, 103], ["mycoses", "OBSERVATION", 104, 111], ["histoplasmosis", "OBSERVATION", 120, 134], ["parasitic diseases", "OBSERVATION", 139, 157], ["strongyloidiasis", "OBSERVATION", 180, 196]]], ["Finally, the patient's background lung structure and function should be considered, because existing structural abnormalities may make certain pathogens more likely.", [["lung", "ANATOMY", 34, 38], ["patient", "ORGANISM", 13, 20], ["lung", "ORGAN", 34, 38], ["patient", "SPECIES", 13, 20], ["existing structural abnormalities", "PROBLEM", 92, 125], ["certain pathogens", "PROBLEM", 135, 152], ["lung", "ANATOMY", 34, 38], ["structure", "OBSERVATION", 39, 48]]], ["For example, bronchiectasis could predispose affected persons to pneumonia caused by P. aeruginosa (Figure 28-1) , and preexisting lung cavities to Aspergillus infection.CLINICAL ASSESSMENT AND DIAGNOSTIC PROTOCOLSThe combination of new respiratory symptoms and/or new radiologic findings with pyrexia suggests lung infection, although incidental radiologic or microbiology results may also identify active lung infection in an asymptomatic patient.", [["lung cavities", "ANATOMY", 131, 144], ["respiratory", "ANATOMY", 237, 248], ["lung", "ANATOMY", 311, 315], ["lung", "ANATOMY", 407, 411], ["bronchiectasis", "DISEASE", 13, 27], ["pneumonia", "DISEASE", 65, 74], ["P. aeruginosa", "DISEASE", 85, 98], ["lung cavities", "DISEASE", 131, 144], ["Aspergillus infection", "DISEASE", 148, 169], ["respiratory symptoms", "DISEASE", 237, 257], ["pyrexia", "DISEASE", 294, 301], ["lung infection", "DISEASE", 311, 325], ["lung infection", "DISEASE", 407, 421], ["persons", "ORGANISM", 54, 61], ["P. aeruginosa", "ORGANISM", 85, 98], ["lung", "ORGAN", 131, 135], ["cavities", "MULTI-TISSUE_STRUCTURE", 136, 144], ["lung", "ORGAN", 311, 315], ["lung", "ORGAN", 407, 411], ["patient", "ORGANISM", 441, 448], ["persons", "SPECIES", 54, 61], ["P. aeruginosa", "SPECIES", 85, 98], ["patient", "SPECIES", 441, 448], ["P. aeruginosa", "SPECIES", 85, 98], ["bronchiectasis", "PROBLEM", 13, 27], ["pneumonia", "PROBLEM", 65, 74], ["P. aeruginosa", "PROBLEM", 85, 98], ["Figure", "TEST", 100, 106], ["preexisting lung cavities", "PROBLEM", 119, 144], ["Aspergillus infection", "PROBLEM", 148, 169], ["CLINICAL ASSESSMENT", "TEST", 170, 189], ["new respiratory symptoms", "PROBLEM", 233, 257], ["new radiologic findings", "PROBLEM", 265, 288], ["pyrexia", "PROBLEM", 294, 301], ["lung infection", "PROBLEM", 311, 325], ["active lung infection", "PROBLEM", 400, 421], ["bronchiectasis", "OBSERVATION", 13, 27], ["pneumonia", "OBSERVATION", 65, 74], ["lung", "ANATOMY", 131, 135], ["cavities", "OBSERVATION", 136, 144], ["Aspergillus infection", "OBSERVATION", 148, 169], ["lung", "ANATOMY", 311, 315], ["infection", "OBSERVATION", 316, 325], ["active", "OBSERVATION_MODIFIER", 400, 406], ["lung", "ANATOMY", 407, 411], ["infection", "OBSERVATION", 412, 421]]], ["The patient should undergo careful clinical assessment, including a review of previous laboratory and radiologic findings; the high mortality associated with lung infections in immunocompro mised patients requires that this is initiated rapidly.", [["lung", "ANATOMY", 158, 162], ["lung infections", "DISEASE", 158, 173], ["patient", "ORGANISM", 4, 11], ["lung", "ORGAN", 158, 162], ["patients", "ORGANISM", 196, 204], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 196, 204], ["careful clinical assessment", "TEST", 27, 54], ["radiologic findings", "TEST", 102, 121], ["the high mortality", "PROBLEM", 123, 141], ["lung infections", "PROBLEM", 158, 173], ["lung", "ANATOMY", 158, 162], ["infections", "OBSERVATION", 163, 173]]], ["The level of oxygenation will characterize the immediate risk to the patient and can also suggest likely pathogens as severe hypoxia is more likely with a bacterial lobar pneumonia, extensive PCP or viral infections.", [["lobar", "ANATOMY", 165, 170], ["hypoxia", "DISEASE", 125, 132], ["pneumonia", "DISEASE", 171, 180], ["PCP", "DISEASE", 192, 195], ["viral infections", "DISEASE", 199, 215], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["pathogens", "PROBLEM", 105, 114], ["severe hypoxia", "PROBLEM", 118, 132], ["a bacterial lobar pneumonia", "PROBLEM", 153, 180], ["extensive PCP", "PROBLEM", 182, 195], ["viral infections", "PROBLEM", 199, 215], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["hypoxia", "OBSERVATION", 125, 132], ["more likely with", "UNCERTAINTY", 136, 152], ["bacterial", "OBSERVATION_MODIFIER", 155, 164], ["lobar", "OBSERVATION_MODIFIER", 165, 170], ["pneumonia", "OBSERVATION", 171, 180], ["extensive", "OBSERVATION_MODIFIER", 182, 191], ["PCP", "OBSERVATION", 192, 195], ["viral", "OBSERVATION_MODIFIER", 199, 204], ["infections", "OBSERVATION", 205, 215]]], ["Chest radiographs are an essential first line investigation and are useful for monitoring progress.", [["Chest radiographs", "TEST", 0, 17], ["an essential first line investigation", "TEST", 22, 59]]], ["However, with the exception of lobar consolidation chest radiographs may not be sufficiently sensitive to make an accurate assess ment of the pattern of lung shadowing.", [["lobar", "ANATOMY", 31, 36], ["lung", "ANATOMY", 153, 157], ["lung", "ORGAN", 153, 157], ["lobar consolidation", "PROBLEM", 31, 50], ["chest radiographs", "TEST", 51, 68], ["lung shadowing", "PROBLEM", 153, 167], ["lobar", "OBSERVATION_MODIFIER", 31, 36], ["consolidation", "OBSERVATION", 37, 50], ["chest", "ANATOMY", 51, 56], ["lung", "ANATOMY", 153, 157], ["shadowing", "OBSERVATION", 158, 167]]], ["Ultimately a computed tomography (CT) scan of the thorax often is required.", [["thorax", "ANATOMY", 50, 56], ["thorax", "ORGAN", 50, 56], ["a computed tomography (CT) scan of the thorax", "TEST", 11, 56], ["thorax", "ANATOMY", 50, 56]]], ["CT scans are approximately 20% more sensitive than chest radiographs at identifying lung involvement and also define whether new changes on a chest radiograph represent consolidation, nodules, ground glass infiltrates, or \"treeinbud\" changes.", [["chest", "ANATOMY", 51, 56], ["lung", "ANATOMY", 84, 88], ["chest", "ANATOMY", 142, 147], ["nodules", "ANATOMY", 184, 191], ["chest", "ORGANISM_SUBDIVISION", 51, 56], ["lung", "ORGAN", 84, 88], ["nodules", "PATHOLOGICAL_FORMATION", 184, 191], ["CT scans", "TEST", 0, 8], ["chest radiographs", "TEST", 51, 68], ["new changes", "PROBLEM", 125, 136], ["a chest radiograph", "TEST", 140, 158], ["consolidation", "PROBLEM", 169, 182], ["nodules", "PROBLEM", 184, 191], ["ground glass infiltrates", "PROBLEM", 193, 217], ["\"treeinbud\" changes", "PROBLEM", 222, 241], ["lung", "ANATOMY", 84, 88], ["involvement", "OBSERVATION", 89, 100], ["new", "OBSERVATION_MODIFIER", 125, 128], ["chest", "ANATOMY", 142, 147], ["consolidation", "OBSERVATION", 169, 182], ["nodules", "OBSERVATION", 184, 191], ["ground glass infiltrates", "OBSERVATION", 193, 217]]], ["All patients with suspected new lung infection require blood and sputum cultures, as well as routine blood tests, and in many cases nasopharyngeal aspirate studies for identification of viruses, assessment of CMV status, and serum testing for fungal antigens (galactomannan or \u03b2Dglucan).", [["lung", "ANATOMY", 32, 36], ["blood", "ANATOMY", 55, 60], ["sputum cultures", "ANATOMY", 65, 80], ["blood", "ANATOMY", 101, 106], ["nasopharyngeal aspirate", "ANATOMY", 132, 155], ["serum", "ANATOMY", 225, 230], ["lung infection", "DISEASE", 32, 46], ["patients", "ORGANISM", 4, 12], ["lung", "ORGAN", 32, 36], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 132, 155], ["CMV", "ORGANISM", 209, 212], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["fungal antigens", "GENE_OR_GENE_PRODUCT", 243, 258], ["galactomannan", "SIMPLE_CHEMICAL", 260, 273], ["\u03b2Dglucan", "SIMPLE_CHEMICAL", 277, 285], ["fungal antigens", "PROTEIN", 243, 258], ["galactomannan", "PROTEIN", 260, 273], ["\u03b2Dglucan", "PROTEIN", 277, 285], ["patients", "SPECIES", 4, 12], ["CMV", "SPECIES", 209, 212], ["new lung infection", "PROBLEM", 28, 46], ["blood and sputum cultures", "TEST", 55, 80], ["routine blood tests", "TEST", 93, 112], ["nasopharyngeal aspirate studies", "TEST", 132, 163], ["viruses", "PROBLEM", 186, 193], ["assessment of CMV status", "TEST", 195, 219], ["serum testing", "TEST", 225, 238], ["fungal antigens", "TEST", 243, 258], ["galactomannan", "TEST", 260, 273], ["new", "OBSERVATION_MODIFIER", 28, 31], ["lung", "ANATOMY", 32, 36], ["infection", "OBSERVATION", 37, 46], ["viruses", "OBSERVATION", 186, 193]]], ["An important ques tion for the respiratory physician is when to utilize more inva sive investigations, either bronchoscopy with bronchoalveolar lavage (BAL) and possibly transbronchial biopsy, percutaneous radiologically guided biopsy, or, on occasion, surgical biopsy, usually videoassisted thoracoscopic surgery (VATS).", [["bronchoalveolar lavage", "ANATOMY", 128, 150], ["BAL", "ANATOMY", 152, 155], ["transbronchial", "ANATOMY", 170, 184], ["percutaneous", "ANATOMY", 193, 205], ["bronchoscopy", "TEST", 110, 122], ["bronchoalveolar lavage", "TEST", 128, 150], ["transbronchial biopsy", "TEST", 170, 191], ["percutaneous radiologically guided biopsy", "TEST", 193, 234], ["surgical biopsy", "TEST", 253, 268], ["usually videoassisted thoracoscopic surgery", "TREATMENT", 270, 313], ["VATS", "TREATMENT", 315, 319], ["bronchoalveolar lavage", "OBSERVATION", 128, 150], ["possibly", "UNCERTAINTY", 161, 169], ["transbronchial", "ANATOMY", 170, 184], ["biopsy", "OBSERVATION", 228, 234]]], ["Which test should be used and when will depend to a large extent on the type of radiologic presentation-consolidation, diffuse ground glass infiltrates, treeinbud changes, and nodules-in accordance with the algorithms for each provided in Figures 282, 284 , 286, and 287, respectively.", [["nodules", "ANATOMY", 176, 183], ["nodules", "PATHOLOGICAL_FORMATION", 176, 183], ["consolidation", "PROBLEM", 104, 117], ["diffuse ground glass infiltrates", "PROBLEM", 119, 151], ["treeinbud changes", "PROBLEM", 153, 170], ["nodules", "PROBLEM", 176, 183], ["the algorithms", "TEST", 203, 217], ["large", "OBSERVATION_MODIFIER", 52, 57], ["consolidation", "OBSERVATION", 104, 117], ["diffuse", "OBSERVATION_MODIFIER", 119, 126], ["ground glass infiltrates", "OBSERVATION", 127, 151], ["treeinbud", "OBSERVATION_MODIFIER", 153, 162], ["nodules", "OBSERVATION", 176, 183]]], ["These suggested pro tocols balance the likelihood and necessity of a positive yield against the clinical probability that a particular disease will be identified with the potential complications of the investiga tions.", [["a positive yield", "PROBLEM", 67, 83], ["a particular disease", "PROBLEM", 122, 142], ["the investiga tions", "TREATMENT", 198, 217]]], ["These protocols are for general guidance; atypical presen tations and dual pathology are not uncommon, and an individual patient often will require a modified approach.", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["general guidance", "TEST", 24, 40], ["dual pathology", "TEST", 70, 84], ["a modified approach", "TREATMENT", 148, 167]]], ["Immunocom promised patients are also at high risk for development of a range of noninfective causes of lung disease, including pulmo nary edema, idiopathic pneumonia syndrome (IPS), and diffuse alveolar hemorrhage (see Chapter 59).", [["lung", "ANATOMY", 103, 107], ["alveolar", "ANATOMY", 194, 202], ["lung disease", "DISEASE", 103, 115], ["pulmo nary edema", "DISEASE", 127, 143], ["idiopathic pneumonia syndrome", "DISEASE", 145, 174], ["IPS", "DISEASE", 176, 179], ["alveolar hemorrhage", "DISEASE", 194, 213], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 103, 107], ["alveolar", "ORGAN", 194, 202], ["patients", "SPECIES", 19, 27], ["lung disease", "PROBLEM", 103, 115], ["pulmo nary edema", "PROBLEM", 127, 143], ["idiopathic pneumonia syndrome", "PROBLEM", 145, 174], ["diffuse alveolar hemorrhage", "PROBLEM", 186, 213], ["lung", "ANATOMY", 103, 107], ["disease", "OBSERVATION", 108, 115], ["nary", "OBSERVATION_MODIFIER", 133, 137], ["edema", "OBSERVATION", 138, 143], ["idiopathic", "OBSERVATION_MODIFIER", 145, 155], ["pneumonia", "OBSERVATION", 156, 165], ["diffuse", "OBSERVATION_MODIFIER", 186, 193], ["alveolar", "ANATOMY_MODIFIER", 194, 202], ["hemorrhage", "OBSERVATION", 203, 213]]], ["These conditions should always be considered in the differential diagnosis for new lung disease.", [["lung", "ANATOMY", 83, 87], ["lung disease", "DISEASE", 83, 95], ["lung", "ORGAN", 83, 87], ["new lung disease", "PROBLEM", 79, 95], ["new", "OBSERVATION_MODIFIER", 79, 82], ["lung", "ANATOMY", 83, 87], ["disease", "OBSERVATION", 88, 95]]], ["The protocols are discussed in detail next.INVESTIGATION OF CONSOLIDATIONRapidly developing focal consolidation usually is due to bacte rial pneumonia and initially can be treated empirically with broadspectrum antibiotics (Figure 28-2) .", [["pneumonia", "DISEASE", 141, 150], ["CONSOLIDATIONRapidly developing focal consolidation", "PROBLEM", 60, 111], ["bacte rial pneumonia", "PROBLEM", 130, 150], ["broadspectrum antibiotics", "TREATMENT", 197, 222], ["focal", "OBSERVATION_MODIFIER", 92, 97], ["consolidation", "OBSERVATION", 98, 111], ["due to", "UNCERTAINTY", 123, 129], ["bacte", "OBSERVATION_MODIFIER", 130, 135], ["rial", "OBSERVATION_MODIFIER", 136, 140], ["pneumonia", "OBSERVATION", 141, 150]]], ["The most likely reason for a lack of improvement in the patient's condition within 48 to 96 hours is infection with bacteria resistant to HSCT, hematopoietic stem cell transplantation. bronchoscopy (FOB) with BAL or percutaneous CTguided biopsy (mainly for evaluation of dense consolidation adjacent to the pleura).", [["hematopoietic stem cell", "ANATOMY", 144, 167], ["BAL", "ANATOMY", 209, 212], ["pleura", "ANATOMY", 307, 313], ["infection", "DISEASE", 101, 110], ["patient", "ORGANISM", 56, 63], ["hematopoietic stem cell", "CELL", 144, 167], ["pleura", "ORGAN", 307, 313], ["patient", "SPECIES", 56, 63], ["the patient's condition", "PROBLEM", 52, 75], ["infection", "PROBLEM", 101, 110], ["bacteria", "PROBLEM", 116, 124], ["HSCT", "TREATMENT", 138, 142], ["hematopoietic stem cell transplantation", "TREATMENT", 144, 183], ["bronchoscopy", "TEST", 185, 197], ["BAL or percutaneous CTguided biopsy", "TEST", 209, 244], ["evaluation", "TEST", 257, 267], ["dense consolidation", "PROBLEM", 271, 290], ["most likely", "UNCERTAINTY", 4, 15], ["infection", "OBSERVATION", 101, 110], ["hematopoietic stem cell transplantation", "OBSERVATION", 144, 183], ["dense", "OBSERVATION_MODIFIER", 271, 276], ["consolidation", "OBSERVATION", 277, 290], ["pleura", "ANATOMY", 307, 313]]], ["These investigations also will be necessary in patients whose pneumonia fails to respond to secondline anti biotic therapy or those with subacute or chronic consolidation in whom sputum microbiologic or cytologic testing is nondiag nostic.", [["sputum", "ANATOMY", 179, 185], ["pneumonia", "DISEASE", 62, 71], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["These investigations", "TEST", 0, 20], ["pneumonia", "PROBLEM", 62, 71], ["secondline anti biotic therapy", "TREATMENT", 92, 122], ["subacute or chronic consolidation", "PROBLEM", 137, 170], ["sputum microbiologic", "TEST", 179, 199], ["cytologic testing", "TEST", 203, 220], ["nondiag nostic", "PROBLEM", 224, 238], ["pneumonia", "OBSERVATION", 62, 71], ["subacute", "OBSERVATION_MODIFIER", 137, 145], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["consolidation", "OBSERVATION", 157, 170]]], ["With progressive disease and lack of a definitive diagno sis after the foregoing tests, surgical biopsy should be seriously considered.INVESTIGATION OF CONSOLIDATIONfirstline antibiotics.", [["progressive disease", "PROBLEM", 5, 24], ["a definitive diagno sis", "PROBLEM", 37, 60], ["the foregoing tests", "TEST", 67, 86], ["surgical biopsy", "TEST", 88, 103], ["CONSOLIDATIONfirstline antibiotics", "TREATMENT", 152, 186], ["progressive", "OBSERVATION_MODIFIER", 5, 16], ["disease", "OBSERVATION", 17, 24], ["CONSOLIDATIONfirstline antibiotics", "OBSERVATION", 152, 186]]], ["At this point, treatment with secondline antibiotics effective against likely resistant organisms should be started.", [["secondline", "SIMPLE_CHEMICAL", 30, 40], ["treatment", "TREATMENT", 15, 24], ["secondline antibiotics", "TREATMENT", 30, 52], ["resistant organisms", "PROBLEM", 78, 97]]], ["Consideration also should be given to starting antibiot ics that are effective against MRSA and anaerobic pathogens if this has not been done already.", [["MRSA", "DISEASE", 87, 91], ["antibiot ics", "SIMPLE_CHEMICAL", 47, 59], ["MRSA", "SPECIES", 87, 91], ["MRSA", "SPECIES", 87, 91], ["antibiot ics", "TREATMENT", 47, 59], ["MRSA", "PROBLEM", 87, 91], ["anaerobic pathogens", "PROBLEM", 96, 115]]], ["In patients at high risk for invasive fungal infection, especially those with CT evidence of associated nodular disease or patchy or infarctshaped consoli dation, failure of firstline therapy warrants testing for fungal antigens (galactomannan or \u03b2Dglucan) and either fiberoptic Figure 28 -1 A, Computed tomography (CT) scan of thorax shows dilated, thick-walled bronchi, characteristic of bronchiectasis.", [["nodular", "ANATOMY", 104, 111], ["thorax", "ANATOMY", 328, 334], ["bronchi", "ANATOMY", 363, 370], ["fungal infection", "DISEASE", 38, 54], ["bronchiectasis", "DISEASE", 390, 404], ["patients", "ORGANISM", 3, 11], ["galactomannan", "SIMPLE_CHEMICAL", 230, 243], ["\u03b2Dglucan", "SIMPLE_CHEMICAL", 247, 255], ["thorax", "ORGAN", 328, 334], ["bronchi", "MULTI-TISSUE_STRUCTURE", 363, 370], ["fungal antigens", "PROTEIN", 213, 228], ["galactomannan", "PROTEIN", 230, 243], ["\u03b2Dglucan", "PROTEIN", 247, 255], ["patients", "SPECIES", 3, 11], ["invasive fungal infection", "PROBLEM", 29, 54], ["associated nodular disease", "PROBLEM", 93, 119], ["patchy or infarctshaped consoli dation", "PROBLEM", 123, 161], ["firstline therapy", "TREATMENT", 174, 191], ["testing", "TEST", 201, 208], ["fungal antigens", "PROBLEM", 213, 228], ["galactomannan", "TEST", 230, 243], ["Computed tomography (CT) scan of thorax", "TEST", 295, 334], ["dilated, thick-walled bronchi", "PROBLEM", 341, 370], ["bronchiectasis", "PROBLEM", 390, 404], ["invasive", "OBSERVATION_MODIFIER", 29, 37], ["fungal", "OBSERVATION_MODIFIER", 38, 44], ["infection", "OBSERVATION", 45, 54], ["nodular", "OBSERVATION_MODIFIER", 104, 111], ["disease", "OBSERVATION", 112, 119], ["patchy", "OBSERVATION_MODIFIER", 123, 129], ["infarctshaped consoli", "OBSERVATION", 133, 154], ["thorax", "ANATOMY", 328, 334], ["dilated", "OBSERVATION", 341, 348], ["thick", "OBSERVATION", 350, 355], ["walled", "ANATOMY_MODIFIER", 356, 362], ["bronchi", "ANATOMY", 363, 370], ["bronchiectasis", "OBSERVATION", 390, 404]]], ["The patient, who had a long history of chronic lymphatic leukemia and immunoglobulin deficiency, produced purulent sputum daily, culture of which grew Pseudomonas aeruginosa.", [["lymphatic leukemia", "ANATOMY", 47, 65], ["purulent sputum", "ANATOMY", 106, 121], ["chronic lymphatic leukemia", "DISEASE", 39, 65], ["immunoglobulin deficiency", "DISEASE", 70, 95], ["patient", "ORGANISM", 4, 11], ["chronic lymphatic leukemia", "CANCER", 39, 65], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 70, 84], ["Pseudomonas aeruginosa", "ORGANISM", 151, 173], ["immunoglobulin", "PROTEIN", 70, 84], ["patient", "SPECIES", 4, 11], ["Pseudomonas aeruginosa", "SPECIES", 151, 173], ["Pseudomonas aeruginosa", "SPECIES", 151, 173], ["chronic lymphatic leukemia", "PROBLEM", 39, 65], ["immunoglobulin deficiency", "PROBLEM", 70, 95], ["purulent sputum", "PROBLEM", 106, 121], ["culture", "TEST", 129, 136], ["Pseudomonas aeruginosa", "PROBLEM", 151, 173], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["lymphatic leukemia", "OBSERVATION", 47, 65], ["immunoglobulin deficiency", "OBSERVATION", 70, 95], ["purulent", "OBSERVATION_MODIFIER", 106, 114]]], ["B, A chest radiograph obtained in the same patient, whose clinical presentation included high fever, productive cough, and marked hypoxia, shows consolidation (most marked in the left middle zone) due to P. aeruginosa pneumonia. respiratory distress syndrome (ARDS), drug toxicity, and IPS associated with HSCT (see Chapter 77).", [["left middle zone", "ANATOMY", 179, 195], ["fever", "DISEASE", 94, 99], ["cough", "DISEASE", 112, 117], ["hypoxia", "DISEASE", 130, 137], ["P. aeruginosa pneumonia", "DISEASE", 204, 227], ["respiratory distress syndrome", "DISEASE", 229, 258], ["ARDS", "DISEASE", 260, 264], ["drug toxicity", "DISEASE", 267, 280], ["IPS", "DISEASE", 286, 289], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["patient", "ORGANISM", 43, 50], ["P. aeruginosa", "ORGANISM", 204, 217], ["patient", "SPECIES", 43, 50], ["P. aeruginosa", "SPECIES", 204, 217], ["P. aeruginosa", "SPECIES", 204, 217], ["A chest radiograph", "TEST", 3, 21], ["high fever", "PROBLEM", 89, 99], ["productive cough", "PROBLEM", 101, 117], ["marked hypoxia", "PROBLEM", 123, 137], ["consolidation", "PROBLEM", 145, 158], ["P. aeruginosa pneumonia", "PROBLEM", 204, 227], ["respiratory distress syndrome", "PROBLEM", 229, 258], ["ARDS", "PROBLEM", 260, 264], ["drug toxicity", "PROBLEM", 267, 280], ["IPS", "PROBLEM", 286, 289], ["chest", "ANATOMY", 5, 10], ["productive", "OBSERVATION_MODIFIER", 101, 111], ["cough", "OBSERVATION", 112, 117], ["marked", "OBSERVATION_MODIFIER", 123, 129], ["hypoxia", "OBSERVATION", 130, 137], ["consolidation", "OBSERVATION", 145, 158], ["marked", "OBSERVATION_MODIFIER", 165, 171], ["left middle zone", "ANATOMY", 179, 195], ["due to", "UNCERTAINTY", 197, 203], ["P.", "OBSERVATION_MODIFIER", 204, 206], ["aeruginosa", "OBSERVATION_MODIFIER", 207, 217], ["pneumonia", "OBSERVATION", 218, 227], ["distress", "OBSERVATION", 241, 249], ["ARDS", "OBSERVATION", 260, 264]]], ["As a consequence, unless nasopharyngeal aspirate studies identify a respiratory viral infection, early FOB with BAL and, if possible, transbron chial biopsy should be attempted.", [["nasopharyngeal aspirate", "ANATOMY", 25, 48], ["BAL", "ANATOMY", 112, 115], ["respiratory viral infection", "DISEASE", 68, 95], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 25, 48], ["BAL", "ORGANISM_SUBSTANCE", 112, 115], ["nasopharyngeal aspirate studies", "TEST", 25, 56], ["a respiratory viral infection", "PROBLEM", 66, 95], ["BAL", "TEST", 112, 115], ["transbron chial biopsy", "TEST", 134, 156], ["respiratory", "ANATOMY", 68, 79], ["viral infection", "OBSERVATION", 80, 95]]], ["Often, however, these patients are markedly hypoxic, increasing the risk associated with the procedure.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["markedly hypoxic", "PROBLEM", 35, 51], ["the procedure", "TREATMENT", 89, 102], ["markedly", "OBSERVATION_MODIFIER", 35, 43], ["hypoxic", "OBSERVATION", 44, 51]]], ["Negative results on FOB do not exclude infective causes, and a decision then needs to be taken about empirical treatment versus VATS lung biopsy.", [["lung", "ANATOMY", 133, 137], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 133, 144], ["FOB", "TEST", 20, 23], ["infective causes", "PROBLEM", 39, 55], ["empirical treatment", "TREATMENT", 101, 120], ["VATS lung biopsy", "TEST", 128, 144], ["lung", "ANATOMY", 133, 137], ["biopsy", "OBSERVATION", 138, 144]]], ["CTguided biopsy for investigation of diffuse lung disease carries a high risk of complications coupled with low diagnostic yield and therefore is not appropriate in this setting.INVESTIGATION OF TREE-IN-BUD CHANGESTreeinbud changes (Figures 28-5 and 28-6) suggest small airway pathology, which in immunocompromised patients isINVESTIGATION OF DIFFUSE GROUND GLASS INFILTRATIONThe differential diagnosis for ground glass infiltrates and cen trilobular nodules (Figures 28-3 and 28-4) is wide in scope and includes CMV infection, viral pneumonias, PCP, extensive bacterial infection, and noninfective causes such as acute widespread bilateral ground glass infiltration in a hematopoietic stem cell transplant recipient.", [["lung", "ANATOMY", 45, 49], ["airway", "ANATOMY", 270, 276], ["cen trilobular nodules", "ANATOMY", 436, 458], ["hematopoietic stem cell", "ANATOMY", 672, 695], ["lung disease", "DISEASE", 45, 57], ["CMV infection", "DISEASE", 513, 526], ["viral pneumonias", "DISEASE", 528, 544], ["PCP", "DISEASE", 546, 549], ["bacterial infection", "DISEASE", 561, 580], ["lung", "ORGAN", 45, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 270, 276], ["patients", "ORGANISM", 315, 323], ["cen trilobular nodules", "CANCER", 436, 458], ["CMV", "ORGANISM", 513, 516], ["hematopoietic stem cell", "CELL", 672, 695], ["patients", "SPECIES", 315, 323], ["CMV", "SPECIES", 513, 516], ["CTguided biopsy", "TEST", 0, 15], ["diffuse lung disease", "PROBLEM", 37, 57], ["complications", "PROBLEM", 81, 94], ["TREE", "TEST", 195, 199], ["Figures", "TEST", 233, 240], ["small airway pathology", "PROBLEM", 264, 286], ["DIFFUSE GROUND GLASS INFILTRATION", "PROBLEM", 343, 376], ["ground glass infiltrates", "PROBLEM", 407, 431], ["cen trilobular nodules", "PROBLEM", 436, 458], ["Figures", "TEST", 460, 467], ["CMV infection", "PROBLEM", 513, 526], ["viral pneumonias", "PROBLEM", 528, 544], ["PCP", "PROBLEM", 546, 549], ["extensive bacterial infection", "PROBLEM", 551, 580], ["noninfective causes", "PROBLEM", 586, 605], ["acute widespread bilateral ground glass infiltration", "PROBLEM", 614, 666], ["a hematopoietic stem cell transplant recipient", "TREATMENT", 670, 716], ["diffuse", "OBSERVATION_MODIFIER", 37, 44], ["lung", "ANATOMY", 45, 49], ["disease", "OBSERVATION", 50, 57], ["TREE", "ANATOMY_MODIFIER", 195, 199], ["small", "OBSERVATION_MODIFIER", 264, 269], ["airway", "ANATOMY", 270, 276], ["pathology", "OBSERVATION", 277, 286], ["DIFFUSE", "OBSERVATION_MODIFIER", 343, 350], ["GROUND GLASS INFILTRATION", "OBSERVATION", 351, 376], ["differential diagnosis for", "UNCERTAINTY", 380, 406], ["ground glass infiltrates", "OBSERVATION", 407, 431], ["trilobular", "OBSERVATION_MODIFIER", 440, 450], ["nodules", "OBSERVATION", 451, 458], ["CMV infection", "OBSERVATION", 513, 526], ["viral", "OBSERVATION_MODIFIER", 528, 533], ["pneumonias", "OBSERVATION", 534, 544], ["extensive", "OBSERVATION_MODIFIER", 551, 560], ["bacterial", "OBSERVATION_MODIFIER", 561, 570], ["infection", "OBSERVATION", 571, 580], ["acute", "OBSERVATION_MODIFIER", 614, 619], ["widespread", "OBSERVATION_MODIFIER", 620, 630], ["bilateral", "ANATOMY_MODIFIER", 631, 640], ["ground glass infiltration", "OBSERVATION", 641, 666], ["hematopoietic stem cell transplant", "OBSERVATION", 672, 706], ["recipient", "OBSERVATION", 707, 716]]], ["The differential diagnosis for this imaging appearance is broad in scope, including cytomegalovirus pneumonia, Pneumocystis pneumonia, drug reactions, and idiopathic pneumonia syndrome, and early invasive investigation typically is required even though with such widespread lung disease the patient is likely to have significant hypoxia. likely to be caused by respiratory virus infection, Chlamydia pneumoniae, Mycoplasma pneumoniae, or, especially if the changes are focal and associated with nodular changes, Aspergillus tracheobronchitis.", [["lung", "ANATOMY", 274, 278], ["nodular", "ANATOMY", 495, 502], ["cytomegalovirus pneumonia", "DISEASE", 84, 109], ["Pneumocystis pneumonia", "DISEASE", 111, 133], ["drug reactions", "DISEASE", 135, 149], ["idiopathic pneumonia syndrome", "DISEASE", 155, 184], ["lung disease", "DISEASE", 274, 286], ["hypoxia", "DISEASE", 329, 336], ["respiratory virus infection", "DISEASE", 361, 388], ["Chlamydia pneumoniae", "DISEASE", 390, 410], ["Mycoplasma pneumoniae", "DISEASE", 412, 433], ["Aspergillus tracheobronchitis", "DISEASE", 512, 541], ["cytomegalovirus", "ORGANISM", 84, 99], ["lung", "ORGAN", 274, 278], ["patient", "ORGANISM", 291, 298], ["respiratory virus", "ORGANISM", 361, 378], ["Chlamydia pneumoniae", "ORGANISM", 390, 410], ["Mycoplasma pneumoniae", "ORGANISM", 412, 433], ["patient", "SPECIES", 291, 298], ["Chlamydia pneumoniae", "SPECIES", 390, 410], ["Mycoplasma pneumoniae", "SPECIES", 412, 433], ["respiratory virus", "SPECIES", 361, 378], ["Chlamydia pneumoniae", "SPECIES", 390, 410], ["Mycoplasma pneumoniae", "SPECIES", 412, 433], ["Aspergillus tracheobronchitis", "SPECIES", 512, 541], ["this imaging appearance", "PROBLEM", 31, 54], ["cytomegalovirus pneumonia", "PROBLEM", 84, 109], ["Pneumocystis pneumonia", "PROBLEM", 111, 133], ["drug reactions", "PROBLEM", 135, 149], ["idiopathic pneumonia syndrome", "PROBLEM", 155, 184], ["early invasive investigation", "TEST", 190, 218], ["such widespread lung disease", "PROBLEM", 258, 286], ["significant hypoxia", "PROBLEM", 317, 336], ["respiratory virus infection", "PROBLEM", 361, 388], ["Chlamydia pneumoniae", "PROBLEM", 390, 410], ["Mycoplasma pneumoniae", "PROBLEM", 412, 433], ["nodular changes", "PROBLEM", 495, 510], ["Aspergillus tracheobronchitis", "PROBLEM", 512, 541], ["broad", "OBSERVATION_MODIFIER", 58, 63], ["cytomegalovirus", "OBSERVATION_MODIFIER", 84, 99], ["pneumonia", "OBSERVATION", 100, 109], ["Pneumocystis", "OBSERVATION_MODIFIER", 111, 123], ["pneumonia", "OBSERVATION", 124, 133], ["idiopathic", "OBSERVATION_MODIFIER", 155, 165], ["pneumonia", "OBSERVATION", 166, 175], ["invasive", "OBSERVATION_MODIFIER", 196, 204], ["widespread", "OBSERVATION_MODIFIER", 263, 273], ["lung", "ANATOMY", 274, 278], ["disease", "OBSERVATION", 279, 286], ["significant", "OBSERVATION_MODIFIER", 317, 328], ["hypoxia", "OBSERVATION", 329, 336], ["respiratory virus", "OBSERVATION", 361, 378], ["Mycoplasma pneumoniae", "OBSERVATION", 412, 433], ["focal", "OBSERVATION_MODIFIER", 469, 474], ["nodular", "OBSERVATION", 495, 502], ["Aspergillus tracheobronchitis", "OBSERVATION", 512, 541]]], ["Subacute or chronic changes also could reflect bacterial infection in bronchiectasis or nontuberculous mycobacteria infection.", [["infection", "DISEASE", 57, 66], ["bronchiectasis", "DISEASE", 70, 84], ["nontuberculous mycobacteria infection", "DISEASE", 88, 125], ["Subacute or chronic changes", "PROBLEM", 0, 27], ["bacterial infection", "PROBLEM", 47, 66], ["bronchiectasis", "PROBLEM", 70, 84], ["nontuberculous mycobacteria infection", "PROBLEM", 88, 125], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["could reflect", "UNCERTAINTY", 33, 46], ["bacterial", "OBSERVATION_MODIFIER", 47, 56], ["infection", "OBSERVATION", 57, 66], ["bronchiectasis", "OBSERVATION", 70, 84], ["nontuberculous", "OBSERVATION_MODIFIER", 88, 102], ["mycobacteria infection", "OBSERVATION", 103, 125]]], ["If results of nasopharyngeal aspirate studies are negative, then early FOB for BAL and bronchial biopsy of macroscopically inflamed bronchial mucosa should be performed.", [["nasopharyngeal aspirate", "ANATOMY", 14, 37], ["BAL", "ANATOMY", 79, 82], ["bronchial", "ANATOMY", 87, 96], ["bronchial mucosa", "ANATOMY", 132, 148], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 14, 37], ["bronchial biopsy", "MULTI-TISSUE_STRUCTURE", 87, 103], ["bronchial mucosa", "MULTI-TISSUE_STRUCTURE", 132, 148], ["nasopharyngeal aspirate studies", "TEST", 14, 45], ["early FOB", "TEST", 65, 74], ["BAL", "TEST", 79, 82], ["bronchial biopsy", "TEST", 87, 103], ["macroscopically inflamed bronchial mucosa", "PROBLEM", 107, 148], ["nasopharyngeal", "ANATOMY", 14, 28], ["bronchial", "ANATOMY", 87, 96], ["bronchial mucosa", "ANATOMY", 132, 148]]], ["Aspergillus tracheobronchitis usually is obvious at FOB and is readily confirmed by culture and cytologic examina tion of bronchial washings and by bronchial biopsy.", [["bronchial", "ANATOMY", 122, 131], ["bronchial", "ANATOMY", 148, 157], ["Aspergillus tracheobronchitis", "DISEASE", 0, 29], ["Aspergillus tracheobronchitis", "ORGANISM", 0, 29], ["bronchial biopsy", "MULTI-TISSUE_STRUCTURE", 148, 164], ["Aspergillus tracheobronchitis", "SPECIES", 0, 29], ["Aspergillus tracheobronchitis", "PROBLEM", 0, 29], ["culture", "TEST", 84, 91], ["cytologic examina", "TEST", 96, 113], ["bronchial washings", "TEST", 122, 140], ["bronchial biopsy", "TEST", 148, 164], ["tracheobronchitis", "OBSERVATION", 12, 29], ["bronchial", "ANATOMY", 122, 131], ["washings", "OBSERVATION", 132, 140], ["bronchial", "ANATOMY", 148, 157], ["biopsy", "OBSERVATION", 158, 164]]], ["Infections due to respiratory viruses, C. pneumoniae, and M. pneumoniae often are difficult to diagnose but usually are either selflimiting illnesses or readily controlled with macrolide therapy.INVESTIGATION OF PULMONARY NODULESConsiderations in the differential diagnosis for pulmonary nodules include infection with Aspergillus (or other invasive fila mentous fungi), Nocardia, or mycobacteria (Figure 28-7) .", [["pulmonary nodules", "ANATOMY", 278, 295], ["Infections", "DISEASE", 0, 10], ["respiratory viruses", "DISEASE", 18, 37], ["C. pneumoniae", "DISEASE", 39, 52], ["M. pneumoniae", "DISEASE", 58, 71], ["macrolide", "CHEMICAL", 177, 186], ["pulmonary nodules", "DISEASE", 278, 295], ["infection", "DISEASE", 304, 313], ["Nocardia, or mycobacteria", "DISEASE", 371, 396], ["macrolide", "CHEMICAL", 177, 186], ["C. pneumoniae", "ORGANISM", 39, 52], ["M. pneumoniae", "ORGANISM", 58, 71], ["macrolide", "SIMPLE_CHEMICAL", 177, 186], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 278, 295], ["C. pneumoniae", "SPECIES", 39, 52], ["M. pneumoniae", "SPECIES", 58, 71], ["C. pneumoniae", "SPECIES", 39, 52], ["M. pneumoniae", "SPECIES", 58, 71], ["Infections", "PROBLEM", 0, 10], ["respiratory viruses", "PROBLEM", 18, 37], ["C. pneumoniae", "PROBLEM", 39, 52], ["M. pneumoniae", "PROBLEM", 58, 71], ["selflimiting illnesses", "PROBLEM", 127, 149], ["macrolide therapy", "TREATMENT", 177, 194], ["pulmonary nodules", "PROBLEM", 278, 295], ["infection", "PROBLEM", 304, 313], ["Aspergillus", "PROBLEM", 319, 330], ["other invasive fila mentous fungi", "PROBLEM", 335, 368], ["Nocardia", "PROBLEM", 371, 379], ["mycobacteria", "PROBLEM", 384, 396], ["respiratory viruses", "OBSERVATION", 18, 37], ["pneumoniae", "OBSERVATION", 42, 52], ["pneumoniae", "OBSERVATION", 61, 71], ["PULMONARY", "ANATOMY", 212, 221], ["NODULESConsiderations", "OBSERVATION", 222, 243], ["pulmonary", "ANATOMY", 278, 287], ["nodules", "OBSERVATION", 288, 295], ["infection", "OBSERVATION", 304, 313], ["Aspergillus", "OBSERVATION", 319, 330], ["invasive", "OBSERVATION_MODIFIER", 341, 349], ["mycobacteria", "OBSERVATION", 384, 396]]], ["Aspergillus and Nocardia tend to cause a small number of nodules, whereas mycobacteria also can cause large numbers of small nodules.", [["nodules", "ANATOMY", 57, 64], ["nodules", "ANATOMY", 125, 132], ["Nocardia", "DISEASE", 16, 24], ["Aspergillus", "ORGANISM", 0, 11], ["nodules", "CANCER", 57, 64], ["nodules", "CANCER", 125, 132], ["Aspergillus", "PROBLEM", 0, 11], ["Nocardia", "PROBLEM", 16, 24], ["a small number of nodules", "PROBLEM", 39, 64], ["mycobacteria", "PROBLEM", 74, 86], ["small nodules", "PROBLEM", 119, 132], ["Nocardia", "OBSERVATION", 16, 24], ["small", "OBSERVATION_MODIFIER", 41, 46], ["number", "OBSERVATION_MODIFIER", 47, 53], ["nodules", "OBSERVATION", 57, 64], ["mycobacteria", "OBSERVATION", 74, 86], ["large", "OBSERVATION_MODIFIER", 102, 107], ["numbers", "OBSERVATION_MODIFIER", 108, 115], ["small", "OBSERVATION_MODIFIER", 119, 124], ["nodules", "OBSERVATION", 125, 132]]], ["In addition, bloodborne spread of bacteria or Candida from infected indwelling devices can cause a variable number (often numerous) of pulmonary nodules.", [["pulmonary nodules", "ANATOMY", 135, 152], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 135, 152], ["bacteria", "PROBLEM", 34, 42], ["Candida", "PROBLEM", 46, 53], ["infected indwelling devices", "TREATMENT", 59, 86], ["pulmonary nodules", "PROBLEM", 135, 152], ["bloodborne", "OBSERVATION_MODIFIER", 13, 23], ["spread", "OBSERVATION_MODIFIER", 24, 30], ["bacteria", "OBSERVATION_MODIFIER", 34, 42], ["Candida", "OBSERVATION_MODIFIER", 46, 53], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["indwelling devices", "OBSERVATION", 68, 86], ["variable", "OBSERVATION_MODIFIER", 99, 107], ["number", "OBSERVATION_MODIFIER", 108, 114], ["pulmonary", "ANATOMY", 135, 144], ["nodules", "OBSERVATION", 145, 152]]], ["Serum testing for fungal antigens (galactomannan or \u03b2Dglucan) should be per formed.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["fungal antigens", "GENE_OR_GENE_PRODUCT", 18, 33], ["galactomannan", "SIMPLE_CHEMICAL", 35, 48], ["\u03b2Dglucan", "SIMPLE_CHEMICAL", 52, 60], ["fungal antigens", "PROTEIN", 18, 33], ["galactomannan", "PROTEIN", 35, 48], ["\u03b2Dglucan", "PROTEIN", 52, 60], ["Serum testing", "TEST", 0, 13], ["fungal antigens", "TEST", 18, 33], ["galactomannan", "TEST", 35, 48], ["\u03b2Dglucan", "TREATMENT", 52, 60]]], ["Nodules caused by pyogenic bacterial and viral pneu monia tend to be associated with other radiographic changes findings such as ground glass infiltrates or consolidation.", [["Nodules", "ANATOMY", 0, 7], ["Nodules", "DISEASE", 0, 7], ["Nodules", "PROBLEM", 0, 7], ["pyogenic bacterial and viral pneu monia", "PROBLEM", 18, 57], ["other radiographic changes findings", "PROBLEM", 85, 120], ["ground glass infiltrates", "PROBLEM", 129, 153], ["consolidation", "PROBLEM", 157, 170], ["pyogenic", "OBSERVATION_MODIFIER", 18, 26], ["bacterial", "OBSERVATION_MODIFIER", 27, 36], ["viral pneu monia", "OBSERVATION", 41, 57], ["ground glass infiltrates", "OBSERVATION", 129, 153], ["consolidation", "OBSERVATION", 157, 170]]], ["The about 40% to 50% of infective episodes.", [["infective episodes", "PROBLEM", 24, 42], ["infective", "OBSERVATION", 24, 33]]], ["The main risk factor is neutropenia, but cellmediated immune defects and func tional defects in phagocyte responses due to cytotoxic or immunosuppressive therapy also will markedly increase the risk for development of pneumonia.", [["phagocyte", "ANATOMY", 96, 105], ["neutropenia", "DISEASE", 24, 35], ["pneumonia", "DISEASE", 218, 227], ["phagocyte", "CELL", 96, 105], ["neutropenia", "PROBLEM", 24, 35], ["cellmediated immune defects", "PROBLEM", 41, 68], ["func tional defects in phagocyte responses", "PROBLEM", 73, 115], ["cytotoxic", "TREATMENT", 123, 132], ["immunosuppressive therapy", "TREATMENT", 136, 161], ["pneumonia", "PROBLEM", 218, 227], ["main", "OBSERVATION_MODIFIER", 4, 8], ["neutropenia", "OBSERVATION", 24, 35], ["immune defects", "OBSERVATION", 54, 68], ["tional defects", "OBSERVATION", 78, 92], ["phagocyte responses", "OBSERVATION", 96, 115], ["pneumonia", "OBSERVATION", 218, 227]]], ["Antibody deficiencies asso ciated with lymphoproliferative disorders, myeloma, and HSCT predispose affected patients to development of pneumonia with encapsulated organisms such as S. pneumoniae and Haemophilus influenzae.", [["myeloma", "ANATOMY", 70, 77], ["lymphoproliferative disorders", "DISEASE", 39, 68], ["myeloma", "DISEASE", 70, 77], ["HSCT", "DISEASE", 83, 87], ["pneumonia", "DISEASE", 135, 144], ["Haemophilus influenzae", "DISEASE", 199, 221], ["myeloma", "CANCER", 70, 77], ["patients", "ORGANISM", 108, 116], ["S. pneumoniae", "ORGANISM", 181, 194], ["Haemophilus influenzae", "ORGANISM", 199, 221], ["patients", "SPECIES", 108, 116], ["S. pneumoniae", "SPECIES", 181, 194], ["Haemophilus influenzae", "SPECIES", 199, 221], ["S. pneumoniae", "SPECIES", 181, 194], ["Haemophilus influenzae", "SPECIES", 199, 221], ["Antibody deficiencies", "PROBLEM", 0, 21], ["lymphoproliferative disorders", "PROBLEM", 39, 68], ["myeloma", "PROBLEM", 70, 77], ["pneumonia", "PROBLEM", 135, 144], ["encapsulated organisms", "PROBLEM", 150, 172], ["S. pneumoniae", "PROBLEM", 181, 194], ["Haemophilus influenzae", "PROBLEM", 199, 221], ["lymphoproliferative disorders", "OBSERVATION", 39, 68], ["myeloma", "OBSERVATION", 70, 77], ["pneumonia", "OBSERVATION", 135, 144], ["pneumoniae", "OBSERVATION", 184, 194], ["Haemophilus influenzae", "OBSERVATION", 199, 221]]], ["Many cases of bacterial pneumonia are nosocomial infections in patients who have been hospitalized for long periods and who previously have been treated with antibiotics so that the normal oropharyngeal flora has been replaced mainly by gramnegative bacteria.", [["oropharyngeal flora", "ANATOMY", 189, 208], ["bacterial pneumonia", "DISEASE", 14, 33], ["nosocomial infections", "DISEASE", 38, 59], ["patients", "ORGANISM", 63, 71], ["oropharyngeal flora", "PATHOLOGICAL_FORMATION", 189, 208], ["patients", "SPECIES", 63, 71], ["bacterial pneumonia", "PROBLEM", 14, 33], ["nosocomial infections", "PROBLEM", 38, 59], ["antibiotics", "TREATMENT", 158, 169], ["the normal oropharyngeal flora", "PROBLEM", 178, 208], ["gramnegative bacteria", "PROBLEM", 237, 258], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["pneumonia", "OBSERVATION", 24, 33], ["nosocomial", "OBSERVATION_MODIFIER", 38, 48], ["infections", "OBSERVATION", 49, 59], ["oropharyngeal flora", "ANATOMY", 189, 208]]], ["As a consequence, the range of potential organisms causing bacterial pneumonia is very different from that seen in communityacquired pneu monia, with a high frequency of resistant organisms such as P. aeruginosa and MRSA (see Table 281 ).Clinical Features and DiagnosisBacterial pneumonia often manifests with a clinical picture similar to that seen in immunocompetent patients, with new onset fever, cough, chest and radiologic signs of lobar consolida tion, and a rapid rise in the level of inflammatory markers such as CRP.", [["chest", "ANATOMY", 408, 413], ["lobar", "ANATOMY", 438, 443], ["pneumonia", "DISEASE", 69, 78], ["P. aeruginosa and MRSA", "DISEASE", 198, 220], ["DiagnosisBacterial pneumonia", "DISEASE", 260, 288], ["fever", "DISEASE", 394, 399], ["cough", "DISEASE", 401, 406], ["lobar consolida tion", "DISEASE", 438, 458], ["pneu monia", "ORGANISM", 133, 143], ["P. aeruginosa", "ORGANISM", 198, 211], ["patients", "ORGANISM", 369, 377], ["chest", "ORGANISM_SUBDIVISION", 408, 413], ["CRP", "GENE_OR_GENE_PRODUCT", 522, 525], ["inflammatory markers", "PROTEIN", 493, 513], ["CRP", "PROTEIN", 522, 525], ["P. aeruginosa", "SPECIES", 198, 211], ["MRSA", "SPECIES", 216, 220], ["patients", "SPECIES", 369, 377], ["P. aeruginosa", "SPECIES", 198, 211], ["MRSA", "SPECIES", 216, 220], ["potential organisms", "PROBLEM", 31, 50], ["bacterial pneumonia", "PROBLEM", 59, 78], ["resistant organisms", "PROBLEM", 170, 189], ["P. aeruginosa", "PROBLEM", 198, 211], ["MRSA", "PROBLEM", 216, 220], ["DiagnosisBacterial pneumonia", "PROBLEM", 260, 288], ["a clinical picture", "PROBLEM", 310, 328], ["new onset fever", "PROBLEM", 384, 399], ["cough", "PROBLEM", 401, 406], ["chest and radiologic signs of lobar consolida tion", "PROBLEM", 408, 458], ["a rapid rise", "PROBLEM", 464, 476], ["inflammatory markers", "PROBLEM", 493, 513], ["CRP", "TEST", 522, 525], ["bacterial", "OBSERVATION_MODIFIER", 59, 68], ["pneumonia", "OBSERVATION", 69, 78], ["DiagnosisBacterial", "OBSERVATION_MODIFIER", 260, 278], ["pneumonia", "OBSERVATION", 279, 288], ["new", "OBSERVATION_MODIFIER", 384, 387], ["onset", "OBSERVATION_MODIFIER", 388, 393], ["fever", "OBSERVATION", 394, 399], ["chest", "ANATOMY", 408, 413], ["lobar consolida", "OBSERVATION", 438, 453], ["rapid", "OBSERVATION_MODIFIER", 466, 471], ["rise", "OBSERVATION_MODIFIER", 472, 476], ["inflammatory", "OBSERVATION", 493, 505]]], ["However, a more insidious or diffuse presentation that is more difficult to differentiate from viral or fungal infection is not uncommon.", [["viral or fungal infection", "DISEASE", 95, 120], ["a more insidious or diffuse presentation", "PROBLEM", 9, 49], ["viral or fungal infection", "PROBLEM", 95, 120], ["insidious", "OBSERVATION_MODIFIER", 16, 25], ["diffuse", "OBSERVATION_MODIFIER", 29, 36], ["viral", "OBSERVATION", 95, 100], ["fungal", "OBSERVATION_MODIFIER", 104, 110], ["infection", "OBSERVATION", 111, 120]]], ["CT scans showing dense focal consolidation with a lobar distribution are helpful in differentiating bacterial from fungal or viral pneumonia (Figure 28-8) , and blood cul tures will be positive in about 20% of cases.", [["lobar", "ANATOMY", 50, 55], ["blood", "ANATOMY", 161, 166], ["viral pneumonia", "DISEASE", 125, 140], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["CT scans", "TEST", 0, 8], ["dense focal consolidation", "PROBLEM", 17, 42], ["a lobar distribution", "PROBLEM", 48, 68], ["bacterial from fungal or viral pneumonia", "PROBLEM", 100, 140], ["Figure", "TEST", 142, 148], ["blood cul tures", "TEST", 161, 176], ["dense", "OBSERVATION_MODIFIER", 17, 22], ["focal", "OBSERVATION_MODIFIER", 23, 28], ["consolidation", "OBSERVATION", 29, 42], ["lobar distribution", "OBSERVATION", 50, 68], ["bacterial", "OBSERVATION_MODIFIER", 100, 109], ["fungal", "OBSERVATION_MODIFIER", 115, 121], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["pneumonia", "OBSERVATION", 131, 140]]], ["Antigen testing of the urine may identify Legionella pneumophila or S. pneumoniae infections.", [["urine", "ANATOMY", 23, 28], ["Legionella pneumophila", "DISEASE", 42, 64], ["S. pneumoniae infections", "DISEASE", 68, 92], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["Legionella pneumophila", "ORGANISM", 42, 64], ["S. pneumoniae", "ORGANISM", 68, 81], ["Legionella pneumophila", "SPECIES", 42, 64], ["S. pneumoniae", "SPECIES", 68, 81], ["Legionella pneumophila", "SPECIES", 42, 64], ["S. pneumoniae", "SPECIES", 68, 81], ["Antigen testing", "TEST", 0, 15], ["the urine", "TEST", 19, 28], ["Legionella pneumophila", "PROBLEM", 42, 64], ["S. pneumoniae infections", "PROBLEM", 68, 92], ["Legionella pneumophila", "OBSERVATION", 42, 64], ["pneumoniae", "OBSERVATION_MODIFIER", 71, 81], ["infections", "OBSERVATION", 82, 92]]], ["Patients with an atypical clinical presentation or those who do not respond to first or secondline antibiotics should have FOB and BAL, which has a reasonably high diag nostic yield for bacterial pneumonia.", [["BAL", "ANATOMY", 131, 134], ["pneumonia", "DISEASE", 196, 205], ["Patients", "ORGANISM", 0, 8], ["BAL", "ORGANISM_SUBSTANCE", 131, 134], ["Patients", "SPECIES", 0, 8], ["secondline antibiotics", "TREATMENT", 88, 110], ["FOB and BAL", "TEST", 123, 134], ["bacterial pneumonia", "PROBLEM", 186, 205], ["atypical", "OBSERVATION_MODIFIER", 17, 25], ["bacterial", "OBSERVATION_MODIFIER", 186, 195], ["pneumonia", "OBSERVATION", 196, 205]]], ["Protected specimen brush procedures probably add little information over and above that obtained with directed BAL.", [["specimen brush", "ANATOMY", 10, 24], ["specimen brush", "MULTI-TISSUE_STRUCTURE", 10, 24], ["Protected specimen brush procedures", "TREATMENT", 0, 35]]], ["Histologic examination is unlikely to reveal specific features, and lung biopsy is mainly used to exclude other causes of lung infiltrates.ManagementOxygen therapy to maintain a normal PaO 2 is essential and may require continuous positive airway pressure (CPAP) support.", [["lung", "ANATOMY", 68, 72], ["lung", "ANATOMY", 122, 126], ["airway", "ANATOMY", 240, 246], ["ManagementOxygen", "CHEMICAL", 139, 155], ["PaO 2", "CHEMICAL", 185, 190], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 68, 79], ["lung", "ORGAN", 122, 126], ["ManagementOxygen", "SIMPLE_CHEMICAL", 139, 155], ["PaO 2", "GENE_OR_GENE_PRODUCT", 185, 190], ["airway", "MULTI-TISSUE_STRUCTURE", 240, 246], ["Histologic examination", "TEST", 0, 22], ["lung biopsy", "TEST", 68, 79], ["lung infiltrates", "PROBLEM", 122, 138], ["ManagementOxygen therapy", "TREATMENT", 139, 163], ["continuous positive airway pressure (CPAP) support", "TREATMENT", 220, 270], ["lung", "ANATOMY", 68, 72], ["biopsy", "OBSERVATION", 73, 79], ["lung", "ANATOMY", 122, 126], ["infiltrates", "OBSERVATION", 127, 138]]], ["Intubation may be necessary if the patient's underlying disease other major causes of nodules are underlying malignant disease and lymphoproliferative disorders secondary to prolonged immunosuppression.", [["nodules", "ANATOMY", 86, 93], ["malignant disease", "ANATOMY", 109, 126], ["malignant disease", "DISEASE", 109, 126], ["lymphoproliferative disorders", "DISEASE", 131, 160], ["patient", "ORGANISM", 35, 42], ["nodules", "CANCER", 86, 93], ["malignant disease", "CANCER", 109, 126], ["patient", "SPECIES", 35, 42], ["Intubation", "TREATMENT", 0, 10], ["the patient's underlying disease", "PROBLEM", 31, 63], ["nodules", "PROBLEM", 86, 93], ["underlying malignant disease", "PROBLEM", 98, 126], ["lymphoproliferative disorders", "PROBLEM", 131, 160], ["prolonged immunosuppression", "TREATMENT", 174, 201], ["nodules", "OBSERVATION", 86, 93], ["malignant", "OBSERVATION_MODIFIER", 109, 118], ["lymphoproliferative", "OBSERVATION", 131, 150], ["prolonged", "OBSERVATION_MODIFIER", 174, 183], ["immunosuppression", "OBSERVATION", 184, 201]]], ["In the absence of CT signs suggestive of invasive filamentous fungal infection (the halo and crescent signs), nodules in patients with line infections or a positive blood culture may be treated empirically as for metastatic infection.", [["nodules", "ANATOMY", 110, 117], ["blood culture", "ANATOMY", 165, 178], ["fungal infection", "DISEASE", 62, 78], ["infections", "DISEASE", 140, 150], ["infection", "DISEASE", 224, 233], ["nodules", "PATHOLOGICAL_FORMATION", 110, 117], ["patients", "ORGANISM", 121, 129], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["patients", "SPECIES", 121, 129], ["CT signs", "TEST", 18, 26], ["invasive filamentous fungal infection", "PROBLEM", 41, 78], ["the halo and crescent signs)", "PROBLEM", 80, 108], ["nodules", "PROBLEM", 110, 117], ["line infections", "PROBLEM", 135, 150], ["a positive blood culture", "PROBLEM", 154, 178], ["metastatic infection", "PROBLEM", 213, 233], ["suggestive of", "UNCERTAINTY", 27, 40], ["invasive", "OBSERVATION_MODIFIER", 41, 49], ["filamentous", "OBSERVATION_MODIFIER", 50, 61], ["fungal", "OBSERVATION_MODIFIER", 62, 68], ["infection", "OBSERVATION", 69, 78], ["crescent", "OBSERVATION_MODIFIER", 93, 101], ["nodules", "OBSERVATION", 110, 117], ["line", "OBSERVATION_MODIFIER", 135, 139], ["infections", "OBSERVATION", 140, 150], ["metastatic", "OBSERVATION_MODIFIER", 213, 223], ["infection", "OBSERVATION", 224, 233]]], ["For a majority of other patients with lung nodules, FOB with BAL is necessary, although for patients at high risk for infection with invasive filamentous fungi, if CT changes suggestive of Aspergillus infection are present, then empirical antifungal therapy is a reasonable alternative strategy, especially if the result of fungal antigen testing is positive.", [["lung nodules", "ANATOMY", 38, 50], ["BAL", "ANATOMY", 61, 64], ["infection", "DISEASE", 118, 127], ["Aspergillus infection", "DISEASE", 189, 210], ["patients", "ORGANISM", 24, 32], ["lung nodules", "CANCER", 38, 50], ["FOB", "MULTI-TISSUE_STRUCTURE", 52, 55], ["patients", "ORGANISM", 92, 100], ["fungal antigen", "GENE_OR_GENE_PRODUCT", 324, 338], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 92, 100], ["lung nodules", "PROBLEM", 38, 50], ["FOB with BAL", "TEST", 52, 64], ["infection", "PROBLEM", 118, 127], ["invasive filamentous fungi", "PROBLEM", 133, 159], ["CT changes", "TEST", 164, 174], ["Aspergillus infection", "PROBLEM", 189, 210], ["empirical antifungal therapy", "TREATMENT", 229, 257], ["fungal antigen testing", "TEST", 324, 346], ["lung", "ANATOMY", 38, 42], ["nodules", "OBSERVATION", 43, 50], ["infection", "OBSERVATION", 118, 127], ["suggestive of", "UNCERTAINTY", 175, 188], ["Aspergillus infection", "OBSERVATION", 189, 210]]], ["If FOB findings are unhelp ful, the patient should progress to percutaneous CTguided or VATS lung biopsy, because infections due to fungi, Nocardia, or mycobacteria are accompanied by specific histopathologic changes, and biopsy frequently is diagnostic.BRONCHOSCOPYAlthough many immunocompromised patients with pneumo nia are hypoxic and have low platelet counts and/or abnormal clotting, FOB generally is safe and has a diagnostic yield of 30 to 50%.", [["percutaneous", "ANATOMY", 63, 75], ["lung", "ANATOMY", 93, 97], ["platelet", "ANATOMY", 348, 356], ["infections", "DISEASE", 114, 124], ["Nocardia, or mycobacteria", "DISEASE", 139, 164], ["abnormal clotting", "DISEASE", 371, 388], ["patient", "ORGANISM", 36, 43], ["lung", "ORGAN", 93, 97], ["patients", "ORGANISM", 298, 306], ["platelet", "CELL", 348, 356], ["patient", "SPECIES", 36, 43], ["patients", "SPECIES", 298, 306], ["percutaneous CTguided or VATS lung biopsy", "TEST", 63, 104], ["infections", "PROBLEM", 114, 124], ["fungi", "PROBLEM", 132, 137], ["Nocardia", "PROBLEM", 139, 147], ["mycobacteria", "PROBLEM", 152, 164], ["specific histopathologic changes", "PROBLEM", 184, 216], ["biopsy", "TEST", 222, 228], ["pneumo nia", "PROBLEM", 312, 322], ["hypoxic", "PROBLEM", 327, 334], ["low platelet counts", "PROBLEM", 344, 363], ["abnormal clotting", "PROBLEM", 371, 388], ["lung", "ANATOMY", 93, 97], ["biopsy", "OBSERVATION", 98, 104], ["Nocardia", "OBSERVATION", 139, 147], ["mycobacteria", "OBSERVATION", 152, 164], ["many", "OBSERVATION_MODIFIER", 275, 279], ["immunocompromised", "OBSERVATION", 280, 297], ["pneumo", "OBSERVATION", 312, 318], ["hypoxic", "OBSERVATION_MODIFIER", 327, 334], ["low platelet counts", "OBSERVATION", 344, 363], ["abnormal", "OBSERVATION_MODIFIER", 371, 379], ["clotting", "OBSERVATION", 380, 388]]], ["Exclusion of active infection is necessary to make a diagnosis of IPS after HSCT, so even a negative result can be useful.", [["infection", "DISEASE", 20, 29], ["IPS", "DISEASE", 66, 69], ["active infection", "PROBLEM", 13, 29], ["IPS", "PROBLEM", 66, 69], ["HSCT", "TEST", 76, 80], ["active", "OBSERVATION_MODIFIER", 13, 19], ["infection", "OBSERVATION", 20, 29]]], ["In our own experience, peroral FOB can be performed without significant bleeding in patients with a platelet count of 10,000/mL.", [["platelet", "ANATOMY", 100, 108], ["bleeding", "DISEASE", 72, 80], ["patients", "ORGANISM", 84, 92], ["platelet", "CELL", 100, 108], ["patients", "SPECIES", 84, 92], ["peroral FOB", "TEST", 23, 34], ["significant bleeding", "PROBLEM", 60, 80], ["a platelet count", "TEST", 98, 114], ["bleeding", "OBSERVATION", 72, 80]]], ["BAL should be performed in patients with marked hypoxia or severe tachypnea only after careful consid eration of risk versus benefit, because the procedure commonly reduces PaO 2 by 20 mm Hg and may precipitate the need for intubation and mechanical ventilation.", [["hypoxia", "DISEASE", 48, 55], ["tachypnea", "DISEASE", 66, 75], ["PaO 2", "CHEMICAL", 173, 178], ["Hg", "CHEMICAL", 188, 190], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["patients", "ORGANISM", 27, 35], ["PaO 2", "GENE_OR_GENE_PRODUCT", 173, 178], ["patients", "SPECIES", 27, 35], ["BAL", "TEST", 0, 3], ["marked hypoxia", "PROBLEM", 41, 55], ["severe tachypnea", "PROBLEM", 59, 75], ["the procedure", "TREATMENT", 142, 155], ["PaO", "TEST", 173, 176], ["intubation", "TREATMENT", 224, 234], ["mechanical ventilation", "TREATMENT", 239, 261], ["marked", "OBSERVATION_MODIFIER", 41, 47], ["hypoxia", "OBSERVATION", 48, 55], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["tachypnea", "OBSERVATION", 66, 75], ["mechanical ventilation", "OBSERVATION", 239, 261]]], ["Transbronchial biopsy improves the diagnostic yield of FOB by perhaps 5% to 10% but often is not possible, because the patient needs to be able to tolerate the potential complication of a pneumothorax and have a platelet count above 50,000/mL.General ConsiderationsPneumonia due to bacterial pathogens is the most common lung infection in the immunocompromised patient, causing Figure 28 -8 A, Chest radiograph showing a mass-like consolidation in the right middle lung zone in a patient with acute myeloid leukemia recently treated with chemotherapy and presenting with a high temperature but no respiratory symptoms after 9 days of neutropenia.", [["platelet", "ANATOMY", 212, 220], ["lung", "ANATOMY", 321, 325], ["right middle lung zone", "ANATOMY", 452, 474], ["acute myeloid leukemia", "ANATOMY", 493, 515], ["respiratory", "ANATOMY", 597, 608], ["pneumothorax", "DISEASE", 188, 200], ["Pneumonia", "DISEASE", 265, 274], ["bacterial pathogens", "DISEASE", 282, 301], ["lung infection", "DISEASE", 321, 335], ["acute myeloid leukemia", "DISEASE", 493, 515], ["respiratory symptoms", "DISEASE", 597, 617], ["neutropenia", "DISEASE", 634, 645], ["FOB", "CANCER", 55, 58], ["patient", "ORGANISM", 119, 126], ["platelet", "CELL", 212, 220], ["lung", "ORGAN", 321, 325], ["patient", "ORGANISM", 361, 368], ["lung", "ORGAN", 465, 469], ["patient", "ORGANISM", 480, 487], ["acute myeloid leukemia", "CANCER", 493, 515], ["patient", "SPECIES", 119, 126], ["patient", "SPECIES", 361, 368], ["patient", "SPECIES", 480, 487], ["Transbronchial biopsy", "TEST", 0, 21], ["FOB", "TEST", 55, 58], ["a pneumothorax", "PROBLEM", 186, 200], ["a platelet count", "TEST", 210, 226], ["Pneumonia", "PROBLEM", 265, 274], ["bacterial pathogens", "PROBLEM", 282, 301], ["the most common lung infection", "PROBLEM", 305, 335], ["Chest radiograph", "TEST", 394, 410], ["a mass-like consolidation in the right middle lung zone", "PROBLEM", 419, 474], ["acute myeloid leukemia", "PROBLEM", 493, 515], ["chemotherapy", "TREATMENT", 538, 550], ["a high temperature", "PROBLEM", 571, 589], ["respiratory symptoms", "PROBLEM", 597, 617], ["neutropenia", "PROBLEM", 634, 645], ["not possible", "UNCERTAINTY", 93, 105], ["pneumothorax", "OBSERVATION", 188, 200], ["Pneumonia", "OBSERVATION", 265, 274], ["bacterial", "OBSERVATION_MODIFIER", 282, 291], ["pathogens", "OBSERVATION", 292, 301], ["most common", "OBSERVATION_MODIFIER", 309, 320], ["lung", "ANATOMY", 321, 325], ["infection", "OBSERVATION", 326, 335], ["immunocompromised", "OBSERVATION_MODIFIER", 343, 360], ["Chest", "ANATOMY", 394, 399], ["mass", "OBSERVATION", 421, 425], ["consolidation", "OBSERVATION", 431, 444], ["right", "ANATOMY_MODIFIER", 452, 457], ["middle", "ANATOMY_MODIFIER", 458, 464], ["lung", "ANATOMY", 465, 469], ["zone", "ANATOMY_MODIFIER", 470, 474], ["acute", "OBSERVATION_MODIFIER", 493, 498], ["myeloid leukemia", "OBSERVATION", 499, 515], ["high temperature", "OBSERVATION_MODIFIER", 573, 589], ["no", "UNCERTAINTY", 594, 596], ["respiratory", "ANATOMY", 597, 608]]], ["B, Computed tomography (CT) scan of thorax in the same patient, showing that the shadowing is due to dense consolidation in the right upper lobe, with a smaller area of consolidation in the left upper lobe.", [["thorax", "ANATOMY", 36, 42], ["right upper lobe", "ANATOMY", 128, 144], ["left upper lobe", "ANATOMY", 190, 205], ["thorax", "ORGAN", 36, 42], ["patient", "ORGANISM", 55, 62], ["upper lobe", "ORGANISM_SUBDIVISION", 134, 144], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 195, 205], ["patient", "SPECIES", 55, 62], ["Computed tomography (CT) scan of thorax", "TEST", 3, 42], ["the shadowing", "PROBLEM", 77, 90], ["dense consolidation in the right upper lobe", "PROBLEM", 101, 144], ["consolidation in the left upper lobe", "PROBLEM", 169, 205], ["thorax", "ANATOMY", 36, 42], ["shadowing", "OBSERVATION", 81, 90], ["due to", "UNCERTAINTY", 94, 100], ["dense", "OBSERVATION_MODIFIER", 101, 106], ["consolidation", "OBSERVATION", 107, 120], ["right upper lobe", "ANATOMY", 128, 144], ["smaller", "OBSERVATION_MODIFIER", 153, 160], ["area", "OBSERVATION_MODIFIER", 161, 165], ["consolidation", "OBSERVATION", 169, 182], ["left upper lobe", "ANATOMY", 190, 205]]], ["The blood cultures grew Escherichia coli, and the patient improved rapidly on appropriate antibiotics, suggesting that the consolidation was a hospital-acquired pneumonia due to E. coli.A Bpatients are due to Nocardia, and like mycobacterial infections, nocardial infections tend to affect patients with defects in cell mediated immunity.", [["blood cultures", "ANATOMY", 4, 18], ["nocardial", "ANATOMY", 254, 263], ["cell", "ANATOMY", 315, 319], ["pneumonia", "DISEASE", 161, 170], ["Nocardia", "DISEASE", 209, 217], ["mycobacterial infections", "DISEASE", 228, 252], ["nocardial infections", "DISEASE", 254, 274], ["blood cultures", "ORGANISM_SUBSTANCE", 4, 18], ["Escherichia coli", "ORGANISM", 24, 40], ["patient", "ORGANISM", 50, 57], ["E. coli", "ORGANISM", 178, 185], ["patients", "ORGANISM", 290, 298], ["cell", "CELL", 315, 319], ["Escherichia coli", "SPECIES", 24, 40], ["patient", "SPECIES", 50, 57], ["E. coli", "SPECIES", 178, 185], ["patients", "SPECIES", 290, 298], ["Escherichia coli", "SPECIES", 24, 40], ["E. coli", "SPECIES", 178, 185], ["The blood cultures", "TEST", 0, 18], ["Escherichia coli", "PROBLEM", 24, 40], ["appropriate antibiotics", "TREATMENT", 78, 101], ["the consolidation", "PROBLEM", 119, 136], ["a hospital-acquired pneumonia", "PROBLEM", 141, 170], ["E. coli", "PROBLEM", 178, 185], ["Nocardia", "PROBLEM", 209, 217], ["mycobacterial infections", "PROBLEM", 228, 252], ["nocardial infections", "PROBLEM", 254, 274], ["defects in cell mediated immunity", "PROBLEM", 304, 337], ["Escherichia coli", "OBSERVATION", 24, 40], ["consolidation", "OBSERVATION", 123, 136], ["pneumonia", "OBSERVATION", 161, 170], ["E. coli", "OBSERVATION", 178, 185], ["Nocardia", "OBSERVATION", 209, 217], ["mycobacterial infections", "OBSERVATION", 228, 252]]], ["In hematopoietic stem cell transplant recipients, the median time to onset is approximately 200 days after transplantation.", [["hematopoietic stem cell", "ANATOMY", 3, 26], ["hematopoietic stem cell", "CELL", 3, 26], ["hematopoietic stem cell transplant recipients", "TREATMENT", 3, 48], ["transplantation", "TREATMENT", 107, 122], ["hematopoietic stem cell transplant", "OBSERVATION", 3, 37]]], ["Risk factors for disease also include cor ticosteroid use, active graftversushost disease, and concomi tant opportunistic infections, especially with CMV.", [["cor ticosteroid", "DISEASE", 38, 53], ["graftversushost disease", "DISEASE", 66, 89], ["opportunistic infections", "DISEASE", 108, 132], ["CMV", "ORGANISM", 150, 153], ["CMV", "SPECIES", 150, 153], ["Risk factors", "PROBLEM", 0, 12], ["disease", "PROBLEM", 17, 24], ["cor ticosteroid use", "TREATMENT", 38, 57], ["active graftversushost disease", "PROBLEM", 59, 89], ["concomi tant opportunistic infections", "PROBLEM", 95, 132], ["CMV", "TREATMENT", 150, 153], ["active", "OBSERVATION_MODIFIER", 59, 65], ["graftversushost disease", "OBSERVATION", 66, 89], ["opportunistic", "OBSERVATION_MODIFIER", 108, 121], ["infections", "OBSERVATION", 122, 132]]], ["Nocardia infection can manifest as a relatively acute pneu monia or as a more indolent disease similar to infection with Mycobacteria or Aspergillus.", [["Nocardia infection", "DISEASE", 0, 18], ["infection", "DISEASE", 106, 115], ["Mycobacteria", "DISEASE", 121, 133], ["Nocardia infection", "PROBLEM", 0, 18], ["a relatively acute pneu monia", "PROBLEM", 35, 64], ["a more indolent disease", "PROBLEM", 71, 94], ["infection", "PROBLEM", 106, 115], ["Mycobacteria", "PROBLEM", 121, 133], ["Aspergillus", "PROBLEM", 137, 148], ["infection", "OBSERVATION", 9, 18], ["relatively", "OBSERVATION_MODIFIER", 37, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["indolent", "OBSERVATION_MODIFIER", 78, 86], ["infection", "OBSERVATION", 106, 115], ["Mycobacteria", "OBSERVATION", 121, 133], ["Aspergillus", "OBSERVATION", 137, 148]]], ["Radiologic changes include patches of consolidation, large nodules, often with cavitation, and pleural involvement in up to a third of cases.", [["nodules", "ANATOMY", 59, 66], ["pleural", "ANATOMY", 95, 102], ["cavitation", "DISEASE", 79, 89], ["nodules", "PATHOLOGICAL_FORMATION", 59, 66], ["pleural", "ORGAN", 95, 102], ["Radiologic changes", "PROBLEM", 0, 18], ["consolidation", "PROBLEM", 38, 51], ["large nodules", "PROBLEM", 53, 66], ["cavitation", "PROBLEM", 79, 89], ["pleural involvement", "PROBLEM", 95, 114], ["patches", "OBSERVATION_MODIFIER", 27, 34], ["consolidation", "OBSERVATION", 38, 51], ["large", "OBSERVATION_MODIFIER", 53, 58], ["nodules", "OBSERVATION", 59, 66], ["cavitation", "OBSERVATION_MODIFIER", 79, 89], ["pleural", "ANATOMY", 95, 102], ["involvement", "OBSERVATION", 103, 114]]], ["Hematogenous spread to other organs such as the brain, joints, and soft tissues occurs in up to 50% of patients.", [["organs", "ANATOMY", 29, 35], ["brain", "ANATOMY", 48, 53], ["joints", "ANATOMY", 55, 61], ["soft tissues", "ANATOMY", 67, 79], ["organs", "ORGAN", 29, 35], ["brain", "ORGAN", 48, 53], ["joints", "MULTI-TISSUE_STRUCTURE", 55, 61], ["soft tissues", "TISSUE", 67, 79], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Hematogenous spread to other organs", "PROBLEM", 0, 35], ["soft tissues", "PROBLEM", 67, 79], ["brain", "ANATOMY", 48, 53], ["joints", "ANATOMY", 55, 61], ["soft tissues", "ANATOMY", 67, 79]]], ["Microscopy or histologic exam ination can make the diagnosis rapidly through identification of characteristic beaded, branching, grampositive and weakly acidfast filaments.", [["filaments", "ANATOMY", 162, 171], ["Microscopy", "TEST", 0, 10], ["histologic exam", "TEST", 14, 29], ["characteristic beaded, branching, grampositive and weakly acidfast filaments", "PROBLEM", 95, 171], ["beaded", "OBSERVATION_MODIFIER", 110, 116], ["branching", "OBSERVATION_MODIFIER", 118, 127]]], ["Respiratory and occasionally blood cultures can be positive but require prolonged aerobic culture.", [["blood cultures", "ANATOMY", 29, 43], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["occasionally blood cultures", "TEST", 16, 43], ["positive", "PROBLEM", 51, 59], ["prolonged aerobic culture", "TEST", 72, 97]]], ["Most Nocardia strains are sensitive to cotrimoxazole as well as car bapenems, amikacin, thirdgeneration cephalosporins, tetracy clines, and coamoxiclav, but treatment needs to be very prolonged, lasting up to 12 months in immunocompromised patients.", [["Nocardia", "DISEASE", 5, 13], ["cotrimoxazole", "CHEMICAL", 39, 52], ["bapenems", "CHEMICAL", 68, 76], ["amikacin", "CHEMICAL", 78, 86], ["cephalosporins", "CHEMICAL", 104, 118], ["coamoxiclav", "CHEMICAL", 140, 151], ["cotrimoxazole", "CHEMICAL", 39, 52], ["bapenems", "CHEMICAL", 68, 76], ["amikacin", "CHEMICAL", 78, 86], ["cephalosporins", "CHEMICAL", 104, 118], ["cotrimoxazole", "SIMPLE_CHEMICAL", 39, 52], ["bapenems", "SIMPLE_CHEMICAL", 68, 76], ["amikacin", "SIMPLE_CHEMICAL", 78, 86], ["thirdgeneration cephalosporins", "SIMPLE_CHEMICAL", 88, 118], ["coamoxiclav", "SIMPLE_CHEMICAL", 140, 151], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["Most Nocardia strains", "PROBLEM", 0, 21], ["cotrimoxazole", "TREATMENT", 39, 52], ["car bapenems", "TREATMENT", 64, 76], ["amikacin", "TREATMENT", 78, 86], ["thirdgeneration cephalosporins", "TREATMENT", 88, 118], ["tetracy clines", "TREATMENT", 120, 134], ["coamoxiclav", "TREATMENT", 140, 151], ["treatment", "TREATMENT", 157, 166]]], ["Mortality is high, reportedly up to 70%.General ConsiderationsCMV infection is one of the most important complications in patients with defects in cellmediated immunity such as trans plant recipients and patients receiving potent immunosuppres sive drugs such as fludarabine or alemtuzumab.", [["infection", "DISEASE", 66, 75], ["fludarabine", "CHEMICAL", 263, 274], ["alemtuzumab", "CHEMICAL", 278, 289], ["fludarabine", "CHEMICAL", 263, 274], ["alemtuzumab", "CHEMICAL", 278, 289], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 204, 212], ["fludarabine", "SIMPLE_CHEMICAL", 263, 274], ["alemtuzumab", "SIMPLE_CHEMICAL", 278, 289], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 204, 212], ["General ConsiderationsCMV infection", "PROBLEM", 40, 75], ["defects in cellmediated immunity", "PROBLEM", 136, 168], ["trans plant recipients", "TREATMENT", 177, 199], ["potent immunosuppres sive drugs", "TREATMENT", 223, 254], ["fludarabine", "TREATMENT", 263, 274], ["alemtuzumab", "TREATMENT", 278, 289], ["high", "OBSERVATION_MODIFIER", 13, 17], ["infection", "OBSERVATION", 66, 75]]], ["CMV is the largest member of the Herpesviridae family of human double stranded DNA viruses.", [["CMV", "ORGANISM", 0, 3], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 33, 46], ["human", "ORGANISM", 57, 62], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["Herpesviridae family", "PROTEIN", 33, 53], ["human", "SPECIES", 57, 62], ["CMV", "SPECIES", 0, 3], ["human", "SPECIES", 57, 62], ["CMV", "PROBLEM", 0, 3], ["human double stranded DNA viruses", "TREATMENT", 57, 90], ["largest", "OBSERVATION_MODIFIER", 11, 18], ["DNA viruses", "OBSERVATION", 79, 90]]], ["It has a 230kb genome that encodes over 200 products, which are expressed during replication in three overlapping phases over 24 hours termed immediate early, early, and late.General ConsiderationsPrimary CMV infection is common in the general popula tion, occurring mainly in children or young adults, but usually is asymptomatic or causes only mild disease.", [["CMV infection", "DISEASE", 205, 218], ["CMV", "ORGANISM", 205, 208], ["children", "ORGANISM", 277, 285], ["230kb genome", "DNA", 9, 21], ["children", "SPECIES", 277, 285], ["Primary CMV infection", "PROBLEM", 197, 218], ["mild disease", "PROBLEM", 346, 358], ["CMV infection", "OBSERVATION", 205, 218], ["mild", "OBSERVATION_MODIFIER", 346, 350], ["disease", "OBSERVATION", 351, 358]]], ["Previous infection is identified by serologic studies and leads to asymptomatic latent infection that can be reactivated in immunocompro mised persons.", [["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 87, 96], ["persons", "ORGANISM", 143, 150], ["persons", "SPECIES", 143, 150], ["Previous infection", "PROBLEM", 0, 18], ["serologic studies", "TEST", 36, 53], ["asymptomatic latent infection", "PROBLEM", 67, 96], ["infection", "OBSERVATION", 9, 18], ["latent", "OBSERVATION_MODIFIER", 80, 86], ["infection", "OBSERVATION", 87, 96]]], ["Reactivation can be initiated by the cytokine tumor necrosis factor and stress catecholamines, so the virus often will be detected in transplant recipients 3 to 4 weeks after an infective episode involving another pathogen.", [["tumor", "DISEASE", 46, 51], ["necrosis", "DISEASE", 52, 60], ["catecholamines", "CHEMICAL", 79, 93], ["catecholamines", "CHEMICAL", 79, 93], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 46, 67], ["catecholamines", "GENE_OR_GENE_PRODUCT", 79, 93], ["cytokine tumor necrosis factor", "PROTEIN", 37, 67], ["the cytokine tumor necrosis factor", "PROBLEM", 33, 67], ["stress catecholamines", "PROBLEM", 72, 93], ["the virus", "PROBLEM", 98, 107], ["transplant recipients", "TREATMENT", 134, 155], ["an infective episode", "PROBLEM", 175, 195], ["another pathogen", "PROBLEM", 206, 222], ["tumor", "OBSERVATION_MODIFIER", 46, 51], ["necrosis", "OBSERVATION", 52, 60], ["infective", "OBSERVATION", 178, 187]]], ["Around 60% of immunocompromised patients with negative results on sero logic testing for CMV who then receive transplants or blood products containing leukocytes from CMVpositive donors will develop CMV infection, which tends to be more severe than disease due to CMV reactivation.", [["blood", "ANATOMY", 125, 130], ["leukocytes", "ANATOMY", 151, 161], ["CMV infection", "DISEASE", 199, 212], ["patients", "ORGANISM", 32, 40], ["CMV", "ORGANISM", 89, 92], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["leukocytes", "CELL", 151, 161], ["donors", "ORGANISM", 179, 185], ["CMV", "ORGANISM", 199, 202], ["CMV", "ORGANISM", 264, 267], ["leukocytes", "CELL_TYPE", 151, 161], ["patients", "SPECIES", 32, 40], ["CMV", "SPECIES", 89, 92], ["CMV", "SPECIES", 199, 202], ["CMV", "SPECIES", 264, 267], ["sero logic testing", "TEST", 66, 84], ["CMV", "PROBLEM", 89, 92], ["transplants", "TREATMENT", 110, 121], ["blood products", "TREATMENT", 125, 139], ["leukocytes", "PROBLEM", 151, 161], ["CMVpositive donors", "TREATMENT", 167, 185], ["CMV infection", "PROBLEM", 199, 212], ["disease", "PROBLEM", 249, 256], ["CMV reactivation", "PROBLEM", 264, 280], ["CMV infection", "OBSERVATION", 199, 212], ["CMV reactivation", "OBSERVATION", 264, 280]]], ["CMVnegative immunocom promised patients also can rarely develop primary infection after exposure to someone with active CMV infection.Clinical Features and DiagnosisThe potential effects of CMV reactivation in immunocompro mised patients are varied and include (1) clinically asymptom atic infection, which is common even in immunocompromised patients; (2) a CMV syndrome, defined as fever, a 50% fall in the leukocyte count, and a 2.5fold increase in transaminases;Clinical Features and Diagnosis(3) organspecific infection, including the liver, central nervous system (CNS), gastrointestinal system, and lungs, often associ ated with more severe involvement of the transplanted organ; (4) accentuated rejectionrelated damage to the target organ (e.g., bronchiolitis obliterans in lung transplant recipients); does not preclude mechanical ventilation but is associated with a poor prognosis in immunocompromised patients (up to a 95% mortality rate).", [["leukocyte", "ANATOMY", 409, 418], ["liver", "ANATOMY", 540, 545], ["central nervous system", "ANATOMY", 547, 569], ["CNS", "ANATOMY", 571, 574], ["gastrointestinal system", "ANATOMY", 577, 600], ["lungs", "ANATOMY", 606, 611], ["organ", "ANATOMY", 680, 685], ["organ", "ANATOMY", 741, 746], ["lung", "ANATOMY", 782, 786], ["primary infection", "DISEASE", 64, 81], ["CMV infection", "DISEASE", 120, 133], ["infection", "DISEASE", 290, 299], ["CMV syndrome", "DISEASE", 359, 371], ["fever", "DISEASE", 384, 389], ["infection", "DISEASE", 515, 524], ["liver, central nervous system (CNS), gastrointestinal system, and lungs", "DISEASE", 540, 611], ["damage to the target organ", "DISEASE", 720, 746], ["bronchiolitis obliterans", "DISEASE", 754, 778], ["patients", "ORGANISM", 31, 39], ["CMV", "ORGANISM", 120, 123], ["CMV", "ORGANISM", 190, 193], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 343, 351], ["CMV", "ORGANISM", 359, 362], ["leukocyte", "CELL", 409, 418], ["liver", "ORGAN", 540, 545], ["central nervous system", "ANATOMICAL_SYSTEM", 547, 569], ["CNS", "ANATOMICAL_SYSTEM", 571, 574], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 577, 600], ["lungs", "ORGAN", 606, 611], ["organ", "ORGAN", 680, 685], ["organ", "ORGAN", 741, 746], ["lung", "ORGAN", 782, 786], ["patients", "ORGANISM", 913, 921], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 913, 921], ["CMV", "SPECIES", 120, 123], ["CMV", "SPECIES", 190, 193], ["primary infection", "PROBLEM", 64, 81], ["active CMV infection", "PROBLEM", 113, 133], ["CMV reactivation", "PROBLEM", 190, 206], ["clinically asymptom atic infection", "PROBLEM", 265, 299], ["a CMV syndrome", "PROBLEM", 357, 371], ["fever", "PROBLEM", 384, 389], ["a 50% fall", "PROBLEM", 391, 401], ["the leukocyte count", "TEST", 405, 424], ["a 2.5fold increase in transaminases", "PROBLEM", 430, 465], ["organspecific infection", "PROBLEM", 501, 524], ["the liver, central nervous system (CNS), gastrointestinal system, and lungs", "PROBLEM", 536, 611], ["more severe involvement of the transplanted organ", "PROBLEM", 636, 685], ["accentuated rejectionrelated damage", "PROBLEM", 691, 726], ["bronchiolitis obliterans", "PROBLEM", 754, 778], ["lung transplant recipients", "TREATMENT", 782, 808], ["mechanical ventilation", "TREATMENT", 829, 851], ["infection", "OBSERVATION", 72, 81], ["active", "OBSERVATION_MODIFIER", 113, 119], ["CMV infection", "OBSERVATION", 120, 133], ["CMV reactivation", "OBSERVATION", 190, 206], ["infection", "OBSERVATION", 290, 299], ["CMV syndrome", "OBSERVATION", 359, 371], ["leukocyte", "ANATOMY", 409, 418], ["2.5fold", "OBSERVATION_MODIFIER", 432, 439], ["increase", "OBSERVATION_MODIFIER", 440, 448], ["infection", "OBSERVATION", 515, 524], ["liver", "ANATOMY", 540, 545], ["central", "ANATOMY_MODIFIER", 547, 554], ["nervous system", "ANATOMY", 555, 569], ["gastrointestinal system", "ANATOMY", 577, 600], ["lungs", "ANATOMY", 606, 611], ["severe", "OBSERVATION_MODIFIER", 641, 647], ["involvement", "OBSERVATION", 648, 659], ["transplanted organ", "ANATOMY", 667, 685], ["damage", "OBSERVATION", 720, 726], ["target organ", "ANATOMY", 734, 746], ["bronchiolitis obliterans", "OBSERVATION", 754, 778], ["lung", "ANATOMY", 782, 786], ["transplant", "OBSERVATION", 787, 797], ["mechanical ventilation", "OBSERVATION", 829, 851]]], ["Initial antibiotic therapy should be effec tive against the local pattern of hospitalacquired infections and will therefore probably include extendedrange betalactams, aminoglycosides, or ciprofloxacin.", [["infections", "DISEASE", 94, 104], ["betalactams", "CHEMICAL", 155, 166], ["aminoglycosides", "CHEMICAL", 168, 183], ["ciprofloxacin", "CHEMICAL", 188, 201], ["betalactams", "CHEMICAL", 155, 166], ["aminoglycosides", "CHEMICAL", 168, 183], ["ciprofloxacin", "CHEMICAL", 188, 201], ["extendedrange betalactams", "SIMPLE_CHEMICAL", 141, 166], ["aminoglycosides", "SIMPLE_CHEMICAL", 168, 183], ["ciprofloxacin", "SIMPLE_CHEMICAL", 188, 201], ["Initial antibiotic therapy", "TREATMENT", 0, 26], ["hospitalacquired infections", "PROBLEM", 77, 104], ["extendedrange betalactams", "TREATMENT", 141, 166], ["aminoglycosides", "TREATMENT", 168, 183], ["ciprofloxacin", "TREATMENT", 188, 201], ["infections", "OBSERVATION", 94, 104]]], ["Lack of response within 72 to 96 hours should prompt a switch to another broadspectrum parenteral antibiotic (e.g., a carbapenem) in case the causative pathogen is resistant to firstline agents.", [["carbapenem", "CHEMICAL", 118, 128], ["carbapenem", "CHEMICAL", 118, 128], ["firstline agents", "SIMPLE_CHEMICAL", 177, 193], ["another broadspectrum parenteral antibiotic", "TREATMENT", 65, 108], ["a carbapenem", "TREATMENT", 116, 128], ["the causative pathogen", "PROBLEM", 138, 160], ["firstline agents", "TREATMENT", 177, 193]]], ["Treatment for infec tions due to MRSA or other resistant grampositive organisms also should be considered.", [["MRSA", "DISEASE", 33, 37], ["MRSA", "SPECIES", 33, 37], ["MRSA", "SPECIES", 33, 37], ["Treatment", "TREATMENT", 0, 9], ["infec tions", "PROBLEM", 14, 25], ["MRSA", "PROBLEM", 33, 37], ["other resistant grampositive organisms", "PROBLEM", 41, 79], ["MRSA", "OBSERVATION", 33, 37]]], ["Carbapenems and extendedrange betalactams usually have good efficacy against anaerobic organisms.PreventionAntibacterial prophylaxis with a fluoroquinolone (e.g., levo floxacin) often is used during the neutropenic phase after HSCT.", [["Carbapenems", "CHEMICAL", 0, 11], ["betalactams", "CHEMICAL", 30, 41], ["fluoroquinolone", "CHEMICAL", 140, 155], ["levo floxacin", "CHEMICAL", 163, 176], ["neutropenic", "DISEASE", 203, 214], ["Carbapenems", "CHEMICAL", 0, 11], ["betalactams", "CHEMICAL", 30, 41], ["fluoroquinolone", "CHEMICAL", 140, 155], ["levo floxacin", "CHEMICAL", 163, 176], ["Carbapenems", "SIMPLE_CHEMICAL", 0, 11], ["extendedrange betalactams", "SIMPLE_CHEMICAL", 16, 41], ["fluoroquinolone", "SIMPLE_CHEMICAL", 140, 155], ["levo floxacin", "SIMPLE_CHEMICAL", 163, 176], ["Carbapenems", "TREATMENT", 0, 11], ["extendedrange betalactams", "TREATMENT", 16, 41], ["anaerobic organisms", "PROBLEM", 77, 96], ["Antibacterial prophylaxis", "TREATMENT", 107, 132], ["a fluoroquinolone", "TREATMENT", 138, 155], ["levo floxacin)", "TREATMENT", 163, 177]]], ["Prolonged antibiotic prophylaxis with penicillin V against encapsulated organisms is necessary for patients ren dered functionally asplenic by their disease or therapy.", [["penicillin V", "CHEMICAL", 38, 50], ["penicillin V", "CHEMICAL", 38, 50], ["penicillin V", "GENE_OR_GENE_PRODUCT", 38, 50], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Prolonged antibiotic prophylaxis", "TREATMENT", 0, 32], ["penicillin V", "TREATMENT", 38, 50], ["encapsulated organisms", "PROBLEM", 59, 81], ["therapy", "TREATMENT", 160, 167], ["asplenic", "OBSERVATION", 131, 139]]], ["Antibi otic prophylaxis also may be indicated in patients with chronic graftversushost disease, immunoglobulin deficiencies, and bronchiectasis.", [["otic", "ANATOMY", 7, 11], ["chronic graftversushost disease", "DISEASE", 63, 94], ["immunoglobulin deficiencies", "DISEASE", 96, 123], ["bronchiectasis", "DISEASE", 129, 143], ["patients", "ORGANISM", 49, 57], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 96, 110], ["immunoglobulin", "PROTEIN", 96, 110], ["patients", "SPECIES", 49, 57], ["Antibi otic prophylaxis", "TREATMENT", 0, 23], ["chronic graftversushost disease", "PROBLEM", 63, 94], ["immunoglobulin deficiencies", "PROBLEM", 96, 123], ["bronchiectasis", "PROBLEM", 129, 143], ["prophylaxis", "OBSERVATION", 12, 23], ["immunoglobulin deficiencies", "OBSERVATION", 96, 123], ["bronchiectasis", "OBSERVATION", 129, 143]]], ["Vaccination against S. pneumoniae is recom mended for all hematopoietic stem cell transplant recipients, and the conjugated vaccine probably should be used because of its stronger immunogenicity.", [["hematopoietic stem cell", "ANATOMY", 58, 81], ["S. pneumoniae", "DISEASE", 20, 33], ["S. pneumoniae", "ORGANISM", 20, 33], ["hematopoietic stem cell", "CELL", 58, 81], ["recipients", "ORGANISM", 93, 103], ["S. pneumoniae", "SPECIES", 20, 33], ["S. pneumoniae", "SPECIES", 20, 33], ["Vaccination", "TREATMENT", 0, 11], ["S. pneumoniae", "PROBLEM", 20, 33], ["all hematopoietic stem cell transplant recipients", "TREATMENT", 54, 103], ["the conjugated vaccine", "TREATMENT", 109, 131], ["pneumoniae", "OBSERVATION", 23, 33], ["hematopoietic stem cell transplant", "OBSERVATION", 58, 92]]], ["Concern has emerged about the risk of whooping cough in recipients of hematopoietic stem cell transplants, who perhaps should receive vaccination against Bordetella pertussis and prophylaxis with azithromycin if exposed to an infected case.MYCOBACTERIAL INFECTIONSMycobacterial infections usually are associated with defects in cellmediated immunity and tend to develop subacutely.", [["hematopoietic stem cell", "ANATOMY", 70, 93], ["whooping cough", "DISEASE", 38, 52], ["Bordetella pertussis", "DISEASE", 154, 174], ["azithromycin", "CHEMICAL", 196, 208], ["infections", "DISEASE", 278, 288], ["azithromycin", "CHEMICAL", 196, 208], ["hematopoietic stem cell", "CELL", 70, 93], ["Bordetella pertussis", "ORGANISM", 154, 174], ["azithromycin", "SIMPLE_CHEMICAL", 196, 208], ["Bordetella pertussis", "SPECIES", 154, 174], ["Bordetella pertussis", "SPECIES", 154, 174], ["whooping cough", "PROBLEM", 38, 52], ["hematopoietic stem cell transplants", "TREATMENT", 70, 105], ["vaccination", "TREATMENT", 134, 145], ["Bordetella pertussis", "TREATMENT", 154, 174], ["prophylaxis", "TREATMENT", 179, 190], ["azithromycin", "TREATMENT", 196, 208], ["an infected case", "PROBLEM", 223, 239], ["MYCOBACTERIAL INFECTIONSMycobacterial infections", "PROBLEM", 240, 288], ["defects in cellmediated immunity", "PROBLEM", 317, 349], ["hematopoietic stem cell transplants", "OBSERVATION", 70, 105], ["infected", "OBSERVATION", 226, 234], ["INFECTIONSMycobacterial infections", "OBSERVATION", 254, 288]]], ["The risk for Mycobacterium tuberculosis infection is strongly depen dent on the ethnic background and country of origin of the patient.", [["Mycobacterium tuberculosis infection", "DISEASE", 13, 49], ["Mycobacterium tuberculosis", "ORGANISM", 13, 39], ["patient", "ORGANISM", 127, 134], ["Mycobacterium tuberculosis", "SPECIES", 13, 39], ["patient", "SPECIES", 127, 134], ["Mycobacterium tuberculosis", "SPECIES", 13, 39], ["Mycobacterium tuberculosis infection", "PROBLEM", 13, 49], ["risk for", "UNCERTAINTY", 4, 12], ["Mycobacterium tuberculosis", "OBSERVATION", 13, 39]]], ["Tuberculosis should be considered in atrisk patients with a cellmediated immune defect or patchy or nodular lung shadowing, particularly those with a highrisk ethnic back ground.", [["nodular lung", "ANATOMY", 100, 112], ["Tuberculosis", "DISEASE", 0, 12], ["patients", "ORGANISM", 44, 52], ["lung", "ORGAN", 108, 112], ["patients", "SPECIES", 44, 52], ["Tuberculosis", "PROBLEM", 0, 12], ["a cellmediated immune defect", "PROBLEM", 58, 86], ["patchy or nodular lung shadowing", "PROBLEM", 90, 122], ["patchy", "OBSERVATION_MODIFIER", 90, 96], ["nodular", "OBSERVATION_MODIFIER", 100, 107], ["lung", "ANATOMY", 108, 112], ["shadowing", "OBSERVATION", 113, 122]]], ["Nontuberculous mycobacterial infections (e.g., Mycobacterium kansasii or Mycobacterium avium complex [MAC]) are infrequent complications in immunocompromised patients.", [["mycobacterial infections", "DISEASE", 15, 39], ["Mycobacterium kansasii", "DISEASE", 47, 69], ["Mycobacterium avium complex", "DISEASE", 73, 100], ["Mycobacterium kansasii", "ORGANISM", 47, 69], ["Mycobacterium avium complex", "ORGANISM", 73, 100], ["patients", "ORGANISM", 158, 166], ["Mycobacterium kansasii", "SPECIES", 47, 69], ["Mycobacterium avium", "SPECIES", 73, 92], ["patients", "SPECIES", 158, 166], ["Mycobacterium kansasii", "SPECIES", 47, 69], ["Mycobacterium avium", "SPECIES", 73, 92], ["Nontuberculous mycobacterial infections", "PROBLEM", 0, 39], ["Mycobacterium kansasii", "PROBLEM", 47, 69], ["Mycobacterium avium complex", "PROBLEM", 73, 100], ["infrequent complications in immunocompromised patients", "PROBLEM", 112, 166], ["mycobacterial infections", "OBSERVATION", 15, 39], ["Mycobacterium kansasii", "OBSERVATION", 47, 69], ["Mycobacterium", "OBSERVATION_MODIFIER", 73, 86], ["infrequent", "OBSERVATION_MODIFIER", 112, 122], ["complications", "OBSERVATION", 123, 136], ["immunocompromised", "OBSERVATION", 140, 157]]], ["Exclusion of the diagnosis by negative culture takes too long to be clinically useful in patients with progressive disease.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["negative culture", "TEST", 30, 46], ["progressive disease", "PROBLEM", 103, 122], ["progressive", "OBSERVATION_MODIFIER", 103, 114], ["disease", "OBSERVATION", 115, 122]]], ["Therefore, with significant clinical suspicion of mycobacterial infection, invasive investigations are necessary to obtain mate rial for a rapid diagnosis by identification of acidfast bacilli, specific histopathologic changes, or possibly polymerase chain reaction (PCR) assay for samples obtained from sterile sites.", [["samples", "ANATOMY", 282, 289], ["sites", "ANATOMY", 312, 317], ["mycobacterial infection", "DISEASE", 50, 73], ["mycobacterial infection", "PROBLEM", 50, 73], ["invasive investigations", "TEST", 75, 98], ["acidfast bacilli", "PROBLEM", 176, 192], ["specific histopathologic changes", "PROBLEM", 194, 226], ["polymerase chain reaction", "PROBLEM", 240, 265], ["PCR) assay", "TEST", 267, 277], ["samples", "TEST", 282, 289], ["mycobacterial", "OBSERVATION_MODIFIER", 50, 63], ["infection", "OBSERVATION", 64, 73], ["possibly", "UNCERTAINTY", 231, 239]]], ["Treatment is with the standard chemotherapy regimens.NOCARDIAL INFECTIONSNocardia are grampositive aerobic organisms found in soil and stagnant water.", [["Treatment", "TREATMENT", 0, 9], ["the standard chemotherapy regimens", "TREATMENT", 18, 52], ["NOCARDIAL INFECTIONSNocardia", "TEST", 53, 81], ["grampositive aerobic organisms", "PROBLEM", 86, 116], ["aerobic organisms", "OBSERVATION", 99, 116], ["stagnant", "OBSERVATION_MODIFIER", 135, 143], ["water", "OBSERVATION_MODIFIER", 144, 149]]], ["Immunocompromised patients should avoid gardening or occupations that result in exposure to soil and plants.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Infec tion occurs through inhalation, so patients who wish to con tinue gardening may minimize exposure by wearing protective clothing such as an N95 mask and gloves.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["protective clothing", "TREATMENT", 115, 134], ["an N95 mask", "TREATMENT", 143, 154], ["gloves", "TREATMENT", 159, 165]]], ["The organisms most commonly causing human infection belong to the Nocardia asteroides complex, but other Nocardia spp. also can cause disease.", [["infection", "DISEASE", 42, 51], ["Nocardia asteroides", "DISEASE", 66, 85], ["Nocardia spp", "DISEASE", 105, 117], ["human", "ORGANISM", 36, 41], ["Nocardia asteroides", "ORGANISM", 66, 85], ["Nocardia spp", "ORGANISM", 105, 117], ["human", "SPECIES", 36, 41], ["Nocardia asteroides", "SPECIES", 66, 85], ["human", "SPECIES", 36, 41], ["Nocardia asteroides", "SPECIES", 66, 85], ["The organisms", "PROBLEM", 0, 13], ["human infection", "PROBLEM", 36, 51], ["the Nocardia asteroides complex", "PROBLEM", 62, 93], ["other Nocardia spp", "PROBLEM", 99, 117], ["disease", "PROBLEM", 134, 141], ["infection", "OBSERVATION", 42, 51], ["disease", "OBSERVATION", 134, 141]]], ["Around 2% of lung infections in immunocompromised (5) impaired host immunity with increased incidence of oppor tunistic infections including pneumonia due to Aspergillus, Pneumocystis jirovecii, gramnegative bacteria, and Nocardia; and (6) increased incidence of EBVassociated lymphoprolif erative disease.NOCARDIAL INFECTIONSCMV pneumonitis commonly manifests with insidious onset of fever, malaise, cough, and dyspnea with hypoxia.", [["lung", "ANATOMY", 13, 17], ["lung infections", "DISEASE", 13, 28], ["immunocompromised", "DISEASE", 32, 49], ["infections", "DISEASE", 120, 130], ["pneumonia", "DISEASE", 141, 150], ["Pneumocystis jirovecii", "DISEASE", 171, 193], ["Nocardia", "DISEASE", 222, 230], ["erative disease", "DISEASE", 290, 305], ["pneumonitis", "DISEASE", 330, 341], ["fever", "DISEASE", 385, 390], ["cough", "DISEASE", 401, 406], ["dyspnea", "DISEASE", 412, 419], ["hypoxia", "DISEASE", 425, 432], ["lung", "ORGAN", 13, 17], ["Pneumocystis jirovecii", "ORGANISM", 171, 193], ["Pneumocystis jirovecii", "SPECIES", 171, 193], ["Pneumocystis jirovecii", "SPECIES", 171, 193], ["lung infections", "PROBLEM", 13, 28], ["oppor tunistic infections", "PROBLEM", 105, 130], ["pneumonia", "PROBLEM", 141, 150], ["Aspergillus", "PROBLEM", 158, 169], ["Pneumocystis jirovecii", "PROBLEM", 171, 193], ["gramnegative bacteria", "PROBLEM", 195, 216], ["Nocardia", "PROBLEM", 222, 230], ["EBVassociated lymphoprolif erative disease", "PROBLEM", 263, 305], ["NOCARDIAL INFECTIONSCMV pneumonitis", "PROBLEM", 306, 341], ["fever", "PROBLEM", 385, 390], ["malaise", "PROBLEM", 392, 399], ["cough", "PROBLEM", 401, 406], ["dyspnea", "PROBLEM", 412, 419], ["hypoxia", "PROBLEM", 425, 432], ["lung", "ANATOMY", 13, 17], ["infections", "OBSERVATION", 18, 28], ["immunocompromised", "OBSERVATION", 32, 49], ["host immunity", "OBSERVATION_MODIFIER", 63, 76], ["pneumonia", "OBSERVATION", 141, 150], ["Aspergillus", "OBSERVATION", 158, 169], ["Pneumocystis jirovecii", "OBSERVATION", 171, 193], ["Nocardia", "OBSERVATION", 222, 230], ["EBVassociated lymphoprolif erative disease", "OBSERVATION", 263, 305], ["pneumonitis", "OBSERVATION", 330, 341], ["insidious", "OBSERVATION_MODIFIER", 366, 375], ["fever", "OBSERVATION", 385, 390], ["malaise", "OBSERVATION", 392, 399], ["cough", "OBSERVATION", 401, 406], ["dyspnea", "OBSERVATION", 412, 419], ["hypoxia", "OBSERVATION", 425, 432]]], ["The chest radiograph may be normal in appearance or show non specific diffuse bilateral infiltrates.", [["chest", "ANATOMY", 4, 9], ["The chest radiograph", "TEST", 0, 20], ["non specific diffuse bilateral infiltrates", "PROBLEM", 57, 99], ["chest", "ANATOMY", 4, 9], ["normal", "OBSERVATION", 28, 34], ["diffuse", "OBSERVATION_MODIFIER", 70, 77], ["bilateral", "ANATOMY_MODIFIER", 78, 87], ["infiltrates", "OBSERVATION", 88, 99]]], ["CT scan is more sensitive at identifying pulmonary infiltrates and classically shows bibasal symmetric ground glass opacities, septal line thickening, and multiple small centrilobular nodules (Figure 28-9) .", [["pulmonary infiltrates", "ANATOMY", 41, 62], ["septal line", "ANATOMY", 127, 138], ["centrilobular nodules", "ANATOMY", 170, 191], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 41, 62], ["centrilobular nodules", "CANCER", 170, 191], ["CT scan", "TEST", 0, 7], ["pulmonary infiltrates", "PROBLEM", 41, 62], ["bibasal symmetric ground glass opacities", "PROBLEM", 85, 125], ["septal line thickening", "PROBLEM", 127, 149], ["multiple small centrilobular nodules", "PROBLEM", 155, 191], ["Figure", "TEST", 193, 199], ["pulmonary", "ANATOMY", 41, 50], ["infiltrates", "OBSERVATION", 51, 62], ["bibasal", "ANATOMY_MODIFIER", 85, 92], ["symmetric", "OBSERVATION_MODIFIER", 93, 102], ["ground glass opacities", "OBSERVATION", 103, 125], ["septal", "ANATOMY_MODIFIER", 127, 133], ["line", "OBSERVATION_MODIFIER", 134, 138], ["thickening", "OBSERVATION", 139, 149], ["multiple", "OBSERVATION_MODIFIER", 155, 163], ["small", "OBSERVATION_MODIFIER", 164, 169], ["centrilobular", "OBSERVATION_MODIFIER", 170, 183], ["nodules", "OBSERVATION", 184, 191]]], ["More asym metric changes, consolidation, and effusions are not uncom mon, however.", [["effusions", "ANATOMY", 45, 54], ["effusions", "DISEASE", 45, 54], ["More asym metric changes", "PROBLEM", 0, 24], ["consolidation", "PROBLEM", 26, 39], ["effusions", "PROBLEM", 45, 54], ["consolidation", "OBSERVATION", 26, 39], ["effusions", "OBSERVATION", 45, 54]]], ["The main considerations in the differential diagnosis are IPS, druginduced pneumonitis, and, in patients not receiving effective prophylaxis, PCP.", [["pneumonitis", "DISEASE", 75, 86], ["PCP", "DISEASE", 142, 145], ["PCP", "CHEMICAL", 142, 145], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["IPS", "PROBLEM", 58, 61], ["druginduced pneumonitis", "PROBLEM", 63, 86], ["effective prophylaxis", "TREATMENT", 119, 140], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pneumonitis", "OBSERVATION", 75, 86]]], ["Serologic determina tion of either IgG or IgM has no place in the diagnosis of CMV disease, because these antibodies merely reflect previous expo sure.", [["CMV disease", "DISEASE", 79, 90], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgM", "GENE_OR_GENE_PRODUCT", 42, 45], ["CMV", "ORGANISM", 79, 82], ["IgG", "PROTEIN", 35, 38], ["IgM", "PROTEIN", 42, 45], ["antibodies", "PROTEIN", 106, 116], ["CMV", "SPECIES", 79, 82], ["Serologic determina", "TEST", 0, 19], ["IgG", "TEST", 35, 38], ["IgM", "PROBLEM", 42, 45], ["CMV disease", "PROBLEM", 79, 90], ["these antibodies", "TEST", 100, 116], ["CMV disease", "OBSERVATION", 79, 90]]], ["However, CMV reactivation is nowadays readily detected by identifying significant viremia through either measuring the level of pp65 antigenemia or CMV DNA using PCR assay in the blood.", [["blood", "ANATOMY", 179, 184], ["viremia", "DISEASE", 82, 89], ["CMV", "ORGANISM", 9, 12], ["pp65", "GENE_OR_GENE_PRODUCT", 128, 132], ["CMV", "ORGANISM", 148, 151], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["pp65", "PROTEIN", 128, 132], ["CMV DNA", "DNA", 148, 155], ["CMV", "SPECIES", 9, 12], ["CMV", "SPECIES", 148, 151], ["CMV reactivation", "PROBLEM", 9, 25], ["significant viremia", "PROBLEM", 70, 89], ["pp65 antigenemia", "TEST", 128, 144], ["CMV DNA", "TEST", 148, 155], ["PCR assay", "TEST", 162, 171], ["the blood", "TEST", 175, 184], ["CMV reactivation", "OBSERVATION", 9, 25], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["viremia", "OBSERVATION", 82, 89], ["pp65 antigenemia", "OBSERVATION", 128, 144]]], ["CMV viremia usually is detectable 2 to 5 days before any clinical manifestations.", [["viremia", "DISEASE", 4, 11], ["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["CMV viremia", "PROBLEM", 0, 11], ["any clinical manifestations", "PROBLEM", 53, 80], ["viremia", "OBSERVATION", 4, 11]]], ["Unfortunately, CMV viremia is not always present in patients with CMV pneumonitis; conversely, evidence of reactivation does not necessarily mean that new lung infiltrates are due to CMV pneumonitis.", [["lung infiltrates", "ANATOMY", 155, 171], ["viremia", "DISEASE", 19, 26], ["pneumonitis", "DISEASE", 70, 81], ["lung infiltrates", "DISEASE", 155, 171], ["pneumonitis", "DISEASE", 187, 198], ["CMV", "ORGANISM", 15, 18], ["patients", "ORGANISM", 52, 60], ["CMV", "ORGANISM", 66, 69], ["lung", "ORGAN", 155, 159], ["CMV", "ORGANISM", 183, 186], ["patients", "SPECIES", 52, 60], ["CMV", "SPECIES", 15, 18], ["CMV", "SPECIES", 66, 69], ["CMV", "SPECIES", 183, 186], ["CMV viremia", "PROBLEM", 15, 26], ["CMV pneumonitis", "PROBLEM", 66, 81], ["reactivation", "PROBLEM", 107, 119], ["new lung infiltrates", "PROBLEM", 151, 171], ["CMV pneumonitis", "PROBLEM", 183, 198], ["CMV viremia", "OBSERVATION", 15, 26], ["not always", "UNCERTAINTY", 30, 40], ["pneumonitis", "OBSERVATION", 70, 81], ["reactivation", "OBSERVATION", 107, 119], ["new", "OBSERVATION_MODIFIER", 151, 154], ["lung", "ANATOMY", 155, 159], ["infiltrates", "OBSERVATION", 160, 171], ["due to", "UNCERTAINTY", 176, 182], ["CMV pneumonitis", "OBSERVATION", 183, 198]]], ["The chance that CMV infection is responsible for new lung infiltrates is propor tional in part to the level of CMV in the blood, especially if the viral load increased rapidly.", [["lung infiltrates", "ANATOMY", 53, 69], ["blood", "ANATOMY", 122, 127], ["CMV infection", "DISEASE", 16, 29], ["CMV", "ORGANISM", 16, 19], ["lung", "ORGAN", 53, 57], ["CMV", "ORGANISM", 111, 114], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["CMV", "SPECIES", 16, 19], ["CMV", "SPECIES", 111, 114], ["CMV infection", "PROBLEM", 16, 29], ["new lung infiltrates", "PROBLEM", 49, 69], ["propor tional", "PROBLEM", 73, 86], ["CMV in the blood", "PROBLEM", 111, 127], ["the viral load", "TEST", 143, 157], ["CMV infection", "OBSERVATION", 16, 29], ["responsible for", "UNCERTAINTY", 33, 48], ["new", "OBSERVATION_MODIFIER", 49, 52], ["lung", "ANATOMY", 53, 57], ["infiltrates", "OBSERVATION", 58, 69], ["CMV", "OBSERVATION", 111, 114], ["viral load", "OBSERVATION", 147, 157]]], ["Definitive confirmation that CMV is causing pneumonia requires identification of CMV in the respiratory tract by FOB for BAL and preferably a trans bronchial biopsy, or possibly a VATS lung biopsy.", [["respiratory tract", "ANATOMY", 92, 109], ["BAL", "ANATOMY", 121, 124], ["bronchial", "ANATOMY", 148, 157], ["lung", "ANATOMY", 185, 189], ["pneumonia", "DISEASE", 44, 53], ["CMV in the respiratory tract", "DISEASE", 81, 109], ["CMV", "ORGANISM", 29, 32], ["CMV", "ORGANISM", 81, 84], ["respiratory tract", "ORGANISM_SUBDIVISION", 92, 109], ["BAL", "ORGANISM_SUBSTANCE", 121, 124], ["lung", "ORGAN", 185, 189], ["CMV", "SPECIES", 29, 32], ["CMV", "SPECIES", 81, 84], ["Definitive confirmation", "TEST", 0, 23], ["CMV", "PROBLEM", 29, 32], ["pneumonia", "PROBLEM", 44, 53], ["CMV in the respiratory tract", "PROBLEM", 81, 109], ["BAL", "TEST", 121, 124], ["a trans bronchial biopsy", "TEST", 140, 164], ["a VATS lung biopsy", "TEST", 178, 196], ["CMV", "OBSERVATION", 29, 32], ["pneumonia", "OBSERVATION", 44, 53], ["CMV", "OBSERVATION", 81, 84], ["respiratory tract", "ANATOMY", 92, 109], ["bronchial", "ANATOMY", 148, 157], ["biopsy", "OBSERVATION", 158, 164], ["lung", "ANATOMY", 185, 189], ["biopsy", "OBSERVATION", 190, 196]]], ["The presence of \"owl's eye\" intranuclear inclusions on cytologic examination is pathognomonic for CMV infection and although this modal ity is rapid, it is a relatively insensitive test.", [["eye", "ANATOMY", 23, 26], ["CMV infection", "DISEASE", 98, 111], ["eye", "ORGAN", 23, 26], ["CMV", "ORGANISM", 98, 101], ["CMV", "SPECIES", 98, 101], ["intranuclear inclusions", "PROBLEM", 28, 51], ["cytologic examination", "TEST", 55, 76], ["CMV infection", "PROBLEM", 98, 111], ["a relatively insensitive test", "PROBLEM", 156, 185], ["eye", "ANATOMY", 23, 26], ["intranuclear", "OBSERVATION_MODIFIER", 28, 40], ["inclusions", "OBSERVATION", 41, 51], ["pathognomonic for", "UNCERTAINTY", 80, 97], ["CMV infection", "OBSERVATION", 98, 111], ["rapid", "OBSERVATION_MODIFIER", 143, 148]]], ["CMV can be cul tured from respiratory samples using fibroblast cell culture to look for the distinctive cytopathogenic effect, but this takes at least a week and therefore is of little clinical benefit.", [["respiratory samples", "ANATOMY", 26, 45], ["fibroblast cell", "ANATOMY", 52, 67], ["CMV", "ORGANISM", 0, 3], ["fibroblast cell culture", "CELL", 52, 75], ["fibroblast cell culture", "CELL_LINE", 52, 75], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["respiratory samples", "TEST", 26, 45], ["fibroblast cell culture", "TEST", 52, 75], ["the distinctive cytopathogenic effect", "PROBLEM", 88, 125], ["distinctive", "OBSERVATION_MODIFIER", 92, 103], ["cytopathogenic effect", "OBSERVATION", 104, 125]]], ["The main diagnostic techniques for CMV pneumonitis are the relatively sensitive rapid tests for CMV antigens using BAL samples directly, or indirectly by probing cell cultures inoculated with the samples after 24 to 48 hours incubation (the shell vial or early antigen detection assays).", [["BAL samples", "ANATOMY", 115, 126], ["cell cultures", "ANATOMY", 162, 175], ["samples", "ANATOMY", 196, 203], ["pneumonitis", "DISEASE", 39, 50], ["CMV", "ORGANISM", 35, 38], ["CMV", "ORGANISM", 96, 99], ["BAL samples", "CANCER", 115, 126], ["cell cultures", "CELL", 162, 175], ["CMV antigens", "PROTEIN", 96, 108], ["cell cultures", "CELL_LINE", 162, 175], ["CMV", "SPECIES", 35, 38], ["CMV", "SPECIES", 96, 99], ["CMV pneumonitis", "PROBLEM", 35, 50], ["CMV antigens", "PROBLEM", 96, 108], ["BAL samples", "TEST", 115, 126], ["probing cell cultures", "TEST", 154, 175], ["the shell vial", "TREATMENT", 237, 251], ["early antigen detection assays", "TEST", 255, 285], ["main", "OBSERVATION_MODIFIER", 4, 8], ["CMV pneumonitis", "OBSERVATION", 35, 50]]], ["Quantitative PCR assay on BAL fluid has been used to improve the predictive value for the diagnosis of CMV pneumonitis but requires further investigation.", [["BAL fluid", "ANATOMY", 26, 35], ["CMV pneumonitis", "DISEASE", 103, 118], ["BAL fluid", "ORGANISM_SUBSTANCE", 26, 35], ["CMV", "ORGANISM", 103, 106], ["CMV", "SPECIES", 103, 106], ["Quantitative PCR assay", "TEST", 0, 22], ["BAL fluid", "TEST", 26, 35], ["CMV pneumonitis", "PROBLEM", 103, 118], ["further investigation", "TEST", 132, 153], ["CMV pneumonitis", "OBSERVATION", 103, 118]]], ["Despite this range of diagnostic techniques, a wellvalidated standard for identifying CMV pneumonitis is lacking, except for VATS biopsy.TreatmentThe currently available antiviral agents for treatment of CMV infection and disease are acyclovir, valacyclovir, ganciclovir, val ganciclovir, foscarnet, and cidofovir (Table 28-4) .", [["pneumonitis", "DISEASE", 90, 101], ["CMV infection", "DISEASE", 204, 217], ["acyclovir", "CHEMICAL", 234, 243], ["valacyclovir", "CHEMICAL", 245, 257], ["ganciclovir", "CHEMICAL", 259, 270], ["ganciclovir", "CHEMICAL", 276, 287], ["foscarnet", "CHEMICAL", 289, 298], ["cidofovir", "CHEMICAL", 304, 313], ["acyclovir", "CHEMICAL", 234, 243], ["valacyclovir", "CHEMICAL", 245, 257], ["ganciclovir", "CHEMICAL", 259, 270], ["ganciclovir", "CHEMICAL", 276, 287], ["foscarnet", "CHEMICAL", 289, 298], ["cidofovir", "CHEMICAL", 304, 313], ["CMV", "ORGANISM", 86, 89], ["CMV", "ORGANISM", 204, 207], ["acyclovir", "SIMPLE_CHEMICAL", 234, 243], ["valacyclovir", "SIMPLE_CHEMICAL", 245, 257], ["ganciclovir", "SIMPLE_CHEMICAL", 259, 270], ["val ganciclovir", "SIMPLE_CHEMICAL", 272, 287], ["foscarnet", "SIMPLE_CHEMICAL", 289, 298], ["cidofovir", "SIMPLE_CHEMICAL", 304, 313], ["CMV", "SPECIES", 86, 89], ["CMV", "SPECIES", 204, 207], ["diagnostic techniques", "TEST", 22, 43], ["a wellvalidated standard", "TREATMENT", 45, 69], ["CMV pneumonitis", "PROBLEM", 86, 101], ["VATS biopsy", "TEST", 125, 136], ["Treatment", "TREATMENT", 137, 146], ["antiviral agents", "TREATMENT", 170, 186], ["treatment", "TREATMENT", 191, 200], ["CMV infection", "PROBLEM", 204, 217], ["disease", "PROBLEM", 222, 229], ["acyclovir", "TREATMENT", 234, 243], ["valacyclovir", "TREATMENT", 245, 257], ["ganciclovir", "TREATMENT", 259, 270], ["val ganciclovir", "TREATMENT", 272, 287], ["foscarnet", "TREATMENT", 289, 298], ["cidofovir", "TREATMENT", 304, 313], ["CMV pneumonitis", "OBSERVATION", 86, 101], ["CMV infection", "OBSERVATION", 204, 217]]], ["A regimen based on the purine analogue ganciclovir is the preferred treat ment; this agent, once phosphorylated within infected cells, competitively inhibits viral DNA polymerase.", [["cells", "ANATOMY", 128, 133], ["purine", "CHEMICAL", 23, 29], ["ganciclovir", "CHEMICAL", 39, 50], ["purine", "CHEMICAL", 23, 29], ["ganciclovir", "CHEMICAL", 39, 50], ["purine", "SIMPLE_CHEMICAL", 23, 29], ["ganciclovir", "SIMPLE_CHEMICAL", 39, 50], ["cells", "CELL", 128, 133], ["DNA", "CELLULAR_COMPONENT", 164, 167], ["infected cells", "CELL_TYPE", 119, 133], ["viral DNA polymerase", "PROTEIN", 158, 178], ["A regimen", "TREATMENT", 0, 9], ["the purine analogue ganciclovir", "TREATMENT", 19, 50], ["this agent", "TREATMENT", 80, 90], ["infected cells", "PROBLEM", 119, 133], ["viral DNA polymerase", "PROBLEM", 158, 178], ["infected cells", "OBSERVATION", 119, 133]]], ["Ganciclovir has significant marrowdepressant effects and may be too toxic for use in hematopoietic stem cell transplant recipients or in patients with existing pancytopenia.", [["hematopoietic stem cell", "ANATOMY", 85, 108], ["Ganciclovir", "CHEMICAL", 0, 11], ["pancytopenia", "DISEASE", 160, 172], ["Ganciclovir", "CHEMICAL", 0, 11], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["hematopoietic stem cell", "CELL", 85, 108], ["recipients", "ORGANISM", 120, 130], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["Ganciclovir", "TREATMENT", 0, 11], ["significant marrowdepressant effects", "PROBLEM", 16, 52], ["hematopoietic stem cell transplant recipients", "TREATMENT", 85, 130], ["existing pancytopenia", "PROBLEM", 151, 172], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["marrowdepressant effects", "OBSERVATION", 28, 52], ["hematopoietic stem cell transplant", "OBSERVATION", 85, 119], ["pancytopenia", "OBSERVATION", 160, 172]]], ["Oral absorption is poor, but oral therapy with the valine ester valganciclovir has excel lent bioavailability.", [["Oral", "ANATOMY", 0, 4], ["oral", "ANATOMY", 29, 33], ["valine ester", "CHEMICAL", 51, 63], ["valganciclovir", "CHEMICAL", 64, 78], ["valine ester", "CHEMICAL", 51, 63], ["valganciclovir", "CHEMICAL", 64, 78], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["valine ester", "SIMPLE_CHEMICAL", 51, 63], ["valganciclovir", "SIMPLE_CHEMICAL", 64, 78], ["oral therapy", "TREATMENT", 29, 41], ["the valine ester valganciclovir", "TREATMENT", 47, 78]]], ["The secondline agent foscarnet also inhibits the activity of viral DNA polymerase (by binding to the pyrophosphatebinding site).", [["foscarnet", "CHEMICAL", 21, 30], ["foscarnet", "CHEMICAL", 21, 30], ["foscarnet", "SIMPLE_CHEMICAL", 21, 30], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["viral DNA polymerase", "PROTEIN", 61, 81], ["pyrophosphatebinding site", "DNA", 101, 126], ["The secondline agent foscarnet", "TREATMENT", 0, 30], ["viral DNA polymerase", "PROBLEM", 61, 81], ["foscarnet", "OBSERVATION", 21, 30]]], ["Foscarnet frequently causes sig nificant renal toxicity.", [["renal", "ANATOMY", 41, 46], ["Foscarnet", "CHEMICAL", 0, 9], ["renal toxicity", "DISEASE", 41, 55], ["Foscarnet", "CHEMICAL", 0, 9], ["Foscarnet", "SIMPLE_CHEMICAL", 0, 9], ["renal", "ORGAN", 41, 46], ["Foscarnet", "TREATMENT", 0, 9], ["sig nificant renal toxicity", "PROBLEM", 28, 55], ["renal", "ANATOMY", 41, 46], ["toxicity", "OBSERVATION", 47, 55]]], ["Alternatively, cidofovir has a broad activ ity against DNA viruses including CMV, acting as a competitive inhibitor of viral DNA polymerases.", [["cidofovir", "CHEMICAL", 15, 24], ["cidofovir", "CHEMICAL", 15, 24], ["cidofovir", "SIMPLE_CHEMICAL", 15, 24], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["CMV", "ORGANISM", 77, 80], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["viral DNA polymerases", "PROTEIN", 119, 140], ["CMV", "SPECIES", 77, 80], ["cidofovir", "TREATMENT", 15, 24], ["a broad activ ity", "TREATMENT", 29, 46], ["DNA viruses", "PROBLEM", 55, 66], ["CMV", "TREATMENT", 77, 80], ["a competitive inhibitor", "TREATMENT", 92, 115], ["viral DNA polymerases", "TREATMENT", 119, 140]]], ["Cidofovir causes both myelosuppression and renal toxicity, and patients should be prehydrated and given probeniced before initiation of treat ment.", [["renal", "ANATOMY", 43, 48], ["Cidofovir", "CHEMICAL", 0, 9], ["myelosuppression", "DISEASE", 22, 38], ["renal toxicity", "DISEASE", 43, 57], ["Cidofovir", "CHEMICAL", 0, 9], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["renal", "ORGAN", 43, 48], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Cidofovir", "TREATMENT", 0, 9], ["both myelosuppression", "PROBLEM", 17, 38], ["renal toxicity", "PROBLEM", 43, 57], ["treat ment", "TREATMENT", 136, 146], ["both", "OBSERVATION_MODIFIER", 17, 21], ["myelosuppression", "OBSERVATION", 22, 38], ["renal", "ANATOMY", 43, 48], ["toxicity", "OBSERVATION", 49, 57]]], ["Patients with CMV disease also are frequently given hyperimmune intravenous immunoglobulin (IVIG) as passive vaccination therapy.", [["intravenous", "ANATOMY", 64, 75], ["CMV disease", "DISEASE", 14, 25], ["Patients", "ORGANISM", 0, 8], ["CMV", "ORGANISM", 14, 17], ["hyperimmune", "ORGANISM", 52, 63], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 75], ["immunoglobulin", "SIMPLE_CHEMICAL", 76, 90], ["IVIG", "SIMPLE_CHEMICAL", 92, 96], ["hyperimmune intravenous immunoglobulin", "PROTEIN", 52, 90], ["Patients", "SPECIES", 0, 8], ["CMV", "SPECIES", 14, 17], ["hyperimmune", "SPECIES", 52, 63], ["CMV disease", "PROBLEM", 14, 25], ["hyperimmune intravenous immunoglobulin", "TREATMENT", 52, 90], ["IVIG)", "TREATMENT", 92, 97], ["passive vaccination therapy", "TREATMENT", 101, 128], ["CMV disease", "OBSERVATION", 14, 25]]], ["Very few studies have compared these drugs for efficacy in CMV pneumonia.", [["CMV pneumonia", "DISEASE", 59, 72], ["CMV", "ORGANISM", 59, 62], ["CMV", "SPECIES", 59, 62], ["these drugs", "TREATMENT", 31, 42], ["CMV pneumonia", "PROBLEM", 59, 72], ["CMV pneumonia", "OBSERVATION", 59, 72]]], ["Treatment lasts from 14 to 21 days and should be guided by blood tests measuring the level of CMV viremia.", [["blood", "ANATOMY", 59, 64], ["viremia", "DISEASE", 98, 105], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["CMV", "ORGANISM", 94, 97], ["CMV", "SPECIES", 94, 97], ["Treatment", "TREATMENT", 0, 9], ["blood tests", "TEST", 59, 70], ["CMV viremia", "PROBLEM", 94, 105], ["CMV viremia", "OBSERVATION", 94, 105]]], ["Patients at risk for such infection often are given antiviral prophylaxis such as with valganciclovir.", [["infection", "DISEASE", 26, 35], ["valganciclovir", "CHEMICAL", 87, 101], ["valganciclovir", "CHEMICAL", 87, 101], ["Patients", "ORGANISM", 0, 8], ["valganciclovir", "SIMPLE_CHEMICAL", 87, 101], ["Patients", "SPECIES", 0, 8], ["such infection", "PROBLEM", 21, 35], ["antiviral prophylaxis", "TREATMENT", 52, 73], ["valganciclovir", "TREATMENT", 87, 101], ["infection", "OBSERVATION", 26, 35]]], ["The mortality rate for established CMV pneumonia is up to 50% in hematopoietic stem cell transplant recipients but is less in other types of immunocompromised patients.", [["hematopoietic stem cell", "ANATOMY", 65, 88], ["CMV pneumonia", "DISEASE", 35, 48], ["CMV", "ORGANISM", 35, 38], ["hematopoietic stem cell", "CELL", 65, 88], ["recipients", "ORGANISM", 100, 110], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["CMV", "SPECIES", 35, 38], ["The mortality rate", "TEST", 0, 18], ["established CMV pneumonia", "PROBLEM", 23, 48], ["hematopoietic stem cell transplant recipients", "TREATMENT", 65, 110], ["pneumonia", "OBSERVATION", 39, 48], ["hematopoietic stem cell transplant", "OBSERVATION", 65, 99], ["recipients", "OBSERVATION", 100, 110], ["less", "OBSERVATION_MODIFIER", 118, 122], ["immunocompromised", "OBSERVATION", 141, 158]]], ["Detection of CMV viremia frequently leads to preemptive therapy before symptomatic CMV infection develops, increasing the numbers of patients requiring treatment but improving overall outcome.LUNG INFECTIONS DUE TO OTHER HERPESVIRUSESHerpes simplex virus (HSV) and varicellazoster virus (VZV) are rare causes of lung infection in immunocompromised patients, with a presentation similar to that for CMV pneumo nia, but patients also may have the characteristic skin involve ment.", [["lung", "ANATOMY", 312, 316], ["skin", "ANATOMY", 460, 464], ["CMV viremia", "DISEASE", 13, 24], ["CMV infection", "DISEASE", 83, 96], ["HERPESVIRUSESHerpes simplex virus (HSV) and varicellazoster virus", "DISEASE", 221, 286], ["lung infection", "DISEASE", 312, 326], ["CMV pneumo nia", "DISEASE", 398, 412], ["CMV", "ORGANISM", 13, 16], ["CMV", "ORGANISM", 83, 86], ["patients", "ORGANISM", 133, 141], ["HERPESVIRUSESHerpes simplex virus", "ORGANISM", 221, 254], ["HSV", "ORGANISM", 256, 259], ["varicellazoster virus", "ORGANISM", 265, 286], ["VZV", "ORGANISM", 288, 291], ["lung", "ORGAN", 312, 316], ["patients", "ORGANISM", 348, 356], ["CMV", "ORGANISM", 398, 401], ["patients", "ORGANISM", 418, 426], ["skin", "ORGAN", 460, 464], ["patients", "SPECIES", 133, 141], ["varicellazoster virus", "SPECIES", 265, 286], ["patients", "SPECIES", 348, 356], ["patients", "SPECIES", 418, 426], ["CMV", "SPECIES", 13, 16], ["CMV", "SPECIES", 83, 86], ["HSV", "SPECIES", 256, 259], ["varicellazoster virus", "SPECIES", 265, 286], ["VZV", "SPECIES", 288, 291], ["CMV pneumo nia", "SPECIES", 398, 412], ["CMV viremia", "PROBLEM", 13, 24], ["preemptive therapy", "TREATMENT", 45, 63], ["symptomatic CMV infection", "PROBLEM", 71, 96], ["treatment", "TREATMENT", 152, 161], ["LUNG INFECTIONS", "PROBLEM", 192, 207], ["OTHER HERPESVIRUSESHerpes simplex virus", "PROBLEM", 215, 254], ["HSV", "PROBLEM", 256, 259], ["varicellazoster virus", "PROBLEM", 265, 286], ["VZV", "PROBLEM", 288, 291], ["lung infection", "PROBLEM", 312, 326], ["CMV pneumo nia", "PROBLEM", 398, 412], ["CMV viremia", "OBSERVATION", 13, 24], ["infection", "OBSERVATION", 87, 96], ["INFECTIONS", "OBSERVATION", 197, 207], ["simplex virus", "OBSERVATION", 241, 254], ["varicellazoster virus", "OBSERVATION", 265, 286], ["rare causes of", "UNCERTAINTY", 297, 311], ["lung", "ANATOMY", 312, 316], ["infection", "OBSERVATION", 317, 326], ["immunocompromised", "OBSERVATION", 330, 347], ["skin", "ANATOMY", 460, 464]]], ["Microbiologic diagnosis relies on isolation of the virus from skin lesions or BAL fluid, and treatment is with highdose acyclovir.", [["skin lesions", "ANATOMY", 62, 74], ["BAL fluid", "ANATOMY", 78, 87], ["acyclovir", "CHEMICAL", 120, 129], ["acyclovir", "CHEMICAL", 120, 129], ["skin lesions", "CANCER", 62, 74], ["BAL fluid", "ORGANISM_SUBSTANCE", 78, 87], ["acyclovir", "SIMPLE_CHEMICAL", 120, 129], ["Microbiologic diagnosis", "TEST", 0, 23], ["the virus", "PROBLEM", 47, 56], ["skin lesions", "PROBLEM", 62, 74], ["BAL fluid", "PROBLEM", 78, 87], ["treatment", "TREATMENT", 93, 102], ["highdose acyclovir", "TREATMENT", 111, 129], ["skin", "ANATOMY", 62, 66], ["lesions", "OBSERVATION", 67, 74], ["BAL fluid", "OBSERVATION", 78, 87]]], ["Human herpesvirus type 6 (HHV6) may be an important pathogen causing infection after HSCT.", [["infection", "DISEASE", 69, 78], ["Human herpesvirus type 6", "ORGANISM", 0, 24], ["HHV6", "GENE_OR_GENE_PRODUCT", 26, 30], ["Human", "SPECIES", 0, 5], ["Human herpesvirus type 6", "SPECIES", 0, 24], ["HHV6", "SPECIES", 26, 30], ["Human herpesvirus type", "PROBLEM", 0, 22], ["HHV6", "PROBLEM", 26, 30], ["infection", "PROBLEM", 69, 78], ["infection", "OBSERVATION", 69, 78]]], ["Patients with HHV6 viremia have more CMV reactivation and unex plained fever and rash compared with patients without HHV6 viremia, and highlevel HHV6 viremia (up to 25,000 copies/ mL) has been associated with culturenegative pneumonitis.General ConsiderationsLower respiratory tract infections with respiratory viruses are relatively common in immunocompromised patients.", [["viremia", "DISEASE", 19, 26], ["fever", "DISEASE", 71, 76], ["rash", "DISEASE", 81, 85], ["viremia", "DISEASE", 122, 129], ["viremia", "DISEASE", 150, 157], ["pneumonitis", "DISEASE", 225, 236], ["Lower respiratory tract infections", "DISEASE", 259, 293], ["respiratory viruses", "DISEASE", 299, 318], ["Patients", "ORGANISM", 0, 8], ["HHV6", "GENE_OR_GENE_PRODUCT", 14, 18], ["CMV", "ORGANISM", 37, 40], ["patients", "ORGANISM", 100, 108], ["HHV6", "GENE_OR_GENE_PRODUCT", 145, 149], ["Lower respiratory tract", "ORGANISM_SUBDIVISION", 259, 282], ["patients", "ORGANISM", 362, 370], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 362, 370], ["HHV6", "SPECIES", 14, 18], ["CMV", "SPECIES", 37, 40], ["HHV6", "SPECIES", 117, 121], ["HHV6", "SPECIES", 145, 149], ["HHV6 viremia", "PROBLEM", 14, 26], ["CMV reactivation", "PROBLEM", 37, 53], ["unex plained fever", "PROBLEM", 58, 76], ["rash", "PROBLEM", 81, 85], ["HHV6 viremia", "PROBLEM", 117, 129], ["highlevel HHV6 viremia", "PROBLEM", 135, 157], ["culturenegative pneumonitis", "PROBLEM", 209, 236], ["Lower respiratory tract infections", "PROBLEM", 259, 293], ["respiratory viruses", "PROBLEM", 299, 318], ["HHV6 viremia", "OBSERVATION", 14, 26], ["CMV reactivation", "OBSERVATION", 37, 53], ["HHV6 viremia", "OBSERVATION", 145, 157], ["associated with", "UNCERTAINTY", 193, 208], ["culturenegative", "OBSERVATION_MODIFIER", 209, 224], ["pneumonitis", "OBSERVATION", 225, 236], ["Lower", "ANATOMY_MODIFIER", 259, 264], ["respiratory tract", "ANATOMY", 265, 282], ["respiratory viruses", "OBSERVATION", 299, 318]]], ["The common relevant viruses are respiratory syncytial virus (RSV), parainfluenza virus (PIV) (90% serotype III), influenza A virus, adenovirus, human metapneumovirus, coronavirus, and possi bly rhinovirus.", [["respiratory syncytial virus (RSV), parainfluenza virus", "DISEASE", 32, 86], ["influenza A virus", "DISEASE", 113, 130], ["human metapneumovirus, coronavirus", "DISEASE", 144, 178], ["respiratory syncytial virus", "ORGANISM", 32, 59], ["RSV", "ORGANISM", 61, 64], ["parainfluenza virus", "ORGANISM", 67, 86], ["serotype III", "ORGANISM", 98, 110], ["influenza A virus", "ORGANISM", 113, 130], ["adenovirus", "ORGANISM", 132, 142], ["human", "ORGANISM", 144, 149], ["metapneumovirus", "ORGANISM", 150, 165], ["coronavirus", "ORGANISM", 167, 178], ["possi bly rhinovirus", "ORGANISM", 184, 204], ["respiratory syncytial virus", "SPECIES", 32, 59], ["parainfluenza virus", "SPECIES", 67, 86], ["influenza A virus", "SPECIES", 113, 130], ["human", "SPECIES", 144, 149], ["metapneumovirus", "SPECIES", 150, 165], ["coronavirus", "SPECIES", 167, 178], ["possi bly rhinovirus", "SPECIES", 184, 204], ["respiratory syncytial virus", "SPECIES", 32, 59], ["RSV", "SPECIES", 61, 64], ["parainfluenza virus", "SPECIES", 67, 86], ["PIV", "SPECIES", 88, 91], ["influenza A virus", "SPECIES", 113, 130], ["adenovirus", "SPECIES", 132, 142], ["human metapneumovirus", "SPECIES", 144, 165], ["possi bly rhinovirus", "SPECIES", 184, 204], ["The common relevant viruses", "PROBLEM", 0, 27], ["respiratory syncytial virus", "PROBLEM", 32, 59], ["parainfluenza virus", "PROBLEM", 67, 86], ["PIV", "TEST", 88, 91], ["influenza A virus", "PROBLEM", 113, 130], ["adenovirus", "PROBLEM", 132, 142], ["human metapneumovirus", "PROBLEM", 144, 165], ["coronavirus", "PROBLEM", 167, 178], ["rhinovirus", "PROBLEM", 194, 204], ["viruses", "OBSERVATION", 20, 27], ["respiratory syncytial virus", "OBSERVATION", 32, 59], ["parainfluenza virus", "OBSERVATION", 67, 86], ["rhinovirus", "OBSERVATION", 194, 204]]], ["Infection is acquired by inhalation of infected respiratory droplets from other infected patients or mildly affected immunocompetent contacts.", [["respiratory droplets", "ANATOMY", 48, 68], ["Infection", "DISEASE", 0, 9], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Infection", "PROBLEM", 0, 9], ["infected respiratory droplets", "PROBLEM", 39, 68], ["mildly affected immunocompetent contacts", "PROBLEM", 101, 141], ["infected", "OBSERVATION_MODIFIER", 39, 47], ["respiratory droplets", "OBSERVATION", 48, 68], ["infected", "OBSERVATION_MODIFIER", 80, 88], ["mildly", "OBSERVATION_MODIFIER", 101, 107], ["affected", "OBSERVATION_MODIFIER", 108, 116], ["immunocompetent", "OBSERVATION", 117, 132]]], ["Consequently, immuno compromised patients should avoid contact with social contacts or members of the hospital staff clearly suffering from upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 140, 163], ["respiratory tract infections", "DISEASE", 146, 174], ["patients", "ORGANISM", 33, 41], ["upper", "ORGANISM_SUBDIVISION", 140, 145], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["patients", "SPECIES", 33, 41], ["upper respiratory tract infections", "PROBLEM", 140, 174], ["upper", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["infections", "OBSERVATION", 164, 174]]], ["Nosocomial epidemics of respiratory viruses readily occur, so infected patients should be effectively isolated.", [["respiratory viruses", "DISEASE", 24, 43], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Nosocomial epidemics of respiratory viruses", "PROBLEM", 0, 43], ["respiratory viruses", "OBSERVATION", 24, 43]]], ["Respiratory viral infections are associated with defects in cellmediated immunity and generally are a late complication after HSCT.Clinical Features and DiagnosisRespiratory virus lung infections often cause a bronchiolitis, manifesting with cough, fever, wheeze, and inspiratory squeaks.", [["lung", "ANATOMY", 180, 184], ["Respiratory viral infections", "DISEASE", 0, 28], ["DiagnosisRespiratory virus lung infections", "DISEASE", 153, 195], ["bronchiolitis", "DISEASE", 210, 223], ["cough", "DISEASE", 242, 247], ["fever", "DISEASE", 249, 254], ["wheeze", "DISEASE", 256, 262], ["inspiratory squeaks", "DISEASE", 268, 287], ["DiagnosisRespiratory virus", "ORGANISM", 153, 179], ["lung", "ORGAN", 180, 184], ["DiagnosisRespiratory virus", "SPECIES", 153, 179], ["Respiratory viral infections", "PROBLEM", 0, 28], ["defects in cellmediated immunity", "PROBLEM", 49, 81], ["a late complication", "PROBLEM", 100, 119], ["Clinical Features", "PROBLEM", 131, 148], ["DiagnosisRespiratory virus lung infections", "PROBLEM", 153, 195], ["a bronchiolitis", "PROBLEM", 208, 223], ["cough", "PROBLEM", 242, 247], ["fever", "PROBLEM", 249, 254], ["wheeze", "PROBLEM", 256, 262], ["inspiratory squeaks", "PROBLEM", 268, 287], ["viral infections", "OBSERVATION", 12, 28], ["defects", "OBSERVATION", 49, 56], ["DiagnosisRespiratory virus", "OBSERVATION", 153, 179], ["lung", "ANATOMY", 180, 184], ["infections", "OBSERVATION", 185, 195], ["bronchiolitis", "OBSERVATION", 210, 223], ["cough", "OBSERVATION", 242, 247], ["inspiratory squeaks", "OBSERVATION", 268, 287]]], ["The chest radiograph may be normal in appearance, but a CT scan will show evidence of small airway involvement, with widespread treeinbud changes (Figure 28-10) .", [["chest", "ANATOMY", 4, 9], ["airway", "ANATOMY", 92, 98], ["airway", "MULTI-TISSUE_STRUCTURE", 92, 98], ["The chest radiograph", "TEST", 0, 20], ["a CT scan", "TEST", 54, 63], ["small airway involvement", "PROBLEM", 86, 110], ["widespread treeinbud changes", "PROBLEM", 117, 145], ["chest", "ANATOMY", 4, 9], ["normal", "OBSERVATION", 28, 34], ["evidence of", "UNCERTAINTY", 74, 85], ["small", "OBSERVATION_MODIFIER", 86, 91], ["airway", "ANATOMY", 92, 98], ["involvement", "OBSERVATION", 99, 110], ["widespread", "OBSERVATION_MODIFIER", 117, 127], ["treeinbud", "OBSERVATION", 128, 137]]], ["The main considerations in the differential diagnosis in this clinical sce nario are Chlamydia or Mycoplasma infection, extensive bacte rial bronchitis (usually associated with bronchiectasis), and possibly Aspergillus tracheobronchitis.", [["Chlamydia", "DISEASE", 85, 94], ["Mycoplasma infection", "DISEASE", 98, 118], ["bronchitis", "DISEASE", 141, 151], ["bronchiectasis", "DISEASE", 177, 191], ["Aspergillus tracheobronchitis", "DISEASE", 207, 236], ["Chlamydia", "ORGANISM", 85, 94], ["Aspergillus tracheobronchitis", "SPECIES", 207, 236], ["Chlamydia", "PROBLEM", 85, 94], ["Mycoplasma infection", "PROBLEM", 98, 118], ["extensive bacte rial bronchitis", "PROBLEM", 120, 151], ["bronchiectasis", "PROBLEM", 177, 191], ["Aspergillus tracheobronchitis", "PROBLEM", 207, 236], ["main", "OBSERVATION_MODIFIER", 4, 8], ["Chlamydia", "OBSERVATION", 85, 94], ["Mycoplasma infection", "OBSERVATION", 98, 118], ["extensive", "OBSERVATION_MODIFIER", 120, 129], ["bacte rial bronchitis", "OBSERVATION", 130, 151], ["bronchiectasis", "OBSERVATION", 177, 191], ["possibly", "UNCERTAINTY", 198, 206], ["Aspergillus tracheobronchitis", "OBSERVATION", 207, 236]]], ["With more severe disease associated with significant pneumonitis, CT evidence will include small, poorly defined centrilobular nodules and usually bilateral patchy areas of peribronchial ground glass opacity and consolidation.", [["centrilobular nodules", "ANATOMY", 113, 134], ["pneumonitis", "DISEASE", 53, 64], ["centrilobular nodules", "CANCER", 113, 134], ["more severe disease", "PROBLEM", 5, 24], ["significant pneumonitis", "PROBLEM", 41, 64], ["CT evidence", "TEST", 66, 77], ["small, poorly defined centrilobular nodules", "PROBLEM", 91, 134], ["usually bilateral patchy areas of peribronchial ground glass opacity", "PROBLEM", 139, 207], ["consolidation", "PROBLEM", 212, 225], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["disease", "OBSERVATION", 17, 24], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["pneumonitis", "OBSERVATION", 53, 64], ["small", "OBSERVATION_MODIFIER", 91, 96], ["poorly defined", "OBSERVATION_MODIFIER", 98, 112], ["centrilobular", "OBSERVATION_MODIFIER", 113, 126], ["nodules", "OBSERVATION", 127, 134], ["usually", "OBSERVATION_MODIFIER", 139, 146], ["bilateral", "OBSERVATION_MODIFIER", 147, 156], ["patchy", "OBSERVATION_MODIFIER", 157, 163], ["areas", "OBSERVATION_MODIFIER", 164, 169], ["peribronchial", "ANATOMY", 173, 186], ["ground glass opacity", "OBSERVATION", 187, 207], ["consolidation", "OBSERVATION", 212, 225]]], ["The differential diagnosis in such cases is much broader in scope, including bacterial pneumonia, CMV pneu monitis, PCP, and noninfective causes of pneumonitis.", [["pneumonia", "DISEASE", 87, 96], ["CMV pneu monitis", "DISEASE", 98, 114], ["PCP", "DISEASE", 116, 119], ["pneumonitis", "DISEASE", 148, 159], ["CMV", "ORGANISM", 98, 101], ["CMV pneu monitis", "SPECIES", 98, 114], ["bacterial pneumonia", "PROBLEM", 77, 96], ["CMV pneu monitis", "PROBLEM", 98, 114], ["PCP", "PROBLEM", 116, 119], ["pneumonitis", "PROBLEM", 148, 159], ["bacterial", "OBSERVATION_MODIFIER", 77, 86], ["pneumonia", "OBSERVATION", 87, 96], ["CMV pneu monitis", "OBSERVATION", 98, 114], ["pneumonitis", "OBSERVATION", 148, 159]]], ["In many patients, the diagnosis of respiratory viral infection can be rapidly confirmed by noninvasive testing using nasopharyngeal aspirate samples for either immunofluorescence for viral anti gens or PCR assay for viral nucleic acids.", [["respiratory", "ANATOMY", 35, 46], ["nasopharyngeal aspirate samples", "ANATOMY", 117, 148], ["respiratory viral infection", "DISEASE", 35, 62], ["nucleic acids", "CHEMICAL", 222, 235], ["patients", "ORGANISM", 8, 16], ["nasopharyngeal aspirate samples", "ORGANISM_SUBSTANCE", 117, 148], ["patients", "SPECIES", 8, 16], ["respiratory viral infection", "PROBLEM", 35, 62], ["noninvasive testing", "TEST", 91, 110], ["nasopharyngeal aspirate samples", "TEST", 117, 148], ["immunofluorescence", "TEST", 160, 178], ["viral anti gens", "TEST", 183, 198], ["PCR assay", "TEST", 202, 211], ["viral nucleic acids", "PROBLEM", 216, 235], ["respiratory", "ANATOMY", 35, 46], ["viral infection", "OBSERVATION", 47, 62]]], ["A negative result on nasopharyngeal aspirate studies should lead to FOB, because these tests are more sensitive with BAL fluid than with naso pharyngeal aspirate samples.", [["nasopharyngeal aspirate", "ANATOMY", 21, 44], ["BAL fluid", "ANATOMY", 117, 126], ["naso pharyngeal aspirate samples", "ANATOMY", 137, 169], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 21, 44], ["BAL fluid", "ORGANISM_SUBSTANCE", 117, 126], ["naso pharyngeal aspirate samples", "MULTI-TISSUE_STRUCTURE", 137, 169], ["nasopharyngeal aspirate studies", "TEST", 21, 52], ["FOB", "TEST", 68, 71], ["these tests", "TEST", 81, 92], ["BAL fluid", "TEST", 117, 126], ["naso pharyngeal aspirate samples", "TEST", 137, 169], ["pharyngeal", "ANATOMY", 142, 152]]], ["Respiratory viral infections in immunocompromised patients are often very prolonged but showing \"tree-in-bud\" changes (most obvious in the right upper lobe) due to PIV serotype 3 bronchiolitis in a patient with relapsed acute myeloid leukemia who had completed chemotherapy 25 days previously and presented with coryzal symptoms, cough, and a mild fever.", [["bud", "ANATOMY", 105, 108], ["right upper lobe", "ANATOMY", 139, 155], ["acute myeloid leukemia", "ANATOMY", 220, 242], ["coryzal", "ANATOMY", 312, 319], ["Respiratory viral infections", "DISEASE", 0, 28], ["bronchiolitis", "DISEASE", 179, 192], ["acute myeloid leukemia", "DISEASE", 220, 242], ["coryzal symptoms", "DISEASE", 312, 328], ["cough", "DISEASE", 330, 335], ["fever", "DISEASE", 348, 353], ["patients", "ORGANISM", 50, 58], ["right", "ORGANISM_SUBDIVISION", 139, 144], ["upper lobe", "ORGAN", 145, 155], ["patient", "ORGANISM", 198, 205], ["acute myeloid leukemia", "CANCER", 220, 242], ["patients", "SPECIES", 50, 58], ["patient", "SPECIES", 198, 205], ["Respiratory viral infections", "PROBLEM", 0, 28], ["PIV serotype 3 bronchiolitis", "PROBLEM", 164, 192], ["relapsed acute myeloid leukemia", "PROBLEM", 211, 242], ["chemotherapy", "TREATMENT", 261, 273], ["coryzal symptoms", "PROBLEM", 312, 328], ["cough", "PROBLEM", 330, 335], ["a mild fever", "PROBLEM", 341, 353], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28], ["immunocompromised", "OBSERVATION", 32, 49], ["tree", "OBSERVATION_MODIFIER", 97, 101], ["right upper lobe", "ANATOMY", 139, 155], ["PIV serotype 3 bronchiolitis", "OBSERVATION", 164, 192], ["relapsed", "OBSERVATION_MODIFIER", 211, 219], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["myeloid leukemia", "OBSERVATION", 226, 242], ["mild", "OBSERVATION_MODIFIER", 343, 347], ["fever", "OBSERVATION", 348, 353]]], ["PIV, parainfluenza virus. not too severe, with symptoms and positive results on nasopha ryngeal aspirate studies persisting for several weeks.Treatment and Special Considerations with Specific VirusesWith the exception of influenza, treatment options for respira tory viruses are limited and depend on the underlying virus (see Table 284 ).", [["parainfluenza virus", "DISEASE", 5, 24], ["influenza", "DISEASE", 222, 231], ["respira tory viruses", "DISEASE", 255, 275], ["parainfluenza virus", "ORGANISM", 5, 24], ["respira tory viruses", "ORGANISM", 255, 275], ["parainfluenza", "SPECIES", 5, 18], ["parainfluenza virus", "SPECIES", 5, 24], ["PIV", "TREATMENT", 0, 3], ["parainfluenza virus", "PROBLEM", 5, 24], ["symptoms", "PROBLEM", 47, 55], ["nasopha ryngeal aspirate studies", "TEST", 80, 112], ["Treatment", "TREATMENT", 142, 151], ["influenza", "PROBLEM", 222, 231], ["treatment options", "TREATMENT", 233, 250], ["respira tory viruses", "PROBLEM", 255, 275], ["the underlying virus", "PROBLEM", 302, 322], ["parainfluenza virus", "OBSERVATION", 5, 24], ["too severe", "OBSERVATION_MODIFIER", 30, 40], ["influenza", "OBSERVATION", 222, 231]]], ["In the absence of pneumonia, the mortality associ ated with respiratory virus infection in immunocompromised antiviral drug therapy for adenoviral infection has been per formed.", [["pneumonia", "DISEASE", 18, 27], ["associ", "DISEASE", 43, 49], ["respiratory virus infection", "DISEASE", 60, 87], ["adenoviral infection", "DISEASE", 136, 156], ["respiratory virus", "ORGANISM", 60, 77], ["adenoviral", "ORGANISM", 136, 146], ["adenoviral", "SPECIES", 136, 146], ["pneumonia", "PROBLEM", 18, 27], ["the mortality associ", "PROBLEM", 29, 49], ["respiratory virus infection", "PROBLEM", 60, 87], ["immunocompromised antiviral drug therapy", "TREATMENT", 91, 131], ["adenoviral infection", "PROBLEM", 136, 156], ["pneumonia", "OBSERVATION", 18, 27], ["respiratory virus infection", "OBSERVATION", 60, 87], ["immunocompromised antiviral", "OBSERVATION", 91, 118], ["infection", "OBSERVATION", 147, 156]]], ["The available data suggest that cidofovir or ribavirin may have some efficacy.Respiratory Viruses and Lung Allograft SyndromesRespiratory viral infection early after hematopoietic cell trans plantation can be a predictor for the development of alloim mune lung syndromes such as progressive airways obstruction due to bronchiolitis obliterans, perhaps as they sensitize the respiratory epithelium for lung involvement by graftversus host disease.", [["Lung", "ANATOMY", 102, 106], ["hematopoietic cell", "ANATOMY", 166, 184], ["lung", "ANATOMY", 256, 260], ["airways", "ANATOMY", 291, 298], ["respiratory epithelium", "ANATOMY", 374, 396], ["lung", "ANATOMY", 401, 405], ["cidofovir", "CHEMICAL", 32, 41], ["ribavirin", "CHEMICAL", 45, 54], ["viral infection", "DISEASE", 138, 153], ["lung syndromes", "DISEASE", 256, 270], ["airways obstruction", "DISEASE", 291, 310], ["bronchiolitis obliterans", "DISEASE", 318, 342], ["cidofovir", "CHEMICAL", 32, 41], ["ribavirin", "CHEMICAL", 45, 54], ["cidofovir", "SIMPLE_CHEMICAL", 32, 41], ["ribavirin", "SIMPLE_CHEMICAL", 45, 54], ["Lung", "ORGAN", 102, 106], ["hematopoietic cell", "CELL", 166, 184], ["lung", "ORGAN", 256, 260], ["airways", "ORGAN", 291, 298], ["respiratory epithelium", "TISSUE", 374, 396], ["lung", "ORGAN", 401, 405], ["cidofovir", "TREATMENT", 32, 41], ["ribavirin", "TREATMENT", 45, 54], ["Respiratory Viruses", "PROBLEM", 78, 97], ["Lung Allograft SyndromesRespiratory viral infection", "PROBLEM", 102, 153], ["hematopoietic cell trans plantation", "TREATMENT", 166, 201], ["alloim mune lung syndromes", "PROBLEM", 244, 270], ["progressive airways obstruction", "PROBLEM", 279, 310], ["bronchiolitis obliterans", "PROBLEM", 318, 342], ["the respiratory epithelium", "PROBLEM", 370, 396], ["lung involvement", "PROBLEM", 401, 417], ["graftversus host disease", "PROBLEM", 421, 445], ["Viruses", "OBSERVATION", 90, 97], ["Lung", "ANATOMY", 102, 106], ["Allograft", "OBSERVATION", 107, 116], ["SyndromesRespiratory", "OBSERVATION_MODIFIER", 117, 137], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153], ["hematopoietic cell", "OBSERVATION", 166, 184], ["lung", "ANATOMY", 256, 260], ["syndromes", "OBSERVATION", 261, 270], ["progressive", "OBSERVATION_MODIFIER", 279, 290], ["airways", "ANATOMY", 291, 298], ["obstruction", "OBSERVATION", 299, 310], ["bronchiolitis obliterans", "OBSERVATION", 318, 342], ["respiratory epithelium", "OBSERVATION", 374, 396], ["lung", "ANATOMY", 401, 405], ["graftversus host disease", "OBSERVATION", 421, 445]]], ["Clinically, patients will present with rapidly pro gressive airway obstruction in the context of active respiratory viral infection and will require aggressive immunosuppression to prevent progression to respiratory failure.General ConsiderationsInvasive infections with Aspergillus constitute a common and important cause of lung infection in immunodeficient patients.", [["airway", "ANATOMY", 60, 66], ["respiratory", "ANATOMY", 104, 115], ["respiratory", "ANATOMY", 204, 215], ["lung", "ANATOMY", 326, 330], ["airway obstruction", "DISEASE", 60, 78], ["respiratory viral infection", "DISEASE", 104, 131], ["respiratory failure", "DISEASE", 204, 223], ["Invasive infections", "DISEASE", 246, 265], ["lung infection", "DISEASE", 326, 340], ["patients", "ORGANISM", 12, 20], ["airway obstruction", "PATHOLOGICAL_FORMATION", 60, 78], ["lung", "ORGAN", 326, 330], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 360, 368], ["rapidly pro gressive airway obstruction", "PROBLEM", 39, 78], ["active respiratory viral infection", "PROBLEM", 97, 131], ["aggressive immunosuppression", "TREATMENT", 149, 177], ["respiratory failure", "PROBLEM", 204, 223], ["Invasive infections", "PROBLEM", 246, 265], ["Aspergillus", "PROBLEM", 271, 282], ["lung infection in immunodeficient patients", "PROBLEM", 326, 368], ["airway", "ANATOMY", 60, 66], ["obstruction", "OBSERVATION", 67, 78], ["active", "OBSERVATION_MODIFIER", 97, 103], ["respiratory", "ANATOMY", 104, 115], ["viral infection", "OBSERVATION", 116, 131], ["respiratory failure", "OBSERVATION", 204, 223], ["Invasive", "OBSERVATION_MODIFIER", 246, 254], ["infections", "OBSERVATION", 255, 265], ["lung", "ANATOMY", 326, 330], ["infection", "OBSERVATION", 331, 340]]], ["Aspergillus organisms are saprophytic filamentous fungi that are found ubiquitously in the environment.", [["Aspergillus organisms", "ORGANISM", 0, 21], ["Aspergillus organisms", "PROBLEM", 0, 21], ["saprophytic filamentous fungi", "PROBLEM", 26, 55], ["saprophytic", "OBSERVATION_MODIFIER", 26, 37], ["filamentous fungi", "OBSERVATION", 38, 55]]], ["They propagate by dispersal of airborne spores, which are 2 to 3 \u00b5m in diameter and can therefore reach the distal airway.", [["spores", "ANATOMY", 40, 46], ["distal airway", "ANATOMY", 108, 121], ["airway", "MULTI-TISSUE_STRUCTURE", 115, 121], ["dispersal", "OBSERVATION_MODIFIER", 18, 27], ["airborne spores", "OBSERVATION", 31, 46], ["2 to 3 \u00b5m", "OBSERVATION_MODIFIER", 58, 67], ["distal", "ANATOMY_MODIFIER", 108, 114], ["airway", "ANATOMY", 115, 121]]], ["Exposure to airborne spores is essentially continuous, but this rarely causes a clinical problem unless the host's immune response is impaired.", [["airborne spores", "PROBLEM", 12, 27], ["a clinical problem", "PROBLEM", 78, 96], ["airborne spores", "OBSERVATION", 12, 27]]], ["In a patient with impaired macrophage or neutrophil function, however, the spores can germinate and form a colony of branch ing multicellular hyphae that gradually expands and penetrates through host tissue, causing invasive pulmonary aspergillosis (IPA).", [["macrophage", "ANATOMY", 27, 37], ["neutrophil", "ANATOMY", 41, 51], ["spores", "ANATOMY", 75, 81], ["colony", "ANATOMY", 107, 113], ["hyphae", "ANATOMY", 142, 148], ["tissue", "ANATOMY", 200, 206], ["invasive pulmonary aspergillosis", "ANATOMY", 216, 248], ["invasive pulmonary aspergillosis", "DISEASE", 216, 248], ["IPA", "DISEASE", 250, 253], ["patient", "ORGANISM", 5, 12], ["macrophage", "CELL", 27, 37], ["neutrophil", "CELL", 41, 51], ["tissue", "TISSUE", 200, 206], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 225, 248], ["patient", "SPECIES", 5, 12], ["impaired macrophage", "PROBLEM", 18, 37], ["neutrophil function", "PROBLEM", 41, 60], ["the spores", "PROBLEM", 71, 81], ["branch ing multicellular hyphae", "PROBLEM", 117, 148], ["invasive pulmonary aspergillosis", "PROBLEM", 216, 248], ["impaired", "OBSERVATION_MODIFIER", 18, 26], ["macrophage", "OBSERVATION", 27, 37], ["neutrophil function", "OBSERVATION", 41, 60], ["colony", "OBSERVATION_MODIFIER", 107, 113], ["branch", "OBSERVATION_MODIFIER", 117, 123], ["multicellular hyphae", "OBSERVATION", 128, 148], ["host tissue", "OBSERVATION_MODIFIER", 195, 206], ["invasive", "OBSERVATION_MODIFIER", 216, 224], ["pulmonary", "ANATOMY", 225, 234], ["aspergillosis", "OBSERVATION", 235, 248]]], ["The usual site of infection is the respiratory tract, includ ing the sinuses, but bloodborne spread to internal organs (especially the CNS), bone, and skin is common.", [["respiratory tract", "ANATOMY", 35, 52], ["sinuses", "ANATOMY", 69, 76], ["internal organs", "ANATOMY", 103, 118], ["CNS", "ANATOMY", 135, 138], ["bone", "ANATOMY", 141, 145], ["skin", "ANATOMY", 151, 155], ["infection", "DISEASE", 18, 27], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["sinuses", "ORGAN", 69, 76], ["organs", "ORGAN", 112, 118], ["CNS", "ANATOMICAL_SYSTEM", 135, 138], ["bone", "TISSUE", 141, 145], ["skin", "ORGAN", 151, 155], ["infection", "PROBLEM", 18, 27], ["the respiratory tract", "PROBLEM", 31, 52], ["bloodborne", "PROBLEM", 82, 92], ["infection", "OBSERVATION", 18, 27], ["respiratory tract", "ANATOMY", 35, 52], ["sinuses", "ANATOMY", 69, 76], ["internal organs", "ANATOMY", 103, 118], ["CNS", "ANATOMY", 135, 138], ["bone", "ANATOMY", 141, 145], ["skin", "ANATOMY", 151, 155], ["common", "OBSERVATION", 159, 165]]], ["The most frequently isolated species causing infection are A. fumigatus (66% of cases), Aspergillus flavus (14%), Aspergillus niger (7%), and Aspergillus terreus (4%).Clinical FeaturesIPA is mainly a disease that affects patients with hematologic malignancies receiving chemotherapy, persons with aplastic anemia, or transplant recipients in the early phase after HSCT.", [["hematologic malignancies", "ANATOMY", 235, 259], ["infection", "DISEASE", 45, 54], ["A. fumigatus", "DISEASE", 59, 71], ["Aspergillus flavus", "DISEASE", 88, 106], ["Aspergillus niger", "DISEASE", 114, 131], ["Aspergillus terreus", "DISEASE", 142, 161], ["hematologic malignancies", "DISEASE", 235, 259], ["aplastic anemia", "DISEASE", 297, 312], ["A. fumigatus", "ORGANISM", 59, 71], ["Aspergillus flavus", "ORGANISM", 88, 106], ["Aspergillus niger", "ORGANISM", 114, 131], ["Aspergillus terreus", "ORGANISM", 142, 161], ["patients", "ORGANISM", 221, 229], ["hematologic malignancies", "CANCER", 235, 259], ["persons", "ORGANISM", 284, 291], ["A. fumigatus", "SPECIES", 59, 71], ["Aspergillus flavus", "SPECIES", 88, 106], ["Aspergillus niger", "SPECIES", 114, 131], ["Aspergillus terreus", "SPECIES", 142, 161], ["patients", "SPECIES", 221, 229], ["persons", "SPECIES", 284, 291], ["A. fumigatus", "SPECIES", 59, 71], ["Aspergillus flavus", "SPECIES", 88, 106], ["Aspergillus niger", "SPECIES", 114, 131], ["Aspergillus terreus", "SPECIES", 142, 161], ["The most frequently isolated species", "PROBLEM", 0, 36], ["infection", "PROBLEM", 45, 54], ["A. fumigatus", "TEST", 59, 71], ["cases", "TEST", 80, 85], ["Aspergillus flavus", "TEST", 88, 106], ["Aspergillus niger", "TEST", 114, 131], ["Aspergillus terreus", "PROBLEM", 142, 161], ["a disease", "PROBLEM", 198, 207], ["hematologic malignancies", "PROBLEM", 235, 259], ["chemotherapy", "TREATMENT", 270, 282], ["aplastic anemia", "PROBLEM", 297, 312], ["transplant recipients", "TREATMENT", 317, 338], ["most frequently", "OBSERVATION_MODIFIER", 4, 19], ["species", "OBSERVATION", 29, 36], ["infection", "OBSERVATION", 45, 54], ["Aspergillus flavus", "OBSERVATION", 88, 106], ["Aspergillus terreus", "OBSERVATION", 142, 161], ["disease", "OBSERVATION", 200, 207], ["aplastic", "OBSERVATION_MODIFIER", 297, 305], ["anemia", "OBSERVATION", 306, 312]]], ["Significant persistent neutropenia is the strongest risk factor, with the incidence proportional to the depth and duration of neutropenia, so that more than 50% of patients with neutro penia lasting for over 4 weeks will develop IPA.", [["neutropenia", "DISEASE", 23, 34], ["neutropenia", "DISEASE", 126, 137], ["neutro penia", "DISEASE", 178, 190], ["IPA", "DISEASE", 229, 232], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["Significant persistent neutropenia", "PROBLEM", 0, 34], ["neutropenia", "PROBLEM", 126, 137], ["neutro penia", "PROBLEM", 178, 190], ["IPA", "PROBLEM", 229, 232], ["persistent", "OBSERVATION_MODIFIER", 12, 22], ["neutropenia", "OBSERVATION", 23, 34], ["neutropenia", "OBSERVATION", 126, 137]]], ["Patients at high risk also include those receiving highdose systemic corticoste roid therapy and/or have graftversushost disease (causing IPA in the late phase after HSCT), lung and liver transplant recipi ents, and patients with inherited disorders of phagocyte func tion such as chronic granulomatous disease (CGD), in which mutations in genes encoding the NADPH oxidase system impair the phagocyte oxidative burst.", [["lung", "ANATOMY", 173, 177], ["liver", "ANATOMY", 182, 187], ["phagocyte", "ANATOMY", 253, 262], ["phagocyte", "ANATOMY", 391, 400], ["graftversushost disease", "DISEASE", 105, 128], ["IPA", "CHEMICAL", 138, 141], ["inherited disorders", "DISEASE", 230, 249], ["chronic granulomatous disease", "DISEASE", 281, 310], ["CGD", "DISEASE", 312, 315], ["NADPH", "CHEMICAL", 359, 364], ["NADPH", "CHEMICAL", 359, 364], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 173, 177], ["liver", "ORGAN", 182, 187], ["patients", "ORGANISM", 216, 224], ["phagocyte", "CELL", 253, 262], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 359, 372], ["phagocyte", "CELL", 391, 400], ["NADPH oxidase", "PROTEIN", 359, 372], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 216, 224], ["highdose systemic corticoste roid therapy", "TREATMENT", 51, 92], ["graftversushost disease", "PROBLEM", 105, 128], ["IPA", "PROBLEM", 138, 141], ["lung and liver transplant recipi ents", "TREATMENT", 173, 210], ["inherited disorders", "PROBLEM", 230, 249], ["phagocyte func tion", "PROBLEM", 253, 272], ["chronic granulomatous disease", "PROBLEM", 281, 310], ["the NADPH oxidase system", "TREATMENT", 355, 379], ["the phagocyte oxidative burst", "PROBLEM", 387, 416], ["lung", "ANATOMY", 173, 177], ["liver", "ANATOMY", 182, 187], ["transplant", "OBSERVATION", 188, 198], ["phagocyte func", "OBSERVATION", 253, 267], ["chronic", "OBSERVATION_MODIFIER", 281, 288], ["granulomatous", "OBSERVATION", 289, 302], ["phagocyte oxidative burst", "OBSERVATION", 391, 416]]], ["Various genetic polymor phisms affecting Tolllike receptors (TLRs) and cytokines seem to modify the risk of invasive aspergillosis for patients in the above risk groups.", [["invasive aspergillosis", "ANATOMY", 108, 130], ["aspergillosis", "DISEASE", 117, 130], ["Tolllike receptors", "GENE_OR_GENE_PRODUCT", 41, 59], ["TLRs", "GENE_OR_GENE_PRODUCT", 61, 65], ["aspergillosis", "CANCER", 117, 130], ["patients", "ORGANISM", 135, 143], ["Tolllike receptors", "PROTEIN", 41, 59], ["TLRs", "PROTEIN", 61, 65], ["cytokines", "PROTEIN", 71, 80], ["patients", "SPECIES", 135, 143], ["Various genetic polymor phisms", "PROBLEM", 0, 30], ["cytokines", "TREATMENT", 71, 80], ["invasive aspergillosis", "PROBLEM", 108, 130], ["polymor phisms", "OBSERVATION", 16, 30], ["invasive", "OBSERVATION_MODIFIER", 108, 116], ["aspergillosis", "OBSERVATION", 117, 130]]], ["The speed of development of IPA is proportional to the level of immunosuppression, but the disease usually evolves rela tively slowly over days and weeks.", [["IPA", "CHEMICAL", 28, 31], ["IPA", "TREATMENT", 28, 31], ["immunosuppression", "TREATMENT", 64, 81], ["the disease", "PROBLEM", 87, 98], ["immunosuppression", "OBSERVATION", 64, 81], ["disease", "OBSERVATION", 91, 98]]], ["Fever may be the only symptom of IPA, although cough, pleuritic chest pain, and hemoptysis are common.", [["chest", "ANATOMY", 64, 69], ["Fever", "DISEASE", 0, 5], ["IPA", "DISEASE", 33, 36], ["cough", "DISEASE", 47, 52], ["pleuritic chest pain", "DISEASE", 54, 74], ["hemoptysis", "DISEASE", 80, 90], ["Fever", "PROBLEM", 0, 5], ["IPA", "PROBLEM", 33, 36], ["cough", "PROBLEM", 47, 52], ["pleuritic chest pain", "PROBLEM", 54, 74], ["hemoptysis", "PROBLEM", 80, 90], ["chest", "ANATOMY", 64, 69], ["hemoptysis", "OBSERVATION", 80, 90]]], ["Chest radiographs show expanding patches of irregular consolidation (often infarct shaped) or nodules that can cavitate.", [["infarct", "ANATOMY", 75, 82], ["nodules", "ANATOMY", 94, 101], ["infarct", "DISEASE", 75, 82], ["Chest radiographs", "TEST", 0, 17], ["irregular consolidation", "PROBLEM", 44, 67], ["nodules", "PROBLEM", 94, 101], ["expanding", "OBSERVATION_MODIFIER", 23, 32], ["patches", "OBSERVATION_MODIFIER", 33, 40], ["irregular", "OBSERVATION_MODIFIER", 44, 53], ["consolidation", "OBSERVATION", 54, 67], ["often", "OBSERVATION_MODIFIER", 69, 74], ["infarct", "OBSERVATION_MODIFIER", 75, 82], ["shaped", "OBSERVATION_MODIFIER", 83, 89], ["nodules", "OBSERVATION", 94, 101]]], ["CT scans are very helpful, because they will define the nodular nature of infiltrates, may show specific signs associated with IPA, and can identify the lung as patients is relatively low, and patients can be given supportive therapy only.", [["lung", "ANATOMY", 153, 157], ["lung", "ORGAN", 153, 157], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 193, 201], ["CT scans", "TEST", 0, 8], ["infiltrates", "PROBLEM", 74, 85], ["IPA", "PROBLEM", 127, 130], ["supportive therapy", "TREATMENT", 215, 233], ["nodular", "OBSERVATION_MODIFIER", 56, 63], ["infiltrates", "OBSERVATION", 74, 85], ["lung", "ANATOMY", 153, 157], ["low", "OBSERVATION_MODIFIER", 184, 187]]], ["By contrast, pneumonia due to respiratory viruses after HSCT is associated with significant mortality (up to 40%).", [["pneumonia", "DISEASE", 13, 22], ["respiratory viruses", "DISEASE", 30, 49], ["pneumonia", "PROBLEM", 13, 22], ["respiratory viruses", "PROBLEM", 30, 49], ["significant mortality", "PROBLEM", 80, 101], ["pneumonia", "OBSERVATION", 13, 22], ["respiratory viruses", "OBSERVATION", 30, 49], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["mortality", "OBSERVATION", 92, 101]]], ["Secondary infections are common, and patients frequently need concurrent treatment with antibiotics.Clinical FeaturesInfluenza Viruses Infection after HSCT with influenza viruses is perhaps surprisingly less common than infection with RSV and PIV.", [["Secondary infections", "DISEASE", 0, 20], ["Influenza Viruses", "DISEASE", 117, 134], ["Infection", "DISEASE", 135, 144], ["influenza viruses", "DISEASE", 161, 178], ["infection", "DISEASE", 220, 229], ["patients", "ORGANISM", 37, 45], ["RSV", "ORGANISM", 235, 238], ["patients", "SPECIES", 37, 45], ["RSV", "SPECIES", 235, 238], ["PIV", "SPECIES", 243, 246], ["Secondary infections", "PROBLEM", 0, 20], ["concurrent treatment", "TREATMENT", 62, 82], ["antibiotics", "TREATMENT", 88, 99], ["Clinical FeaturesInfluenza Viruses Infection", "PROBLEM", 100, 144], ["influenza viruses", "PROBLEM", 161, 178], ["RSV", "TREATMENT", 235, 238], ["PIV", "TREATMENT", 243, 246], ["infections", "OBSERVATION", 10, 20], ["Influenza Viruses", "OBSERVATION", 117, 134], ["less common", "OBSERVATION_MODIFIER", 203, 214], ["RSV", "OBSERVATION", 235, 238], ["PIV", "OBSERVATION", 243, 246]]], ["Firstline therapy is with neuraminidase inhibi tors (zanamivir or oseltamivir), which do seem to be effective at limiting disease severity and duration.", [["zanamivir", "CHEMICAL", 53, 62], ["oseltamivir", "CHEMICAL", 66, 77], ["zanamivir", "CHEMICAL", 53, 62], ["oseltamivir", "CHEMICAL", 66, 77], ["neuraminidase inhibi", "SIMPLE_CHEMICAL", 26, 46], ["zanamivir", "SIMPLE_CHEMICAL", 53, 62], ["oseltamivir", "SIMPLE_CHEMICAL", 66, 77], ["Firstline therapy", "TREATMENT", 0, 17], ["neuraminidase inhibi tors", "TREATMENT", 26, 51], ["zanamivir", "TREATMENT", 53, 62], ["oseltamivir", "TREATMENT", 66, 77]]], ["An alternative agent for treatment of influenza virus infection is amantidine, but its efficacy is not clear.", [["influenza virus infection", "DISEASE", 38, 63], ["amantidine", "CHEMICAL", 67, 77], ["amantidine", "CHEMICAL", 67, 77], ["influenza virus", "ORGANISM", 38, 53], ["amantidine", "SIMPLE_CHEMICAL", 67, 77], ["influenza virus", "SPECIES", 38, 53], ["influenza virus", "SPECIES", 38, 53], ["An alternative agent", "TREATMENT", 0, 20], ["treatment", "TREATMENT", 25, 34], ["influenza virus infection", "PROBLEM", 38, 63], ["amantidine", "TREATMENT", 67, 77], ["influenza", "OBSERVATION", 38, 47], ["clear", "OBSERVATION", 103, 108]]], ["Transplant recipients (and their family members or household contacts) should receive lifelong sea sonal influenza vaccination with the trivalent inactivated vaccine.", [["Transplant recipients", "TREATMENT", 0, 21], ["lifelong sea sonal influenza vaccination", "TREATMENT", 86, 126], ["the trivalent inactivated vaccine", "TREATMENT", 132, 165]]], ["If an outbreak occurs with a nonvaccine influenza strain, chemoprophylaxis with zanamivir or oseltamivir should be considered.Parainfluenza VirusAlthough infection with PIV probably is among the most common causes of respiratory viral infection after HSCT, currently data on effective treatments are scarce.", [["influenza", "DISEASE", 40, 49], ["zanamivir", "CHEMICAL", 80, 89], ["oseltamivir", "CHEMICAL", 93, 104], ["infection", "DISEASE", 154, 163], ["respiratory viral infection", "DISEASE", 217, 244], ["zanamivir", "CHEMICAL", 80, 89], ["oseltamivir", "CHEMICAL", 93, 104], ["zanamivir", "SIMPLE_CHEMICAL", 80, 89], ["oseltamivir", "SIMPLE_CHEMICAL", 93, 104], ["Parainfluenza VirusAlthough", "ORGANISM", 126, 153], ["an outbreak", "PROBLEM", 3, 14], ["a nonvaccine influenza strain", "PROBLEM", 27, 56], ["chemoprophylaxis", "TREATMENT", 58, 74], ["zanamivir", "TREATMENT", 80, 89], ["oseltamivir", "TREATMENT", 93, 104], ["Parainfluenza VirusAlthough infection", "PROBLEM", 126, 163], ["PIV", "TREATMENT", 169, 172], ["respiratory viral infection", "PROBLEM", 217, 244], ["effective treatments", "TREATMENT", 275, 295], ["respiratory", "ANATOMY", 217, 228], ["viral", "OBSERVATION_MODIFIER", 229, 234], ["infection", "OBSERVATION", 235, 244]]], ["Ribavarin and IVIG may have activity against PIV infection but have not yet been shown to be beneficial in clinical practice.", [["Ribavarin", "CHEMICAL", 0, 9], ["IVIG", "CHEMICAL", 14, 18], ["PIV infection", "DISEASE", 45, 58], ["Ribavarin", "CHEMICAL", 0, 9], ["Ribavarin", "SIMPLE_CHEMICAL", 0, 9], ["IVIG", "SIMPLE_CHEMICAL", 14, 18], ["PIV", "SPECIES", 45, 48], ["Ribavarin", "TREATMENT", 0, 9], ["IVIG", "TREATMENT", 14, 18], ["PIV infection", "PROBLEM", 45, 58], ["infection", "OBSERVATION", 49, 58]]], ["No useful vaccine is generally available as yet.Respiratory Syncytial VirusHematopoietic stem cell trans plant recipients, particularly those who are preengraftment and lymphopenic or those who have preexisting obstructive airway disease, are at highest risk for severe RSV pneumonia.", [["Respiratory Syncytial VirusHematopoietic stem cell", "ANATOMY", 48, 98], ["airway", "ANATOMY", 223, 229], ["obstructive airway disease", "DISEASE", 211, 237], ["pneumonia", "DISEASE", 274, 283], ["Respiratory Syncytial VirusHematopoietic stem cell", "CELL", 48, 98], ["airway", "ORGAN", 223, 229], ["RSV", "ORGANISM", 270, 273], ["RSV", "SPECIES", 270, 273], ["useful vaccine", "TREATMENT", 3, 17], ["Respiratory Syncytial VirusHematopoietic stem", "PROBLEM", 48, 93], ["lymphopenic", "PROBLEM", 169, 180], ["preexisting obstructive airway disease", "PROBLEM", 199, 237], ["severe RSV pneumonia", "PROBLEM", 263, 283], ["Syncytial", "OBSERVATION_MODIFIER", 60, 69], ["VirusHematopoietic stem cell", "OBSERVATION", 70, 98], ["lymphopenic", "OBSERVATION", 169, 180], ["obstructive", "OBSERVATION_MODIFIER", 211, 222], ["airway", "ANATOMY", 223, 229], ["disease", "OBSERVATION", 230, 237], ["severe", "OBSERVATION_MODIFIER", 263, 269], ["RSV", "OBSERVATION", 270, 273], ["pneumonia", "OBSERVATION", 274, 283]]], ["Therapies for RSV infection include systemic or aerosolized ribavirin, passive immunization with highRSVtiter immunoglobulin, and monoclonal antibody directed at the RSV F antigen (palivi zumab).", [["RSV infection", "DISEASE", 14, 27], ["ribavirin", "CHEMICAL", 60, 69], ["ribavirin", "CHEMICAL", 60, 69], ["RSV", "ORGANISM", 14, 17], ["ribavirin", "SIMPLE_CHEMICAL", 60, 69], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 110, 124], ["RSV", "ORGANISM", 166, 169], ["F antigen", "GENE_OR_GENE_PRODUCT", 170, 179], ["palivi zumab", "ORGANISM", 181, 193], ["highRSVtiter immunoglobulin", "PROTEIN", 97, 124], ["monoclonal antibody", "PROTEIN", 130, 149], ["RSV F antigen", "PROTEIN", 166, 179], ["RSV", "SPECIES", 14, 17], ["RSV", "SPECIES", 14, 17], ["RSV", "SPECIES", 166, 169], ["Therapies", "TREATMENT", 0, 9], ["RSV infection", "PROBLEM", 14, 27], ["systemic or aerosolized ribavirin", "TREATMENT", 36, 69], ["passive immunization", "TREATMENT", 71, 91], ["highRSVtiter immunoglobulin", "TREATMENT", 97, 124], ["monoclonal antibody", "TEST", 130, 149], ["infection", "OBSERVATION", 18, 27], ["aerosolized ribavirin", "OBSERVATION", 48, 69]]], ["No randomized trial has been completed to test the efficacy of these strategies, and efficacy data are limited.", [["these strategies", "TEST", 63, 79], ["efficacy data", "TEST", 85, 98]]], ["Some centers provide monthly palivizumab prophylaxis for hemato poietic stem cell transplant recipients during the RSV season (November to April in the Northern Hemisphere), particularly for pediatric recipients.", [["hemato poietic stem cell", "ANATOMY", 57, 81], ["palivizumab", "CHEMICAL", 29, 40], ["hemato poietic stem cell", "CELL", 57, 81], ["recipients", "ORGANISM", 93, 103], ["RSV", "ORGANISM", 115, 118], ["recipients", "ORGANISM", 201, 211], ["RSV", "SPECIES", 115, 118], ["monthly palivizumab prophylaxis", "TREATMENT", 21, 52], ["hemato poietic stem cell transplant recipients", "TREATMENT", 57, 103], ["stem cell transplant", "OBSERVATION", 72, 92], ["Northern Hemisphere", "ANATOMY", 152, 171]]], ["Preemptive aerosolized ribavirin may be effective in those transplant recipients with lymphopenia and preexisting impaired lung function who develop RSV upper respiratory tract infection before the emergence of evi dence that the infection has spread to the lungs.Human MetapneumovirusHuman metapneumovirus (hMPV) is a relatively recently identified RNA paramyxovirus related to RSV.", [["lung", "ANATOMY", 123, 127], ["respiratory tract", "ANATOMY", 159, 176], ["lungs", "ANATOMY", 258, 263], ["ribavirin", "CHEMICAL", 23, 32], ["lymphopenia", "DISEASE", 86, 97], ["impaired lung function", "DISEASE", 114, 136], ["RSV upper respiratory tract infection", "DISEASE", 149, 186], ["infection", "DISEASE", 230, 239], ["MetapneumovirusHuman metapneumovirus", "DISEASE", 270, 306], ["RSV", "DISEASE", 379, 382], ["ribavirin", "CHEMICAL", 23, 32], ["ribavirin", "SIMPLE_CHEMICAL", 23, 32], ["recipients", "ORGANISM", 70, 80], ["lung", "ORGAN", 123, 127], ["RSV", "ORGANISM", 149, 152], ["upper", "ORGANISM_SUBDIVISION", 153, 158], ["respiratory tract", "ORGANISM_SUBDIVISION", 159, 176], ["lungs", "ORGAN", 258, 263], ["Human", "ORGANISM", 264, 269], ["MetapneumovirusHuman metapneumovirus", "ORGANISM", 270, 306], ["hMPV", "ORGANISM", 308, 312], ["RSV", "ORGANISM", 379, 382], ["Human", "SPECIES", 264, 269], ["MetapneumovirusHuman metapneumovirus", "SPECIES", 270, 306], ["hMPV", "SPECIES", 308, 312], ["RSV", "SPECIES", 149, 152], ["Human MetapneumovirusHuman metapneumovirus", "SPECIES", 264, 306], ["hMPV", "SPECIES", 308, 312], ["RSV", "SPECIES", 379, 382], ["Preemptive aerosolized ribavirin", "TREATMENT", 0, 32], ["those transplant recipients", "TREATMENT", 53, 80], ["lymphopenia", "PROBLEM", 86, 97], ["preexisting impaired lung function", "PROBLEM", 102, 136], ["RSV upper respiratory tract infection", "PROBLEM", 149, 186], ["the infection", "PROBLEM", 226, 239], ["Human MetapneumovirusHuman metapneumovirus (hMPV", "PROBLEM", 264, 312], ["RNA paramyxovirus", "PROBLEM", 350, 367], ["RSV", "PROBLEM", 379, 382], ["ribavirin", "OBSERVATION", 23, 32], ["may be", "UNCERTAINTY", 33, 39], ["effective", "OBSERVATION_MODIFIER", 40, 49], ["lymphopenia", "OBSERVATION", 86, 97], ["impaired", "OBSERVATION_MODIFIER", 114, 122], ["lung", "ANATOMY", 123, 127], ["upper", "ANATOMY_MODIFIER", 153, 158], ["respiratory tract", "ANATOMY", 159, 176], ["infection", "OBSERVATION", 177, 186], ["infection", "OBSERVATION", 230, 239], ["lungs", "ANATOMY", 258, 263], ["metapneumovirus", "OBSERVATION", 291, 306], ["RNA paramyxovirus", "OBSERVATION", 350, 367]]], ["It has been increasingly associated with lower respiratory tract infection and pneumonia in hematopoietic stem cell transplant recipients, with mortality rates of up to 50%.", [["lower respiratory tract", "ANATOMY", 41, 64], ["hematopoietic stem cell", "ANATOMY", 92, 115], ["respiratory tract infection", "DISEASE", 47, 74], ["pneumonia", "DISEASE", 79, 88], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 41, 64], ["hematopoietic stem cell", "CELL", 92, 115], ["lower respiratory tract infection", "PROBLEM", 41, 74], ["pneumonia", "PROBLEM", 79, 88], ["hematopoietic stem cell transplant recipients", "TREATMENT", 92, 137], ["mortality rates", "TEST", 144, 159], ["lower", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["infection", "OBSERVATION", 65, 74], ["pneumonia", "OBSERVATION", 79, 88], ["hematopoietic stem cell transplant recipients", "OBSERVATION", 92, 137]]], ["IVIG and ribavirin have in vitro activity against hMPV, but no recommendations on treatment are currently available owing to lack of data.Human MetapneumovirusAdenovirus Adenovirus infections can occur in patients with impaired cellmediated immunity due to reactivation or de novo acquisition.", [["IVIG", "CHEMICAL", 0, 4], ["ribavirin", "CHEMICAL", 9, 18], ["hMPV", "DISEASE", 50, 54], ["Adenovirus infections", "DISEASE", 170, 191], ["impaired cellmediated immunity", "DISEASE", 219, 249], ["ribavirin", "CHEMICAL", 9, 18], ["IVIG", "SIMPLE_CHEMICAL", 0, 4], ["ribavirin", "SIMPLE_CHEMICAL", 9, 18], ["hMPV", "ORGANISM", 50, 54], ["Human", "ORGANISM", 138, 143], ["MetapneumovirusAdenovirus Adenovirus", "ORGANISM", 144, 180], ["patients", "ORGANISM", 205, 213], ["Human", "SPECIES", 138, 143], ["patients", "SPECIES", 205, 213], ["hMPV", "SPECIES", 50, 54], ["Human MetapneumovirusAdenovirus Adenovirus", "SPECIES", 138, 180], ["IVIG", "TREATMENT", 0, 4], ["ribavirin", "TREATMENT", 9, 18], ["hMPV", "PROBLEM", 50, 54], ["treatment", "TREATMENT", 82, 91], ["Human MetapneumovirusAdenovirus Adenovirus infections", "PROBLEM", 138, 191], ["impaired cellmediated immunity", "PROBLEM", 219, 249], ["ribavirin", "OBSERVATION", 9, 18]]], ["Many different adenovirus serotypes exist, so pretransplant serology is not helpful.", [["adenovirus", "ORGANISM", 15, 25], ["Many different adenovirus serotypes", "PROBLEM", 0, 35], ["pretransplant serology", "TEST", 46, 68], ["adenovirus serotypes", "OBSERVATION", 15, 35]]], ["In HSCT, the risk of adenovirus infection is increased for allograft recipients, after T cell depletion or treatment with antithymocyte globulin (alem tuzumab), and for patients with graftversushost disease receiving systemic steroids.", [["allograft", "ANATOMY", 59, 68], ["T cell", "ANATOMY", 87, 93], ["adenovirus infection", "DISEASE", 21, 41], ["antithymocyte globulin", "CHEMICAL", 122, 144], ["alem tuzumab", "CHEMICAL", 146, 158], ["graftversushost disease", "DISEASE", 183, 206], ["steroids", "CHEMICAL", 226, 234], ["steroids", "CHEMICAL", 226, 234], ["adenovirus", "ORGANISM", 21, 31], ["T cell", "CELL", 87, 93], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 122, 144], ["alem tuzumab", "SIMPLE_CHEMICAL", 146, 158], ["patients", "ORGANISM", 169, 177], ["antithymocyte globulin", "PROTEIN", 122, 144], ["patients", "SPECIES", 169, 177], ["adenovirus", "SPECIES", 21, 31], ["adenovirus infection", "PROBLEM", 21, 41], ["allograft recipients", "TREATMENT", 59, 79], ["T cell depletion", "TREATMENT", 87, 103], ["treatment", "TREATMENT", 107, 116], ["antithymocyte globulin (alem tuzumab", "TREATMENT", 122, 158], ["graftversushost disease", "PROBLEM", 183, 206], ["systemic steroids", "TREATMENT", 217, 234], ["adenovirus", "OBSERVATION_MODIFIER", 21, 31], ["infection", "OBSERVATION", 32, 41], ["increased", "OBSERVATION_MODIFIER", 45, 54]]], ["Clearance of adenovirus has been shown to be associated with recovery of adenovirusspecific T cell immunity.", [["T cell", "ANATOMY", 92, 98], ["adenovirus", "ORGANISM", 13, 23], ["adenovirusspecific T cell", "CELL", 73, 98], ["adenovirus", "SPECIES", 13, 23], ["adenovirus", "PROBLEM", 13, 23], ["adenovirusspecific T cell immunity", "TREATMENT", 73, 107], ["adenovirus", "OBSERVATION", 13, 23], ["cell immunity", "OBSERVATION", 94, 107]]], ["Few antiviral agents have in vivo activity against adenoviruses, and no randomized, placebocontrolled study of the source of infection in patients with pyrexia and a normal chest radiograph.", [["chest", "ANATOMY", 173, 178], ["infection", "DISEASE", 125, 134], ["pyrexia", "DISEASE", 152, 159], ["adenoviruses", "ORGANISM", 51, 63], ["patients", "ORGANISM", 138, 146], ["chest", "ORGANISM_SUBDIVISION", 173, 178], ["patients", "SPECIES", 138, 146], ["Few antiviral agents", "TREATMENT", 0, 20], ["adenoviruses", "PROBLEM", 51, 63], ["placebocontrolled study", "TEST", 84, 107], ["infection", "PROBLEM", 125, 134], ["pyrexia", "PROBLEM", 152, 159], ["a normal chest radiograph", "TEST", 164, 189], ["antiviral agents", "OBSERVATION", 4, 20], ["infection", "OBSERVATION", 125, 134], ["chest", "ANATOMY", 173, 178]]], ["Specific CT appearances for IPA include the halo sign, an area of lower attenuation shadowing around a nodule or patch of consolidation reported in 50% of cases of IPA and usually occurring in the first week of infection ( Figure 28-11) ; the air crescent sign, a partial cavity formed by infarcted necrotic lung, which is a very specific but lateronset sign occurring around the third week of infection; and an intrapulmonary cavity containing a fungal ball, especially associated with recovery of the patient's neutrophil count (see Figure 2811 ).", [["nodule", "ANATOMY", 103, 109], ["cavity", "ANATOMY", 272, 278], ["necrotic lung", "ANATOMY", 299, 312], ["intrapulmonary cavity", "ANATOMY", 412, 433], ["neutrophil", "ANATOMY", 513, 523], ["IPA", "DISEASE", 164, 167], ["infection", "DISEASE", 211, 220], ["necrotic", "DISEASE", 299, 307], ["infection", "DISEASE", 394, 403], ["IPA", "CANCER", 164, 167], ["lung", "ORGAN", 308, 312], ["intrapulmonary cavity", "PATHOLOGICAL_FORMATION", 412, 433], ["patient", "ORGANISM", 503, 510], ["neutrophil", "CELL", 513, 523], ["patient", "SPECIES", 503, 510], ["Specific CT appearances", "TEST", 0, 23], ["IPA", "PROBLEM", 28, 31], ["the halo sign", "TEST", 40, 53], ["lower attenuation shadowing", "PROBLEM", 66, 93], ["a nodule", "PROBLEM", 101, 109], ["consolidation", "PROBLEM", 122, 135], ["IPA", "PROBLEM", 164, 167], ["infection", "PROBLEM", 211, 220], ["the air crescent sign", "PROBLEM", 239, 260], ["a partial cavity", "PROBLEM", 262, 278], ["infarcted necrotic lung", "PROBLEM", 289, 312], ["lateronset sign", "PROBLEM", 343, 358], ["infection", "PROBLEM", 394, 403], ["an intrapulmonary cavity", "PROBLEM", 409, 433], ["a fungal ball", "PROBLEM", 445, 458], ["the patient's neutrophil count", "TEST", 499, 529], ["area", "OBSERVATION_MODIFIER", 58, 62], ["lower attenuation", "OBSERVATION_MODIFIER", 66, 83], ["shadowing", "OBSERVATION", 84, 93], ["nodule", "OBSERVATION", 103, 109], ["patch", "OBSERVATION_MODIFIER", 113, 118], ["consolidation", "OBSERVATION", 122, 135], ["infection", "OBSERVATION", 211, 220], ["air crescent", "OBSERVATION", 243, 255], ["partial", "OBSERVATION_MODIFIER", 264, 271], ["cavity", "OBSERVATION_MODIFIER", 272, 278], ["infarcted", "OBSERVATION_MODIFIER", 289, 298], ["necrotic", "OBSERVATION_MODIFIER", 299, 307], ["lung", "ANATOMY", 308, 312], ["very", "OBSERVATION_MODIFIER", 325, 329], ["third week", "OBSERVATION_MODIFIER", 380, 390], ["infection", "OBSERVATION", 394, 403], ["intrapulmonary", "ANATOMY", 412, 426], ["cavity", "ANATOMY_MODIFIER", 427, 433], ["fungal ball", "OBSERVATION", 447, 458]]], ["The halo sign may be detected in other infections, with neo plasms (adenocarcinoma, bronchoalveolar carcinoma, Kaposi sarcoma, and metastases), and in vasculitis.", [["neo plasms", "ANATOMY", 56, 66], ["adenocarcinoma", "ANATOMY", 68, 82], ["bronchoalveolar carcinoma", "ANATOMY", 84, 109], ["Kaposi sarcoma", "ANATOMY", 111, 125], ["metastases", "ANATOMY", 131, 141], ["infections", "DISEASE", 39, 49], ["adenocarcinoma", "DISEASE", 68, 82], ["bronchoalveolar carcinoma", "DISEASE", 84, 109], ["Kaposi sarcoma", "DISEASE", 111, 125], ["metastases", "DISEASE", 131, 141], ["vasculitis", "DISEASE", 151, 161], ["neo plasms", "CANCER", 56, 66], ["adenocarcinoma", "CANCER", 68, 82], ["bronchoalveolar carcinoma", "CANCER", 84, 109], ["Kaposi sarcoma", "CANCER", 111, 125], ["The halo sign", "PROBLEM", 0, 13], ["other infections", "PROBLEM", 33, 49], ["neo plasms (adenocarcinoma", "PROBLEM", 56, 82], ["bronchoalveolar carcinoma", "PROBLEM", 84, 109], ["Kaposi sarcoma", "PROBLEM", 111, 125], ["metastases", "PROBLEM", 131, 141], ["vasculitis", "PROBLEM", 151, 161], ["halo", "OBSERVATION", 4, 8], ["may be detected", "UNCERTAINTY", 14, 29], ["infections", "OBSERVATION", 39, 49], ["adenocarcinoma", "OBSERVATION", 68, 82], ["bronchoalveolar carcinoma", "OBSERVATION", 84, 109], ["Kaposi sarcoma", "OBSERVATION", 111, 125], ["metastases", "OBSERVATION", 131, 141], ["vasculitis", "OBSERVATION", 151, 161]]], ["Aspergillus has a predilection for growing into blood vessels, and patients with IPA may suffer fatal massive hemorrhage.", [["blood vessels", "ANATOMY", 48, 61], ["IPA", "CHEMICAL", 81, 84], ["hemorrhage", "DISEASE", 110, 120], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 48, 61], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Aspergillus", "PROBLEM", 0, 11], ["growing into blood vessels", "PROBLEM", 35, 61], ["fatal massive hemorrhage", "PROBLEM", 96, 120], ["blood vessels", "ANATOMY", 48, 61], ["fatal", "OBSERVATION_MODIFIER", 96, 101], ["massive", "OBSERVATION_MODIFIER", 102, 109], ["hemorrhage", "OBSERVATION", 110, 120]]], ["Other manifestations of invasive Aspergillus infections affecting the lung include Aspergillus tracheobronchitis, chronic necrotizing pulmonary aspergillosis (CNPA), and chronic cavitary pulmonary aspergil losis (CCPA).Human MetapneumovirusWith Aspergillus tracheobronchitis, infection is restricted to the tracheobronchial tree and manifests with a severe unremit ting cough and pyrexia.", [["lung", "ANATOMY", 70, 74], ["pulmonary", "ANATOMY", 134, 143], ["pulmonary", "ANATOMY", 187, 196], ["tracheobronchial tree", "ANATOMY", 307, 328], ["Aspergillus infections", "DISEASE", 33, 55], ["Aspergillus tracheobronchitis", "DISEASE", 83, 112], ["necrotizing pulmonary aspergillosis", "DISEASE", 122, 157], ["CNPA", "DISEASE", 159, 163], ["cavitary pulmonary aspergil losis", "DISEASE", 178, 211], ["CCPA", "DISEASE", 213, 217], ["Aspergillus tracheobronchitis", "DISEASE", 245, 274], ["infection", "DISEASE", 276, 285], ["cough", "DISEASE", 370, 375], ["pyrexia", "DISEASE", 380, 387], ["lung", "ORGAN", 70, 74], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 134, 157], ["Human", "ORGANISM", 219, 224], ["MetapneumovirusWith Aspergillus tracheobronchitis", "ORGANISM", 225, 274], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 307, 328], ["Human", "SPECIES", 219, 224], ["Aspergillus tracheobronchitis", "SPECIES", 245, 274], ["Aspergillus tracheobronchitis", "SPECIES", 83, 112], ["Human MetapneumovirusWith Aspergillus tracheobronchitis", "SPECIES", 219, 274], ["invasive Aspergillus infections", "PROBLEM", 24, 55], ["Aspergillus tracheobronchitis", "PROBLEM", 83, 112], ["chronic necrotizing pulmonary aspergillosis", "PROBLEM", 114, 157], ["chronic cavitary pulmonary aspergil losis", "PROBLEM", 170, 211], ["Human MetapneumovirusWith Aspergillus tracheobronchitis", "PROBLEM", 219, 274], ["infection", "PROBLEM", 276, 285], ["a severe unremit ting cough", "PROBLEM", 348, 375], ["pyrexia", "PROBLEM", 380, 387], ["invasive", "OBSERVATION_MODIFIER", 24, 32], ["Aspergillus infections", "OBSERVATION", 33, 55], ["lung", "ANATOMY", 70, 74], ["Aspergillus tracheobronchitis", "OBSERVATION", 83, 112], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["necrotizing", "OBSERVATION_MODIFIER", 122, 133], ["pulmonary", "ANATOMY", 134, 143], ["aspergillosis", "OBSERVATION", 144, 157], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["cavitary", "OBSERVATION_MODIFIER", 178, 186], ["pulmonary", "ANATOMY", 187, 196], ["aspergil losis", "OBSERVATION", 197, 211], ["Aspergillus tracheobronchitis", "OBSERVATION", 245, 274], ["infection", "OBSERVATION", 276, 285], ["tracheobronchial", "ANATOMY", 307, 323], ["tree", "ANATOMY_MODIFIER", 324, 328], ["severe", "OBSERVATION_MODIFIER", 350, 356], ["unremit", "OBSERVATION_MODIFIER", 357, 364], ["ting", "OBSERVATION_MODIFIER", 365, 369], ["cough", "OBSERVATION", 370, 375], ["pyrexia", "OBSERVATION", 380, 387]]], ["CT scans may show focal areas of bronchial wall thickening and treeinbud small airway disease (Figure 28-12) .", [["bronchial wall", "ANATOMY", 33, 47], ["treeinbud small airway", "ANATOMY", 63, 85], ["airway disease", "DISEASE", 79, 93], ["bronchial wall", "TISSUE", 33, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 79, 85], ["CT scans", "TEST", 0, 8], ["bronchial wall thickening", "PROBLEM", 33, 58], ["treeinbud small airway disease", "PROBLEM", 63, 93], ["Figure", "TEST", 95, 101], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["bronchial", "ANATOMY", 33, 42], ["wall", "ANATOMY_MODIFIER", 43, 47], ["thickening", "OBSERVATION", 48, 58], ["treeinbud", "OBSERVATION_MODIFIER", 63, 72], ["small", "OBSERVATION_MODIFIER", 73, 78], ["airway disease", "OBSERVATION", 79, 93]]], ["FOB usually is diagnostic, with a distinctive macroscopic appearance of patchy, highly inflamed mucosa with necrotic white slough.", [["mucosa", "ANATOMY", 96, 102], ["necrotic", "DISEASE", 108, 116], ["mucosa", "MULTI-TISSUE_STRUCTURE", 96, 102], ["patchy, highly inflamed mucosa", "PROBLEM", 72, 102], ["necrotic white slough", "PROBLEM", 108, 129], ["patchy", "OBSERVATION_MODIFIER", 72, 78], ["highly", "OBSERVATION_MODIFIER", 80, 86], ["inflamed mucosa", "OBSERVATION", 87, 102], ["necrotic", "OBSERVATION_MODIFIER", 108, 116], ["white", "OBSERVATION_MODIFIER", 117, 122], ["slough", "OBSERVATION_MODIFIER", 123, 129]]], ["Aspergillus can be found in cultures and/or cytology of bronchial washings, and there may be evi dence of fungal invasion of the respiratory mucosa in bronchial biopsy specimens.Human MetapneumovirusThe more indolent forms of invasive aspergillosis such as CCPA or CNPA are increasing in incidence and are associated with milder degrees of immunosuppression, including steroid and cytotoxic therapies, chronic lung disease or cystic fibrosis.", [["cultures", "ANATOMY", 28, 36], ["bronchial", "ANATOMY", 56, 65], ["respiratory mucosa", "ANATOMY", 129, 147], ["bronchial biopsy specimens", "ANATOMY", 151, 177], ["invasive aspergillosis", "ANATOMY", 226, 248], ["lung", "ANATOMY", 410, 414], ["cystic", "ANATOMY", 426, 432], ["aspergillosis", "DISEASE", 235, 248], ["steroid", "CHEMICAL", 369, 376], ["chronic lung disease", "DISEASE", 402, 422], ["cystic fibrosis", "DISEASE", 426, 441], ["steroid", "CHEMICAL", 369, 376], ["respiratory mucosa", "MULTI-TISSUE_STRUCTURE", 129, 147], ["bronchial biopsy specimens", "CANCER", 151, 177], ["Human", "ORGANISM", 178, 183], ["Metapneumovirus", "ORGANISM", 184, 199], ["aspergillosis", "CANCER", 235, 248], ["CCPA", "GENE_OR_GENE_PRODUCT", 257, 261], ["steroid", "SIMPLE_CHEMICAL", 369, 376], ["lung", "ORGAN", 410, 414], ["cystic", "ORGAN", 426, 432], ["Human", "SPECIES", 178, 183], ["Human Metapneumovirus", "SPECIES", 178, 199], ["Aspergillus", "PROBLEM", 0, 11], ["cultures", "TEST", 28, 36], ["cytology of bronchial washings", "TEST", 44, 74], ["fungal invasion of the respiratory mucosa", "PROBLEM", 106, 147], ["bronchial biopsy specimens", "TEST", 151, 177], ["Human Metapneumovirus", "PROBLEM", 178, 199], ["invasive aspergillosis", "PROBLEM", 226, 248], ["CCPA", "PROBLEM", 257, 261], ["CNPA", "PROBLEM", 265, 269], ["immunosuppression", "TREATMENT", 340, 357], ["steroid", "TREATMENT", 369, 376], ["cytotoxic therapies", "TREATMENT", 381, 400], ["chronic lung disease", "PROBLEM", 402, 422], ["cystic fibrosis", "PROBLEM", 426, 441], ["bronchial", "ANATOMY", 56, 65], ["washings", "OBSERVATION", 66, 74], ["fungal", "OBSERVATION_MODIFIER", 106, 112], ["invasion", "OBSERVATION", 113, 121], ["respiratory mucosa", "ANATOMY", 129, 147], ["bronchial", "ANATOMY", 151, 160], ["biopsy", "OBSERVATION", 161, 167], ["Metapneumovirus", "OBSERVATION", 184, 199], ["more", "OBSERVATION_MODIFIER", 203, 207], ["indolent", "OBSERVATION_MODIFIER", 208, 216], ["invasive", "OBSERVATION_MODIFIER", 226, 234], ["aspergillosis", "OBSERVATION", 235, 248], ["increasing", "OBSERVATION_MODIFIER", 274, 284], ["milder degrees", "OBSERVATION_MODIFIER", 322, 336], ["immunosuppression", "OBSERVATION", 340, 357], ["chronic", "OBSERVATION_MODIFIER", 402, 409], ["lung", "ANATOMY", 410, 414], ["disease", "OBSERVATION", 415, 422], ["cystic", "OBSERVATION_MODIFIER", 426, 432], ["fibrosis", "OBSERVATION", 433, 441]]], ["Affected patients present with a long history of cough and marked systemic symptoms of malaise, fatigue, and weight loss.", [["cough", "DISEASE", 49, 54], ["fatigue", "DISEASE", 96, 103], ["weight loss", "DISEASE", 109, 120], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["cough", "PROBLEM", 49, 54], ["marked systemic symptoms", "PROBLEM", 59, 83], ["malaise", "PROBLEM", 87, 94], ["fatigue", "PROBLEM", 96, 103], ["weight loss", "PROBLEM", 109, 120], ["cough", "OBSERVATION", 49, 54], ["marked", "OBSERVATION_MODIFIER", 59, 65], ["systemic", "OBSERVATION_MODIFIER", 66, 74], ["malaise", "OBSERVATION", 87, 94], ["weight loss", "OBSERVATION", 109, 120]]], ["On chest radiographs, CNPA manifests as an indolent patch of consolidation with or without cavitation that progresses over weeks or months (Figure 28-13) , whereas CCPA manifests with an expanding upper lobe dry cavity with a thickened and irregular wall.", [["upper lobe dry cavity", "ANATOMY", 197, 218], ["wall", "ANATOMY", 250, 254], ["CCPA", "DISEASE", 164, 168], ["upper lobe", "ORGANISM_SUBDIVISION", 197, 207], ["wall", "TISSUE", 250, 254], ["chest radiographs", "TEST", 3, 20], ["CNPA", "TREATMENT", 22, 26], ["an indolent patch", "TREATMENT", 40, 57], ["consolidation", "PROBLEM", 61, 74], ["cavitation", "PROBLEM", 91, 101], ["Figure", "TEST", 140, 146], ["an expanding upper lobe dry cavity", "PROBLEM", 184, 218], ["a thickened and irregular wall", "PROBLEM", 224, 254], ["chest", "ANATOMY", 3, 8], ["indolent", "OBSERVATION_MODIFIER", 43, 51], ["consolidation", "OBSERVATION", 61, 74], ["without", "UNCERTAINTY", 83, 90], ["cavitation", "OBSERVATION", 91, 101], ["upper lobe", "ANATOMY", 197, 207], ["cavity", "OBSERVATION", 212, 218], ["thickened", "OBSERVATION", 226, 235], ["irregular", "OBSERVATION_MODIFIER", 240, 249], ["wall", "OBSERVATION_MODIFIER", 250, 254]]], ["There may be associated pleural thickening.", [["pleural", "ANATOMY", 24, 31], ["pleural thickening", "DISEASE", 24, 42], ["pleural", "PATHOLOGICAL_FORMATION", 24, 31], ["associated pleural thickening", "PROBLEM", 13, 42], ["may be", "UNCERTAINTY", 6, 12], ["pleural", "ANATOMY", 24, 31], ["thickening", "OBSERVATION", 32, 42]]], ["Aspergillus infection also can cause a progressive upper lobe fibrosis.", [["upper lobe", "ANATOMY", 51, 61], ["Aspergillus infection", "DISEASE", 0, 21], ["fibrosis", "DISEASE", 62, 70], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 51, 61], ["Aspergillus infection", "PROBLEM", 0, 21], ["a progressive upper lobe fibrosis", "PROBLEM", 37, 70], ["infection", "OBSERVATION", 12, 21], ["progressive", "OBSERVATION_MODIFIER", 39, 50], ["upper lobe", "ANATOMY", 51, 61], ["fibrosis", "OBSERVATION", 62, 70]]], ["A B Figure 28 -12 Computed tomography (CT) scan of thorax in a patient with acute lymphocytic leukemia treated with chemotherapy who presented with persistent cough and fever.", [["thorax", "ANATOMY", 51, 57], ["acute lymphocytic leukemia", "ANATOMY", 76, 102], ["acute lymphocytic leukemia", "DISEASE", 76, 102], ["cough", "DISEASE", 159, 164], ["fever", "DISEASE", 169, 174], ["thorax", "ORGAN", 51, 57], ["patient", "ORGANISM", 63, 70], ["acute lymphocytic leukemia", "CANCER", 76, 102], ["patient", "SPECIES", 63, 70], ["A B Figure", "TEST", 0, 10], ["Computed tomography (CT) scan of thorax", "TEST", 18, 57], ["acute lymphocytic leukemia", "PROBLEM", 76, 102], ["chemotherapy", "TREATMENT", 116, 128], ["persistent cough", "PROBLEM", 148, 164], ["fever", "PROBLEM", 169, 174], ["thorax", "ANATOMY", 51, 57], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["lymphocytic leukemia", "OBSERVATION", 82, 102], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["cough", "OBSERVATION", 159, 164], ["fever", "OBSERVATION", 169, 174]]], ["The scan shows asymmetric \"tree-in-bud\" and nodular changes mainly affecting the right upper lobe, which were caused by Aspergillus tracheobronchitis.Microbiologic DiagnosisInvestigations that can be helpful in making the diagnosis of IPA are described in A B histopathologic examination of the sample can readily identify fungal hyphae infiltrating through lung tissue if fungal stains are used.", [["bud", "ANATOMY", 35, 38], ["nodular", "ANATOMY", 44, 51], ["right upper lobe", "ANATOMY", 81, 97], ["sample", "ANATOMY", 295, 301], ["hyphae", "ANATOMY", 330, 336], ["lung tissue", "ANATOMY", 358, 369], ["Aspergillus tracheobronchitis", "DISEASE", 120, 149], ["IPA", "DISEASE", 235, 238], ["bud", "TISSUE", 35, 38], ["upper lobe", "ORGAN", 87, 97], ["IPA", "CANCER", 235, 238], ["lung tissue", "TISSUE", 358, 369], ["Aspergillus tracheobronchitis", "SPECIES", 120, 149], ["The scan", "TEST", 0, 8], ["asymmetric \"tree-in-bud\"", "PROBLEM", 15, 39], ["nodular changes", "PROBLEM", 44, 59], ["Aspergillus tracheobronchitis", "PROBLEM", 120, 149], ["Microbiologic DiagnosisInvestigations", "TEST", 150, 187], ["IPA", "PROBLEM", 235, 238], ["A B histopathologic examination", "TEST", 256, 287], ["fungal hyphae infiltrating through lung tissue", "PROBLEM", 323, 369], ["fungal stains", "TEST", 373, 386], ["asymmetric", "OBSERVATION_MODIFIER", 15, 25], ["\"", "OBSERVATION_MODIFIER", 26, 27], ["tree", "OBSERVATION_MODIFIER", 27, 31], ["bud", "ANATOMY_MODIFIER", 35, 38], ["nodular", "OBSERVATION", 44, 51], ["right upper lobe", "ANATOMY", 81, 97], ["Aspergillus tracheobronchitis", "OBSERVATION", 120, 149], ["lung", "ANATOMY", 358, 362]]], ["Hence, strong consideration should be given to biopsy of lung nodules not responding to conventional antibacterial antibiotics, especially if BAL was nondiagnostic.", [["lung nodules", "ANATOMY", 57, 69], ["BAL", "ANATOMY", 142, 145], ["lung nodules", "CANCER", 57, 69], ["biopsy", "TEST", 47, 53], ["lung nodules", "PROBLEM", 57, 69], ["conventional antibacterial antibiotics", "TREATMENT", 88, 126], ["BAL", "TEST", 142, 145], ["lung", "ANATOMY", 57, 61], ["nodules", "OBSERVATION", 62, 69]]], ["To decrease mortality by allowing rapid identification of cases of IPA before the fungal load is high, several noninvasive tests have been developed.", [["IPA", "CHEMICAL", 67, 70], ["IPA", "TREATMENT", 67, 70], ["the fungal load", "TEST", 78, 93], ["several noninvasive tests", "TEST", 103, 128], ["fungal load", "OBSERVATION", 82, 93]]], ["These include detection of galactomannan or \u03b2D glucan cell wall antigen in the blood (or BAL fluid if FOB has been performed), or PCR assay for Aspergillus DNA from the blood or BAL fluid.", [["cell wall", "ANATOMY", 54, 63], ["blood", "ANATOMY", 79, 84], ["BAL fluid", "ANATOMY", 89, 98], ["blood", "ANATOMY", 169, 174], ["BAL fluid", "ANATOMY", 178, 187], ["\u03b2D glucan", "CHEMICAL", 44, 53], ["\u03b2D glucan cell wall antigen", "GENE_OR_GENE_PRODUCT", 44, 71], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["BAL fluid", "ORGANISM_SUBSTANCE", 89, 98], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["BAL fluid", "ORGANISM_SUBSTANCE", 178, 187], ["galactomannan", "PROTEIN", 27, 40], ["\u03b2D glucan cell wall antigen", "PROTEIN", 44, 71], ["detection of galactomannan or \u03b2D glucan cell wall antigen", "TEST", 14, 71], ["the blood", "TEST", 75, 84], ["BAL fluid", "TEST", 89, 98], ["FOB", "TEST", 102, 105], ["PCR assay", "TEST", 130, 139], ["Aspergillus DNA", "PROBLEM", 144, 159], ["the blood", "TEST", 165, 174], ["BAL fluid", "TEST", 178, 187], ["BAL fluid", "OBSERVATION", 178, 187]]], ["These tests are highly sensitive and when used as surveillance in highrisk patients could lead to preemp tive antifungal therapy before clinically apparent disease has developed, leading to an improved mortality.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["These tests", "TEST", 0, 11], ["surveillance", "TEST", 50, 62], ["preemp tive antifungal therapy", "TREATMENT", 98, 128], ["clinically apparent disease", "PROBLEM", 136, 163], ["disease", "OBSERVATION", 156, 163], ["improved", "OBSERVATION_MODIFIER", 193, 201], ["mortality", "OBSERVATION", 202, 211]]], ["However, detec tion of fungal DNA in a single sample of peripheral blood is a poor indicator of early invasive fungal infection, and galacto mannan antigen is not specific for Aspergillus spp., frequently giving falsepositive results (especially in patients treated with piperacillintazobactam or in young children).", [["sample", "ANATOMY", 46, 52], ["peripheral blood", "ANATOMY", 56, 72], ["fungal infection", "DISEASE", 111, 127], ["piperacillintazobactam", "CHEMICAL", 271, 293], ["piperacillintazobactam", "CHEMICAL", 271, 293], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["peripheral blood", "ORGANISM_SUBSTANCE", 56, 72], ["galacto mannan antigen", "GENE_OR_GENE_PRODUCT", 133, 155], ["Aspergillus spp.", "ORGANISM", 176, 192], ["patients", "ORGANISM", 249, 257], ["piperacillintazobactam", "SIMPLE_CHEMICAL", 271, 293], ["children", "ORGANISM", 306, 314], ["galacto mannan antigen", "PROTEIN", 133, 155], ["Aspergillus spp.", "SPECIES", 176, 192], ["patients", "SPECIES", 249, 257], ["children", "SPECIES", 306, 314], ["Aspergillus spp.", "SPECIES", 176, 192], ["fungal DNA", "PROBLEM", 23, 33], ["peripheral blood", "PROBLEM", 56, 72], ["early invasive fungal infection", "PROBLEM", 96, 127], ["galacto mannan antigen", "TEST", 133, 155], ["Aspergillus spp.", "PROBLEM", 176, 192], ["piperacillintazobactam", "TREATMENT", 271, 293], ["fungal DNA", "OBSERVATION", 23, 33], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["blood", "ANATOMY", 67, 72], ["early", "OBSERVATION_MODIFIER", 96, 101], ["invasive", "OBSERVATION_MODIFIER", 102, 110], ["fungal", "OBSERVATION_MODIFIER", 111, 117], ["infection", "OBSERVATION", 118, 127]]], ["Despite these caveats, a negative galactomannan assay result makes active IPA infection unlikely.", [["IPA", "CHEMICAL", 74, 77], ["infection", "DISEASE", 78, 87], ["IPA", "CANCER", 74, 77], ["a negative galactomannan assay", "TEST", 23, 53], ["active IPA infection", "PROBLEM", 67, 87], ["active", "OBSERVATION_MODIFIER", 67, 73], ["IPA", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87]]], ["Serologic tests for antibodies to Aspergillus usually yield negative results in immunocompromised patients with IPA.", [["IPA", "CHEMICAL", 112, 115], ["patients", "ORGANISM", 98, 106], ["antibodies", "PROTEIN", 20, 30], ["patients", "SPECIES", 98, 106], ["Serologic tests", "TEST", 0, 15], ["antibodies", "TEST", 20, 30], ["Aspergillus", "TEST", 34, 45], ["IPA", "TEST", 112, 115]]], ["Diagnosing chronic forms of IPA in less immunocompro mised patients often is difficult owing to lack of sensitivity of culture and the lack of data on the predictive values for antigen testing.", [["IPA", "CHEMICAL", 28, 31], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["IPA", "PROBLEM", 28, 31], ["culture", "TEST", 119, 126], ["the predictive values", "TEST", 151, 172], ["antigen testing", "TEST", 177, 192], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["IPA", "OBSERVATION_MODIFIER", 28, 31]]], ["CTguided or VATS biopsy frequently is necessary to exclude malignancy and to confirm fungal invasion of lung tissue.", [["lung tissue", "ANATOMY", 104, 115], ["malignancy", "DISEASE", 59, 69], ["malignancy", "CANCER", 59, 69], ["lung tissue", "TISSUE", 104, 115], ["VATS biopsy", "TEST", 12, 23], ["malignancy", "PROBLEM", 59, 69], ["fungal invasion of lung tissue", "PROBLEM", 85, 115], ["fungal", "OBSERVATION_MODIFIER", 85, 91], ["invasion", "OBSERVATION", 92, 100], ["lung", "ANATOMY", 104, 108], ["tissue", "OBSERVATION", 109, 115]]], ["Aspergillus IgG levels usually are raised in patients with CCPA, but not necessarily so in those with CNPA.Microbiologic DiagnosisAzoles can be used for prophylaxis in atrisk groups, including hematopoietic stem cell transplant recipients.", [["hematopoietic stem cell", "ANATOMY", 193, 216], ["CNPA", "DISEASE", 102, 106], ["DiagnosisAzoles", "CHEMICAL", 121, 136], ["Aspergillus IgG", "GENE_OR_GENE_PRODUCT", 0, 15], ["patients", "ORGANISM", 45, 53], ["CNPA", "CANCER", 102, 106], ["DiagnosisAzoles", "SIMPLE_CHEMICAL", 121, 136], ["hematopoietic stem cell", "CELL", 193, 216], ["recipients", "ORGANISM", 228, 238], ["IgG", "PROTEIN", 12, 15], ["patients", "SPECIES", 45, 53], ["Aspergillus IgG levels", "TEST", 0, 22], ["CCPA", "TEST", 59, 63], ["CNPA", "TREATMENT", 102, 106], ["Microbiologic DiagnosisAzoles", "TREATMENT", 107, 136], ["prophylaxis in atrisk groups", "TREATMENT", 153, 181], ["hematopoietic stem cell transplant recipients", "TREATMENT", 193, 238], ["hematopoietic stem cell transplant", "OBSERVATION", 193, 227]]], ["Fluconazole is not effective at preventing mold infections such as IPA, and despite its efficacy against Aspergillus, voriconazole seems to offer no clinical benefit over prophylaxis with fluconazole.", [["Fluconazole", "CHEMICAL", 0, 11], ["infections", "DISEASE", 48, 58], ["IPA", "CHEMICAL", 67, 70], ["voriconazole", "CHEMICAL", 118, 130], ["fluconazole", "CHEMICAL", 188, 199], ["Fluconazole", "CHEMICAL", 0, 11], ["voriconazole", "CHEMICAL", 118, 130], ["fluconazole", "CHEMICAL", 188, 199], ["Fluconazole", "SIMPLE_CHEMICAL", 0, 11], ["voriconazole", "SIMPLE_CHEMICAL", 118, 130], ["fluconazole", "SIMPLE_CHEMICAL", 188, 199], ["Fluconazole", "TREATMENT", 0, 11], ["mold infections", "PROBLEM", 43, 58], ["IPA", "PROBLEM", 67, 70], ["Aspergillus", "PROBLEM", 105, 116], ["voriconazole", "TREATMENT", 118, 130], ["fluconazole", "TREATMENT", 188, 199], ["infections", "OBSERVATION", 48, 58]]], ["However, prophylaxis with the newer extendedspectrum tri azole posaconazole reduced the incidence of invasive asper gillosis in patients with prolonged neutropenia, from 7% to 1%.", [["extendedspectrum tri azole", "CHEMICAL", 36, 62], ["posaconazole", "CHEMICAL", 63, 75], ["invasive asper gillosis", "DISEASE", 101, 124], ["neutropenia", "DISEASE", 152, 163], ["azole", "CHEMICAL", 57, 62], ["posaconazole", "CHEMICAL", 63, 75], ["extendedspectrum tri azole", "SIMPLE_CHEMICAL", 36, 62], ["posaconazole", "SIMPLE_CHEMICAL", 63, 75], ["asper gillosis", "ORGANISM", 110, 124], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["prophylaxis", "TREATMENT", 9, 20], ["the newer extendedspectrum tri azole posaconazole", "TREATMENT", 26, 75], ["invasive asper gillosis", "TREATMENT", 101, 124], ["prolonged neutropenia", "PROBLEM", 142, 163], ["invasive", "OBSERVATION_MODIFIER", 101, 109], ["asper gillosis", "OBSERVATION", 110, 124], ["neutropenia", "OBSERVATION", 152, 163]]], ["Acquired resistance of A. fumigatus to posaconazole has emerged during the course of therapy, which may potentially limit its use for prophylaxis.Infections Due to Non-Aspergillus Filamentous FungiAlthough Aspergillus spp. dominate infections due to molds, other filamentous fungi can cause invasive pulmonary infec tions in immunocompromised patients, including Fusarium, Zygomycetes, Scedosporium, and Penicillium.", [["pulmonary", "ANATOMY", 300, 309], ["posaconazole", "CHEMICAL", 39, 51], ["Aspergillus spp", "DISEASE", 206, 221], ["infections", "DISEASE", 232, 242], ["pulmonary infec tions", "DISEASE", 300, 321], ["Fusarium, Zygomycetes, Scedosporium, and Penicillium", "DISEASE", 363, 415], ["posaconazole", "CHEMICAL", 39, 51], ["A. fumigatus", "ORGANISM", 23, 35], ["posaconazole", "SIMPLE_CHEMICAL", 39, 51], ["pulmonary", "ORGAN", 300, 309], ["patients", "ORGANISM", 343, 351], ["A. fumigatus", "SPECIES", 23, 35], ["patients", "SPECIES", 343, 351], ["A. fumigatus", "SPECIES", 23, 35], ["A. fumigatus", "PROBLEM", 23, 35], ["posaconazole", "TREATMENT", 39, 51], ["therapy", "TREATMENT", 85, 92], ["prophylaxis", "TREATMENT", 134, 145], ["Infections", "PROBLEM", 146, 156], ["Non-Aspergillus Filamentous FungiAlthough Aspergillus spp", "PROBLEM", 164, 221], ["dominate infections", "PROBLEM", 223, 242], ["molds", "PROBLEM", 250, 255], ["other filamentous fungi", "PROBLEM", 257, 280], ["invasive pulmonary infec tions", "PROBLEM", 291, 321], ["Fusarium", "PROBLEM", 363, 371], ["Zygomycetes", "TREATMENT", 373, 384], ["Scedosporium", "TREATMENT", 386, 398], ["Penicillium", "TREATMENT", 404, 415], ["fumigatus", "OBSERVATION", 26, 35], ["Filamentous", "OBSERVATION_MODIFIER", 180, 191], ["FungiAlthough", "OBSERVATION_MODIFIER", 192, 205], ["Aspergillus spp", "OBSERVATION", 206, 221], ["infections", "OBSERVATION", 232, 242], ["filamentous fungi", "OBSERVATION", 263, 280], ["invasive", "OBSERVATION_MODIFIER", 291, 299], ["pulmonary", "ANATOMY", 300, 309], ["infec", "OBSERVATION", 310, 315]]], ["These infections often are clinically similar to invasive aspergillosis but have a different spectrum of susceptibilities to antifungal agents.", [["invasive aspergillosis", "ANATOMY", 49, 71], ["infections", "DISEASE", 6, 16], ["aspergillosis", "DISEASE", 58, 71], ["aspergillosis", "CANCER", 58, 71], ["antifungal agents", "SIMPLE_CHEMICAL", 125, 142], ["These infections", "PROBLEM", 0, 16], ["invasive aspergillosis", "PROBLEM", 49, 71], ["antifungal agents", "TREATMENT", 125, 142], ["infections", "OBSERVATION", 6, 16], ["invasive", "OBSERVATION_MODIFIER", 49, 57], ["aspergillosis", "OBSERVATION", 58, 71], ["antifungal agents", "OBSERVATION", 125, 142]]], ["Hence, nonAspergillus filamentous fungal infection needs to be considered in patients with a clinical diagnosis of IPA who are not responding to antifungal therapy.", [["fungal infection", "DISEASE", 34, 50], ["nonAspergillus filamentous fungal", "ORGANISM", 7, 40], ["patients", "ORGANISM", 77, 85], ["antifungal", "CANCER", 145, 155], ["patients", "SPECIES", 77, 85], ["nonAspergillus filamentous fungal infection", "PROBLEM", 7, 50], ["IPA", "PROBLEM", 115, 118], ["antifungal therapy", "TREATMENT", 145, 163], ["filamentous", "OBSERVATION_MODIFIER", 22, 33], ["fungal", "OBSERVATION_MODIFIER", 34, 40], ["infection", "OBSERVATION", 41, 50]]], ["Diagnosis is made by culture from respiratory samples or lung biopsy, and mortality is very high.", [["respiratory samples", "ANATOMY", 34, 53], ["lung", "ANATOMY", 57, 61], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 57, 68], ["culture", "TEST", 21, 28], ["respiratory samples", "TEST", 34, 53], ["lung biopsy", "TEST", 57, 68], ["lung", "ANATOMY", 57, 61], ["biopsy", "OBSERVATION", 62, 68]]], ["Galactomannan and \u03b2Dglucan cell wall antigen test results are negative in patients infected with zygomycetes.", [["cell", "ANATOMY", 27, 31], ["zygomycetes", "ANATOMY", 97, 108], ["Galactomannan", "CHEMICAL", 0, 13], ["zygomycetes", "DISEASE", 97, 108], ["Galactomannan", "CHEMICAL", 0, 13], ["Galactomannan", "SIMPLE_CHEMICAL", 0, 13], ["\u03b2Dglucan cell wall antigen", "GENE_OR_GENE_PRODUCT", 18, 44], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Galactomannan", "TEST", 0, 13], ["\u03b2Dglucan cell wall antigen test", "TEST", 18, 49], ["zygomycetes", "PROBLEM", 97, 108]]], ["Treatment is with surgical d\u00e9bridement combined with ampho tericin and, for infections due to Fusarium and Scedosporium but not zygomycetes, voriconazole or posaconazole.Infections Due to Candida Spp.Infection with Candida rarely manifests as a pneumonia, but candidemia may lead to metastatic lung infection that causesTreatmentThe treatment options for invasive aspergillosis have been con siderably improved by the introduction of new azoles, voricon azole and more recently posaconazole, and a new class of antifungal agents, the echinocandins, the first example of which is caspofungin.", [["metastatic lung", "ANATOMY", 283, 298], ["invasive aspergillosis", "ANATOMY", 355, 377], ["ampho tericin", "CHEMICAL", 53, 66], ["infections", "DISEASE", 76, 86], ["Fusarium and Scedosporium", "DISEASE", 94, 119], ["voriconazole", "CHEMICAL", 141, 153], ["posaconazole", "CHEMICAL", 157, 169], ["pneumonia", "DISEASE", 245, 254], ["candidemia", "DISEASE", 260, 270], ["lung infection", "DISEASE", 294, 308], ["aspergillosis", "DISEASE", 364, 377], ["azoles", "CHEMICAL", 438, 444], ["voricon azole", "CHEMICAL", 446, 459], ["posaconazole", "CHEMICAL", 478, 490], ["echinocandins", "CHEMICAL", 534, 547], ["caspofungin", "CHEMICAL", 579, 590], ["voriconazole", "CHEMICAL", 141, 153], ["posaconazole", "CHEMICAL", 157, 169], ["azoles", "CHEMICAL", 438, 444], ["voricon azole", "CHEMICAL", 446, 459], ["posaconazole", "CHEMICAL", 478, 490], ["echinocandins", "CHEMICAL", 534, 547], ["caspofungin", "CHEMICAL", 579, 590], ["ampho tericin", "SIMPLE_CHEMICAL", 53, 66], ["zygomycetes", "SIMPLE_CHEMICAL", 128, 139], ["voriconazole", "SIMPLE_CHEMICAL", 141, 153], ["posaconazole", "SIMPLE_CHEMICAL", 157, 169], ["lung", "ORGAN", 294, 298], ["aspergillosis", "CANCER", 364, 377], ["azoles", "SIMPLE_CHEMICAL", 438, 444], ["voricon azole", "SIMPLE_CHEMICAL", 446, 459], ["posaconazole", "SIMPLE_CHEMICAL", 478, 490], ["echinocandins", "SIMPLE_CHEMICAL", 534, 547], ["caspofungin", "SIMPLE_CHEMICAL", 579, 590], ["surgical d\u00e9bridement", "TREATMENT", 18, 38], ["ampho tericin", "TREATMENT", 53, 66], ["infections", "PROBLEM", 76, 86], ["Fusarium", "PROBLEM", 94, 102], ["Scedosporium", "PROBLEM", 107, 119], ["zygomycetes", "PROBLEM", 128, 139], ["voriconazole", "TREATMENT", 141, 153], ["posaconazole", "TREATMENT", 157, 169], ["Infections", "PROBLEM", 170, 180], ["Candida Spp", "PROBLEM", 188, 199], ["Infection", "PROBLEM", 200, 209], ["Candida", "PROBLEM", 215, 222], ["a pneumonia", "PROBLEM", 243, 254], ["candidemia", "PROBLEM", 260, 270], ["metastatic lung infection", "PROBLEM", 283, 308], ["Treatment", "TREATMENT", 320, 329], ["The treatment options", "TREATMENT", 329, 350], ["invasive aspergillosis", "PROBLEM", 355, 377], ["new azoles", "TREATMENT", 434, 444], ["voricon azole", "TREATMENT", 446, 459], ["posaconazole", "TREATMENT", 478, 490], ["antifungal agents", "TREATMENT", 511, 528], ["the echinocandins", "TREATMENT", 530, 547], ["caspofungin", "TREATMENT", 579, 590], ["Candida Spp", "OBSERVATION", 188, 199], ["Candida", "OBSERVATION", 215, 222], ["pneumonia", "OBSERVATION", 245, 254], ["candidemia", "OBSERVATION", 260, 270], ["may lead to", "UNCERTAINTY", 271, 282], ["metastatic", "OBSERVATION_MODIFIER", 283, 293], ["lung", "ANATOMY", 294, 298], ["infection", "OBSERVATION", 299, 308], ["invasive", "OBSERVATION_MODIFIER", 355, 363], ["aspergillosis", "OBSERVATION", 364, 377], ["caspofungin", "OBSERVATION", 579, 590]]], ["Doses, modes of action, and common toxicities for the different treatment options are given in Table 28 -6.", [["toxicities", "DISEASE", 35, 45], ["common toxicities", "PROBLEM", 28, 45], ["the different treatment options", "TREATMENT", 50, 81]]], ["Voriconazole may be more effective than amphotericin B for treating IPA, but which drug is used depends on the patient's tolerance for that agent and any preexisting medical conditions (e.g., amphotericin B should be avoided in patients with renal problems, and azoles in patients with liver disease).", [["renal", "ANATOMY", 242, 247], ["liver", "ANATOMY", 286, 291], ["Voriconazole", "CHEMICAL", 0, 12], ["amphotericin B", "CHEMICAL", 40, 54], ["IPA", "CHEMICAL", 68, 71], ["amphotericin B", "CHEMICAL", 192, 206], ["renal problems", "DISEASE", 242, 256], ["azoles", "CHEMICAL", 262, 268], ["liver disease", "DISEASE", 286, 299], ["Voriconazole", "CHEMICAL", 0, 12], ["amphotericin B", "CHEMICAL", 40, 54], ["amphotericin B", "CHEMICAL", 192, 206], ["azoles", "CHEMICAL", 262, 268], ["Voriconazole", "SIMPLE_CHEMICAL", 0, 12], ["amphotericin B", "SIMPLE_CHEMICAL", 40, 54], ["patient", "ORGANISM", 111, 118], ["amphotericin B", "SIMPLE_CHEMICAL", 192, 206], ["patients", "ORGANISM", 228, 236], ["renal", "ORGAN", 242, 247], ["azoles", "SIMPLE_CHEMICAL", 262, 268], ["patients", "ORGANISM", 272, 280], ["liver", "ORGAN", 286, 291], ["patient", "SPECIES", 111, 118], ["patients", "SPECIES", 228, 236], ["patients", "SPECIES", 272, 280], ["Voriconazole", "TREATMENT", 0, 12], ["amphotericin B", "TREATMENT", 40, 54], ["that agent", "TREATMENT", 135, 145], ["any preexisting medical conditions", "PROBLEM", 150, 184], ["amphotericin B", "TREATMENT", 192, 206], ["renal problems", "PROBLEM", 242, 256], ["azoles", "TREATMENT", 262, 268], ["liver disease", "PROBLEM", 286, 299], ["renal", "ANATOMY", 242, 247], ["liver", "ANATOMY", 286, 291], ["disease", "OBSERVATION", 292, 299]]], ["Itracon azole is less efficacious and should be reserved for oral treat ment in patients recovering from IPA after induction treatment with amphotericin B, caspofungin, or voriconazole or for the longterm treatment required for chronic forms of invasive aspergillosis.", [["oral", "ANATOMY", 61, 65], ["invasive aspergillosis", "ANATOMY", 245, 267], ["Itracon azole", "CHEMICAL", 0, 13], ["IPA", "CHEMICAL", 105, 108], ["amphotericin B", "CHEMICAL", 140, 154], ["caspofungin", "CHEMICAL", 156, 167], ["voriconazole", "CHEMICAL", 172, 184], ["aspergillosis", "DISEASE", 254, 267], ["Itracon azole", "CHEMICAL", 0, 13], ["amphotericin B", "CHEMICAL", 140, 154], ["caspofungin", "CHEMICAL", 156, 167], ["voriconazole", "CHEMICAL", 172, 184], ["Itracon azole", "SIMPLE_CHEMICAL", 0, 13], ["oral", "ORGANISM_SUBDIVISION", 61, 65], ["patients", "ORGANISM", 80, 88], ["amphotericin B", "SIMPLE_CHEMICAL", 140, 154], ["caspofungin", "SIMPLE_CHEMICAL", 156, 167], ["voriconazole", "SIMPLE_CHEMICAL", 172, 184], ["aspergillosis", "CANCER", 254, 267], ["patients", "SPECIES", 80, 88], ["Itracon azole", "TREATMENT", 0, 13], ["oral treat ment", "TREATMENT", 61, 76], ["IPA", "TREATMENT", 105, 108], ["induction treatment", "TREATMENT", 115, 134], ["amphotericin B", "TREATMENT", 140, 154], ["caspofungin", "TREATMENT", 156, 167], ["voriconazole", "TREATMENT", 172, 184], ["the longterm treatment", "TREATMENT", 192, 214], ["invasive aspergillosis", "PROBLEM", 245, 267], ["less efficacious", "OBSERVATION_MODIFIER", 17, 33], ["invasive", "OBSERVATION_MODIFIER", 245, 253], ["aspergillosis", "OBSERVATION", 254, 267]]], ["Drug levels probably should be monitored for patients receiving itraconazole, voriconazole, and posaconazole, at least for patients on prolonged therapy.", [["itraconazole", "CHEMICAL", 64, 76], ["voriconazole", "CHEMICAL", 78, 90], ["posaconazole", "CHEMICAL", 96, 108], ["itraconazole", "CHEMICAL", 64, 76], ["voriconazole", "CHEMICAL", 78, 90], ["posaconazole", "CHEMICAL", 96, 108], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["patients", "ORGANISM", 45, 53], ["itraconazole", "SIMPLE_CHEMICAL", 64, 76], ["voriconazole", "SIMPLE_CHEMICAL", 78, 90], ["posaconazole", "SIMPLE_CHEMICAL", 96, 108], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 123, 131], ["Drug levels", "TEST", 0, 11], ["itraconazole", "TREATMENT", 64, 76], ["voriconazole", "TREATMENT", 78, 90], ["posaconazole", "TREATMENT", 96, 108], ["prolonged therapy", "TREATMENT", 135, 152]]], ["The role of combina tion therapy remains unclear, but this strategy is potentially attractive in view of different mechanisms of action for the three effective classes of drugs.", [["combina tion", "CHEMICAL", 12, 24], ["combina tion therapy", "TREATMENT", 12, 32], ["drugs", "TREATMENT", 171, 176]]], ["Urgent surgical resection should be considered in patients with major hemoptysis, because fatal bleeding is not uncommon.", [["hemoptysis", "DISEASE", 70, 80], ["bleeding", "DISEASE", 96, 104], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Urgent surgical resection", "TREATMENT", 0, 25], ["major hemoptysis", "PROBLEM", 64, 80], ["fatal bleeding", "PROBLEM", 90, 104], ["surgical resection", "OBSERVATION", 7, 25], ["hemoptysis", "OBSERVATION", 70, 80], ["fatal", "OBSERVATION_MODIFIER", 90, 95], ["bleeding", "OBSERVATION", 96, 104], ["not uncommon", "UNCERTAINTY", 108, 120]]], ["Elective resection can be used as primary therapy for single lesions due to IPA, especially those containing an intracavitary mycetoma that might lead to reac tivation of IPA during subsequent immunosuppression.", [["lesions", "ANATOMY", 61, 68], ["IPA", "DISEASE", 76, 79], ["mycetoma", "DISEASE", 126, 134], ["IPA", "CHEMICAL", 171, 174], ["lesions", "PATHOLOGICAL_FORMATION", 61, 68], ["Elective resection", "TREATMENT", 0, 18], ["primary therapy", "TREATMENT", 34, 49], ["single lesions", "PROBLEM", 54, 68], ["IPA", "PROBLEM", 76, 79], ["an intracavitary mycetoma", "PROBLEM", 109, 134], ["IPA", "TREATMENT", 171, 174], ["subsequent immunosuppression", "TREATMENT", 182, 210], ["resection", "OBSERVATION", 9, 18], ["lesions", "OBSERVATION", 61, 68], ["intracavitary", "ANATOMY", 112, 125], ["mycetoma", "OBSERVATION", 126, 134], ["immunosuppression", "OBSERVATION", 193, 210]]], ["Treat ment of IPA for several weeks often is necessary, followed by prophylactic therapy in cases with persisting radiologic changes.", [["IPA", "CHEMICAL", 14, 17], ["IPA", "TREATMENT", 14, 17], ["prophylactic therapy", "TREATMENT", 68, 88], ["persisting radiologic changes", "PROBLEM", 103, 132]]], ["Treatment of CNPA and CCPA will need to be continued for months if not years (and even lifelong).", [["CNPA", "CHEMICAL", 13, 17], ["CCPA", "CHEMICAL", 22, 26], ["CNPA", "CANCER", 13, 17], ["CCPA", "SIMPLE_CHEMICAL", 22, 26], ["CNPA", "TREATMENT", 13, 17], ["CCPA", "TREATMENT", 22, 26]]], ["Owing to a combina tion of uncontrolled infection and the underlying disease, the mortality rate for IPA is around 50%, and with chronic forms of aspergillosis, the infection rate remains as high as 33%. in an atrisk patient and should be confirmed by cytologic identification of the characteristic P. jirovecii cysts in BAL fluid.", [["cysts", "ANATOMY", 312, 317], ["BAL fluid", "ANATOMY", 321, 330], ["infection", "DISEASE", 40, 49], ["IPA", "CHEMICAL", 101, 104], ["aspergillosis", "DISEASE", 146, 159], ["infection", "DISEASE", 165, 174], ["P. jirovecii cysts", "DISEASE", 299, 317], ["aspergillosis", "CANCER", 146, 159], ["patient", "ORGANISM", 217, 224], ["P. jirovecii", "ORGANISM", 299, 311], ["BAL fluid", "ORGANISM_SUBSTANCE", 321, 330], ["patient", "SPECIES", 217, 224], ["P. jirovecii", "SPECIES", 299, 311], ["P. jirovecii", "SPECIES", 299, 311], ["uncontrolled infection", "PROBLEM", 27, 49], ["the underlying disease", "PROBLEM", 54, 76], ["the mortality rate", "TEST", 78, 96], ["IPA", "TEST", 101, 104], ["aspergillosis", "PROBLEM", 146, 159], ["the infection rate", "TEST", 161, 179], ["cytologic identification", "TEST", 252, 276], ["the characteristic P. jirovecii cysts in BAL fluid", "PROBLEM", 280, 330], ["uncontrolled", "OBSERVATION_MODIFIER", 27, 39], ["infection", "OBSERVATION", 40, 49], ["disease", "OBSERVATION", 69, 76], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["aspergillosis", "OBSERVATION", 146, 159], ["infection", "OBSERVATION", 165, 174], ["jirovecii", "OBSERVATION_MODIFIER", 302, 311], ["cysts", "OBSERVATION", 312, 317], ["BAL fluid", "OBSERVATION", 321, 330]]], ["Diagnosis can be improved using immunohistochemistry assay for Pneumocystis antigens, and perhaps by PCR analysis, although the latter will have a significant falsepositive rate as a consequence of colonization in the absence of disease.", [["Pneumocystis antigens", "DISEASE", 63, 84], ["Pneumocystis antigens", "GENE_OR_GENE_PRODUCT", 63, 84], ["immunohistochemistry assay", "TEST", 32, 58], ["Pneumocystis antigens", "PROBLEM", 63, 84], ["PCR analysis", "TEST", 101, 113], ["a significant falsepositive rate", "PROBLEM", 145, 177], ["colonization", "PROBLEM", 198, 210], ["disease", "PROBLEM", 229, 236], ["colonization", "OBSERVATION", 198, 210], ["disease", "OBSERVATION", 229, 236]]], ["Firstline treatment is with highdose cotrimoxazole and adjuvant steroids given according to the protocols used for PCP in HIVinfected patients.", [["cotrimoxazole", "CHEMICAL", 37, 50], ["steroids", "CHEMICAL", 64, 72], ["PCP", "DISEASE", 115, 118], ["cotrimoxazole", "CHEMICAL", 37, 50], ["steroids", "CHEMICAL", 64, 72], ["PCP", "CHEMICAL", 115, 118], ["cotrimoxazole", "SIMPLE_CHEMICAL", 37, 50], ["steroids", "SIMPLE_CHEMICAL", 64, 72], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Firstline treatment", "TREATMENT", 0, 19], ["highdose cotrimoxazole", "TREATMENT", 28, 50], ["adjuvant steroids", "TREATMENT", 55, 72]]], ["Myelosuppression due to cotrimoxazole means that many patients with hematologic disorders have to switch to secondline therapy with clindamy cin and primaquine.", [["hematologic", "ANATOMY", 68, 79], ["Myelosuppression", "DISEASE", 0, 16], ["cotrimoxazole", "CHEMICAL", 24, 37], ["hematologic disorders", "DISEASE", 68, 89], ["clindamy cin", "CHEMICAL", 132, 144], ["primaquine", "CHEMICAL", 149, 159], ["cotrimoxazole", "CHEMICAL", 24, 37], ["primaquine", "CHEMICAL", 149, 159], ["cotrimoxazole", "SIMPLE_CHEMICAL", 24, 37], ["patients", "ORGANISM", 54, 62], ["clindamy cin", "SIMPLE_CHEMICAL", 132, 144], ["primaquine", "SIMPLE_CHEMICAL", 149, 159], ["patients", "SPECIES", 54, 62], ["Myelosuppression", "PROBLEM", 0, 16], ["cotrimoxazole means", "TREATMENT", 24, 43], ["hematologic disorders", "PROBLEM", 68, 89], ["secondline therapy", "TREATMENT", 108, 126], ["clindamy cin", "TREATMENT", 132, 144], ["primaquine", "TREATMENT", 149, 159]]], ["In nonHIV immunocompromised patients, PCP is associated with intubation and mortality rates of around 30% each.", [["HIV immunocompromised", "DISEASE", 6, 27], ["PCP", "DISEASE", 38, 41], ["PCP", "CHEMICAL", 38, 41], ["patients", "ORGANISM", 28, 36], ["HIV", "SPECIES", 6, 9], ["patients", "SPECIES", 28, 36], ["HIV", "SPECIES", 6, 9], ["intubation", "TREATMENT", 61, 71], ["mortality rates", "TEST", 76, 91], ["nonHIV", "OBSERVATION_MODIFIER", 3, 9], ["immunocompromised", "OBSERVATION", 10, 27]]], ["PCP prophylaxis usually is prescribed for several months after allograft HSCT or organ transplantation, and occasionally longer in patients who continue to receive immu nosuppressive drugs.", [["allograft", "ANATOMY", 63, 72], ["organ", "ANATOMY", 81, 86], ["PCP", "CHEMICAL", 0, 3], ["PCP", "CHEMICAL", 0, 3], ["allograft", "TISSUE", 63, 72], ["organ", "ORGAN", 81, 86], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["PCP prophylaxis", "TREATMENT", 0, 15], ["allograft HSCT", "TREATMENT", 63, 77], ["organ transplantation", "TREATMENT", 81, 102], ["immu nosuppressive drugs", "TREATMENT", 164, 188], ["organ", "ANATOMY", 81, 86], ["transplantation", "OBSERVATION", 87, 102]]], ["Patients recovering from PCP should con tinue on chemoprophylaxis until their immunosuppression is resolved, although there are no clear parameters for defining this endpoint.", [["PCP", "DISEASE", 25, 28], ["PCP", "CHEMICAL", 25, 28], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["chemoprophylaxis", "TREATMENT", 49, 65], ["their immunosuppression", "TREATMENT", 72, 95]]], ["Consensus is lacking on the requirement for PCP prophylaxis after autograft HSCT and for severe nontransplantationrelated immunosuppression.", [["PCP", "CHEMICAL", 44, 47], ["PCP", "CHEMICAL", 44, 47], ["PCP prophylaxis", "TREATMENT", 44, 59], ["autograft HSCT", "TREATMENT", 66, 80], ["severe nontransplantationrelated immunosuppression", "TREATMENT", 89, 139], ["immunosuppression", "OBSERVATION", 122, 139]]], ["Cotrimoxazole prophylaxis given either daily or three times per week is very effective (greater than 90% efficacy) and provides some protec tion against other pathogens, including Toxoplasma, Nocardia, and bacteria.CONTROVERSIES AND PITFALLS\u2022 Exactly when bronchoscopy should be used for diagnosing respiratory infections in immunocompromised patients remains controversial, with no clear consensus on early versus late bronchoscopy.", [["respiratory", "ANATOMY", 299, 310], ["Cotrimoxazole", "CHEMICAL", 0, 13], ["Toxoplasma, Nocardia", "DISEASE", 180, 200], ["respiratory infections", "DISEASE", 299, 321], ["Cotrimoxazole", "CHEMICAL", 0, 13], ["Cotrimoxazole", "SIMPLE_CHEMICAL", 0, 13], ["Toxoplasma", "ORGANISM", 180, 190], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 343, 351], ["Cotrimoxazole prophylaxis", "TREATMENT", 0, 25], ["some protec tion", "TREATMENT", 128, 144], ["other pathogens", "PROBLEM", 153, 168], ["Toxoplasma", "PROBLEM", 180, 190], ["Nocardia", "PROBLEM", 192, 200], ["bacteria", "PROBLEM", 206, 214], ["bronchoscopy", "TREATMENT", 256, 268], ["diagnosing respiratory infections", "PROBLEM", 288, 321], ["late bronchoscopy", "TEST", 415, 432], ["infections", "OBSERVATION", 311, 321]]], ["The approach described in this chapter based on the type of lung shadowing aims to target bronchoscopy to the patients for whom it may be most helpful. \u2022 CMV pneumonitis is an especially difficult diagnosis to confirm; the specific diagnostic tests often are inconclusive, and the clinician is left with presumptive evidence of involvement of CMV consisting of the combination of a pneumonitis with blood test results indicating reactivation of the virus. \u2022 A major pitfall to avoid is failure to consider noninfective causes of respiratory problems in the nonHIVinfected immunocompromised patient; pulmonary edema, alveolar hemorrhage, ARDS, drugrelated or idiopathic pneumonitis, and rapidly progressive airway obstruction due to lung graft versushost disease (often precipitated by respiratory viral infections) often need to be included in the differential diagnosis. \u2022 Although most infective causes of lung problems in the non-HIVinfected immunocompromised patient generally have fairly characteristic presentations and affect selected risk groups, considerable overlap between clinical presenta tions for illnesses due to specific infectious agents is typical.", [["lung", "ANATOMY", 60, 64], ["blood", "ANATOMY", 399, 404], ["respiratory", "ANATOMY", 529, 540], ["pulmonary", "ANATOMY", 599, 608], ["alveolar", "ANATOMY", 616, 624], ["airway", "ANATOMY", 706, 712], ["lung graft", "ANATOMY", 732, 742], ["lung", "ANATOMY", 908, 912], ["CMV pneumonitis", "DISEASE", 154, 169], ["pneumonitis", "DISEASE", 382, 393], ["respiratory problems", "DISEASE", 529, 549], ["pulmonary edema", "DISEASE", 599, 614], ["alveolar hemorrhage", "DISEASE", 616, 635], ["ARDS", "DISEASE", 637, 641], ["idiopathic pneumonitis", "DISEASE", 658, 680], ["airway obstruction", "DISEASE", 706, 724], ["lung graft versushost disease", "DISEASE", 732, 761], ["respiratory viral infections", "DISEASE", 785, 813], ["lung problems", "DISEASE", 908, 921], ["lung", "ORGAN", 60, 64], ["patients", "ORGANISM", 110, 118], ["CMV", "ORGANISM", 154, 157], ["CMV", "ORGANISM", 343, 346], ["blood", "ORGANISM_SUBSTANCE", 399, 404], ["patient", "ORGANISM", 590, 597], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 599, 614], ["alveolar", "MULTI-TISSUE_STRUCTURE", 616, 624], ["airway obstruction", "PATHOLOGICAL_FORMATION", 706, 724], ["lung", "ORGAN", 732, 736], ["lung", "ORGAN", 908, 912], ["patient", "ORGANISM", 963, 970], ["patients", "SPECIES", 110, 118], ["patient", "SPECIES", 590, 597], ["patient", "SPECIES", 963, 970], ["CMV", "SPECIES", 154, 157], ["CMV", "SPECIES", 343, 346], ["target bronchoscopy", "TREATMENT", 83, 102], ["CMV pneumonitis", "PROBLEM", 154, 169], ["the specific diagnostic tests", "TEST", 219, 248], ["CMV", "PROBLEM", 343, 346], ["a pneumonitis", "PROBLEM", 380, 393], ["blood test", "TEST", 399, 409], ["the virus", "PROBLEM", 445, 454], ["failure", "PROBLEM", 486, 493], ["noninfective causes", "PROBLEM", 506, 525], ["respiratory problems", "PROBLEM", 529, 549], ["the nonHIVinfected immunocompromised patient", "PROBLEM", 553, 597], ["pulmonary edema", "PROBLEM", 599, 614], ["alveolar hemorrhage", "PROBLEM", 616, 635], ["ARDS", "PROBLEM", 637, 641], ["idiopathic pneumonitis", "PROBLEM", 658, 680], ["rapidly progressive airway obstruction", "PROBLEM", 686, 724], ["lung graft versushost disease", "PROBLEM", 732, 761], ["respiratory viral infections", "PROBLEM", 785, 813], ["lung problems", "PROBLEM", 908, 921], ["illnesses", "PROBLEM", 1112, 1121], ["specific infectious agents", "PROBLEM", 1129, 1155], ["lung", "ANATOMY", 60, 64], ["shadowing", "OBSERVATION", 65, 74], ["CMV pneumonitis", "OBSERVATION", 154, 169], ["presumptive evidence of", "UNCERTAINTY", 304, 327], ["CMV", "OBSERVATION", 343, 346], ["pneumonitis", "OBSERVATION", 382, 393], ["virus", "OBSERVATION", 449, 454], ["failure", "OBSERVATION", 486, 493], ["respiratory problems", "OBSERVATION", 529, 549], ["immunocompromised", "OBSERVATION", 572, 589], ["pulmonary", "ANATOMY", 599, 608], ["edema", "OBSERVATION", 609, 614], ["alveolar", "ANATOMY_MODIFIER", 616, 624], ["hemorrhage", "OBSERVATION", 625, 635], ["ARDS", "OBSERVATION", 637, 641], ["idiopathic", "OBSERVATION_MODIFIER", 658, 668], ["pneumonitis", "OBSERVATION", 669, 680], ["rapidly", "OBSERVATION_MODIFIER", 686, 693], ["progressive", "OBSERVATION_MODIFIER", 694, 705], ["airway", "ANATOMY", 706, 712], ["obstruction", "OBSERVATION", 713, 724], ["lung", "ANATOMY", 732, 736], ["graft versushost", "OBSERVATION", 737, 753], ["viral infections", "OBSERVATION", 797, 813], ["most", "OBSERVATION_MODIFIER", 883, 887], ["infective", "OBSERVATION", 888, 897], ["lung", "ANATOMY", 908, 912], ["problems", "OBSERVATION", 913, 921], ["immunocompromised", "OBSERVATION", 945, 962], ["infectious", "OBSERVATION", 1138, 1148]]], ["This is especially true for the more severely immunosup pressed patient, in whom the usual clinical presentations become less characteristic. \u2022 Finally, the clinician needs to remember that non-HIV infected immunocompromised patients often have two simultaneous pathologic conditions (e.g., a bacterial pneu monia complicated by ARDS, or a respiratory viral infection with lung graftversushost disease).CONTROVERSIES AND PITFALLSpyrexia and is associated with radiologic evidence of lung nodules that often are peripheral in location and sometimes very large.", [["lung", "ANATOMY", 373, 377], ["lung nodules", "ANATOMY", 483, 495], ["non-HIV infected", "DISEASE", 190, 206], ["bacterial pneu monia", "DISEASE", 293, 313], ["ARDS", "DISEASE", 329, 333], ["respiratory viral infection", "DISEASE", 340, 367], ["lung graftversushost disease", "DISEASE", 373, 401], ["PITFALLSpyrexia", "DISEASE", 421, 436], ["patient", "ORGANISM", 64, 71], ["patients", "ORGANISM", 225, 233], ["lung", "ORGAN", 373, 377], ["lung nodules", "CANCER", 483, 495], ["patient", "SPECIES", 64, 71], ["patients", "SPECIES", 225, 233], ["non-HIV infected immunocompromised", "PROBLEM", 190, 224], ["two simultaneous pathologic conditions", "PROBLEM", 245, 283], ["a bacterial pneu monia", "PROBLEM", 291, 313], ["ARDS", "PROBLEM", 329, 333], ["a respiratory viral infection", "PROBLEM", 338, 367], ["lung graftversushost disease", "PROBLEM", 373, 401], ["PITFALLSpyrexia", "PROBLEM", 421, 436], ["lung nodules", "PROBLEM", 483, 495], ["less characteristic", "OBSERVATION_MODIFIER", 121, 140], ["ARDS", "OBSERVATION", 329, 333], ["respiratory", "ANATOMY", 340, 351], ["viral infection", "OBSERVATION", 352, 367], ["lung", "ANATOMY", 373, 377], ["graftversushost disease", "OBSERVATION", 378, 401], ["lung", "ANATOMY", 483, 487], ["nodules", "OBSERVATION", 488, 495], ["peripheral", "OBSERVATION_MODIFIER", 511, 521], ["very", "OBSERVATION_MODIFIER", 548, 552], ["large", "OBSERVATION", 553, 558]]], ["Neutropenic patients with mucositis or indwelling lines are at risk for invasive candidemia, which usually is caused by dissemination of endogenous colonizing Candida spp.", [["indwelling lines", "ANATOMY", 39, 55], ["mucositis", "DISEASE", 26, 35], ["candidemia", "DISEASE", 81, 91], ["patients", "ORGANISM", 12, 20], ["Candida spp", "ORGANISM", 159, 170], ["patients", "SPECIES", 12, 20], ["Neutropenic", "PROBLEM", 0, 11], ["mucositis", "PROBLEM", 26, 35], ["indwelling lines", "TREATMENT", 39, 55], ["invasive candidemia", "PROBLEM", 72, 91], ["endogenous colonizing Candida spp", "PROBLEM", 137, 170], ["mucositis", "OBSERVATION", 26, 35], ["indwelling lines", "OBSERVATION", 39, 55], ["invasive", "OBSERVATION_MODIFIER", 72, 80], ["candidemia", "OBSERVATION", 81, 91], ["endogenous", "OBSERVATION_MODIFIER", 137, 147], ["colonizing", "OBSERVATION_MODIFIER", 148, 158], ["Candida spp", "OBSERVATION", 159, 170]]], ["The frequent use of fluconazole for prophylaxis has led to increasing isolation of nonalbicans species such as Candida glabrata and Candida parapsilosis.", [["fluconazole", "CHEMICAL", 20, 31], ["Candida glabrata", "DISEASE", 111, 127], ["Candida parapsilosis", "DISEASE", 132, 152], ["fluconazole", "CHEMICAL", 20, 31], ["fluconazole", "SIMPLE_CHEMICAL", 20, 31], ["nonalbicans species", "ORGANISM", 83, 102], ["Candida glabrata", "ORGANISM", 111, 127], ["Candida parapsilosis", "ORGANISM", 132, 152], ["Candida glabrata", "SPECIES", 111, 127], ["Candida parapsilosis", "SPECIES", 132, 152], ["Candida glabrata", "SPECIES", 111, 127], ["Candida parapsilosis", "SPECIES", 132, 152], ["fluconazole", "TREATMENT", 20, 31], ["prophylaxis", "TREATMENT", 36, 47], ["nonalbicans species", "PROBLEM", 83, 102], ["Candida glabrata", "PROBLEM", 111, 127], ["Candida parapsilosis", "PROBLEM", 132, 152], ["increasing", "OBSERVATION_MODIFIER", 59, 69], ["Candida glabrata", "OBSERVATION", 111, 127], ["Candida parapsilosis", "OBSERVATION", 132, 152]]], ["Treatment is with caspofungin, ampho tericin, voriconazole, or posaconazole.Infections Due to Cryptococcus and Endemic FungiCryptococcus neoformans infections are acquired by inhalation of the fungal spores.", [["spores", "ANATOMY", 200, 206], ["caspofungin", "CHEMICAL", 18, 29], ["ampho tericin", "CHEMICAL", 31, 44], ["voriconazole", "CHEMICAL", 46, 58], ["posaconazole", "CHEMICAL", 63, 75], ["FungiCryptococcus neoformans infections", "DISEASE", 119, 158], ["caspofungin", "CHEMICAL", 18, 29], ["ampho tericin", "CHEMICAL", 31, 44], ["voriconazole", "CHEMICAL", 46, 58], ["posaconazole", "CHEMICAL", 63, 75], ["caspofungin", "SIMPLE_CHEMICAL", 18, 29], ["ampho tericin", "SIMPLE_CHEMICAL", 31, 44], ["voriconazole", "SIMPLE_CHEMICAL", 46, 58], ["posaconazole", "SIMPLE_CHEMICAL", 63, 75], ["Endemic FungiCryptococcus neoformans", "ORGANISM", 111, 147], ["FungiCryptococcus neoformans", "SPECIES", 119, 147], ["FungiCryptococcus neoformans", "SPECIES", 119, 147], ["caspofungin", "TREATMENT", 18, 29], ["ampho tericin", "TREATMENT", 31, 44], ["voriconazole", "TREATMENT", 46, 58], ["posaconazole", "TREATMENT", 63, 75], ["Infections", "PROBLEM", 76, 86], ["Cryptococcus", "PROBLEM", 94, 106], ["Endemic FungiCryptococcus neoformans infections", "PROBLEM", 111, 158], ["the fungal spores", "PROBLEM", 189, 206], ["Cryptococcus", "OBSERVATION", 94, 106], ["Endemic", "OBSERVATION_MODIFIER", 111, 118], ["FungiCryptococcus", "OBSERVATION_MODIFIER", 119, 136], ["neoformans infections", "OBSERVATION", 137, 158], ["fungal spores", "OBSERVATION", 193, 206]]], ["Although respiratory infection often is asymptomatic, cryptococcal disease can cause multifocal con solidation and severe pneumonia in patients with defects in cellmediated immunity and carries a mortality rate of 30%.", [["respiratory", "ANATOMY", 9, 20], ["respiratory infection", "DISEASE", 9, 30], ["cryptococcal disease", "DISEASE", 54, 74], ["pneumonia", "DISEASE", 122, 131], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["respiratory infection", "PROBLEM", 9, 30], ["asymptomatic", "PROBLEM", 40, 52], ["cryptococcal disease", "PROBLEM", 54, 74], ["multifocal con solidation", "PROBLEM", 85, 110], ["severe pneumonia", "PROBLEM", 115, 131], ["defects in cellmediated immunity", "PROBLEM", 149, 181], ["a mortality rate", "TEST", 194, 210], ["respiratory", "ANATOMY", 9, 20], ["infection", "OBSERVATION", 21, 30], ["cryptococcal disease", "OBSERVATION", 54, 74], ["multifocal", "OBSERVATION_MODIFIER", 85, 95], ["con solidation", "OBSERVATION", 96, 110], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["pneumonia", "OBSERVATION", 122, 131]]], ["The diagnosis is made by microscopic identification or culture of C. neoformans from respiratory tract samples.", [["respiratory tract samples", "ANATOMY", 85, 110], ["C. neoformans", "ORGANISM", 66, 79], ["respiratory tract samples", "CANCER", 85, 110], ["C. neoformans", "SPECIES", 66, 79], ["C. neoformans", "SPECIES", 66, 79], ["microscopic identification", "TEST", 25, 51], ["culture", "TEST", 55, 62], ["C. neoformans", "PROBLEM", 66, 79], ["respiratory tract samples", "TEST", 85, 110], ["respiratory tract", "ANATOMY", 85, 102]]], ["Treatment is with intravenous amphotericin B in combination with flucyto sine, followed by oral fluconazole.", [["intravenous", "ANATOMY", 18, 29], ["oral", "ANATOMY", 91, 95], ["amphotericin B", "CHEMICAL", 30, 44], ["fluconazole", "CHEMICAL", 96, 107], ["amphotericin B", "CHEMICAL", 30, 44], ["fluconazole", "CHEMICAL", 96, 107], ["intravenous", "SIMPLE_CHEMICAL", 18, 29], ["amphotericin B", "SIMPLE_CHEMICAL", 30, 44], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["fluconazole", "SIMPLE_CHEMICAL", 96, 107], ["intravenous amphotericin B", "TREATMENT", 18, 44], ["flucyto sine", "TREATMENT", 65, 77], ["oral fluconazole", "TREATMENT", 91, 107]]], ["Reactivation of latent infec tion with endemic fungi such as Histoplasma and Coccidioides should be considered in patients with defects in cellmediated immunity presenting with multifocal lung shadowing who have lived in relevant geographic areas, especially if there is evidence of extrapulmonary involvement.", [["lung", "ANATOMY", 188, 192], ["extrapulmonary", "ANATOMY", 283, 297], ["Histoplasma and Coccidioides", "DISEASE", 61, 89], ["patients", "ORGANISM", 114, 122], ["lung", "ORGAN", 188, 192], ["patients", "SPECIES", 114, 122], ["latent infec tion", "PROBLEM", 16, 33], ["endemic fungi", "PROBLEM", 39, 52], ["Histoplasma", "PROBLEM", 61, 72], ["Coccidioides", "PROBLEM", 77, 89], ["defects in cellmediated immunity", "PROBLEM", 128, 160], ["multifocal lung shadowing", "PROBLEM", 177, 202], ["extrapulmonary involvement", "PROBLEM", 283, 309], ["latent", "OBSERVATION_MODIFIER", 16, 22], ["endemic", "OBSERVATION_MODIFIER", 39, 46], ["fungi", "OBSERVATION", 47, 52], ["Coccidioides", "OBSERVATION", 77, 89], ["defects", "OBSERVATION", 128, 135], ["multifocal", "OBSERVATION_MODIFIER", 177, 187], ["lung", "ANATOMY", 188, 192], ["shadowing", "OBSERVATION", 193, 202], ["evidence of", "UNCERTAINTY", 271, 282], ["extrapulmonary", "ANATOMY", 283, 297], ["involvement", "OBSERVATION", 298, 309]]], ["Diagnosis generally requires identification of the fungus in tissues samples.Pneumocystis jirovecii InfectionIn addition to its close association with HIV infection, PCP is an important type of pneumonia in non-HIVinfected immu nocompromised patients with defects in cellmediated immu nity or who are receiving systemic corticosteroid therapy equivalent to greater than 20 mg daily of prednisolone.", [["fungus", "ANATOMY", 51, 57], ["tissues samples", "ANATOMY", 61, 76], ["Pneumocystis jirovecii", "DISEASE", 77, 99], ["HIV infection", "DISEASE", 151, 164], ["PCP", "DISEASE", 166, 169], ["pneumonia", "DISEASE", 194, 203], ["prednisolone", "CHEMICAL", 385, 397], ["prednisolone", "CHEMICAL", 385, 397], ["tissues samples", "TISSUE", 61, 76], ["Pneumocystis jirovecii", "ORGANISM", 77, 99], ["HIV", "ORGANISM", 151, 154], ["patients", "ORGANISM", 242, 250], ["prednisolone", "SIMPLE_CHEMICAL", 385, 397], ["Pneumocystis jirovecii", "SPECIES", 77, 99], ["HIV", "SPECIES", 151, 154], ["patients", "SPECIES", 242, 250], ["Pneumocystis jirovecii", "SPECIES", 77, 99], ["HIV", "SPECIES", 151, 154], ["the fungus in tissues samples", "PROBLEM", 47, 76], ["Pneumocystis jirovecii InfectionIn", "PROBLEM", 77, 111], ["HIV infection", "PROBLEM", 151, 164], ["pneumonia", "PROBLEM", 194, 203], ["defects", "PROBLEM", 256, 263], ["systemic corticosteroid therapy", "TREATMENT", 311, 342], ["prednisolone", "TREATMENT", 385, 397], ["fungus", "OBSERVATION", 51, 57], ["jirovecii", "OBSERVATION", 90, 99], ["HIV", "OBSERVATION_MODIFIER", 151, 154], ["infection", "OBSERVATION", 155, 164], ["important type", "OBSERVATION_MODIFIER", 176, 190], ["pneumonia", "OBSERVATION", 194, 203]]], ["The clinical presentation generally is insidious in onset, with cough and progressive dyspnea developing over weeks, but can be more fulminant.", [["cough", "DISEASE", 64, 69], ["dyspnea", "DISEASE", 86, 93], ["fulminant", "DISEASE", 133, 142], ["cough", "PROBLEM", 64, 69], ["progressive dyspnea", "PROBLEM", 74, 93], ["insidious", "OBSERVATION_MODIFIER", 39, 48], ["progressive", "OBSERVATION_MODIFIER", 74, 85], ["dyspnea", "OBSERVATION", 86, 93], ["more", "OBSERVATION_MODIFIER", 128, 132], ["fulminant", "OBSERVATION", 133, 142]]], ["Impaired gas transfer and hypoxia on exertion with progression to respiratory failure are common.", [["respiratory", "ANATOMY", 66, 77], ["hypoxia", "DISEASE", 26, 33], ["respiratory failure", "DISEASE", 66, 85], ["Impaired gas transfer", "PROBLEM", 0, 21], ["hypoxia", "PROBLEM", 26, 33], ["respiratory failure", "PROBLEM", 66, 85], ["gas", "OBSERVATION", 9, 12], ["hypoxia", "OBSERVATION_MODIFIER", 26, 33], ["respiratory failure", "OBSERVATION", 66, 85]]], ["The chest radiograph usually shows bilateral infiltrates but may be normal in appearance.", [["chest", "ANATOMY", 4, 9], ["The chest radiograph", "TEST", 0, 20], ["bilateral infiltrates", "PROBLEM", 35, 56], ["chest", "ANATOMY", 4, 9], ["bilateral", "ANATOMY_MODIFIER", 35, 44], ["infiltrates", "OBSERVATION", 45, 56], ["may be", "UNCERTAINTY", 61, 67], ["normal", "OBSERVATION", 68, 74]]], ["Generally the CT scan will show ground glass infiltrates, which classically mainly affect the upper lobes and spare the lung peripheries (Figure 28-14) .", [["upper lobes", "ANATOMY", 94, 105], ["lung", "ANATOMY", 120, 124], ["upper lobes", "ORGAN", 94, 105], ["lung", "ORGAN", 120, 124], ["the CT scan", "TEST", 10, 21], ["ground glass infiltrates", "PROBLEM", 32, 56], ["Figure", "TEST", 138, 144], ["ground glass infiltrates", "OBSERVATION", 32, 56], ["upper lobes", "ANATOMY", 94, 105], ["lung", "ANATOMY", 120, 124], ["peripheries", "ANATOMY_MODIFIER", 125, 136]]], ["On rare occasions, however, even the CT scan may show only minimal abnormali ties.", [["the CT scan", "TEST", 33, 44], ["minimal abnormali ties", "PROBLEM", 59, 81], ["minimal", "OBSERVATION_MODIFIER", 59, 66], ["abnormali", "OBSERVATION", 67, 76]]], ["The diagnosis is made by recognition of the clinical picture", [["the clinical picture", "PROBLEM", 40, 60]]]], "fa083540bf578c654c566a952a9144f6fef1960f": [["In the middle of the 19th century,it became clear that micro-organisms could cause disease.", [["micro-organisms", "PROBLEM", 55, 70], ["disease", "PROBLEM", 83, 90], ["middle", "ANATOMY_MODIFIER", 7, 13]]], ["Effective treatment, however, was not possible at that time; prevention and spread of infectious diseases depended solely on proper hygienic means.At the beginning of the 20th century, passive and active vaccination procedures were developed against a number of these pathogenic micro-organisms in order to prevent the diseases in question (rabies, diphtheria, tetanus, etc.) and due to the discovery of antimicrobial chemicals (Ehrlich) and antibiotics (Fleming), the threat of infectious diseases seemed to be minimized.", [["infectious diseases", "DISEASE", 86, 105], ["rabies, diphtheria, tetanus", "DISEASE", 341, 368], ["infectious diseases", "DISEASE", 479, 498], ["Ehrlich", "CANCER", 429, 436], ["rabies", "SPECIES", 341, 347], ["Effective treatment", "TREATMENT", 0, 19], ["infectious diseases", "PROBLEM", 86, 105], ["active vaccination procedures", "TREATMENT", 197, 226], ["these pathogenic micro-organisms", "PROBLEM", 262, 294], ["the diseases", "PROBLEM", 315, 327], ["rabies", "PROBLEM", 341, 347], ["diphtheria", "PROBLEM", 349, 359], ["tetanus", "PROBLEM", 361, 368], ["antimicrobial chemicals", "TREATMENT", 404, 427], ["antibiotics", "TREATMENT", 442, 453], ["infectious diseases", "PROBLEM", 479, 498], ["infectious", "OBSERVATION", 86, 96], ["active", "OBSERVATION_MODIFIER", 197, 203], ["diseases", "OBSERVATION", 319, 327], ["infectious", "OBSERVATION", 479, 489]]], ["Largescale vaccination programs against childhood diseases (diphtheria, whooping cough and polio) started in the early fifties, giving hope to finally eradicate these diseases from the planet.", [["diphtheria", "DISEASE", 60, 70], ["whooping cough", "DISEASE", 72, 86], ["polio", "DISEASE", 91, 96], ["Largescale vaccination programs", "TREATMENT", 0, 31], ["childhood diseases", "PROBLEM", 40, 58], ["diphtheria", "PROBLEM", 60, 70], ["whooping cough", "PROBLEM", 72, 86], ["polio", "PROBLEM", 91, 96], ["these diseases", "PROBLEM", 161, 175]]], ["This approach was successful for smallpox (1980) ; however, new infectious diseases emerged (e.g., Legionella, HIV, Helicobacter, SARS, etc.).", [["smallpox", "DISEASE", 33, 41], ["infectious diseases", "DISEASE", 64, 83], ["Legionella, HIV, Helicobacter, SARS", "DISEASE", 99, 134], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["new infectious diseases", "PROBLEM", 60, 83], ["Legionella", "PROBLEM", 99, 109], ["HIV", "PROBLEM", 111, 114], ["Helicobacter", "PROBLEM", 116, 128], ["SARS", "PROBLEM", 130, 134], ["new", "OBSERVATION_MODIFIER", 60, 63], ["infectious", "OBSERVATION", 64, 74]]], ["New vaccines and antibiotics are needed.", [["New vaccines", "TREATMENT", 0, 12], ["antibiotics", "TREATMENT", 17, 28]]], ["Furthermore, due to the intensive medical treatment with antibiotics and immunosuppressive drugs,hospital infections are a growing problem.", [["infections", "DISEASE", 106, 116], ["the intensive medical treatment", "TREATMENT", 20, 51], ["antibiotics", "TREATMENT", 57, 68], ["immunosuppressive drugs", "TREATMENT", 73, 96], ["hospital infections", "PROBLEM", 97, 116], ["a growing problem", "PROBLEM", 121, 138]]], ["Bacteria hitherto deemed harmless are causing opportunistic infections in immunocompromised patients.The pathogens develop multiple resistances to antibiotics and sometimes no effective antibiotics are available to treat those patients.", [["opportunistic infections", "DISEASE", 46, 70], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 227, 235], ["Bacteria hitherto", "PROBLEM", 0, 17], ["opportunistic infections in immunocompromised patients", "PROBLEM", 46, 100], ["The pathogens", "PROBLEM", 101, 114], ["antibiotics", "TREATMENT", 147, 158], ["effective antibiotics", "TREATMENT", 176, 197], ["opportunistic", "OBSERVATION_MODIFIER", 46, 59], ["infections", "OBSERVATION", 60, 70], ["immunocompromised", "OBSERVATION", 74, 91], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["resistances", "OBSERVATION", 132, 143]]]], "PMC7087614": [["IntroductionThere have been a number of publicized incidents in which biopharmaceutical production has experienced contamination with a virus or bacterial agent [6, 10, 24, 33, 72].", [["a virus", "PROBLEM", 134, 141], ["bacterial agent", "TREATMENT", 145, 160]]], ["These contamination events are highly disruptive, requiring that production be halted, inventory be quarantined, and extensive testing be conducted to identify the nature and source of the contamination.", [["These contamination events", "PROBLEM", 0, 26], ["extensive testing", "TEST", 117, 134], ["the contamination", "PROBLEM", 185, 202]]], ["The cost of a contamination event can be significant.", [["a contamination event", "PROBLEM", 12, 33]]], ["For example, costs associated with a vesivirus 2117 contamination event at Genzyme in 2009 were estimated at more than $200 million including a fine of $\\end{document}N=N010-FoD10.", [["a vesivirus", "PROBLEM", 35, 46]]]], "d9cff1807bc1595078f72b1fc5b80c575d3ed2be": [["Currently, the world is experiencing a novel and highly transmissible coronavirus (SARS-CoV-2) outbreak, which also causes high mortality [1, 2] .", [["coronavirus", "DISEASE", 70, 81], ["SARS", "DISEASE", 83, 87], ["coronavirus", "ORGANISM", 70, 81], ["SARS-CoV-2", "ORGANISM", 83, 93], ["a novel and highly transmissible coronavirus", "PROBLEM", 37, 81], ["outbreak", "PROBLEM", 95, 103]]], ["SARS-CoV-2 induces a severe acute respiratory syndrome, termed COVID-19, in which immunology is part of the process of clinical evolution consisting of lung tissue damage induced by an inflammatory response, such as a cytokine storm and macrophage and neutrophil activation [1, 2] .", [["lung tissue", "ANATOMY", 152, 163], ["macrophage", "ANATOMY", 237, 247], ["neutrophil", "ANATOMY", 252, 262], ["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome", "DISEASE", 28, 54], ["tissue damage", "DISEASE", 157, 170], ["SARS-CoV-2", "ORGANISM", 0, 10], ["lung tissue", "TISSUE", 152, 163], ["macrophage", "CELL", 237, 247], ["neutrophil", "CELL", 252, 262], ["cytokine", "PROTEIN", 218, 226], ["SARS-CoV", "SPECIES", 0, 8], ["a severe acute respiratory syndrome", "PROBLEM", 19, 54], ["lung tissue damage", "PROBLEM", 152, 170], ["an inflammatory response", "PROBLEM", 182, 206], ["a cytokine storm", "TREATMENT", 216, 232], ["neutrophil activation", "PROBLEM", 252, 273], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory syndrome", "OBSERVATION", 34, 54], ["lung", "ANATOMY", 152, 156], ["tissue damage", "OBSERVATION", 157, 170], ["inflammatory", "OBSERVATION", 185, 197], ["neutrophil activation", "OBSERVATION", 252, 273]]], ["A few studies have presented information about the immune response during this infection, which involves antibody production and lymphocyte T cell activation, but the information is restricted to those patients who were hospitalized because they had the virus and were symptomatic.", [["lymphocyte T cell", "ANATOMY", 129, 146], ["infection", "DISEASE", 79, 88], ["lymphocyte T cell", "CELL", 129, 146], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["A few studies", "TEST", 0, 13], ["the immune response", "PROBLEM", 47, 66], ["this infection", "PROBLEM", 74, 88], ["antibody production", "PROBLEM", 105, 124], ["lymphocyte T cell activation", "PROBLEM", 129, 157], ["the virus", "PROBLEM", 250, 259], ["symptomatic", "PROBLEM", 269, 280], ["infection", "OBSERVATION", 79, 88], ["lymphocyte T cell activation", "OBSERVATION", 129, 157]]], ["Over the course of the disease in the hospitalized patients who recovered, antibody production was shown to increase after the first week of symptom onset, which is suggestive positive correlation with disease severity [3, 4] while T cells were also activated; it seems that memory phenotype also showed an increase after 14 days of hospitalization [5, 6] .", [["T cells", "ANATOMY", 232, 239], ["patients", "ORGANISM", 51, 59], ["T cells", "CELL", 232, 239], ["T cells", "CELL_TYPE", 232, 239], ["patients", "SPECIES", 51, 59], ["antibody production", "PROBLEM", 75, 94], ["symptom onset", "PROBLEM", 141, 154], ["disease severity", "PROBLEM", 202, 218], ["T cells", "PROBLEM", 232, 239], ["memory phenotype", "PROBLEM", 275, 291], ["increase", "OBSERVATION_MODIFIER", 307, 315]]], ["The non-hospitalized population is considered a viral host by carrying the virus around and contributing to the spread of the virus.", [["a viral host", "PROBLEM", 46, 58], ["the virus", "PROBLEM", 71, 80], ["the virus", "PROBLEM", 122, 131], ["virus", "OBSERVATION", 126, 131]]], ["Also, the other barrier in this outbreak is related to asymptomatic cases, mainly in health care professionals in the hospital, which could contribute to the increase in the number of cases.", [["increase", "OBSERVATION_MODIFIER", 158, 166]]], ["The solution to stopping the viral spread appears to be social distancing and massive testing, mainly for antibody detection.", [["The solution", "TREATMENT", 0, 12], ["the viral spread", "PROBLEM", 25, 41], ["massive testing", "TEST", 78, 93], ["antibody detection", "TEST", 106, 124], ["viral spread", "OBSERVATION", 29, 41]]], ["Surprisingly, some people who presented positivity in results from the molecular test did not have detectable levels of protective antibody IgG; furthermore, neutralizing antibodies were low or not at all present even in hospitalized patients [3, 4] .", [["people", "ORGANISM", 19, 25], ["patients", "ORGANISM", 234, 242], ["protective antibody IgG", "PROTEIN", 120, 143], ["neutralizing antibodies", "PROTEIN", 158, 181], ["people", "SPECIES", 19, 25], ["patients", "SPECIES", 234, 242], ["the molecular test", "TEST", 67, 85], ["protective antibody IgG", "PROBLEM", 120, 143], ["neutralizing antibodies", "TEST", 158, 181]]], ["This situation raises questions about protective immunity and about the time needed for quarantine.", [["quarantine", "TREATMENT", 88, 98]]], ["Given that, a few studies have already shown that T cells might be the key to solving this dilemma.", [["T cells", "ANATOMY", 50, 57], ["T cells", "CELL", 50, 57], ["T cells", "CELL_TYPE", 50, 57], ["a few studies", "TEST", 12, 25], ["T cells", "PROBLEM", 50, 57]]], ["Despite the finding that the virus can induce lymphopenia and cause a delay in T cell pathway activation during the first days of infection, after two weeks of symptoms, SARS-CoV-2-specific memory T cell phenotypes (central memory for CD4 and effector memory for CD8 lymphocytes) start to emerge in the peripheral blood.", [["T cell", "ANATOMY", 79, 85], ["memory T cell", "ANATOMY", 190, 203], ["CD4", "ANATOMY", 235, 238], ["CD8 lymphocytes", "ANATOMY", 263, 278], ["peripheral blood", "ANATOMY", 303, 319], ["lymphopenia", "DISEASE", 46, 57], ["infection", "DISEASE", 130, 139], ["SARS", "DISEASE", 170, 174], ["T cell", "CELL", 79, 85], ["SARS-CoV-2", "ORGANISM", 170, 180], ["memory T cell", "CELL", 190, 203], ["CD4", "GENE_OR_GENE_PRODUCT", 235, 238], ["CD8", "GENE_OR_GENE_PRODUCT", 263, 266], ["peripheral blood", "ORGANISM_SUBSTANCE", 303, 319], ["CD4", "PROTEIN", 235, 238], ["CD8 lymphocytes", "CELL_TYPE", 263, 278], ["the virus", "PROBLEM", 25, 34], ["lymphopenia", "PROBLEM", 46, 57], ["a delay in T cell pathway activation", "PROBLEM", 68, 104], ["infection", "PROBLEM", 130, 139], ["symptoms", "PROBLEM", 160, 168], ["SARS", "PROBLEM", 170, 174], ["CoV", "TEST", 175, 178], ["memory T cell phenotypes", "PROBLEM", 190, 214], ["CD4", "PROBLEM", 235, 238], ["CD8 lymphocytes)", "PROBLEM", 263, 279], ["lymphopenia", "OBSERVATION", 46, 57], ["infection", "OBSERVATION", 130, 139], ["cell phenotypes", "OBSERVATION", 199, 214], ["peripheral", "ANATOMY_MODIFIER", 303, 313], ["blood", "ANATOMY", 314, 319]]], ["The data that are needed to describe how the memory phenotypes of T cells can differentiate has not been elucidated yet.", [["T cells", "ANATOMY", 66, 73], ["T cells", "CELL", 66, 73], ["T cells", "CELL_TYPE", 66, 73], ["T cells", "PROBLEM", 66, 73]]], ["The minimal amount of information is restricted to preprinted manuscripts, but it is enough to start a discussion about how the immune response should be evaluated.", [["minimal", "OBSERVATION_MODIFIER", 4, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18]]], ["Nowadays, we have some vaccines targeting only T cell activation, thus providing robust memory T cell response, but these studies are still in the preclinical phase.", [["T cell", "ANATOMY", 47, 53], ["T cell", "ANATOMY", 95, 101], ["T cell", "CELL", 47, 53], ["memory T cell", "CELL", 88, 101], ["some vaccines", "TREATMENT", 18, 31], ["these studies", "TEST", 116, 129]]], ["Actually, we have seen a change in the protective immunity status of viral diseases during vaccination in which no antibody detection does not relate to protective status because memory T cells can be activated and protect people from subsequent reinfection [7, 8] .", [["memory T cells", "ANATOMY", 179, 193], ["viral diseases", "DISEASE", 69, 83], ["memory T cells", "CELL", 179, 193], ["people", "ORGANISM", 223, 229], ["memory T cells", "CELL_TYPE", 179, 193], ["people", "SPECIES", 223, 229], ["viral diseases", "PROBLEM", 69, 83], ["vaccination", "TREATMENT", 91, 102], ["antibody detection", "PROBLEM", 115, 133], ["memory T cells", "PROBLEM", 179, 193], ["subsequent reinfection", "PROBLEM", 235, 257], ["viral diseases", "OBSERVATION", 69, 83]]], ["Regarding respiratory infections, it also should be noted that viruses are constantly changing via the induction of viral mutations that can contribute to the viral escape of the host immune system.", [["respiratory", "ANATOMY", 10, 21], ["immune system", "ANATOMY", 184, 197], ["respiratory infections", "DISEASE", 10, 32], ["immune system", "ANATOMICAL_SYSTEM", 184, 197], ["respiratory infections", "PROBLEM", 10, 32], ["viruses", "PROBLEM", 63, 70], ["viral mutations", "PROBLEM", 116, 131], ["respiratory", "ANATOMY", 10, 21], ["infections", "OBSERVATION", 22, 32], ["viruses", "OBSERVATION", 63, 70], ["viral escape", "OBSERVATION", 159, 171], ["host immune", "OBSERVATION", 179, 190]]], ["One of our hypotheses concerning the novel coronavirus suggest it has the power to reduce B cell activity.", [["B cell", "ANATOMY", 90, 96], ["coronavirus", "ORGANISM", 43, 54], ["B cell", "CELL", 90, 96], ["the novel coronavirus", "PROBLEM", 33, 54], ["B cell activity", "OBSERVATION", 90, 105]]], ["There is urgent need for solutions addressing the time needed for quarantine in order to prevent shutting the economy down.", [["solutions", "TREATMENT", 25, 34], ["quarantine", "TREATMENT", 66, 76]]], ["There may be an answer to this problem in cellular response assays, in which the cost is similar compared to neutralizing antibodies tests.", [["cellular", "ANATOMY", 42, 50], ["cellular", "CELL", 42, 50], ["neutralizing antibodies", "PROTEIN", 109, 132], ["cellular response assays", "TEST", 42, 66], ["neutralizing antibodies tests", "TEST", 109, 138]]], ["Once we can evaluate a small subpopulation that does not produce IgG antibodies, but has activated T cells after disease, this will be enough to guarantee the immunity protection.", [["T cells", "ANATOMY", 99, 106], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 65, 79], ["T cells", "CELL", 99, 106], ["IgG antibodies", "PROTEIN", 65, 79], ["T cells", "CELL_TYPE", 99, 106], ["a small subpopulation", "PROBLEM", 21, 42], ["IgG antibodies", "PROBLEM", 65, 79], ["activated T cells", "PROBLEM", 89, 106], ["disease", "PROBLEM", 113, 120], ["the immunity protection", "TREATMENT", 155, 178], ["small", "OBSERVATION_MODIFIER", 23, 28], ["subpopulation", "OBSERVATION", 29, 42]]], ["Lymphocyte T cell assays have high specificity and sensitivity.", [["Lymphocyte T cell", "ANATOMY", 0, 17], ["Lymphocyte T cell", "CELL", 0, 17], ["Lymphocyte T cell assays", "TEST", 0, 24], ["sensitivity", "TEST", 51, 62]]], ["There is a lot of information about how to assay T cell immunity after infection, such as proliferation assays using viral particles as stimulators [9, 10] and also by optimizing the assays in Biosafety Level 2 labs.", [["T cell", "ANATOMY", 49, 55], ["infection", "DISEASE", 71, 80], ["T cell", "CELL", 49, 55], ["infection", "PROBLEM", 71, 80], ["proliferation assays", "TEST", 90, 110], ["viral particles", "TREATMENT", 117, 132], ["the assays", "TEST", 179, 189]]], ["The T cell assays could help estimate the population's (hospitalized or not) immunity and will be feasible for countries with specialized immunology laboratories.", [["T cell", "ANATOMY", 4, 10], ["T cell", "CELL", 4, 10], ["The T cell assays", "TEST", 0, 17]]], ["Adding to that, the cellular assays will provide information that is useful for vaccine development to prevent and control this viral disease.", [["cellular", "ANATOMY", 20, 28], ["viral disease", "DISEASE", 128, 141], ["cellular", "CELL", 20, 28], ["the cellular assays", "TEST", 16, 35], ["vaccine development", "TREATMENT", 80, 99], ["this viral disease", "PROBLEM", 123, 141]]]], "530f4d7148e6959bc8b981e3dbf69befdf05208d": [["INTRODUCTIONIn 1959, Abinanti and Warfield isolated from the intestine of calves a virus that was later identified as a parvovirus (Storz and Warren, 1970; Bachmann, 1971) .", [["intestine", "ANATOMY", 61, 70], ["parvovirus", "DISEASE", 120, 130], ["intestine", "ORGAN", 61, 70], ["calves", "ORGANISM", 74, 80], ["parvovirus", "ORGANISM", 120, 130], ["calves", "SPECIES", 74, 80], ["Abinanti", "TREATMENT", 21, 29], ["a virus", "PROBLEM", 81, 88], ["intestine", "ANATOMY", 61, 70], ["virus", "OBSERVATION", 83, 88]]], ["It is now well established that replication of nondefective parvoviruses depends on cellular functions expressed during the S phase of the eukaryotic cell cycle (Margolis and Kilham, 1965; Tennant et al., 1969; Siegl, 1976) .", [["cellular", "ANATOMY", 84, 92], ["cell", "ANATOMY", 150, 154], ["nondefective parvoviruses", "ORGANISM", 47, 72], ["cellular", "CELL", 84, 92], ["cell", "CELL", 150, 154], ["nondefective parvoviruses", "PROBLEM", 47, 72], ["nondefective parvoviruses", "OBSERVATION", 47, 72], ["eukaryotic cell cycle", "OBSERVATION", 139, 160]]], ["Considering the turnover of intestinal cells and their gradient of differentiation, it is not surprising that parvoviruses were cultured frequently from the intestinal tract of calves when specific attempts for isolation were made (Vincent, 1971; Bates et al., 1972; Hinaidy, 1978; Hinaidy et al., 1979; Wosu et al., 1979) .", [["intestinal cells", "ANATOMY", 28, 44], ["intestinal tract", "ANATOMY", 157, 173], ["intestinal cells", "CELL", 28, 44], ["parvoviruses", "ORGANISM", 110, 122], ["intestinal tract", "ORGANISM_SUBDIVISION", 157, 173], ["calves", "ORGANISM", 177, 183], ["intestinal cells", "CELL_TYPE", 28, 44], ["calves", "SPECIES", 177, 183], ["intestinal cells", "PROBLEM", 28, 44], ["parvoviruses", "PROBLEM", 110, 122], ["intestinal cells", "ANATOMY", 28, 44], ["gradient", "OBSERVATION_MODIFIER", 55, 63], ["not surprising", "UNCERTAINTY", 90, 104], ["parvoviruses", "OBSERVATION", 110, 122], ["intestinal tract", "ANATOMY", 157, 173]]], ["Furthermore, evidence for intrauterine infections of bovine fetuses was found when high titers of HI antibodies of bovine parvovirus (BPoV) were detected in commercial bovine fetal serum .Physical and chemical characteristicsParvoviruses are extremely resistant to chemical and physical inactivating factors.", [["intrauterine", "ANATOMY", 26, 38], ["fetuses", "ANATOMY", 60, 67], ["fetal serum", "ANATOMY", 175, 186], ["intrauterine infections", "DISEASE", 26, 49], ["Parvoviruses", "DISEASE", 225, 237], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 38], ["bovine", "ORGANISM", 53, 59], ["fetuses", "ORGAN", 60, 67], ["HI antibodies", "GENE_OR_GENE_PRODUCT", 98, 111], ["bovine parvovirus", "ORGANISM", 115, 132], ["BPoV", "GENE_OR_GENE_PRODUCT", 134, 138], ["bovine", "ORGANISM", 168, 174], ["fetal serum", "ORGANISM_SUBSTANCE", 175, 186], ["HI antibodies", "PROTEIN", 98, 111], ["bovine", "SPECIES", 53, 59], ["bovine", "SPECIES", 115, 121], ["parvovirus", "SPECIES", 122, 132], ["bovine", "SPECIES", 168, 174], ["bovine", "SPECIES", 53, 59], ["HI", "SPECIES", 98, 100], ["bovine parvovirus", "SPECIES", 115, 132], ["BPoV", "SPECIES", 134, 138], ["bovine", "SPECIES", 168, 174], ["intrauterine infections of bovine fetuses", "PROBLEM", 26, 67], ["HI antibodies", "TEST", 98, 111], ["bovine parvovirus", "PROBLEM", 115, 132], ["commercial bovine fetal serum", "TEST", 157, 186], ["Parvoviruses", "PROBLEM", 225, 237], ["evidence for", "UNCERTAINTY", 13, 25], ["intrauterine", "OBSERVATION_MODIFIER", 26, 38], ["infections", "OBSERVATION", 39, 49], ["bovine fetuses", "OBSERVATION", 53, 67], ["bovine parvovirus", "OBSERVATION", 115, 132]]], ["The most reliable disinfection is achieved with 0.5% chlorox or ethylene oxide in the form of the nonexplosive mixture of 10% ethylene oxide and 90% carbon dioxide.Antigenic propertiesAll the parvoviral isolates studied agglutinate guinea pig and human type \u039f erythrocytes.", [["erythrocytes", "ANATOMY", 260, 272], ["chlorox", "CHEMICAL", 53, 60], ["ethylene oxide", "CHEMICAL", 64, 78], ["ethylene oxide", "CHEMICAL", 126, 140], ["carbon dioxide", "CHEMICAL", 149, 163], ["chlorox", "CHEMICAL", 53, 60], ["ethylene oxide", "CHEMICAL", 64, 78], ["ethylene oxide", "CHEMICAL", 126, 140], ["carbon dioxide", "CHEMICAL", 149, 163], ["chlorox", "SIMPLE_CHEMICAL", 53, 60], ["ethylene oxide", "SIMPLE_CHEMICAL", 64, 78], ["ethylene oxide", "SIMPLE_CHEMICAL", 126, 140], ["carbon dioxide", "SIMPLE_CHEMICAL", 149, 163], ["guinea pig", "ORGANISM", 232, 242], ["human", "ORGANISM", 247, 252], ["erythrocytes", "CELL", 260, 272], ["human type \u039f erythrocytes", "CELL_TYPE", 247, 272], ["guinea pig", "SPECIES", 232, 242], ["human", "SPECIES", 247, 252], ["pig", "SPECIES", 239, 242], ["human", "SPECIES", 247, 252], ["0.5% chlorox or ethylene oxide", "TREATMENT", 48, 78], ["the nonexplosive mixture", "TREATMENT", 94, 118], ["10% ethylene oxide", "TREATMENT", 122, 140], ["90% carbon dioxide", "TREATMENT", 145, 163], ["Antigenic properties", "TREATMENT", 164, 184], ["All the parvoviral isolates", "TEST", 184, 211], ["reliable", "OBSERVATION_MODIFIER", 9, 17], ["disinfection", "OBSERVATION", 18, 30]]], ["The isolates from cattle of different countries all are antigenically related or identical to prototype BPoV-1 (Abinanti and Warfield, 1961) .", [["cattle", "ORGANISM", 18, 24], ["BPoV-1", "CELL", 104, 110], ["cattle", "SPECIES", 18, 24], ["cattle", "SPECIES", 18, 24], ["BPoV-1", "SPECIES", 104, 110]]], ["One BPoV strain isolated in Japan appears to differ and is separated as BPoV-2 (Inaba et al., 1973a) .", [["BPoV", "GENE_OR_GENE_PRODUCT", 4, 8], ["One BPoV strain", "PROBLEM", 0, 15], ["strain isolated", "OBSERVATION", 9, 24]]], ["Bovine parvoviruses differ antigenically from parvoviruses isolated from man, pigs, cats, dogs, rats and rabbits.", [["Bovine", "ORGANISM", 0, 6], ["parvoviruses", "ORGANISM", 7, 19], ["parvoviruses", "ORGANISM", 46, 58], ["man", "ORGANISM", 73, 76], ["pigs", "ORGANISM", 78, 82], ["cats", "ORGANISM", 84, 88], ["dogs", "ORGANISM", 90, 94], ["rats", "ORGANISM", 96, 100], ["rabbits", "ORGANISM", 105, 112], ["Bovine", "SPECIES", 0, 6], ["man", "SPECIES", 73, 76], ["pigs", "SPECIES", 78, 82], ["cats", "SPECIES", 84, 88], ["dogs", "SPECIES", 90, 94], ["rats", "SPECIES", 96, 100], ["rabbits", "SPECIES", 105, 112], ["Bovine", "SPECIES", 0, 6], ["rabbits", "SPECIES", 105, 112], ["Bovine parvoviruses", "PROBLEM", 0, 19], ["parvoviruses", "PROBLEM", 46, 58], ["parvoviruses", "OBSERVATION", 7, 19]]], ["This is further substantiated by comparisons of genomic nucleotide sequences among parvoviruses, which revealed virtually no homology between rodent parvoviruses, Lu III and BPoV (Banerjee et. al., 1983) .", [["nucleotide", "CHEMICAL", 56, 66], ["nucleotide", "CHEMICAL", 56, 66], ["Lu III", "ORGANISM", 163, 169], ["genomic nucleotide sequences", "DNA", 48, 76], ["rodent", "SPECIES", 142, 148], ["genomic nucleotide sequences", "TEST", 48, 76], ["parvoviruses", "PROBLEM", 83, 95], ["parvoviruses", "OBSERVATION", 149, 161], ["Lu III", "OBSERVATION_MODIFIER", 163, 169]]], ["A defective parvovirus was found associated with BAV types 1, 2 and 3 (Luchsinger et al., 1970; Myrup et al., 1976; Coria and Lehmkuhl, 1978) .CultivationBPoV-1 replicated in all primary bovine fetal cells tested.", [["fetal cells", "ANATOMY", 194, 205], ["parvovirus", "ORGANISM", 12, 22], ["CultivationBPoV-1", "GENE_OR_GENE_PRODUCT", 143, 160], ["bovine", "ORGANISM", 187, 193], ["fetal cells", "CELL", 194, 205], ["primary bovine fetal cells", "CELL_TYPE", 179, 205], ["bovine", "SPECIES", 187, 193], ["bovine", "SPECIES", 187, 193], ["A defective parvovirus", "PROBLEM", 0, 22], ["CultivationBPoV", "TEST", 143, 158], ["all primary bovine fetal cells", "TREATMENT", 175, 205], ["defective", "OBSERVATION_MODIFIER", 2, 11], ["parvovirus", "OBSERVATION", 12, 22], ["fetal cells", "OBSERVATION", 194, 205]]], ["High levels of hemagglutinin were present in tissue culture fluids following passage in different cell types Hinaidy et al., 1979; Durham and Johnson, 1985) .", [["tissue culture fluids", "ANATOMY", 45, 66], ["cell", "ANATOMY", 98, 102], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 15, 28], ["tissue", "TISSUE", 45, 51], ["cell", "CELL", 98, 102], ["hemagglutinin", "PROTEIN", 15, 28], ["High levels of hemagglutinin", "PROBLEM", 0, 28], ["tissue culture fluids", "TREATMENT", 45, 66]]], ["The virus reached cytopathic and hemadsorption titers of 10 6 2 and 10 68 TCID 50 /ml, respectively, on assay after three passages in bovine fetal lung (BFL) cells.", [["fetal lung (BFL) cells", "ANATOMY", 141, 163], ["bovine", "ORGANISM", 134, 140], ["fetal lung (BFL) cells", "CELL", 141, 163], ["bovine fetal lung (BFL) cells", "CELL_TYPE", 134, 163], ["bovine", "SPECIES", 134, 140], ["bovine", "SPECIES", 134, 140], ["The virus", "PROBLEM", 0, 9], ["hemadsorption titers", "TEST", 33, 53], ["assay", "TEST", 104, 109], ["virus", "OBSERVATION", 4, 9], ["cytopathic", "OBSERVATION_MODIFIER", 18, 28], ["hemadsorption", "OBSERVATION_MODIFIER", 33, 46], ["titers", "OBSERVATION_MODIFIER", 47, 53], ["fetal", "ANATOMY_MODIFIER", 141, 146], ["lung", "ANATOMY", 147, 151]]], ["Replication occurred to similar titers in bovine fetal testicle (BFT), spleen (BFS), and adrenal (BFA) cells.", [["fetal testicle", "ANATOMY", 49, 63], ["BFT", "ANATOMY", 65, 68], ["spleen", "ANATOMY", 71, 77], ["adrenal (BFA) cells", "ANATOMY", 89, 108], ["bovine", "ORGANISM", 42, 48], ["fetal testicle", "MULTI-TISSUE_STRUCTURE", 49, 63], ["BFT", "CELL", 65, 68], ["spleen", "ORGAN", 71, 77], ["adrenal (BFA) cells", "CELL", 89, 108], ["adrenal (BFA) cells", "CELL_TYPE", 89, 108], ["bovine", "SPECIES", 42, 48], ["bovine", "SPECIES", 42, 48], ["Replication", "TREATMENT", 0, 11], ["fetal testicle", "ANATOMY", 49, 63], ["spleen", "ANATOMY", 71, 77], ["adrenal", "ANATOMY", 89, 96]]], ["The least efficient replication of BPoV-1 occurred in bovine fetal kidney (BFK) and bovine fetal intestine (BFI) cells with cytopathic endpoints of 10 42 and 10 35 TCID 50 /ml, respectively.", [["fetal kidney", "ANATOMY", 61, 73], ["BFK", "ANATOMY", 75, 78], ["fetal intestine (BFI) cells", "ANATOMY", 91, 118], ["BPoV-1", "GENE_OR_GENE_PRODUCT", 35, 41], ["bovine", "ORGANISM", 54, 60], ["fetal kidney", "MULTI-TISSUE_STRUCTURE", 61, 73], ["BFK", "CELL", 75, 78], ["bovine", "ORGANISM", 84, 90], ["fetal intestine (BFI) cells", "CELL", 91, 118], ["BPoV", "PROTEIN", 35, 39], ["bovine fetal intestine (BFI) cells", "CELL_TYPE", 84, 118], ["bovine", "SPECIES", 54, 60], ["bovine", "SPECIES", 84, 90], ["bovine", "SPECIES", 54, 60], ["bovine", "SPECIES", 84, 90], ["BPoV", "TEST", 35, 39], ["bovine fetal kidney", "PROBLEM", 54, 73], ["bovine fetal intestine (BFI) cells", "PROBLEM", 84, 118], ["cytopathic endpoints", "TEST", 124, 144], ["least", "OBSERVATION_MODIFIER", 4, 9], ["efficient", "OBSERVATION_MODIFIER", 10, 19], ["replication", "OBSERVATION", 20, 31], ["bovine", "ANATOMY_MODIFIER", 54, 60], ["fetal", "ANATOMY_MODIFIER", 61, 66], ["kidney", "ANATOMY", 67, 73], ["bovine", "ANATOMY_MODIFIER", 84, 90], ["fetal intestine", "ANATOMY", 91, 106], ["cytopathic", "OBSERVATION_MODIFIER", 124, 134]]], ["In all cases, hemadsorption endpoints were approximately 10-fold higher than cytopathic endpoints.CultivationCell lines from a variety of animal species were tested for their susceptibility to BPoV infection .", [["Cell lines", "ANATOMY", 109, 119], ["BPoV infection", "DISEASE", 193, 207], ["Cell lines", "CELL", 109, 119], ["BPoV", "SIMPLE_CHEMICAL", 193, 197], ["BPoV", "SPECIES", 193, 197], ["hemadsorption endpoints", "TEST", 14, 37], ["cytopathic endpoints", "PROBLEM", 77, 97], ["CultivationCell lines", "TREATMENT", 98, 119], ["animal species", "PROBLEM", 138, 152], ["BPoV infection", "PROBLEM", 193, 207], ["Cell lines", "OBSERVATION", 109, 119], ["variety", "OBSERVATION_MODIFIER", 127, 134], ["infection", "OBSERVATION", 198, 207]]], ["The line cells examined did not support replication of BPoV-1.", [["line cells", "ANATOMY", 4, 14], ["line cells", "CELL", 4, 14], ["BPoV-1", "GENE_OR_GENE_PRODUCT", 55, 61], ["line cells", "CELL_LINE", 4, 14], ["BPoV", "PROTEIN", 55, 59], ["The line cells", "TREATMENT", 0, 14], ["BPoV", "TEST", 55, 59], ["line cells", "OBSERVATION", 4, 14]]], ["Except for decreasing titers observed in the cell strain FB4BN, established from bovine bone marrow, hemagglutinins were not detected in these tissue cultures.", [["cell strain", "ANATOMY", 45, 56], ["bone marrow", "ANATOMY", 88, 99], ["tissue cultures", "ANATOMY", 143, 158], ["cell", "CELL", 45, 49], ["FB4BN", "CELL", 57, 62], ["bovine", "ORGANISM", 81, 87], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 88, 99], ["tissue cultures", "CELL", 143, 158], ["bovine", "SPECIES", 81, 87], ["bovine", "SPECIES", 81, 87], ["decreasing titers", "PROBLEM", 11, 28], ["the cell strain FB4BN", "TEST", 41, 62], ["bovine bone marrow", "TREATMENT", 81, 99], ["hemagglutinins", "PROBLEM", 101, 115], ["these tissue cultures", "TEST", 137, 158], ["decreasing", "OBSERVATION_MODIFIER", 11, 21], ["titers", "OBSERVATION", 22, 28], ["bone marrow", "ANATOMY", 88, 99]]], ["Low levels of infectivity and hemagglutinin were detected in BFL cells after three passages of BPoV-1 in MDBK and BHK-21 cells.", [["BFL cells", "ANATOMY", 61, 70], ["MDBK", "ANATOMY", 105, 109], ["BHK-21 cells", "ANATOMY", 114, 126], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 30, 43], ["BFL cells", "CELL", 61, 70], ["BPoV-1", "CELL", 95, 101], ["MDBK", "CELL", 105, 109], ["BHK-21 cells", "CELL", 114, 126], ["hemagglutinin", "PROTEIN", 30, 43], ["BFL cells", "CELL_LINE", 61, 70], ["BPoV", "PROTEIN", 95, 99], ["MDBK", "CELL_LINE", 105, 109], ["BHK-21 cells", "CELL_LINE", 114, 126], ["MDBK", "SPECIES", 105, 109], ["BHK-21", "SPECIES", 114, 120], ["Low levels of infectivity", "PROBLEM", 0, 25], ["hemagglutinin", "PROBLEM", 30, 43], ["BPoV", "TEST", 95, 99], ["MDBK", "TEST", 105, 109], ["BHK", "TEST", 114, 117], ["infectivity", "OBSERVATION", 14, 25]]], ["Plaques resulting from BPoV replication in BFS cells were detected within 5 days after inoculation .", [["Plaques", "ANATOMY", 0, 7], ["BFS cells", "ANATOMY", 43, 52], ["Plaques", "DISEASE", 0, 7], ["BPoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["BFS cells", "CELL", 43, 52], ["BFS cells", "CELL_LINE", 43, 52], ["Plaques", "PROBLEM", 0, 7], ["BPoV replication in BFS cells", "PROBLEM", 23, 52], ["inoculation", "PROBLEM", 87, 98], ["BPoV replication", "OBSERVATION", 23, 39], ["BFS cells", "OBSERVATION", 43, 52]]], ["The plaque sizes ranged from 1 to 3 mm in diameter at 5 days and increased to 3-5 mm at 7 days p.i.", [["plaque", "ANATOMY", 4, 10], ["plaque", "DISEASE", 4, 10], ["plaque", "PATHOLOGICAL_FORMATION", 4, 10], ["The plaque sizes", "TEST", 0, 16], ["plaque", "OBSERVATION", 4, 10], ["sizes", "OBSERVATION_MODIFIER", 11, 16], ["ranged", "OBSERVATION_MODIFIER", 17, 23], ["1 to 3 mm", "OBSERVATION_MODIFIER", 29, 38], ["diameter", "OBSERVATION_MODIFIER", 42, 50], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["3-5 mm", "OBSERVATION_MODIFIER", 78, 84]]], ["All plaques, irrespective of their size, had fuzzy edges.CultivationThe CPE resulting from BPoV replication in actively dividing BFL cells was distinct and reproducible.", [["plaques", "ANATOMY", 4, 11], ["BFL cells", "ANATOMY", 129, 138], ["plaques", "PATHOLOGICAL_FORMATION", 4, 11], ["BPoV", "GENE_OR_GENE_PRODUCT", 91, 95], ["BFL cells", "CELL", 129, 138], ["actively dividing BFL cells", "CELL_LINE", 111, 138], ["BPoV", "SPECIES", 91, 95], ["All plaques", "PROBLEM", 0, 11], ["fuzzy edges", "PROBLEM", 45, 56], ["The CPE", "PROBLEM", 68, 75], ["BPoV replication", "TREATMENT", 91, 107], ["plaques", "OBSERVATION", 4, 11], ["irrespective", "OBSERVATION_MODIFIER", 13, 25], ["size", "OBSERVATION_MODIFIER", 35, 39], ["fuzzy edges", "OBSERVATION", 45, 56], ["BPoV replication", "OBSERVATION", 91, 107], ["BFL cells", "OBSERVATION", 129, 138], ["reproducible", "OBSERVATION_MODIFIER", 156, 168]]], ["At 20-24 h after inoculation, infected cells were swollen, refractile, and exhibited a stellate appearance.", [["cells", "ANATOMY", 39, 44], ["stellate", "ANATOMY", 87, 95], ["cells", "CELL", 39, 44], ["stellate", "TISSUE", 87, 95], ["infected cells", "CELL_TYPE", 30, 44], ["inoculation", "PROBLEM", 17, 28], ["infected cells", "PROBLEM", 30, 44], ["swollen", "PROBLEM", 50, 57], ["a stellate appearance", "PROBLEM", 85, 106], ["infected cells", "OBSERVATION", 30, 44], ["swollen", "OBSERVATION_MODIFIER", 50, 57], ["refractile", "OBSERVATION_MODIFIER", 59, 69], ["stellate", "OBSERVATION_MODIFIER", 87, 95]]], ["These cells were scattered over the cell monolayer and ultimately became uniformly round and highly refractile.", [["cells", "ANATOMY", 6, 11], ["cell monolayer", "ANATOMY", 36, 50], ["cells", "CELL", 6, 11], ["cell monolayer", "CELL", 36, 50], ["These cells", "PROBLEM", 0, 11], ["the cell monolayer", "TEST", 32, 50], ["scattered", "OBSERVATION_MODIFIER", 17, 26], ["cell monolayer", "OBSERVATION", 36, 50], ["uniformly", "OBSERVATION_MODIFIER", 73, 82], ["round", "OBSERVATION_MODIFIER", 83, 88], ["highly", "OBSERVATION_MODIFIER", 93, 99], ["refractile", "OBSERVATION_MODIFIER", 100, 110]]], ["Soon after rounding, the cells detached from the glass surface.", [["cells", "ANATOMY", 25, 30], ["glass surface", "ANATOMY", 49, 62], ["cells", "CELL", 25, 30], ["glass", "OBSERVATION_MODIFIER", 49, 54], ["surface", "OBSERVATION_MODIFIER", 55, 62]]], ["The cytopathic changes continued until all cells were involved, usually by 72 h after inoculation.CultivationParvovirus-specific fluorescence in infected BFS cells was detected exclusively in the nuclei.", [["cells", "ANATOMY", 43, 48], ["BFS cells", "ANATOMY", 154, 163], ["nuclei", "ANATOMY", 196, 202], ["cells", "CELL", 43, 48], ["Parvovirus", "ORGANISM", 109, 119], ["BFS cells", "CELL", 154, 163], ["nuclei", "CELLULAR_COMPONENT", 196, 202], ["BFS cells", "CELL_LINE", 154, 163], ["The cytopathic changes", "PROBLEM", 0, 22], ["CultivationParvovirus", "TEST", 98, 119], ["infected BFS cells", "PROBLEM", 145, 163], ["cytopathic", "OBSERVATION", 4, 14], ["infected", "OBSERVATION_MODIFIER", 145, 153], ["BFS cells", "OBSERVATION", 154, 163], ["nuclei", "ANATOMY", 196, 202]]], ["Intranuclear inclusions with a unique morphology are formed and can be detected following acridine orange or Giemsa staining (Hinaidy et al., 1979; Storz, 1980, 1982) .", [["acridine orange", "CHEMICAL", 90, 105], ["acridine orange", "CHEMICAL", 90, 105], ["acridine orange", "SIMPLE_CHEMICAL", 90, 105], ["Giemsa", "SIMPLE_CHEMICAL", 109, 115], ["Intranuclear inclusions", "PROBLEM", 0, 23], ["Giemsa staining", "TEST", 109, 124], ["inclusions", "OBSERVATION", 13, 23]]], ["Initial changes resulted in a uniformly basophilic nucleoplasm giving the nuclei a glassy appearance.", [["basophilic nucleoplasm", "ANATOMY", 40, 62], ["nuclei", "ANATOMY", 74, 80], ["basophilic nucleoplasm", "ORGANISM_SUBSTANCE", 40, 62], ["nuclei", "CELLULAR_COMPONENT", 74, 80], ["a uniformly basophilic nucleoplasm", "PROBLEM", 28, 62], ["uniformly", "OBSERVATION_MODIFIER", 30, 39], ["basophilic nucleoplasm", "OBSERVATION", 40, 62], ["glassy appearance", "OBSERVATION", 83, 100]]], ["Clumps of dark blue marginated chromatin appeared on the inner nuclear envelope.", [["chromatin", "ANATOMY", 31, 40], ["inner nuclear envelope", "ANATOMY", 57, 79], ["chromatin", "CELLULAR_COMPONENT", 31, 40], ["inner nuclear envelope", "CELLULAR_COMPONENT", 57, 79], ["dark blue marginated chromatin", "DNA", 10, 40], ["Clumps of dark blue marginated chromatin", "PROBLEM", 0, 40], ["dark blue", "OBSERVATION", 10, 19], ["marginated chromatin", "OBSERVATION", 20, 40], ["inner", "ANATOMY_MODIFIER", 57, 62], ["nuclear envelope", "ANATOMY", 63, 79]]], ["Along with greater numbers of glassy nuclei, a second nuclear change became apparent, which was characterized by an intensely stained, eosinophilic, finely granular nucleoplasm with a prominent dark blue nucleolus.", [["glassy nuclei", "ANATOMY", 30, 43], ["nuclear", "ANATOMY", 54, 61], ["nucleoplasm", "ANATOMY", 165, 176], ["nucleolus", "ANATOMY", 204, 213], ["nuclei", "CELLULAR_COMPONENT", 37, 43], ["nuclear", "CELLULAR_COMPONENT", 54, 61], ["nucleoplasm", "CELLULAR_COMPONENT", 165, 176], ["nucleolus", "CELLULAR_COMPONENT", 204, 213], ["a second nuclear change", "PROBLEM", 45, 68], ["an intensely stained, eosinophilic, finely granular nucleoplasm", "PROBLEM", 113, 176], ["a prominent dark blue nucleolus", "PROBLEM", 182, 213], ["greater", "OBSERVATION_MODIFIER", 11, 18], ["numbers", "OBSERVATION_MODIFIER", 19, 26], ["glassy nuclei", "OBSERVATION", 30, 43], ["change", "OBSERVATION", 62, 68], ["intensely", "OBSERVATION_MODIFIER", 116, 125], ["eosinophilic", "OBSERVATION_MODIFIER", 135, 147], ["finely", "OBSERVATION_MODIFIER", 149, 155], ["granular nucleoplasm", "OBSERVATION", 156, 176], ["prominent", "OBSERVATION_MODIFIER", 184, 193], ["dark blue nucleolus", "OBSERVATION", 194, 213]]], ["Thin halos formed around the entire finely granulated nucleoplasm by 18 h after infection.", [["Thin halos", "ANATOMY", 0, 10], ["nucleoplasm", "ANATOMY", 54, 65], ["infection", "DISEASE", 80, 89], ["nucleoplasm", "ORGANISM_SUBSTANCE", 54, 65], ["Thin halos", "PROBLEM", 0, 10], ["infection", "PROBLEM", 80, 89], ["halos", "OBSERVATION", 5, 10], ["entire", "OBSERVATION_MODIFIER", 29, 35], ["finely", "OBSERVATION_MODIFIER", 36, 42], ["granulated nucleoplasm", "OBSERVATION", 43, 65]]], ["Halo width, intensity of staining, and basophilia of the central inclusion mass increased after 24 h to reach the form of Cowdry type A inclusions ( Figs.", [["staining", "PROBLEM", 25, 33], ["basophilia", "PROBLEM", 39, 49], ["the central inclusion mass", "PROBLEM", 53, 79], ["width", "OBSERVATION_MODIFIER", 5, 10], ["intensity", "OBSERVATION_MODIFIER", 12, 21], ["staining", "OBSERVATION", 25, 33], ["basophilia", "OBSERVATION_MODIFIER", 39, 49], ["central", "OBSERVATION_MODIFIER", 57, 64], ["inclusion", "OBSERVATION_MODIFIER", 65, 74], ["mass", "OBSERVATION", 75, 79], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["inclusions", "OBSERVATION", 136, 146]]], ["82 and 83 ).CultivationAn additional type of inclusion consisting of multiple round, smooth, eosinophilic foci emerged in both glassy and finely granular nuclei at 18-24 h.", [["eosinophilic foci", "ANATOMY", 93, 110], ["granular nuclei", "ANATOMY", 145, 160], ["nuclei", "CELLULAR_COMPONENT", 154, 160], ["multiple round, smooth, eosinophilic foci", "PROBLEM", 69, 110], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["round", "OBSERVATION_MODIFIER", 78, 83], ["smooth", "OBSERVATION_MODIFIER", 85, 91], ["eosinophilic", "OBSERVATION_MODIFIER", 93, 105], ["foci", "OBSERVATION", 106, 110], ["both glassy", "OBSERVATION_MODIFIER", 122, 133], ["finely", "OBSERVATION_MODIFIER", 138, 144], ["granular nuclei", "OBSERVATION", 145, 160]]], ["Halos formed later around individual foci, which remained clearly distinct from nucleoli (Figs.", [["foci", "ANATOMY", 37, 41], ["nucleoli", "ANATOMY", 80, 88], ["nucleoli", "CELLULAR_COMPONENT", 80, 88], ["Halos formed", "PROBLEM", 0, 12], ["individual foci", "PROBLEM", 26, 41], ["foci", "OBSERVATION", 37, 41], ["distinct", "OBSERVATION_MODIFIER", 66, 74], ["nucleoli", "OBSERVATION", 80, 88]]], ["These foci were often marginally arranged, but they appeared also throughout the nucleoplasm (Hinaidy et al., 1979) .", [["foci", "ANATOMY", 6, 10], ["nucleoplasm", "ANATOMY", 81, 92], ["nucleoplasm", "CELLULAR_COMPONENT", 81, 92], ["These foci", "PROBLEM", 0, 10], ["foci", "OBSERVATION", 6, 10]]], ["All our BPoV strains tested induced multifocal as well as Cowdry type A inclusions Storz, 1980, 1982) .CultivationUltrathin sections of many nuclei of infected BFS cells fixed 18-24 h after inoculation contained distinct, fine-grained, electron-dense, circular foci in the nucleoplasm.", [["sections", "ANATOMY", 124, 132], ["nuclei", "ANATOMY", 141, 147], ["BFS cells", "ANATOMY", 160, 169], ["foci", "ANATOMY", 261, 265], ["nucleoplasm", "ANATOMY", 273, 284], ["nuclei", "CELLULAR_COMPONENT", 141, 147], ["BFS cells", "CELL", 160, 169], ["nucleoplasm", "CELLULAR_COMPONENT", 273, 284], ["infected BFS cells", "CELL_TYPE", 151, 169], ["CultivationUltrathin sections", "TEST", 103, 132], ["infected BFS cells", "TEST", 151, 169], ["inoculation", "PROBLEM", 190, 201], ["circular foci in the nucleoplasm", "PROBLEM", 252, 284], ["multifocal", "OBSERVATION_MODIFIER", 36, 46], ["infected", "OBSERVATION_MODIFIER", 151, 159], ["BFS cells", "OBSERVATION", 160, 169], ["distinct", "OBSERVATION_MODIFIER", 212, 220], ["dense", "OBSERVATION_MODIFIER", 245, 250], ["circular", "OBSERVATION_MODIFIER", 252, 260], ["foci", "OBSERVATION", 261, 265], ["nucleoplasm", "OBSERVATION", 273, 284]]], ["The foci are local accumulations of viral capsids as revealed by EM (Fig. 86 ).", [["foci", "ANATOMY", 4, 8], ["The foci", "PROBLEM", 0, 8], ["local accumulations of viral capsids", "PROBLEM", 13, 49], ["foci", "OBSERVATION", 4, 8], ["local", "OBSERVATION_MODIFIER", 13, 18], ["accumulations", "OBSERVATION_MODIFIER", 19, 32], ["viral capsids", "OBSERVATION", 36, 49]]], ["There appeared to be nuclear compartmentalization of viral replication sites (Bates et al., 1974; Leary and Storz, 1982) .", [["nuclear", "ANATOMY", 21, 28], ["nuclear", "CELLULAR_COMPONENT", 21, 28], ["viral replication sites", "DNA", 53, 76], ["viral replication sites", "PROBLEM", 53, 76], ["appeared to be", "UNCERTAINTY", 6, 20], ["nuclear compartmentalization", "OBSERVATION", 21, 49], ["viral replication", "OBSERVATION", 53, 70]]], ["Inclusions were not detectable in infected mitotic cells where the nuclear envelope was dispersed.", [["cells", "ANATOMY", 51, 56], ["nuclear envelope", "ANATOMY", 67, 83], ["mitotic cells", "CELL", 43, 56], ["nuclear", "CELLULAR_COMPONENT", 67, 74], ["infected mitotic cells", "CELL_TYPE", 34, 56], ["infected mitotic cells", "PROBLEM", 34, 56], ["not detectable", "UNCERTAINTY", 16, 30], ["infected mitotic cells", "OBSERVATION", 34, 56], ["envelope", "OBSERVATION_MODIFIER", 75, 83]]], ["The presence of characteristic tubular forms in these cells revealed them as infected.CultivationThe nucleopathic changes described are characteristic for BPoV and can be used to indicate the infection in cultured cells.", [["tubular", "ANATOMY", 31, 38], ["cells", "ANATOMY", 54, 59], ["cells", "ANATOMY", 214, 219], ["infection", "DISEASE", 192, 201], ["tubular", "MULTI-TISSUE_STRUCTURE", 31, 38], ["cells", "CELL", 54, 59], ["BPoV", "GENE_OR_GENE_PRODUCT", 155, 159], ["cells", "CELL", 214, 219], ["cultured cells", "CELL_LINE", 205, 219], ["characteristic tubular forms in these cells", "PROBLEM", 16, 59], ["infected", "PROBLEM", 77, 85], ["Cultivation", "TREATMENT", 86, 97], ["BPoV", "PROBLEM", 155, 159], ["the infection in cultured cells", "PROBLEM", 188, 219], ["characteristic", "OBSERVATION_MODIFIER", 16, 30], ["tubular forms", "OBSERVATION", 31, 44], ["infected", "OBSERVATION", 77, 85], ["infection", "OBSERVATION", 192, 201]]], ["Their appearance in infected cells of tissues from animals can be exploited diagnostically.EPIZOOTIOLOGYEvidence for parvovirus infection of cattle through detection of antibodies neutralizing infectivity or inhibiting hemagglutination of BPoV was detected in the USA, Algiers, Japan, Brazil, England and Austria (Leary and Storz, 1980) .", [["cells", "ANATOMY", 29, 34], ["tissues", "ANATOMY", 38, 45], ["parvovirus infection", "DISEASE", 117, 137], ["cells", "CELL", 29, 34], ["tissues", "TISSUE", 38, 45], ["parvovirus", "ORGANISM", 117, 127], ["cattle", "ORGANISM", 141, 147], ["BPoV", "GENE_OR_GENE_PRODUCT", 239, 243], ["infected cells", "CELL_TYPE", 20, 34], ["antibodies", "PROTEIN", 169, 179], ["cattle", "SPECIES", 141, 147], ["parvovirus", "SPECIES", 117, 127], ["cattle", "SPECIES", 141, 147], ["BPoV", "SPECIES", 239, 243], ["infected cells of tissues", "PROBLEM", 20, 45], ["parvovirus infection", "PROBLEM", 117, 137], ["antibodies neutralizing infectivity", "PROBLEM", 169, 204], ["inhibiting hemagglutination of BPoV", "PROBLEM", 208, 243], ["infected cells", "OBSERVATION", 20, 34]]], ["The incidence of cattle with antibodies ranged from 46 to 86% (Table 20) .EPIZOOTIOLOGYThe age of the animals tested was not specified, but the majority of the serum samples involved newborn calves and cattle to 12 months of age.", [["serum samples", "ANATOMY", 160, 173], ["cattle", "ORGANISM", 17, 23], ["serum samples", "ORGANISM_SUBSTANCE", 160, 173], ["calves", "ORGANISM", 191, 197], ["antibodies", "PROTEIN", 29, 39], ["cattle", "SPECIES", 17, 23], ["calves", "SPECIES", 191, 197], ["cattle", "SPECIES", 202, 208], ["cattle", "SPECIES", 17, 23], ["cattle", "SPECIES", 202, 208], ["antibodies", "TEST", 29, 39], ["the serum samples", "TEST", 156, 173]]], ["The highest percentage of positive calves was found in February in Austria, where the only attempt was made to analyze seasonal distribution (Hinaidy and B\u00fcrki, 1980) .Fig.", [["calves", "ORGANISM", 35, 41], ["calves", "SPECIES", 35, 41], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22], ["positive calves", "OBSERVATION", 26, 41]]], ["84 (left).", [["left", "ANATOMY", 4, 8], ["left", "ANATOMY_MODIFIER", 4, 8]]], ["Multifocal inclusion located peripherally in nucleus of B F S cell infected with BPoV-1;Giemsa stain ( \u03c7 1280).Fig.", [["peripherally", "ANATOMY", 29, 41], ["nucleus", "ANATOMY", 45, 52], ["B F S cell", "ANATOMY", 56, 66], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["B F S cell", "CELL", 56, 66], ["BPoV-1", "GENE_OR_GENE_PRODUCT", 81, 87], ["Multifocal inclusion", "PROBLEM", 0, 20], ["BPoV", "TEST", 81, 85], ["Giemsa stain", "TEST", 88, 100], ["inclusion", "OBSERVATION", 11, 20], ["peripherally", "ANATOMY_MODIFIER", 29, 41], ["nucleus", "ANATOMY_MODIFIER", 45, 52], ["infected", "OBSERVATION_MODIFIER", 67, 75]]], ["85 (right).", [["right", "ANATOMY_MODIFIER", 4, 9]]], ["Large and small multifocal inclusions within the nucleus of B F S cell infected withBPoV-1; Giemsa stain ( \u03c7 1280).Fig.", [["nucleus", "ANATOMY", 49, 56], ["B F S cell", "ANATOMY", 60, 70], ["nucleus", "CELLULAR_COMPONENT", 49, 56], ["B F S cell", "CELL", 60, 70], ["withBPoV-1", "GENE_OR_GENE_PRODUCT", 80, 90], ["Large and small multifocal inclusions", "PROBLEM", 0, 37], ["Giemsa stain", "TEST", 92, 104], ["small", "OBSERVATION_MODIFIER", 10, 15], ["multifocal", "OBSERVATION_MODIFIER", 16, 26], ["inclusions", "OBSERVATION", 27, 37], ["nucleus", "ANATOMY_MODIFIER", 49, 56], ["B F S cell", "OBSERVATION_MODIFIER", 60, 70], ["infected", "OBSERVATION_MODIFIER", 71, 79]]], ["Ultrastructural detail of section from a nucleus of a B F S cell infected with BPoV-1.Serum samples from 35 herds of cattle representing 433 animals were tested in the western USA.", [["nucleus", "ANATOMY", 41, 48], ["B F S cell", "ANATOMY", 54, 64], ["Serum samples", "ANATOMY", 86, 99], ["nucleus", "CELLULAR_COMPONENT", 41, 48], ["B F S cell", "CELL", 54, 64], ["BPoV-1", "CELL", 79, 85], ["Serum samples", "ORGANISM_SUBSTANCE", 86, 99], ["cattle", "ORGANISM", 117, 123], ["B F S cell", "CELL_LINE", 54, 64], ["cattle", "SPECIES", 117, 123], ["cattle", "SPECIES", 117, 123], ["BPoV", "TEST", 79, 83], ["Serum samples", "TEST", 86, 99], ["infected", "OBSERVATION", 65, 73]]], ["Antibodies were detected in sera from 243 of 377 animals in 29 herds.", [["sera", "ANATOMY", 28, 32], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["Antibodies", "TEST", 0, 10], ["sera", "TEST", 28, 32]]], ["Six of the herds did not have cattle with parvovirus antibodies .", [["parvovirus antibodies", "DISEASE", 42, 63], ["cattle", "ORGANISM", 30, 36], ["parvovirus", "ORGANISM", 42, 52], ["parvovirus antibodies", "PROTEIN", 42, 63], ["cattle", "SPECIES", 30, 36], ["cattle", "SPECIES", 30, 36], ["parvovirus antibodies", "PROBLEM", 42, 63]]], ["Parvoviruses were isolated from cattle of all the countries where serological surveys had been made.", [["cattle", "SPECIES", 32, 38], ["Parvoviruses", "PROBLEM", 0, 12], ["serological surveys", "TEST", 66, 85]]], ["Considering their antigenic properties and minimal homology with parvoviruses of other animal species, one can assume that BPoV antibodies in cattle were not induced through cross-reactions after infection with parvoviruses of other animal species .", [["infection", "DISEASE", 196, 205], ["BPoV antibodies", "GENE_OR_GENE_PRODUCT", 123, 138], ["cattle", "ORGANISM", 142, 148], ["BPoV antibodies", "PROTEIN", 123, 138], ["cattle", "SPECIES", 142, 148], ["BPoV", "SPECIES", 123, 127], ["cattle", "SPECIES", 142, 148], ["other animal species", "PROBLEM", 81, 101], ["BPoV antibodies in cattle", "PROBLEM", 123, 148], ["infection", "PROBLEM", 196, 205], ["parvoviruses of other animal species", "PROBLEM", 211, 247]]], ["In addition, the host cell range of BPoV was found to be virtually restricted to bovine cells.", [["cell", "ANATOMY", 22, 26], ["cells", "ANATOMY", 88, 93], ["host cell", "CELL", 17, 26], ["BPoV", "GENE_OR_GENE_PRODUCT", 36, 40], ["bovine", "ORGANISM", 81, 87], ["cells", "CELL", 88, 93], ["BPoV", "PROTEIN", 36, 40], ["bovine cells", "CELL_TYPE", 81, 93], ["bovine", "SPECIES", 81, 87], ["bovine", "SPECIES", 81, 87], ["host cell range", "OBSERVATION", 17, 32], ["bovine cells", "OBSERVATION", 81, 93]]], ["Accordingly, the chain of infection is maintained within the cattle population.Fig.", [["infection", "DISEASE", 26, 35], ["cattle", "SPECIES", 61, 67], ["cattle", "SPECIES", 61, 67], ["infection", "PROBLEM", 26, 35], ["chain", "OBSERVATION_MODIFIER", 17, 22], ["infection", "OBSERVATION", 26, 35], ["cattle", "OBSERVATION_MODIFIER", 61, 67], ["population", "OBSERVATION_MODIFIER", 68, 78]]], ["Ultrastructural detail of section from a nucleus of a B F S cell infected with BPoV-1.Vertical transmission of BPoV was proven through detection of significant antibody titers in fetal serum and isolation of parvovirus from tissues of a naturally occurring abortion Inaba et al., 1973b) ; it was confirmed through experimental inoculations of pregnant cows or direct fetal inoculations (Storz et al., 1978) .How do parvoviruses induce enteritis in calves?The spread of BPoV during infection and its distribution in newborn calves after oral or intravenous inoculations was studied (Storz et al., 1978) .", [["nucleus", "ANATOMY", 41, 48], ["B F S cell", "ANATOMY", 54, 64], ["fetal serum", "ANATOMY", 179, 190], ["tissues", "ANATOMY", 224, 231], ["fetal", "ANATOMY", 367, 372], ["oral", "ANATOMY", 536, 540], ["intravenous", "ANATOMY", 544, 555], ["parvovirus", "DISEASE", 208, 218], ["enteritis", "DISEASE", 435, 444], ["BPoV", "CHEMICAL", 469, 473], ["infection", "DISEASE", 481, 490], ["nucleus", "CELLULAR_COMPONENT", 41, 48], ["B F S cell", "CELL", 54, 64], ["BPoV-1", "CELL", 79, 85], ["BPoV", "GENE_OR_GENE_PRODUCT", 111, 115], ["fetal serum", "ORGANISM_SUBSTANCE", 179, 190], ["parvovirus", "ORGANISM", 208, 218], ["tissues", "TISSUE", 224, 231], ["cows", "ORGANISM", 352, 356], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 367, 372], ["parvoviruses", "ORGANISM", 415, 427], ["calves", "ORGANISM", 448, 454], ["BPoV", "GENE_OR_GENE_PRODUCT", 469, 473], ["calves", "ORGANISM", 523, 529], ["oral", "ORGANISM_SUBDIVISION", 536, 540], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 544, 555], ["B F S cell", "CELL_LINE", 54, 64], ["BPoV", "PROTEIN", 111, 115], ["cows", "SPECIES", 352, 356], ["calves", "SPECIES", 448, 454], ["calves", "SPECIES", 523, 529], ["BPoV", "TEST", 79, 83], ["significant antibody titers", "PROBLEM", 148, 175], ["fetal serum", "TEST", 179, 190], ["parvovirus", "PROBLEM", 208, 218], ["pregnant cows", "PROBLEM", 343, 356], ["direct fetal inoculations", "PROBLEM", 360, 385], ["parvoviruses", "PROBLEM", 415, 427], ["enteritis in calves", "PROBLEM", 435, 454], ["BPoV", "PROBLEM", 469, 473], ["infection", "PROBLEM", 481, 490], ["oral or intravenous inoculations", "TREATMENT", 536, 568], ["infected", "OBSERVATION", 65, 73], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["antibody titers", "OBSERVATION", 160, 175], ["parvovirus", "OBSERVATION", 208, 218], ["enteritis", "OBSERVATION", 435, 444], ["calves", "ANATOMY", 448, 454], ["spread", "OBSERVATION_MODIFIER", 459, 465], ["infection", "OBSERVATION", 481, 490], ["distribution", "OBSERVATION_MODIFIER", 499, 511]]], ["Parvoviral antigen was demonstrated by IF test and virus was reisolated.How do parvoviruses induce enteritis in calves?Calves excreted BPoV 24-48 h after oral as well as intravenous inoculation and continued to do so during the course of the experiment lasting for 11 days.", [["oral", "ANATOMY", 154, 158], ["intravenous", "ANATOMY", 170, 181], ["enteritis", "DISEASE", 99, 108], ["BPoV", "CHEMICAL", 135, 139], ["Parvoviral antigen", "GENE_OR_GENE_PRODUCT", 0, 18], ["parvoviruses", "ORGANISM", 79, 91], ["calves", "ORGANISM", 112, 118], ["Calves", "ORGANISM", 119, 125], ["oral", "ORGANISM_SUBDIVISION", 154, 158], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 170, 181], ["Parvoviral antigen", "PROTEIN", 0, 18], ["IF", "PROTEIN", 39, 41], ["calves", "SPECIES", 112, 118], ["Calves", "SPECIES", 119, 125], ["Parvoviral antigen", "TEST", 0, 18], ["virus", "PROBLEM", 51, 56], ["parvoviruses", "PROBLEM", 79, 91], ["enteritis in calves", "PROBLEM", 99, 118], ["intravenous inoculation", "TREATMENT", 170, 193], ["enteritis", "OBSERVATION", 99, 108], ["calves", "ANATOMY", 112, 118]]], ["Virus was isolated from mucosal scrapings of the duodenum and lower levels of the intestine for 6 days.", [["mucosal scrapings", "ANATOMY", 24, 41], ["duodenum", "ANATOMY", 49, 57], ["intestine", "ANATOMY", 82, 91], ["Virus", "ORGANISM", 0, 5], ["mucosal scrapings", "MULTI-TISSUE_STRUCTURE", 24, 41], ["duodenum", "ORGAN", 49, 57], ["intestine", "ORGAN", 82, 91], ["Virus", "PROBLEM", 0, 5], ["mucosal", "ANATOMY_MODIFIER", 24, 31], ["scrapings", "OBSERVATION", 32, 41], ["duodenum", "ANATOMY", 49, 57], ["lower levels", "ANATOMY_MODIFIER", 62, 74], ["intestine", "ANATOMY", 82, 91]]], ["The regions most consistently infected were the jejunum, ileum and caecum; the highest titers were measured in the intestinal mucosa of intravenously inoculated calves.", [["jejunum", "ANATOMY", 48, 55], ["ileum", "ANATOMY", 57, 62], ["caecum", "ANATOMY", 67, 73], ["intestinal mucosa", "ANATOMY", 115, 132], ["intravenously", "ANATOMY", 136, 149], ["calves", "ANATOMY", 161, 167], ["jejunum", "MULTI-TISSUE_STRUCTURE", 48, 55], ["ileum", "MULTI-TISSUE_STRUCTURE", 57, 62], ["caecum", "ORGAN", 67, 73], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 115, 132], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 149], ["calves", "ORGANISM", 161, 167], ["calves", "SPECIES", 161, 167], ["the highest titers", "TEST", 75, 93], ["consistently", "OBSERVATION_MODIFIER", 17, 29], ["infected", "OBSERVATION", 30, 38], ["jejunum", "ANATOMY", 48, 55], ["ileum", "ANATOMY", 57, 62], ["caecum", "ANATOMY", 67, 73], ["highest", "OBSERVATION_MODIFIER", 79, 86], ["titers", "OBSERVATION_MODIFIER", 87, 93], ["intestinal mucosa", "ANATOMY", 115, 132], ["intravenously", "OBSERVATION_MODIFIER", 136, 149], ["inoculated calves", "OBSERVATION", 150, 167]]], ["Patches of cells with fluorescent nuclei were found in the epithelium of the Lieberk\u00fchn crypts, in the transition and intervillous zones of villi, in cells of central lacteals (a site where more fluorescent cells were found after intravenous inoculation) and in cells of the lamina propria.", [["cells", "ANATOMY", 11, 16], ["nuclei", "ANATOMY", 34, 40], ["epithelium", "ANATOMY", 59, 69], ["Lieberk\u00fchn crypts", "ANATOMY", 77, 94], ["intervillous zones", "ANATOMY", 118, 136], ["villi", "ANATOMY", 140, 145], ["cells", "ANATOMY", 150, 155], ["lacteals", "ANATOMY", 167, 175], ["site", "ANATOMY", 179, 183], ["cells", "ANATOMY", 207, 212], ["intravenous", "ANATOMY", 230, 241], ["cells", "ANATOMY", 262, 267], ["lamina propria", "ANATOMY", 275, 289], ["cells", "CELL", 11, 16], ["nuclei", "CELLULAR_COMPONENT", 34, 40], ["epithelium", "TISSUE", 59, 69], ["Lieberk\u00fchn crypts", "TISSUE", 77, 94], ["intervillous zones", "CELLULAR_COMPONENT", 118, 136], ["villi", "MULTI-TISSUE_STRUCTURE", 140, 145], ["cells", "CELL", 150, 155], ["central lacteals", "PATHOLOGICAL_FORMATION", 159, 175], ["cells", "CELL", 207, 212], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 230, 241], ["cells", "CELL", 262, 267], ["lamina propria", "TISSUE", 275, 289], ["central lacteals", "CELL_TYPE", 159, 175], ["fluorescent cells", "CELL_TYPE", 195, 212], ["Patches of cells", "PROBLEM", 0, 16], ["fluorescent nuclei", "PROBLEM", 22, 40], ["the transition and intervillous zones of villi", "PROBLEM", 99, 145], ["central lacteals", "PROBLEM", 159, 175], ["more fluorescent cells", "PROBLEM", 190, 212], ["intravenous inoculation", "TREATMENT", 230, 253], ["cells", "ANATOMY", 11, 16], ["fluorescent nuclei", "OBSERVATION", 22, 40], ["epithelium", "ANATOMY_MODIFIER", 59, 69], ["Lieberk\u00fchn crypts", "OBSERVATION", 77, 94], ["transition", "OBSERVATION_MODIFIER", 103, 113], ["intervillous", "ANATOMY_MODIFIER", 118, 130], ["zones", "ANATOMY_MODIFIER", 131, 136], ["villi", "ANATOMY", 140, 145], ["central", "ANATOMY_MODIFIER", 159, 166], ["lacteals", "ANATOMY", 167, 175], ["fluorescent cells", "OBSERVATION", 195, 212], ["lamina propria", "ANATOMY", 275, 289]]], ["The range and distribution of fluorescent cells was similar to that found in newborn kittens inoculated with feline panleukopenia virus, another parvovirus (Hammon and Enders, 1939; Csiza et al., 1971; Carlson et al., 1977 , see volume Virus Infections of Carnivores of this series).", [["cells", "ANATOMY", 42, 47], ["feline panleukopenia", "DISEASE", 109, 129], ["parvovirus", "DISEASE", 145, 155], ["cells", "CELL", 42, 47], ["kittens", "ORGANISM", 85, 92], ["feline panleukopenia virus", "ORGANISM", 109, 135], ["parvovirus", "ORGANISM", 145, 155], ["fluorescent cells", "CELL_TYPE", 30, 47], ["feline panleukopenia virus", "SPECIES", 109, 135], ["feline panleukopenia virus", "SPECIES", 109, 135], ["fluorescent cells", "PROBLEM", 30, 47], ["newborn kittens", "PROBLEM", 77, 92], ["feline panleukopenia virus", "PROBLEM", 109, 135], ["range", "OBSERVATION_MODIFIER", 4, 9], ["fluorescent cells", "OBSERVATION", 30, 47]]], ["It differed from the range of infected cells of adult conventional cats, where the cells of Lieberk\u00fchn crypts are the initial sites of intestinal infection.How do parvoviruses induce enteritis in calves?Viremia associated with leukocytes developed after oral inoculation and reemerged when virus was given intravenously, and more serious diarrhea was then induced.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 83, 88], ["Lieberk\u00fchn crypts", "ANATOMY", 92, 109], ["sites", "ANATOMY", 126, 131], ["intestinal", "ANATOMY", 135, 145], ["leukocytes", "ANATOMY", 227, 237], ["oral", "ANATOMY", 254, 258], ["intravenously", "ANATOMY", 306, 319], ["intestinal infection", "DISEASE", 135, 155], ["enteritis", "DISEASE", 183, 192], ["Viremia", "DISEASE", 203, 210], ["diarrhea", "DISEASE", 338, 346], ["cells", "CELL", 39, 44], ["cats", "ORGANISM", 67, 71], ["cells", "CELL", 83, 88], ["Lieberk\u00fchn crypts", "MULTI-TISSUE_STRUCTURE", 92, 109], ["intestinal", "ORGAN", 135, 145], ["parvoviruses", "ORGANISM", 163, 175], ["calves", "ORGANISM", 196, 202], ["leukocytes", "CELL", 227, 237], ["oral", "ORGANISM_SUBDIVISION", 254, 258], ["infected cells", "CELL_TYPE", 30, 44], ["leukocytes", "CELL_TYPE", 227, 237], ["cats", "SPECIES", 67, 71], ["calves", "SPECIES", 196, 202], ["Lieberk\u00fchn crypts", "PROBLEM", 92, 109], ["intestinal infection", "PROBLEM", 135, 155], ["parvoviruses", "PROBLEM", 163, 175], ["enteritis in calves", "PROBLEM", 183, 202], ["Viremia", "PROBLEM", 203, 210], ["leukocytes", "PROBLEM", 227, 237], ["oral inoculation", "TREATMENT", 254, 270], ["virus", "PROBLEM", 290, 295], ["more serious diarrhea", "PROBLEM", 325, 346], ["infected cells", "OBSERVATION", 30, 44], ["Lieberk\u00fchn crypts", "OBSERVATION", 92, 109], ["intestinal", "ANATOMY", 135, 145], ["infection", "OBSERVATION", 146, 155], ["enteritis", "OBSERVATION", 183, 192], ["calves", "ANATOMY", 196, 202], ["leukocytes", "OBSERVATION_MODIFIER", 227, 237], ["serious", "OBSERVATION_MODIFIER", 330, 337], ["diarrhea", "OBSERVATION", 338, 346]]], ["Infections of intestinal cells in crypts, central lacteal and other sites occurred during the systemic phase.", [["intestinal cells", "ANATOMY", 14, 30], ["crypts", "ANATOMY", 34, 40], ["lacteal", "ANATOMY", 50, 57], ["sites", "ANATOMY", 68, 73], ["intestinal cells", "CELL", 14, 30], ["crypts", "MULTI-TISSUE_STRUCTURE", 34, 40], ["central lacteal", "MULTI-TISSUE_STRUCTURE", 42, 57], ["intestinal cells", "CELL_TYPE", 14, 30], ["Infections of intestinal cells in crypts", "PROBLEM", 0, 40], ["central lacteal and other sites", "PROBLEM", 42, 73], ["the systemic phase", "TEST", 90, 108], ["intestinal cells", "ANATOMY", 14, 30], ["crypts", "OBSERVATION_MODIFIER", 34, 40], ["central", "OBSERVATION_MODIFIER", 42, 49], ["lacteal", "OBSERVATION_MODIFIER", 50, 57]]], ["Also, infection of cells in the cortex of the adrenal gland (Fig. 87) , the thymus, lymph nodes and heart muscle became pronounced during the systemic phase, which is a characteristic feature of the pathogenesis of parvovirus-induced enteric disease.How do parvoviruses induce enteritis in calves?Fluorescence in intestinal and other lymph nodes was distributed randomly and involved large cells in paracortical areas.", [["cells", "ANATOMY", 19, 24], ["cortex", "ANATOMY", 32, 38], ["adrenal gland", "ANATOMY", 46, 59], ["thymus", "ANATOMY", 76, 82], ["lymph nodes", "ANATOMY", 84, 95], ["heart muscle", "ANATOMY", 100, 112], ["intestinal", "ANATOMY", 313, 323], ["lymph nodes", "ANATOMY", 334, 345], ["cells", "ANATOMY", 390, 395], ["paracortical areas", "ANATOMY", 399, 417], ["infection", "DISEASE", 6, 15], ["heart muscle", "DISEASE", 100, 112], ["parvovirus-induced enteric disease", "DISEASE", 215, 249], ["enteritis", "DISEASE", 277, 286], ["cells", "CELL", 19, 24], ["cortex", "CANCER", 32, 38], ["adrenal gland", "ORGAN", 46, 59], ["thymus", "ORGAN", 76, 82], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 84, 95], ["heart muscle", "ORGAN", 100, 112], ["parvovirus", "ORGANISM", 215, 225], ["parvoviruses", "ORGANISM", 257, 269], ["calves", "ORGANISM", 290, 296], ["intestinal", "ORGAN", 313, 323], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 334, 345], ["cells", "CELL", 390, 395], ["paracortical areas", "TISSUE", 399, 417], ["calves", "SPECIES", 290, 296], ["infection of cells", "PROBLEM", 6, 24], ["the thymus, lymph nodes and heart muscle", "PROBLEM", 72, 112], ["the systemic phase", "TEST", 138, 156], ["parvovirus", "PROBLEM", 215, 225], ["enteric disease", "PROBLEM", 234, 249], ["parvoviruses", "PROBLEM", 257, 269], ["enteritis in calves", "PROBLEM", 277, 296], ["Fluorescence in intestinal and other lymph nodes", "PROBLEM", 297, 345], ["large cells in paracortical areas", "PROBLEM", 384, 417], ["infection", "OBSERVATION", 6, 15], ["cortex", "ANATOMY_MODIFIER", 32, 38], ["adrenal gland", "ANATOMY", 46, 59], ["thymus", "ANATOMY", 76, 82], ["lymph nodes", "OBSERVATION", 84, 95], ["heart muscle", "ANATOMY", 100, 112], ["pronounced", "OBSERVATION_MODIFIER", 120, 130], ["systemic phase", "OBSERVATION_MODIFIER", 142, 156], ["parvovirus", "OBSERVATION", 215, 225], ["enteric disease", "OBSERVATION", 234, 249], ["enteritis", "OBSERVATION", 277, 286], ["calves", "ANATOMY", 290, 296], ["intestinal", "ANATOMY", 313, 323], ["lymph nodes", "OBSERVATION", 334, 345], ["large cells", "OBSERVATION", 384, 395], ["paracortical", "ANATOMY_MODIFIER", 399, 411], ["areas", "ANATOMY_MODIFIER", 412, 417]]], ["The thymus showed fluorescence in large nuclei or reticulum-like cells in the medullar region and cortex.", [["thymus", "ANATOMY", 4, 10], ["nuclei", "ANATOMY", 40, 46], ["reticulum-like cells", "ANATOMY", 50, 70], ["medullar region", "ANATOMY", 78, 93], ["cortex", "ANATOMY", 98, 104], ["thymus", "ORGAN", 4, 10], ["nuclei", "CELLULAR_COMPONENT", 40, 46], ["reticulum-like cells", "CELL", 50, 70], ["medullar region", "MULTI-TISSUE_STRUCTURE", 78, 93], ["cortex", "CANCER", 98, 104], ["reticulum-like cells", "CELL_TYPE", 50, 70], ["fluorescence in large nuclei or reticulum-like cells in the medullar region and cortex", "PROBLEM", 18, 104], ["thymus", "ANATOMY", 4, 10], ["fluorescence", "OBSERVATION", 18, 30], ["large nuclei", "OBSERVATION", 34, 46], ["reticulum", "ANATOMY", 50, 59], ["like cells", "OBSERVATION", 60, 70], ["medullar", "ANATOMY", 78, 86], ["region", "ANATOMY_MODIFIER", 87, 93], ["cortex", "ANATOMY_MODIFIER", 98, 104]]], ["Fluorescent cells were present in the nodular areas of the spleen.", [["cells", "ANATOMY", 12, 17], ["nodular areas", "ANATOMY", 38, 51], ["spleen", "ANATOMY", 59, 65], ["cells", "CELL", 12, 17], ["spleen", "ORGAN", 59, 65], ["Fluorescent cells", "TEST", 0, 17], ["cells", "OBSERVATION", 12, 17], ["nodular", "OBSERVATION", 38, 45], ["spleen", "ANATOMY", 59, 65]]], ["The adrenal glands examined had abundant fluorescence in the zona glomerulosa and fasciculata.", [["adrenal glands", "ANATOMY", 4, 18], ["zona glomerulosa", "ANATOMY", 61, 77], ["fasciculata", "ANATOMY", 82, 93], ["adrenal glands", "ORGAN", 4, 18], ["zona glomerulosa", "ORGANISM_SUBSTANCE", 61, 77], ["fasciculata", "ORGANISM_SUBSTANCE", 82, 93], ["adrenal glands", "ANATOMY", 4, 18], ["abundant", "OBSERVATION_MODIFIER", 32, 40], ["fluorescence", "OBSERVATION", 41, 53], ["zona", "ANATOMY_MODIFIER", 61, 65], ["glomerulosa", "ANATOMY", 66, 77], ["fasciculata", "ANATOMY_MODIFIER", 82, 93]]], ["Net-like pronounced fluorescence was present in heart muscle cells.", [["heart muscle cells", "ANATOMY", 48, 66], ["heart muscle cells", "CELL", 48, 66], ["heart muscle cells", "CELL_TYPE", 48, 66], ["Net-like pronounced fluorescence", "PROBLEM", 0, 32], ["pronounced", "OBSERVATION_MODIFIER", 9, 19], ["fluorescence", "OBSERVATION", 20, 32], ["heart muscle", "ANATOMY", 48, 60]]], ["Fluorescent cells were not found with parvovirus-specific conjugates in the corresponding tissues of one normal control calf or calves inoculated with bovine enteroviruses.How do parvoviruses induce enteritis in calves?Conventional calves inoculated orally or intravenously with parvovirus propagated in BFS or BFK cells for 8-10 passages developed diarrhea (Storz et al., 1978) .", [["cells", "ANATOMY", 12, 17], ["tissues", "ANATOMY", 90, 97], ["calves", "ANATOMY", 232, 238], ["orally", "ANATOMY", 250, 256], ["intravenously", "ANATOMY", 260, 273], ["BFK cells", "ANATOMY", 311, 320], ["enteroviruses", "DISEASE", 158, 171], ["enteritis", "DISEASE", 199, 208], ["diarrhea", "DISEASE", 349, 357], ["cells", "CELL", 12, 17], ["parvovirus", "ORGANISM", 38, 48], ["tissues", "TISSUE", 90, 97], ["calf", "ORGANISM", 120, 124], ["calves", "ORGANISM", 128, 134], ["bovine", "ORGANISM", 151, 157], ["enteroviruses", "ORGANISM", 158, 171], ["parvoviruses", "ORGANISM", 179, 191], ["calves", "ORGANISM", 212, 218], ["calves", "ORGANISM", 232, 238], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 260, 273], ["parvovirus", "ORGANISM", 279, 289], ["BFK cells", "CELL", 311, 320], ["BFK cells", "CELL_LINE", 311, 320], ["calf", "SPECIES", 120, 124], ["calves", "SPECIES", 128, 134], ["bovine", "SPECIES", 151, 157], ["calves", "SPECIES", 212, 218], ["calves", "SPECIES", 232, 238], ["calves", "SPECIES", 128, 134], ["bovine", "SPECIES", 151, 157], ["parvovirus", "SPECIES", 279, 289], ["Fluorescent cells", "TEST", 0, 17], ["parvovirus", "PROBLEM", 38, 48], ["bovine enteroviruses", "PROBLEM", 151, 171], ["parvoviruses", "PROBLEM", 179, 191], ["enteritis in calves", "PROBLEM", 199, 218], ["Conventional calves", "TREATMENT", 219, 238], ["parvovirus", "PROBLEM", 279, 289], ["BFK cells", "PROBLEM", 311, 320], ["diarrhea", "PROBLEM", 349, 357], ["normal", "OBSERVATION", 105, 111], ["calf", "ANATOMY", 120, 124], ["calves", "ANATOMY", 128, 134], ["bovine enteroviruses", "OBSERVATION", 151, 171], ["enteritis", "OBSERVATION", 199, 208], ["calves", "ANATOMY", 212, 218]]], ["Also 2-8-month-old calves became diarrheic 4-7 days after oral or intranasal inoculation with BPoV-1 of an unspecified passage level (Spahn et al., 1966) .", [["oral", "ANATOMY", 58, 62], ["diarrheic", "DISEASE", 33, 42], ["calves", "ORGANISM", 19, 25], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["calves", "SPECIES", 19, 25], ["diarrheic", "PROBLEM", 33, 42], ["oral or intranasal inoculation", "TREATMENT", 58, 88], ["BPoV", "TEST", 94, 98], ["diarrheic", "OBSERVATION", 33, 42]]], ["Calves inoculated intravenously had more severe diarrhea, which was initially watery and then mucoid, than orally inoculated calves.", [["intravenously", "ANATOMY", 18, 31], ["mucoid", "ANATOMY", 94, 100], ["calves", "ANATOMY", 125, 131], ["diarrhea", "DISEASE", 48, 56], ["watery", "DISEASE", 78, 84], ["Calves", "ORGANISM", 0, 6], ["calves", "ORGANISM", 125, 131], ["Calves", "SPECIES", 0, 6], ["calves", "SPECIES", 125, 131], ["more severe diarrhea", "PROBLEM", 36, 56], ["watery", "PROBLEM", 78, 84], ["mucoid", "PROBLEM", 94, 100], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["diarrhea", "OBSERVATION", 48, 56], ["watery", "OBSERVATION_MODIFIER", 78, 84], ["mucoid", "OBSERVATION_MODIFIER", 94, 100]]], ["Since parvoviruses were also isolated from conjunctival and tonsillar specimens, it appears that the oropharyngeal and respiratory routes of infections are more common under natural conditions than direct oral intestinal infections.", [["conjunctival", "ANATOMY", 43, 55], ["tonsillar specimens", "ANATOMY", 60, 79], ["oropharyngeal", "ANATOMY", 101, 114], ["respiratory", "ANATOMY", 119, 130], ["oral intestinal", "ANATOMY", 205, 220], ["infections", "DISEASE", 141, 151], ["intestinal infections", "DISEASE", 210, 231], ["parvoviruses", "ORGANISM", 6, 18], ["conjunctival", "TISSUE", 43, 55], ["tonsillar specimens", "CANCER", 60, 79], ["oropharyngeal", "ORGANISM_SUBDIVISION", 101, 114], ["oral intestinal", "ORGANISM_SUBDIVISION", 205, 220], ["parvoviruses", "PROBLEM", 6, 18], ["conjunctival and tonsillar specimens", "PROBLEM", 43, 79], ["the oropharyngeal and respiratory routes of infections", "PROBLEM", 97, 151], ["direct oral intestinal infections", "PROBLEM", 198, 231], ["conjunctival", "ANATOMY", 43, 55], ["tonsillar", "ANATOMY", 60, 69], ["specimens", "OBSERVATION", 70, 79], ["oropharyngeal", "ANATOMY", 101, 114], ["infections", "OBSERVATION", 141, 151], ["intestinal", "ANATOMY", 210, 220], ["infections", "OBSERVATION", 221, 231]]], ["The oropharyngeal and respiratory or parenteral routes of infection are most effective in experimental induction of feline panleukopenia (Csiza et al., 1971) .How do parvoviruses induce enteritis in calves?The most reliable inocula for inducing enteric disease with clinical signs comparable to those observed under natural conditions were suspensions of wild-type virus derived from diarrheic fluid and intestinal mucosal samples in experimental coronaviral and rotaviral enteritis (Storz et al., 1978; Storz and Leary, 1979) .", [["oropharyngeal", "ANATOMY", 4, 17], ["respiratory", "ANATOMY", 22, 33], ["diarrheic fluid", "ANATOMY", 384, 399], ["intestinal mucosal samples", "ANATOMY", 404, 430], ["coronaviral", "ANATOMY", 447, 458], ["infection", "DISEASE", 58, 67], ["feline panleukopenia", "DISEASE", 116, 136], ["enteritis", "DISEASE", 186, 195], ["enteric disease", "DISEASE", 245, 260], ["enteritis", "DISEASE", 473, 482], ["oropharyngeal", "ORGANISM_SUBDIVISION", 4, 17], ["feline", "ORGANISM", 116, 122], ["parvoviruses", "ORGANISM", 166, 178], ["calves", "ORGANISM", 199, 205], ["wild-type virus", "ORGANISM", 355, 370], ["diarrheic fluid", "ORGANISM_SUBSTANCE", 384, 399], ["intestinal mucosal samples", "TISSUE", 404, 430], ["feline", "SPECIES", 116, 122], ["calves", "SPECIES", 199, 205], ["infection", "PROBLEM", 58, 67], ["parvoviruses", "PROBLEM", 166, 178], ["enteritis in calves", "PROBLEM", 186, 205], ["inducing enteric disease", "PROBLEM", 236, 260], ["clinical signs", "PROBLEM", 266, 280], ["wild-type virus", "PROBLEM", 355, 370], ["diarrheic fluid", "PROBLEM", 384, 399], ["intestinal mucosal samples", "PROBLEM", 404, 430], ["experimental coronaviral and rotaviral enteritis", "PROBLEM", 434, 482], ["oropharyngeal", "ANATOMY", 4, 17], ["respiratory", "ANATOMY", 22, 33], ["infection", "OBSERVATION", 58, 67], ["enteritis", "OBSERVATION", 186, 195], ["calves", "ANATOMY", 199, 205], ["intestinal mucosal", "ANATOMY", 404, 422], ["coronaviral", "ANATOMY", 447, 458], ["rotaviral enteritis", "OBSERVATION", 463, 482]]], ["Similarly, a reliable inoculum for inducing panleukopenia in cats was a wild-type parvovirus maintained by intestinal infections in pathogenfree cats (Carlson et al., 1977) .", [["intestinal", "ANATOMY", 107, 117], ["panleukopenia", "DISEASE", 44, 57], ["parvovirus", "DISEASE", 82, 92], ["intestinal infections", "DISEASE", 107, 128], ["cats", "ORGANISM", 61, 65], ["parvovirus", "ORGANISM", 82, 92], ["intestinal", "ORGAN", 107, 117], ["cats", "ORGANISM", 145, 149], ["cats", "SPECIES", 61, 65], ["cats", "SPECIES", 145, 149], ["a reliable inoculum", "PROBLEM", 11, 30], ["inducing panleukopenia in cats", "PROBLEM", 35, 65], ["type parvovirus", "PROBLEM", 77, 92], ["intestinal infections", "PROBLEM", 107, 128], ["reliable", "OBSERVATION_MODIFIER", 13, 21], ["inoculum", "OBSERVATION", 22, 30], ["intestinal", "ANATOMY", 107, 117], ["infections", "OBSERVATION", 118, 128]]], ["Cell culture propagated BPoV did not reproducibly cause diarrhea.", [["Cell", "ANATOMY", 0, 4], ["diarrhea", "DISEASE", 56, 64], ["Cell", "CELL", 0, 4], ["Cell culture", "TEST", 0, 12], ["diarrhea", "PROBLEM", 56, 64]]], ["Evidently, enteropathogenic viruses rapidly become attenuated during passage in cell culture due to mutation and selection of host range mutants with reduced virulence.", [["cell culture", "ANATOMY", 80, 92], ["cell culture", "CELL", 80, 92], ["enteropathogenic viruses", "PROBLEM", 11, 35], ["attenuated", "PROBLEM", 51, 61], ["cell culture", "TEST", 80, 92], ["mutation", "PROBLEM", 100, 108], ["reduced virulence", "PROBLEM", 150, 167], ["enteropathogenic", "OBSERVATION_MODIFIER", 11, 27], ["viruses", "OBSERVATION", 28, 35], ["attenuated", "OBSERVATION_MODIFIER", 51, 61], ["reduced", "OBSERVATION_MODIFIER", 150, 157], ["virulence", "OBSERVATION", 158, 167]]], ["Although enteritis was induced in our experiments involving parvovirus passed serially in cultured cells at least eight times, we may not have reproduced the naturally occurring infection.How do parvoviruses induce enteritis in calves?Parvoviruses were detected in mixed intestinal viral infections of calves involving enteroviruses, adenoviruses, pestiviruses and coronaviruses.", [["cells", "ANATOMY", 99, 104], ["intestinal", "ANATOMY", 271, 281], ["enteritis", "DISEASE", 9, 18], ["infection", "DISEASE", 178, 187], ["enteritis", "DISEASE", 215, 224], ["viral infections", "DISEASE", 282, 298], ["enteroviruses", "DISEASE", 319, 332], ["parvovirus", "ORGANISM", 60, 70], ["cells", "CELL", 99, 104], ["parvoviruses", "ORGANISM", 195, 207], ["calves", "ORGANISM", 228, 234], ["intestinal", "ORGAN", 271, 281], ["calves", "ORGANISM", 302, 308], ["enteroviruses", "ORGANISM", 319, 332], ["adenoviruses", "ORGANISM", 334, 346], ["coronaviruses", "ORGANISM", 365, 378], ["cultured cells", "CELL_LINE", 90, 104], ["calves", "SPECIES", 228, 234], ["calves", "SPECIES", 302, 308], ["parvovirus", "SPECIES", 60, 70], ["calves", "SPECIES", 302, 308], ["enteritis", "PROBLEM", 9, 18], ["parvovirus", "PROBLEM", 60, 70], ["the naturally occurring infection", "PROBLEM", 154, 187], ["parvoviruses", "PROBLEM", 195, 207], ["enteritis in calves", "PROBLEM", 215, 234], ["Parvoviruses", "PROBLEM", 235, 247], ["mixed intestinal viral infections of calves", "PROBLEM", 265, 308], ["enteroviruses", "PROBLEM", 319, 332], ["adenoviruses", "PROBLEM", 334, 346], ["pestiviruses", "PROBLEM", 348, 360], ["coronaviruses", "PROBLEM", 365, 378], ["enteritis", "OBSERVATION", 9, 18], ["infection", "OBSERVATION", 178, 187], ["enteritis", "OBSERVATION", 215, 224], ["calves", "ANATOMY", 228, 234], ["mixed", "OBSERVATION_MODIFIER", 265, 270], ["intestinal", "ANATOMY", 271, 281], ["viral infections", "OBSERVATION", 282, 298], ["calves", "ANATOMY", 302, 308]]], ["Because multiple viral infections in enteric diseases are quite common but seldom mentioned and hardly studied, the significance of a parvovirus component should be investigated.", [["viral infections", "DISEASE", 17, 33], ["enteric diseases", "DISEASE", 37, 53], ["parvovirus", "DISEASE", 134, 144], ["parvovirus", "ORGANISM", 134, 144], ["parvovirus", "SPECIES", 134, 144], ["multiple viral infections in enteric diseases", "PROBLEM", 8, 53], ["a parvovirus component", "PROBLEM", 132, 154], ["multiple", "OBSERVATION_MODIFIER", 8, 16], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["infections", "OBSERVATION", 23, 33], ["enteric diseases", "OBSERVATION", 37, 53], ["parvovirus", "OBSERVATION", 134, 144]]], ["The parvoviral infection involves the host cell niche left unoccupied by intestinal coronaviruses or rotaviruses.Pathogenesis of fetal infectionsThe pathogenic potential of BPoV to establish infection of the placenta and fetus was investigated by intravenously inoculating pregnant cows or by direct fetal inoculation during laparotomy (Storz et al., 1978) .", [["parvoviral", "ANATOMY", 4, 14], ["cell niche", "ANATOMY", 43, 53], ["intestinal", "ANATOMY", 73, 83], ["fetal", "ANATOMY", 129, 134], ["placenta", "ANATOMY", 208, 216], ["fetus", "ANATOMY", 221, 226], ["intravenously", "ANATOMY", 247, 260], ["cows", "ANATOMY", 282, 286], ["fetal", "ANATOMY", 300, 305], ["parvoviral infection", "DISEASE", 4, 24], ["fetal infections", "DISEASE", 129, 145], ["BPoV", "CHEMICAL", 173, 177], ["infection", "DISEASE", 191, 200], ["host cell", "CELL", 38, 47], ["intestinal coronaviruses", "ORGANISM", 73, 97], ["fetal", "ORGANISM_SUBDIVISION", 129, 134], ["BPoV", "GENE_OR_GENE_PRODUCT", 173, 177], ["placenta", "ORGAN", 208, 216], ["fetus", "ORGAN", 221, 226], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 247, 260], ["cows", "ORGANISM", 282, 286], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 300, 305], ["cows", "SPECIES", 282, 286], ["cows", "SPECIES", 282, 286], ["The parvoviral infection", "PROBLEM", 0, 24], ["intestinal coronaviruses", "PROBLEM", 73, 97], ["rotaviruses", "PROBLEM", 101, 112], ["fetal infections", "PROBLEM", 129, 145], ["BPoV", "PROBLEM", 173, 177], ["infection of the placenta", "PROBLEM", 191, 216], ["direct fetal inoculation during laparotomy", "TREATMENT", 293, 335], ["infection", "OBSERVATION", 15, 24], ["host cell", "OBSERVATION", 38, 47], ["niche", "ANATOMY_MODIFIER", 48, 53], ["left", "ANATOMY_MODIFIER", 54, 58], ["intestinal coronaviruses", "ANATOMY", 73, 97], ["rotaviruses", "OBSERVATION", 101, 112], ["fetal", "ANATOMY", 129, 134], ["infections", "OBSERVATION", 135, 145], ["infection", "OBSERVATION", 191, 200], ["placenta", "ANATOMY", 208, 216]]], ["Following intravenous inoculation of pregnant cows, virus was isolated from their blood leukocytes 3 and 6 days later, and placental as well as fetal infection occurred.", [["intravenous", "ANATOMY", 10, 21], ["blood leukocytes", "ANATOMY", 82, 98], ["placental", "ANATOMY", 123, 132], ["fetal", "ANATOMY", 144, 149], ["fetal infection", "DISEASE", 144, 159], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 21], ["cows", "ORGANISM", 46, 50], ["blood leukocytes", "CELL", 82, 98], ["placental", "MULTI-TISSUE_STRUCTURE", 123, 132], ["fetal", "ANATOMICAL_SYSTEM", 144, 149], ["blood leukocytes", "CELL_TYPE", 82, 98], ["cows", "SPECIES", 46, 50], ["intravenous inoculation", "TREATMENT", 10, 33], ["pregnant cows", "PROBLEM", 37, 50], ["virus", "PROBLEM", 52, 57], ["their blood leukocytes", "TEST", 76, 98], ["fetal infection", "PROBLEM", 144, 159], ["infection", "OBSERVATION", 150, 159]]], ["Fetuses of the first trimester of gestation were highly susceptible.", [["Fetuses", "ANATOMY", 0, 7], ["Fetuses", "ORGANISM", 0, 7]]], ["Nuclei of cells of the cotyledonary villi fluoresced in a honeycomb pattern when stained with parvovirus-specific antibodies.", [["Nuclei", "ANATOMY", 0, 6], ["cells", "ANATOMY", 10, 15], ["cotyledonary villi", "ANATOMY", 23, 41], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["cells", "CELL", 10, 15], ["cotyledonary villi", "TISSUE", 23, 41], ["parvovirus", "ORGANISM", 94, 104], ["parvovirus-specific antibodies", "PROTEIN", 94, 124], ["the cotyledonary villi fluoresced", "PROBLEM", 19, 52], ["parvovirus", "PROBLEM", 94, 104], ["cells", "OBSERVATION", 10, 15], ["cotyledonary villi", "ANATOMY", 23, 41], ["honeycomb pattern", "OBSERVATION", 58, 75]]], ["The uterine mucosal glands contained some fluorescent cells which were also present in the adrenal glands, lungs, spleen, heart muscle, kidneys and thymus of the fetuses.", [["uterine mucosal glands", "ANATOMY", 4, 26], ["cells", "ANATOMY", 54, 59], ["adrenal glands", "ANATOMY", 91, 105], ["lungs", "ANATOMY", 107, 112], ["spleen", "ANATOMY", 114, 120], ["heart muscle", "ANATOMY", 122, 134], ["kidneys", "ANATOMY", 136, 143], ["thymus", "ANATOMY", 148, 154], ["fetuses", "ANATOMY", 162, 169], ["uterine mucosal glands", "ORGAN", 4, 26], ["cells", "CELL", 54, 59], ["adrenal glands", "ORGAN", 91, 105], ["lungs", "ORGAN", 107, 112], ["spleen", "ORGAN", 114, 120], ["heart muscle", "TISSUE", 122, 134], ["kidneys", "ORGAN", 136, 143], ["thymus", "ORGAN", 148, 154], ["fetuses", "ORGAN", 162, 169], ["fluorescent cells", "CELL_TYPE", 42, 59], ["some fluorescent cells", "PROBLEM", 37, 59], ["uterine", "ANATOMY_MODIFIER", 4, 11], ["mucosal glands", "ANATOMY", 12, 26], ["fluorescent cells", "OBSERVATION", 42, 59], ["adrenal glands", "ANATOMY", 91, 105], ["lungs", "ANATOMY", 107, 112], ["spleen", "ANATOMY", 114, 120], ["heart muscle", "ANATOMY", 122, 134], ["kidneys", "ANATOMY", 136, 143], ["thymus", "ANATOMY", 148, 154], ["fetuses", "ANATOMY", 162, 169]]], ["Virus was isolated from uterine fluid and the fetal organs.Pathogenesis of fetal infectionsAlso fetuses from the second trimester of gestation were susceptible to BPoV infection.", [["uterine fluid", "ANATOMY", 24, 37], ["fetal organs", "ANATOMY", 46, 58], ["fetal", "ANATOMY", 75, 80], ["fetuses", "ANATOMY", 96, 103], ["fetal infections", "DISEASE", 75, 91], ["infection", "DISEASE", 168, 177], ["Virus", "ORGANISM", 0, 5], ["uterine fluid", "MULTI-TISSUE_STRUCTURE", 24, 37], ["fetal organs", "MULTI-TISSUE_STRUCTURE", 46, 58], ["fetal", "ANATOMICAL_SYSTEM", 75, 80], ["fetuses", "ORGAN", 96, 103], ["BPoV", "GENE_OR_GENE_PRODUCT", 163, 167], ["BPoV", "SPECIES", 163, 167], ["Virus", "PROBLEM", 0, 5], ["fetal infections", "PROBLEM", 75, 91], ["fetuses", "PROBLEM", 96, 103], ["BPoV infection", "PROBLEM", 163, 177], ["uterine", "ANATOMY", 24, 31], ["fluid", "OBSERVATION", 32, 37], ["fetal organs", "ANATOMY", 46, 58], ["fetal", "OBSERVATION_MODIFIER", 75, 80], ["infections", "OBSERVATION", 81, 91], ["BPoV", "OBSERVATION_MODIFIER", 163, 167], ["infection", "OBSERVATION", 168, 177]]], ["When gravid uteri were removed 5-13 days after exposure of the fetuses, parvovirus could be isolated from placental fluids and most organs, including the intestinal tract.", [["uteri", "ANATOMY", 12, 17], ["fetuses", "ANATOMY", 63, 70], ["placental fluids", "ANATOMY", 106, 122], ["organs", "ANATOMY", 132, 138], ["intestinal tract", "ANATOMY", 154, 170], ["uteri", "ORGAN", 12, 17], ["fetuses", "ORGANISM", 63, 70], ["parvovirus", "ORGANISM", 72, 82], ["placental fluids", "MULTI-TISSUE_STRUCTURE", 106, 122], ["organs", "ORGAN", 132, 138], ["intestinal tract", "ORGANISM_SUBDIVISION", 154, 170], ["parvovirus", "SPECIES", 72, 82], ["gravid uteri", "TREATMENT", 5, 17], ["the fetuses", "PROBLEM", 59, 70], ["parvovirus", "PROBLEM", 72, 82], ["uteri", "ANATOMY", 12, 17], ["fetuses", "ANATOMY", 63, 70], ["parvovirus", "OBSERVATION", 72, 82], ["intestinal tract", "ANATOMY", 154, 170]]], ["The infectivity levels of placental fluids varied from 10 4 to 10 6 PFU per ml.", [["placental fluids", "ANATOMY", 26, 42], ["placental fluids", "MULTI-TISSUE_STRUCTURE", 26, 42], ["The infectivity levels", "TEST", 0, 22], ["placental fluids", "TEST", 26, 42], ["infectivity", "OBSERVATION", 4, 15]]], ["The liver of one fetus contained 7 \u03c7 10 5 PFU/g, and titers of similar levels were detected in adrenal glands, lymph nodes and intestinal tissues.", [["liver", "ANATOMY", 4, 9], ["fetus", "ANATOMY", 17, 22], ["adrenal glands", "ANATOMY", 95, 109], ["lymph nodes", "ANATOMY", 111, 122], ["intestinal tissues", "ANATOMY", 127, 145], ["liver", "ORGAN", 4, 9], ["fetus", "ORGANISM", 17, 22], ["adrenal glands", "MULTI-TISSUE_STRUCTURE", 95, 109], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 111, 122], ["intestinal tissues", "TISSUE", 127, 145], ["PFU/g", "TEST", 42, 47], ["liver", "ANATOMY", 4, 9], ["one fetus", "ANATOMY", 13, 22], ["adrenal glands", "ANATOMY", 95, 109], ["lymph nodes", "OBSERVATION", 111, 122], ["intestinal tissues", "ANATOMY", 127, 145]]], ["Immunofluorescence findings corresponded with viral isola-tion results.", [["Immunofluorescence findings", "TEST", 0, 27], ["viral isola-tion results", "PROBLEM", 46, 70]]], ["If fetuses survived and were tested 2 weeks after inoculation or later, virus isolation was irregular because the fetuses had produced antibodies.Pathogenesis of fetal infectionsFetuses of the third trimester of gestation became infected, developed antibodies and recovered.", [["fetuses", "ANATOMY", 3, 10], ["fetuses", "ANATOMY", 114, 121], ["fetal", "ANATOMY", 162, 167], ["Fetuses", "ANATOMY", 178, 185], ["fetal infections", "DISEASE", 162, 178], ["fetuses", "ORGANISM", 3, 10], ["fetuses", "ORGANISM", 114, 121], ["fetal", "ANATOMICAL_SYSTEM", 162, 167], ["antibodies", "PROTEIN", 135, 145], ["antibodies", "PROTEIN", 249, 259], ["fetuses", "PROBLEM", 3, 10], ["inoculation", "PROBLEM", 50, 61], ["virus isolation", "PROBLEM", 72, 87], ["the fetuses", "PROBLEM", 110, 121], ["fetal infections", "PROBLEM", 162, 178], ["infected", "PROBLEM", 229, 237], ["antibodies", "PROBLEM", 249, 259], ["fetal", "ANATOMY_MODIFIER", 162, 167], ["infections", "OBSERVATION", 168, 178], ["infected", "OBSERVATION", 229, 237]]], ["These calves were born alive at term, and virus was isolated from them irregularly.Repeat breeders and embryonic deathA serological survey in 12 commercial dairy herds indicated that BPoV may be involved in other reproductive problems (Barnes et al., 1982) .", [["embryonic", "ANATOMY", 103, 112], ["BPoV", "CHEMICAL", 183, 187], ["calves", "ORGANISM", 6, 12], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 103, 112], ["BPoV", "GENE_OR_GENE_PRODUCT", 183, 187], ["calves", "SPECIES", 6, 12], ["virus", "PROBLEM", 42, 47], ["Repeat breeders", "PROBLEM", 83, 98], ["embryonic deathA serological survey", "PROBLEM", 103, 138], ["irregularly", "OBSERVATION_MODIFIER", 71, 82]]], ["The BPoV seroreactor cows commonly experienced higher rates of embryonic mortality and required more services per conception than did nonreactor cattle.", [["embryonic", "ANATOMY", 63, 72], ["cows", "ORGANISM", 21, 25], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 63, 72], ["cows", "SPECIES", 21, 25], ["cattle", "SPECIES", 145, 151], ["cattle", "SPECIES", 145, 151], ["The BPoV seroreactor cows", "PROBLEM", 0, 25], ["embryonic mortality", "PROBLEM", 63, 82], ["embryonic mortality", "OBSERVATION", 63, 82]]], ["The cows in these herds were adequately protected against the major reproductive diseases.", [["reproductive diseases", "DISEASE", 68, 89], ["cows", "ORGANISM", 4, 8], ["cows", "SPECIES", 4, 8], ["the major reproductive diseases", "PROBLEM", 58, 89], ["major", "OBSERVATION_MODIFIER", 62, 67], ["reproductive", "OBSERVATION_MODIFIER", 68, 80], ["diseases", "OBSERVATION", 81, 89]]], ["Regular disease prevention programs and vaccination against brucellosis, leptospirosis, BVD, IBR and parainfluenza were applied in these herds.", [["brucellosis", "DISEASE", 60, 71], ["leptospirosis", "DISEASE", 73, 86], ["BVD", "DISEASE", 88, 91], ["IBR", "DISEASE", 93, 96], ["parainfluenza", "DISEASE", 101, 114], ["BVD", "ORGANISM", 88, 91], ["parainfluenza", "ORGANISM", 101, 114], ["parainfluenza", "SPECIES", 101, 114], ["BVD", "SPECIES", 88, 91], ["Regular disease prevention programs", "TREATMENT", 0, 35], ["vaccination", "TREATMENT", 40, 51], ["brucellosis", "PROBLEM", 60, 71], ["leptospirosis", "PROBLEM", 73, 86], ["BVD", "PROBLEM", 88, 91], ["IBR", "PROBLEM", 93, 96], ["parainfluenza", "PROBLEM", 101, 114], ["disease", "OBSERVATION", 8, 15], ["parainfluenza", "OBSERVATION", 101, 114]]], ["Bluetongue virus infection also was not associated with reproductive problems in these herds.DISEASE SIGNSCalves with naturally occurring parvoviral infections proven by isolation had various clinical signs and varied in age from 1 week to 12 months (Abinanti and Warfield, 1961; Vincent, 1971; Bates et al., 1972; Huck et al., 1975; Hinaidy et al., 1979) .", [["Bluetongue virus infection", "DISEASE", 0, 26], ["parvoviral infections", "DISEASE", 138, 159], ["Bluetongue virus", "ORGANISM", 0, 16], ["Bluetongue virus", "SPECIES", 0, 16], ["Bluetongue virus", "SPECIES", 0, 16], ["Bluetongue virus infection", "PROBLEM", 0, 26], ["reproductive problems", "PROBLEM", 56, 77], ["DISEASE SIGNSCalves", "PROBLEM", 93, 112], ["parvoviral infections", "PROBLEM", 138, 159], ["various clinical signs", "PROBLEM", 184, 206], ["virus", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26], ["not associated with", "UNCERTAINTY", 36, 55], ["infections", "OBSERVATION", 149, 159]]], ["Diarrhea affected most calves from which we recovered parvoviruses.", [["Diarrhea", "DISEASE", 0, 8], ["calves", "ORGANISM", 23, 29], ["parvoviruses", "ORGANISM", 54, 66], ["calves", "SPECIES", 23, 29], ["Diarrhea affected most calves", "PROBLEM", 0, 29], ["parvoviruses", "PROBLEM", 54, 66], ["most calves", "OBSERVATION_MODIFIER", 18, 29], ["parvoviruses", "OBSERVATION", 54, 66]]], ["Calves surviving the diarrheic episode developed circulating antibodies, but parvoviruses could be isolated intermittently from their feces.", [["feces", "ANATOMY", 134, 139], ["diarrheic", "DISEASE", 21, 30], ["Calves", "ORGANISM", 0, 6], ["parvoviruses", "ORGANISM", 77, 89], ["feces", "ORGANISM_SUBDIVISION", 134, 139], ["circulating antibodies", "PROTEIN", 49, 71], ["Calves", "SPECIES", 0, 6], ["the diarrheic episode", "PROBLEM", 17, 38], ["circulating antibodies", "PROBLEM", 49, 71], ["parvoviruses", "PROBLEM", 77, 89], ["diarrheic episode", "OBSERVATION", 21, 38], ["circulating antibodies", "OBSERVATION", 49, 71]]], ["Most isolates were made from fecal specimens of calves suffering from enteritis, combined occasionally with febrile respiratory illness and conjunctivitis (Table 21 ).", [["fecal specimens", "ANATOMY", 29, 44], ["respiratory", "ANATOMY", 116, 127], ["enteritis", "DISEASE", 70, 79], ["febrile respiratory illness", "DISEASE", 108, 135], ["conjunctivitis", "DISEASE", 140, 154], ["fecal specimens", "ORGANISM_SUBSTANCE", 29, 44], ["calves", "ORGANISM", 48, 54], ["calves", "SPECIES", 48, 54], ["fecal specimens of calves", "PROBLEM", 29, 54], ["enteritis", "PROBLEM", 70, 79], ["febrile respiratory illness", "PROBLEM", 108, 135], ["conjunctivitis", "PROBLEM", 140, 154], ["fecal specimens", "OBSERVATION_MODIFIER", 29, 44], ["enteritis", "OBSERVATION", 70, 79], ["febrile", "OBSERVATION_MODIFIER", 108, 115], ["respiratory illness", "OBSERVATION", 116, 135], ["conjunctivitis", "OBSERVATION", 140, 154]]], ["In some instances parvoviruses were isolated from feces of clinically normal young cattle.", [["feces", "ANATOMY", 50, 55], ["parvoviruses", "ORGANISM", 18, 30], ["feces", "ORGANISM_SUBDIVISION", 50, 55], ["cattle", "ORGANISM", 83, 89], ["cattle", "SPECIES", 83, 89], ["cattle", "SPECIES", 83, 89], ["some instances parvoviruses", "PROBLEM", 3, 30], ["parvoviruses", "OBSERVATION", 18, 30]]], ["Holstein calves that had recovered from episodes of parvovirus diarrhea appeared retarded in growth.DISEASE SIGNSNewborn calves deprived of colostrum or given colostrum free of parvoviral (HI) antibodies developed enteritis 24-48 h after oral or intravenous inoculation with cell culture propagated strain 71-1-20W of the eighth-tenth passage in BFS cells (Storz et al., 1978) .", [["colostrum", "ANATOMY", 140, 149], ["colostrum", "ANATOMY", 159, 168], ["oral", "ANATOMY", 238, 242], ["intravenous", "ANATOMY", 246, 257], ["cell", "ANATOMY", 275, 279], ["BFS cells", "ANATOMY", 346, 355], ["parvovirus diarrhea", "DISEASE", 52, 71], ["enteritis", "DISEASE", 214, 223], ["calves", "ORGANISM", 9, 15], ["parvovirus", "ORGANISM", 52, 62], ["calves", "ORGANISM", 121, 127], ["colostrum", "ORGANISM", 140, 149], ["colostrum", "ORGANISM_SUBSTANCE", 159, 168], ["oral", "ORGANISM_SUBDIVISION", 238, 242], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 246, 257], ["cell", "CELL", 275, 279], ["BFS cells", "CELL", 346, 355], ["parvoviral (HI) antibodies", "PROTEIN", 177, 203], ["BFS cells", "CELL_LINE", 346, 355], ["calves", "SPECIES", 9, 15], ["calves", "SPECIES", 121, 127], ["Holstein", "SPECIES", 0, 8], ["Holstein calves", "PROBLEM", 0, 15], ["parvovirus diarrhea", "PROBLEM", 52, 71], ["colostrum", "TREATMENT", 140, 149], ["parvoviral (HI) antibodies", "PROBLEM", 177, 203], ["enteritis", "PROBLEM", 214, 223], ["oral or intravenous inoculation", "TREATMENT", 238, 269], ["cell culture", "TEST", 275, 287], ["parvovirus", "OBSERVATION", 52, 62], ["enteritis", "OBSERVATION", 214, 223]]], ["The diarrhea was mild to moderately severe in orally inoculated calves.", [["calves", "ANATOMY", 64, 70], ["diarrhea", "DISEASE", 4, 12], ["calves", "ORGANISM", 64, 70], ["calves", "SPECIES", 64, 70], ["The diarrhea", "PROBLEM", 0, 12], ["mild to moderately severe in orally inoculated calves", "PROBLEM", 17, 70], ["diarrhea", "OBSERVATION", 4, 12], ["mild", "OBSERVATION_MODIFIER", 17, 21], ["moderately", "OBSERVATION_MODIFIER", 25, 35], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["inoculated calves", "OBSERVATION", 53, 70]]], ["Calves given the inoculum intravenously developed a more severe, watery diarrhea and became prostrate.", [["diarrhea", "DISEASE", 72, 80], ["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["Calves", "TREATMENT", 0, 6], ["the inoculum intravenously", "TREATMENT", 13, 39], ["watery diarrhea", "PROBLEM", 65, 80], ["prostrate", "PROBLEM", 92, 101], ["more severe", "OBSERVATION_MODIFIER", 52, 63], ["watery", "OBSERVATION_MODIFIER", 65, 71], ["diarrhea", "OBSERVATION", 72, 80], ["prostrate", "OBSERVATION", 92, 101]]], ["The body temperatures reached 41\u00b0C 2 days after exposure.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["The body temperatures", "TEST", 0, 21]]], ["The calves were listless, but they usually drank the offered milk.", [["milk", "ANATOMY", 61, 65], ["calves", "ORGANISM", 4, 10], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["calves", "SPECIES", 4, 10], ["calves", "ANATOMY", 4, 10]]], ["Others observed diarrhea in 2-8-month-old calves 4-7 days after oral or intranasal inoculation with BPoV-1 of an unspecified passage level in cell cultures (Spahn et al., 1966) .DISEASE SIGNSPregnant cows did not develop clinical signs immediately following inoculation.", [["oral", "ANATOMY", 64, 68], ["cell cultures", "ANATOMY", 142, 155], ["diarrhea", "DISEASE", 16, 24], ["calves", "ORGANISM", 42, 48], ["oral", "ORGANISM_SUBDIVISION", 64, 68], ["cell cultures", "CELL", 142, 155], ["cell cultures", "CELL_LINE", 142, 155], ["calves", "SPECIES", 42, 48], ["cows", "SPECIES", 200, 204], ["diarrhea", "PROBLEM", 16, 24], ["oral or intranasal inoculation", "TREATMENT", 64, 94], ["BPoV", "TEST", 100, 104], ["an unspecified passage level", "PROBLEM", 110, 138], ["cell cultures", "TEST", 142, 155], ["clinical signs", "PROBLEM", 221, 235], ["inoculation", "PROBLEM", 258, 269], ["diarrhea", "OBSERVATION", 16, 24]]], ["Their temperature and behavior remained normal.", [["normal", "OBSERVATION", 40, 46]]], ["Abortions occurred in the first and early second trimester.", [["Abortions", "DISEASE", 0, 9], ["Abortions", "PROBLEM", 0, 9]]], ["The aborted fetuses were edematous, and the placentas were edematous and had necrotic cotyledons (Storz et al., 1978) .PATHOLOGYMost calves infected with BPoV had a catarrhal enteritis.", [["fetuses", "ANATOMY", 12, 19], ["placentas", "ANATOMY", 44, 53], ["cotyledons", "ANATOMY", 86, 96], ["necrotic", "DISEASE", 77, 85], ["BPoV", "CHEMICAL", 154, 158], ["catarrhal enteritis", "DISEASE", 165, 184], ["fetuses", "ORGANISM", 12, 19], ["placentas", "ORGANISM", 44, 53], ["cotyledons", "ORGAN", 86, 96], ["calves", "ORGANISM", 133, 139], ["calves", "SPECIES", 133, 139], ["BPoV", "SPECIES", 154, 158], ["catarrhal enteritis", "SPECIES", 165, 184], ["The aborted fetuses", "PROBLEM", 0, 19], ["edematous", "PROBLEM", 25, 34], ["edematous", "PROBLEM", 59, 68], ["necrotic cotyledons", "PROBLEM", 77, 96], ["PATHOLOGYMost calves infected", "PROBLEM", 119, 148], ["a catarrhal enteritis", "PROBLEM", 163, 184], ["edematous", "OBSERVATION", 25, 34], ["edematous", "OBSERVATION", 59, 68], ["necrotic", "OBSERVATION_MODIFIER", 77, 85], ["infected", "OBSERVATION", 140, 148], ["catarrhal enteritis", "OBSERVATION", 165, 184]]], ["The levels of the gastrointestinal tract consistently infected were the jejunum, ileum and cecum.", [["gastrointestinal tract", "ANATOMY", 18, 40], ["jejunum", "ANATOMY", 72, 79], ["ileum", "ANATOMY", 81, 86], ["cecum", "ANATOMY", 91, 96], ["gastrointestinal tract", "ORGAN", 18, 40], ["jejunum", "MULTI-TISSUE_STRUCTURE", 72, 79], ["ileum", "MULTI-TISSUE_STRUCTURE", 81, 86], ["cecum", "ORGAN", 91, 96], ["gastrointestinal tract", "ANATOMY", 18, 40], ["infected", "OBSERVATION", 54, 62], ["jejunum", "ANATOMY", 72, 79], ["ileum", "ANATOMY", 81, 86], ["cecum", "ANATOMY", 91, 96]]], ["Single small patches of fluorescent cells were found in the epithelium of the crypts, in the transition and intervillous zones of villi, the central Virus infections of ruminants lacteals, and in cells of the lamina propia mucosae.", [["cells", "ANATOMY", 36, 41], ["epithelium", "ANATOMY", 60, 70], ["crypts", "ANATOMY", 78, 84], ["intervillous zones", "ANATOMY", 108, 126], ["villi", "ANATOMY", 130, 135], ["lacteals", "ANATOMY", 179, 187], ["cells", "ANATOMY", 196, 201], ["lamina propia mucosae", "ANATOMY", 209, 230], ["Virus infections", "DISEASE", 149, 165], ["cells", "CELL", 36, 41], ["epithelium", "TISSUE", 60, 70], ["crypts", "MULTI-TISSUE_STRUCTURE", 78, 84], ["intervillous zones", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 126], ["villi", "MULTI-TISSUE_STRUCTURE", 130, 135], ["cells", "CELL", 196, 201], ["lamina propia mucosae", "TISSUE", 209, 230], ["fluorescent cells", "CELL_TYPE", 24, 41], ["Single small patches of fluorescent cells", "PROBLEM", 0, 41], ["the transition and intervillous zones of villi", "PROBLEM", 89, 135], ["the central Virus infections of ruminants lacteals", "PROBLEM", 137, 187], ["small", "OBSERVATION_MODIFIER", 7, 12], ["patches", "OBSERVATION_MODIFIER", 13, 20], ["fluorescent cells", "OBSERVATION", 24, 41], ["epithelium", "ANATOMY_MODIFIER", 60, 70], ["crypts", "OBSERVATION", 78, 84], ["intervillous", "ANATOMY_MODIFIER", 108, 120], ["zones", "ANATOMY_MODIFIER", 121, 126], ["villi", "ANATOMY", 130, 135], ["central Virus infections", "OBSERVATION", 141, 165], ["ruminants lacteals", "OBSERVATION", 169, 187], ["lamina", "ANATOMY_MODIFIER", 209, 215], ["propia mucosae", "ANATOMY", 216, 230]]], ["Clusters of fluorescent epithelial cells were also found in the crypts of Lieberk\u00fchn.", [["epithelial cells", "ANATOMY", 24, 40], ["crypts", "ANATOMY", 64, 70], ["epithelial cells", "CELL", 24, 40], ["crypts", "TISSUE", 64, 70], ["fluorescent epithelial cells", "CELL_TYPE", 12, 40], ["fluorescent epithelial cells", "PROBLEM", 12, 40], ["fluorescent epithelial cells", "OBSERVATION", 12, 40], ["crypts", "ANATOMY_MODIFIER", 64, 70]]], ["Fluorescence in lymph nodes was distributed randomly and involved single large cells, probably lymphoblasts, in paracortical areas; they were also seen in the germinal centers.", [["lymph nodes", "ANATOMY", 16, 27], ["cells", "ANATOMY", 79, 84], ["lymphoblasts", "ANATOMY", 95, 107], ["paracortical areas", "ANATOMY", 112, 130], ["germinal centers", "ANATOMY", 159, 175], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 16, 27], ["cells", "CELL", 79, 84], ["lymphoblasts", "CELL", 95, 107], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 159, 175], ["lymphoblasts", "CELL_TYPE", 95, 107], ["Fluorescence in lymph nodes", "TEST", 0, 27], ["single large cells", "PROBLEM", 66, 84], ["lymphoblasts", "PROBLEM", 95, 107], ["lymph nodes", "OBSERVATION", 16, 27], ["large cells", "OBSERVATION", 73, 84], ["probably", "UNCERTAINTY", 86, 94], ["lymphoblasts", "OBSERVATION", 95, 107], ["paracortical", "ANATOMY_MODIFIER", 112, 124], ["germinal", "ANATOMY_MODIFIER", 159, 167]]], ["Fluorescence in large nuclei of reticulum-like cells in the medullar regions of the thymus and infrequently in cells of the cortex was observed.", [["nuclei", "ANATOMY", 22, 28], ["reticulum-like cells", "ANATOMY", 32, 52], ["medullar regions", "ANATOMY", 60, 76], ["thymus", "ANATOMY", 84, 90], ["cells", "ANATOMY", 111, 116], ["cortex", "ANATOMY", 124, 130], ["nuclei", "CELLULAR_COMPONENT", 22, 28], ["reticulum-like cells", "CELL", 32, 52], ["medullar regions", "MULTI-TISSUE_STRUCTURE", 60, 76], ["thymus", "ORGAN", 84, 90], ["cells", "CELL", 111, 116], ["cortex", "CANCER", 124, 130], ["reticulum-like cells", "CELL_TYPE", 32, 52], ["Fluorescence", "TEST", 0, 12], ["large", "OBSERVATION_MODIFIER", 16, 21], ["nuclei", "OBSERVATION_MODIFIER", 22, 28], ["reticulum", "ANATOMY", 32, 41], ["like cells", "OBSERVATION", 42, 52], ["medullar", "ANATOMY_MODIFIER", 60, 68], ["regions", "ANATOMY_MODIFIER", 69, 76], ["thymus", "ANATOMY", 84, 90], ["cortex", "ANATOMY_MODIFIER", 124, 130]]], ["Similarly, fluorescent cells were found in the nodular areas of the spleen.", [["cells", "ANATOMY", 23, 28], ["nodular areas", "ANATOMY", 47, 60], ["spleen", "ANATOMY", 68, 74], ["fluorescent cells", "CELL", 11, 28], ["spleen", "ORGAN", 68, 74], ["fluorescent cells", "TEST", 11, 28], ["fluorescent cells", "OBSERVATION", 11, 28], ["nodular", "OBSERVATION", 47, 54], ["spleen", "ANATOMY", 68, 74]]], ["The adrenal glands examined showed large numbers of fluorescent cells in the zona glomerulosa and fasciolata.", [["adrenal glands", "ANATOMY", 4, 18], ["cells", "ANATOMY", 64, 69], ["zona glomerulosa", "ANATOMY", 77, 93], ["fasciolata", "ANATOMY", 98, 108], ["adrenal glands", "ORGAN", 4, 18], ["cells", "CELL", 64, 69], ["zona glomerulosa", "CELL", 77, 93], ["fasciolata", "CANCER", 98, 108], ["fluorescent cells", "CELL_TYPE", 52, 69], ["large numbers of fluorescent cells", "PROBLEM", 35, 69], ["adrenal glands", "ANATOMY", 4, 18], ["large", "OBSERVATION_MODIFIER", 35, 40], ["numbers", "OBSERVATION_MODIFIER", 41, 48], ["fluorescent cells", "OBSERVATION", 52, 69], ["zona", "ANATOMY_MODIFIER", 77, 81], ["glomerulosa", "ANATOMY", 82, 93]]], ["The nuclei of numerous heart muscle cells had net-like fluorescence.", [["nuclei", "ANATOMY", 4, 10], ["heart muscle cells", "ANATOMY", 23, 41], ["nuclei", "CELLULAR_COMPONENT", 4, 10], ["heart muscle cells", "CELL", 23, 41], ["heart muscle cells", "CELL_TYPE", 23, 41], ["net-like fluorescence", "PROBLEM", 46, 67], ["nuclei", "ANATOMY_MODIFIER", 4, 10], ["heart", "ANATOMY", 23, 28], ["muscle cells", "ANATOMY", 29, 41]]], ["Histological samples were taken from the experimental calves that were studied virologically.", [["samples", "ANATOMY", 13, 20], ["Histological samples", "CANCER", 0, 20], ["calves", "ORGANISM", 54, 60], ["calves", "SPECIES", 54, 60], ["Histological samples", "TEST", 0, 20], ["experimental calves", "ANATOMY", 41, 60]]], ["Evaluations of these tissues were not fruitful because of fixation problems.", [["tissues", "ANATOMY", 21, 28], ["tissues", "TISSUE", 21, 28], ["these tissues", "PROBLEM", 15, 28], ["fixation problems", "PROBLEM", 58, 75], ["fixation", "OBSERVATION", 58, 66]]], ["Recognizable nuclear changes (see Fig. 87 ) were detected in the adrenal glands, which had high titers of infectious virus .", [["nuclear", "ANATOMY", 13, 20], ["adrenal glands", "ANATOMY", 65, 79], ["nuclear", "CELLULAR_COMPONENT", 13, 20], ["adrenal glands", "ORGAN", 65, 79], ["infectious virus", "ORGANISM", 106, 122], ["Recognizable nuclear changes", "PROBLEM", 0, 28], ["high titers of infectious virus", "PROBLEM", 91, 122], ["adrenal glands", "ANATOMY", 65, 79], ["infectious virus", "OBSERVATION", 106, 122]]], ["Fetuses aborted during the first and early second trimester of gestation were edematous and had increased amounts of pleural and peritoneal fluid.", [["Fetuses", "ANATOMY", 0, 7], ["pleural", "ANATOMY", 117, 124], ["peritoneal fluid", "ANATOMY", 129, 145], ["Fetuses", "ORGANISM", 0, 7], ["pleural", "MULTI-TISSUE_STRUCTURE", 117, 124], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 129, 145], ["Fetuses aborted", "PROBLEM", 0, 15], ["edematous", "PROBLEM", 78, 87], ["increased amounts of pleural and peritoneal fluid", "PROBLEM", 96, 145], ["edematous", "OBSERVATION", 78, 87], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["amounts", "OBSERVATION_MODIFIER", 106, 113], ["pleural", "ANATOMY", 117, 124], ["peritoneal", "ANATOMY", 129, 139], ["fluid", "OBSERVATION", 140, 145]]], ["Intranuclear inclusions were formed in cells of the small intestine, liver, lymph nodes, and the cerebellum.", [["cells", "ANATOMY", 39, 44], ["small intestine", "ANATOMY", 52, 67], ["liver", "ANATOMY", 69, 74], ["lymph nodes", "ANATOMY", 76, 87], ["cerebellum", "ANATOMY", 97, 107], ["cells", "CELL", 39, 44], ["small intestine", "ORGAN", 52, 67], ["liver", "ORGAN", 69, 74], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 76, 87], ["cerebellum", "ORGAN", 97, 107], ["Intranuclear inclusions", "PROBLEM", 0, 23], ["inclusions", "OBSERVATION", 13, 23], ["small intestine", "ANATOMY", 52, 67], ["liver", "ANATOMY", 69, 74], ["lymph nodes", "OBSERVATION", 76, 87], ["cerebellum", "ANATOMY", 97, 107]]], ["Microscopic lesions consisted of excessive cellular necrosis in the external granule cell layer of the germinative sites of the cerebellum.", [["lesions", "ANATOMY", 12, 19], ["cellular", "ANATOMY", 43, 51], ["external granule cell layer", "ANATOMY", 68, 95], ["germinative sites", "ANATOMY", 103, 120], ["cerebellum", "ANATOMY", 128, 138], ["necrosis", "DISEASE", 52, 60], ["Microscopic lesions", "PATHOLOGICAL_FORMATION", 0, 19], ["cellular", "CELL", 43, 51], ["granule cell layer", "TISSUE", 77, 95], ["germinative sites", "MULTI-TISSUE_STRUCTURE", 103, 120], ["cerebellum", "ORGAN", 128, 138], ["Microscopic lesions", "PROBLEM", 0, 19], ["excessive cellular necrosis", "PROBLEM", 33, 60], ["lesions", "OBSERVATION", 12, 19], ["excessive", "OBSERVATION_MODIFIER", 33, 42], ["cellular", "OBSERVATION_MODIFIER", 43, 51], ["necrosis", "OBSERVATION", 52, 60], ["external", "ANATOMY_MODIFIER", 68, 76], ["granule cell", "OBSERVATION", 77, 89], ["layer", "ANATOMY_MODIFIER", 90, 95], ["germinative", "ANATOMY_MODIFIER", 103, 114], ["sites", "ANATOMY_MODIFIER", 115, 120], ["cerebellum", "ANATOMY", 128, 138]]], ["Lymphoid hyperplasia was also observed in fetuses examined at 10 days p.i.", [["Lymphoid hyperplasia", "ANATOMY", 0, 20], ["fetuses", "ANATOMY", 42, 49], ["Lymphoid hyperplasia", "DISEASE", 0, 20], ["Lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 0, 20], ["fetuses", "ORGAN", 42, 49], ["Lymphoid hyperplasia", "PROBLEM", 0, 20], ["hyperplasia", "OBSERVATION", 9, 20]]], ["There was no evidence of lymphoid depletion or necrosis in lymph nodes, spleen, or thymus (Storz et al., 1978; Barros, 1980) .\u03bd/ IMMUNE REACTIONNewborn calves and pregnant cows inoculated intravenously had a brisk HI antibody response within 5-7 days.", [["lymphoid", "ANATOMY", 25, 33], ["lymph nodes", "ANATOMY", 59, 70], ["spleen", "ANATOMY", 72, 78], ["thymus", "ANATOMY", 83, 89], ["intravenously", "ANATOMY", 188, 201], ["necrosis", "DISEASE", 47, 55], ["lymphoid", "CELL", 25, 33], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 59, 70], ["spleen", "ORGAN", 72, 78], ["thymus", "ORGAN", 83, 89], ["calves", "ORGANISM", 152, 158], ["cows", "ORGANISM", 172, 176], ["calves", "SPECIES", 152, 158], ["cows", "SPECIES", 172, 176], ["cows", "SPECIES", 172, 176], ["lymphoid depletion", "PROBLEM", 25, 43], ["necrosis in lymph nodes", "PROBLEM", 47, 70], ["no evidence of", "UNCERTAINTY", 10, 24], ["lymphoid depletion", "OBSERVATION", 25, 43], ["necrosis", "OBSERVATION", 47, 55], ["lymph nodes", "OBSERVATION", 59, 70], ["spleen", "ANATOMY", 72, 78], ["thymus", "ANATOMY", 83, 89]]], ["These antibodies also neutralized virus infectivity as tested in the plaque assay.", [["plaque", "ANATOMY", 69, 75], ["antibodies", "PROTEIN", 6, 16], ["These antibodies", "TEST", 0, 16], ["neutralized virus infectivity", "PROBLEM", 22, 51], ["neutralized virus infectivity", "OBSERVATION", 22, 51], ["plaque", "ANATOMY", 69, 75]]], ["A high percentage of cattle in different herds had antibodies, but there were closed herds found free of this infection (Spahn et al., 1966; Vincent, 1971; Storz et al., 1972; Hinaidy and B\u00fcrki, 1980) .\u03bd/ IMMUNE REACTIONThe humoral immune response of bovine fetuses to BPoV infection during the second and third trimesters was studied by the single radial immunodiffusion, HI, indirect IF test, micro-neutralization (MN), plaque-neutralization (PN), and double ID tests (Storz et al., 1978; Hayder et al., 1983) .", [["fetuses", "ANATOMY", 258, 265], ["plaque", "ANATOMY", 422, 428], ["infection", "DISEASE", 110, 119], ["BPoV", "CHEMICAL", 269, 273], ["infection", "DISEASE", 274, 283], ["cattle", "ORGANISM", 21, 27], ["bovine", "ORGANISM", 251, 257], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 258, 265], ["antibodies", "PROTEIN", 51, 61], ["cattle", "SPECIES", 21, 27], ["bovine", "SPECIES", 251, 257], ["cattle", "SPECIES", 21, 27], ["bovine", "SPECIES", 251, 257], ["BPoV", "SPECIES", 269, 273], ["antibodies", "PROBLEM", 51, 61], ["this infection", "PROBLEM", 105, 119], ["IMMUNE REACTION", "PROBLEM", 205, 220], ["bovine fetuses", "PROBLEM", 251, 265], ["BPoV infection", "PROBLEM", 269, 283], ["the single radial immunodiffusion", "TEST", 338, 371], ["indirect IF test", "TEST", 377, 393], ["plaque", "PROBLEM", 422, 428], ["neutralization (PN", "TREATMENT", 429, 447], ["double ID tests", "TEST", 454, 469], ["high", "OBSERVATION_MODIFIER", 2, 6], ["percentage", "OBSERVATION_MODIFIER", 7, 17], ["infection", "OBSERVATION", 110, 119], ["humoral immune", "OBSERVATION", 224, 238], ["bovine fetuses", "OBSERVATION", 251, 265], ["infection", "OBSERVATION", 274, 283], ["plaque", "OBSERVATION", 422, 428]]], ["Serum samples collected from 23 virus-inoculated and several control fetuses were tested.", [["Serum samples", "ANATOMY", 0, 13], ["fetuses", "ANATOMY", 69, 76], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["fetuses", "ORGANISM", 69, 76], ["Serum samples", "TEST", 0, 13]]], ["The IgM concentration reached 355mg/100ml at 10 days after fetal inoculation and then decreased.", [["fetal", "ANATOMY", 59, 64], ["IgM", "GENE_OR_GENE_PRODUCT", 4, 7], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 59, 64], ["IgM", "PROTEIN", 4, 7], ["The IgM concentration", "TREATMENT", 0, 21], ["fetal inoculation", "TEST", 59, 76], ["decreased", "OBSERVATION_MODIFIER", 86, 95]]], ["The IgG concentration increased 10 days after inoculation and was maximal 142 days later.", [["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG", "PROTEIN", 4, 7], ["The IgG concentration", "TREATMENT", 0, 21]]], ["A correlation between Ig concentrations and antibodies reacting in the HI, MN, PN, IF, and ID tests existed in all samples.", [["samples", "ANATOMY", 115, 122], ["Ig", "GENE_OR_GENE_PRODUCT", 22, 24], ["Ig", "PROTEIN", 22, 24], ["antibodies", "PROTEIN", 44, 54], ["Ig concentrations", "TEST", 22, 39], ["antibodies", "TEST", 44, 54], ["PN", "TREATMENT", 79, 81], ["ID tests", "TEST", 91, 99]]], ["Neutralizing and HI antibodies were detected 10 days after fetal inoculation.", [["fetal", "ANATOMY", 59, 64], ["HI antibodies", "GENE_OR_GENE_PRODUCT", 17, 30], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 59, 64], ["HI antibodies", "PROTEIN", 17, 30], ["HI", "SPECIES", 17, 19], ["Neutralizing and HI antibodies", "TEST", 0, 30], ["fetal inoculation", "PROBLEM", 59, 76]]], ["The highest MN titer of 4096 was detected in a fetus 10 days after inoculation done during the third trimester.", [["fetus", "ANATOMY", 47, 52], ["fetus", "ORGANISM", 47, 52], ["The highest MN titer", "TEST", 0, 20], ["inoculation", "TEST", 67, 78]]], ["Six sera were positive in the IF test.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["Six sera", "TEST", 0, 8], ["positive", "OBSERVATION", 14, 22]]], ["These samples were collected 10-60 days after the fetuses had been inoculated; they had IgG concentrations of 615mg/100ml or higher and titers of 16-64.\u03bd/ IMMUNE REACTIONBetween 5 and 10 days p.i. fetal blood lymphocyte counts tripled, due primarily to an increase in E-rosetting lymphocytes.", [["samples", "ANATOMY", 6, 13], ["fetuses", "ANATOMY", 50, 57], ["fetal blood lymphocyte", "ANATOMY", 197, 219], ["E-rosetting lymphocytes", "ANATOMY", 268, 291], ["fetuses", "ORGANISM", 50, 57], ["IgG", "GENE_OR_GENE_PRODUCT", 88, 91], ["fetal blood lymphocyte", "CELL", 197, 219], ["E-rosetting lymphocytes", "CELL", 268, 291], ["IgG", "PROTEIN", 88, 91], ["E-rosetting lymphocytes", "CELL_TYPE", 268, 291], ["These samples", "TEST", 0, 13], ["IgG concentrations", "TREATMENT", 88, 106], ["titers", "TEST", 136, 142], ["fetal blood lymphocyte counts", "TEST", 197, 226], ["an increase in E-rosetting lymphocytes", "PROBLEM", 253, 291], ["increase", "OBSERVATION_MODIFIER", 256, 264], ["E-rosetting lymphocytes", "OBSERVATION", 268, 291]]], ["Peripheral blood lymphocytes of all fetuses reponded well to nonspecific mitogens of phytohemagglutinin, concanavalin A, and pokeweed (Liggitt et al., 1982) .LABORATORY DIAGNOSISThe BPoV isolates established by investigators in different countries were cultured in BFK or calf testicle cells.", [["Peripheral blood lymphocytes", "ANATOMY", 0, 28], ["fetuses", "ANATOMY", 36, 43], ["BFK", "ANATOMY", 265, 268], ["testicle cells", "ANATOMY", 277, 291], ["concanavalin A", "CHEMICAL", 105, 119], ["Peripheral blood lymphocytes", "CELL", 0, 28], ["fetuses", "ORGANISM", 36, 43], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 85, 103], ["concanavalin A", "SIMPLE_CHEMICAL", 105, 119], ["BFK", "CELL", 265, 268], ["calf testicle cells", "CELL", 272, 291], ["Peripheral blood lymphocytes", "CELL_TYPE", 0, 28], ["phytohemagglutinin", "PROTEIN", 85, 103], ["calf testicle cells", "CELL_TYPE", 272, 291], ["calf", "SPECIES", 272, 276], ["Peripheral blood lymphocytes", "TEST", 0, 28], ["all fetuses", "PROBLEM", 32, 43], ["nonspecific mitogens of phytohemagglutinin", "TREATMENT", 61, 103], ["BPoV isolates", "TEST", 182, 195], ["blood lymphocytes", "OBSERVATION", 11, 28], ["calf testicle", "ANATOMY", 272, 285]]], ["Considering the high incidence of cattleVirus infections of ruminantswith antibody titers it is apparent that isolation of parvovirus from natural infections was relatively sporadic and inefficient with the various methods used.", [["infections", "DISEASE", 46, 56], ["parvovirus", "DISEASE", 123, 133], ["infections", "DISEASE", 147, 157], ["cattleVirus", "ORGANISM", 34, 45], ["parvovirus", "ORGANISM", 123, 133], ["parvovirus", "SPECIES", 123, 133], ["cattleVirus infections of ruminantswith antibody titers", "PROBLEM", 34, 89], ["parvovirus", "PROBLEM", 123, 133], ["natural infections", "PROBLEM", 139, 157], ["the various methods", "TREATMENT", 203, 222], ["high", "OBSERVATION_MODIFIER", 16, 20], ["parvovirus", "OBSERVATION", 123, 133]]], ["Optimal replication and pronounced cytopathic changes were observed in BFL and BFS cells .", [["BFL", "ANATOMY", 71, 74], ["BFS cells", "ANATOMY", 79, 88], ["BFL", "CELL", 71, 74], ["BFS cells", "CELL", 79, 88], ["BFL", "CELL_TYPE", 71, 74], ["BFS cells", "CELL_LINE", 79, 88], ["Optimal replication", "PROBLEM", 0, 19], ["pronounced cytopathic changes", "PROBLEM", 24, 53], ["pronounced", "OBSERVATION_MODIFIER", 24, 34], ["cytopathic", "OBSERVATION_MODIFIER", 35, 45], ["BFS cells", "OBSERVATION", 79, 88]]], ["These were used as actively growing cultures in a state of parasynchrony.", [["growing cultures", "TEST", 28, 44]]], ["The cellular requirements of BPoV must be considered before attempting in vitro studies, in viral isolation trials, and in the interpretation of pathogenetic mechanisms.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["BPoV", "SIMPLE_CHEMICAL", 29, 33], ["BPoV", "TREATMENT", 29, 33], ["vitro studies", "TEST", 74, 87], ["viral isolation trials", "TREATMENT", 92, 114]]], ["Cultures of BFS cells synthesize DNA in a parasynchronous manner between 18 and 48 hours after passage (Leary and Storz, 1982) .", [["BFS cells", "ANATOMY", 12, 21], ["BFS cells", "CELL", 12, 21], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["BFS cells", "CELL_LINE", 12, 21], ["Cultures", "TEST", 0, 8], ["BFS cells", "TEST", 12, 21]]], ["Optimum interaction of BPoV with DNA-synthesizing, S-phase cells was insured by infecting cells 18 h after passage.", [["S-phase cells", "ANATOMY", 51, 64], ["cells", "ANATOMY", 90, 95], ["BPoV", "CHEMICAL", 23, 27], ["BPoV", "SIMPLE_CHEMICAL", 23, 27], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["cells", "CELL", 59, 64], ["cells", "CELL", 90, 95], ["BPoV", "PROTEIN", 23, 27], ["S-phase cells", "CELL_LINE", 51, 64], ["BPoV", "TEST", 23, 27], ["DNA", "TEST", 33, 36], ["infecting cells", "PROBLEM", 80, 95]]], ["Intracellular infectivity rose 18-24 h p.i., at which time both cytopathic changes and intranuclear inclusions were detected.", [["Intracellular", "ANATOMY", 0, 13], ["intranuclear inclusions", "ANATOMY", 87, 110], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Intracellular infectivity", "TEST", 0, 25], ["both cytopathic changes", "PROBLEM", 59, 82], ["intranuclear inclusions", "PROBLEM", 87, 110], ["infectivity", "OBSERVATION_MODIFIER", 14, 25], ["cytopathic", "OBSERVATION", 64, 74], ["intranuclear inclusions", "OBSERVATION", 87, 110]]], ["Three methods of BPoV isolation from IF pretested samples of experimentally inoculated calves were compared (Storz et al., 1978) : (1) parasynchronous BFS cells with freezing and thawing between subpassages to disrupt cells; (2) direct culture of cells from selected organs; and (3) parasynchronous BFS cells and cell-associated virus techniques to maintain cell viability on subpassages.Virus infections of ruminantsCell-free virus techniques with parasynchronous BFS cells detected parvovirus in only 25.5% of the samples that were IF positive.", [["samples", "ANATOMY", 50, 57], ["BFS cells", "ANATOMY", 151, 160], ["cells", "ANATOMY", 218, 223], ["cells", "ANATOMY", 247, 252], ["organs", "ANATOMY", 267, 273], ["BFS cells", "ANATOMY", 299, 308], ["cell", "ANATOMY", 313, 317], ["cell", "ANATOMY", 358, 362], ["Cell", "ANATOMY", 417, 421], ["BFS cells", "ANATOMY", 465, 474], ["samples", "ANATOMY", 516, 523], ["Virus infections", "DISEASE", 388, 404], ["calves", "ORGANISM", 87, 93], ["parasynchronous BFS cells", "CELL", 135, 160], ["cells", "CELL", 218, 223], ["cells", "CELL", 247, 252], ["organs", "ORGAN", 267, 273], ["parasynchronous BFS cells", "CELL", 283, 308], ["cell", "CELL", 313, 317], ["cell", "CELL", 358, 362], ["Virus", "ORGANISM", 388, 393], ["ruminants", "ORGANISM", 408, 417], ["Cell", "CELL", 417, 421], ["BFS cells", "CELL", 465, 474], ["parvovirus", "ORGANISM", 484, 494], ["samples", "CANCER", 516, 523], ["IF", "GENE_OR_GENE_PRODUCT", 534, 536], ["parasynchronous BFS cells", "CELL_TYPE", 135, 160], ["BFS cells", "CELL_TYPE", 299, 308], ["parasynchronous BFS cells", "CELL_LINE", 449, 474], ["calves", "SPECIES", 87, 93], ["BPoV isolation", "TREATMENT", 17, 31], ["experimentally inoculated calves", "PROBLEM", 61, 93], ["parasynchronous BFS cells", "PROBLEM", 135, 160], ["freezing", "PROBLEM", 166, 174], ["disrupt cells", "PROBLEM", 210, 223], ["direct culture of cells", "TEST", 229, 252], ["parasynchronous BFS cells", "PROBLEM", 283, 308], ["cell", "TEST", 313, 317], ["virus techniques", "TREATMENT", 329, 345], ["Virus infections of ruminants", "PROBLEM", 388, 417], ["Cell-free virus techniques", "TEST", 417, 443], ["parasynchronous BFS cells", "TEST", 449, 474], ["parvovirus", "PROBLEM", 484, 494], ["the samples", "TEST", 512, 523], ["cell viability", "OBSERVATION", 358, 372], ["infections", "OBSERVATION", 394, 404], ["ruminants", "OBSERVATION_MODIFIER", 408, 417], ["free virus", "OBSERVATION", 422, 432]]], ["Direct culture of cells from kidneys or testicles produced parvovirus where this technique failed.", [["cells", "ANATOMY", 18, 23], ["kidneys", "ANATOMY", 29, 36], ["testicles", "ANATOMY", 40, 49], ["cells", "CELL", 18, 23], ["kidneys", "ORGAN", 29, 36], ["testicles", "ORGAN", 40, 49], ["parvovirus", "ORGANISM", 59, 69], ["Direct culture of cells from kidneys", "TEST", 0, 36], ["parvovirus", "PROBLEM", 59, 69], ["this technique", "TEST", 76, 90], ["kidneys", "ANATOMY", 29, 36], ["testicles", "ANATOMY", 40, 49], ["parvovirus", "OBSERVATION", 59, 69]]], ["The cell-associated virus technique employing parasynchronous BFS cells was most reliable and recovered parvovirus from 82.5% of IF-positive tissue specimens.", [["cell", "ANATOMY", 4, 8], ["parasynchronous BFS cells", "ANATOMY", 46, 71], ["tissue specimens", "ANATOMY", 141, 157], ["cell", "CELL", 4, 8], ["BFS cells", "CELL", 62, 71], ["parvovirus", "ORGANISM", 104, 114], ["IF", "GENE_OR_GENE_PRODUCT", 129, 131], ["tissue", "TISSUE", 141, 147], ["parasynchronous BFS cells", "CELL_LINE", 46, 71], ["The cell-associated virus technique", "TREATMENT", 0, 35], ["parasynchronous BFS cells", "TEST", 46, 71], ["parvovirus", "TEST", 104, 114], ["positive tissue specimens", "PROBLEM", 132, 157], ["virus technique", "OBSERVATION", 20, 35], ["positive tissue", "OBSERVATION_MODIFIER", 132, 147]]], ["Reports of investigations of parvoviral infections in other animal species, mainly the cat, also infer that it is difficult to isolate virus from infected organs.", [["organs", "ANATOMY", 155, 161], ["parvoviral infections", "DISEASE", 29, 50], ["parvoviral", "ORGANISM", 29, 39], ["cat", "ORGANISM", 87, 90], ["organs", "ORGAN", 155, 161], ["cat", "SPECIES", 87, 90], ["parvoviral infections", "PROBLEM", 29, 50], ["other animal species", "PROBLEM", 54, 74], ["infected organs", "PROBLEM", 146, 161], ["parvoviral", "OBSERVATION_MODIFIER", 29, 39], ["infections", "OBSERVATION", 40, 50]]], ["Method 3 is recommended and should be employed to isolate field strains.", [["Method", "TEST", 0, 6]]], ["Serum free of antibodies against BPoV and of HI inhibitors must be used for successful isolation and virus propagation .Virus infections of ruminantsDirect EM examination of diarrhea fluid is not reliable because of the possible presence of many other small particles, including enteroviruses, caliciviruses, astroviruses, togavirus cores and even small bacteriophages.", [["Serum", "ANATOMY", 0, 5], ["caliciviruses", "ANATOMY", 294, 307], ["astroviruses", "ANATOMY", 309, 321], ["Virus infections", "DISEASE", 120, 136], ["diarrhea", "DISEASE", 174, 182], ["enteroviruses", "DISEASE", 279, 292], ["caliciviruses", "DISEASE", 294, 307], ["astroviruses", "DISEASE", 309, 321], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["BPoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["Virus", "ORGANISM", 120, 125], ["ruminants", "ORGANISM", 140, 149], ["caliciviruses", "CANCER", 294, 307], ["antibodies", "PROTEIN", 14, 24], ["BPoV", "PROTEIN", 33, 37], ["Serum free of antibodies", "TEST", 0, 24], ["BPoV", "PROBLEM", 33, 37], ["HI inhibitors", "TREATMENT", 45, 58], ["successful isolation and virus propagation", "TREATMENT", 76, 118], ["Virus infections of ruminants", "PROBLEM", 120, 149], ["Direct EM examination", "TEST", 149, 170], ["diarrhea fluid", "PROBLEM", 174, 188], ["many other small particles", "PROBLEM", 241, 267], ["enteroviruses", "PROBLEM", 279, 292], ["caliciviruses", "PROBLEM", 294, 307], ["astroviruses", "PROBLEM", 309, 321], ["togavirus cores", "TREATMENT", 323, 338], ["small bacteriophages", "PROBLEM", 348, 368], ["infections", "OBSERVATION", 126, 136], ["ruminants", "OBSERVATION_MODIFIER", 140, 149], ["small", "OBSERVATION_MODIFIER", 252, 257], ["particles", "OBSERVATION", 258, 267], ["enteroviruses", "OBSERVATION", 279, 292], ["small", "OBSERVATION_MODIFIER", 348, 353], ["bacteriophages", "OBSERVATION", 354, 368]]], ["Recourse to the use of immune EM would be more specific, and enzyme immune assays should be developed.Virus infections of ruminantsA unique variety of nucleopathic changes was detected in cultured BFS cells infected with BPoV (Leary and Storz, 1980) .", [["BFS cells", "ANATOMY", 197, 206], ["Virus infections", "DISEASE", 102, 118], ["Virus", "ORGANISM", 102, 107], ["BFS cells", "CELL", 197, 206], ["cultured BFS cells", "CELL_LINE", 188, 206], ["immune EM", "TREATMENT", 23, 32], ["enzyme immune assays", "TEST", 61, 81], ["Virus infections", "PROBLEM", 102, 118], ["nucleopathic changes", "PROBLEM", 151, 171], ["infections", "OBSERVATION", 108, 118], ["variety", "OBSERVATION_MODIFIER", 140, 147]]], ["They consisted of Cowdry type A as well as multifocal inclusions (see .", [["multifocal inclusions", "PROBLEM", 43, 64], ["multifocal", "OBSERVATION_MODIFIER", 43, 53], ["inclusions", "OBSERVATION", 54, 64]]], ["Formation of distinct halos occurred in both instances.", [["distinct halos", "PROBLEM", 13, 27], ["distinct", "OBSERVATION_MODIFIER", 13, 21], ["halos", "OBSERVATION", 22, 27], ["both instances", "OBSERVATION", 40, 54]]], ["The appearance of these nucleopathic changes in infected host tissues has to be analyzed further to establish its diagnostic value.Virus infections of ruminantsA most efficient method to detect antibodies against BPoV is the HI test employing guinea pig or human type \u039f red blood cells (Abinanti and Warfield, 1961; Storz et al., 1972) .", [["tissues", "ANATOMY", 62, 69], ["red blood cells", "ANATOMY", 270, 285], ["Virus infections", "DISEASE", 131, 147], ["host tissues", "TISSUE", 57, 69], ["Virus", "ORGANISM", 131, 136], ["BPoV", "GENE_OR_GENE_PRODUCT", 213, 217], ["guinea pig", "ORGANISM", 243, 253], ["human", "ORGANISM", 257, 262], ["red blood cells", "CELL", 270, 285], ["Abinanti", "CELL", 287, 295], ["antibodies", "PROTEIN", 194, 204], ["BPoV", "PROTEIN", 213, 217], ["human type \u039f red blood cells", "CELL_TYPE", 257, 285], ["guinea pig", "SPECIES", 243, 253], ["human", "SPECIES", 257, 262], ["pig", "SPECIES", 250, 253], ["human", "SPECIES", 257, 262], ["these nucleopathic changes in infected host tissues", "PROBLEM", 18, 69], ["Virus infections of ruminants", "PROBLEM", 131, 160], ["antibodies", "TEST", 194, 204], ["the HI test", "TEST", 221, 232], ["red blood cells", "TEST", 270, 285], ["nucleopathic", "OBSERVATION", 24, 36], ["infected host tissues", "OBSERVATION", 48, 69]]], ["In some serum samples, nonspecific inhibitors of BPoV hemagglutination may be present and must be removed before testing for BPoV antibodies.", [["serum samples", "ANATOMY", 8, 21], ["serum samples", "ORGANISM_SUBSTANCE", 8, 21], ["BPoV", "GENE_OR_GENE_PRODUCT", 49, 53], ["BPoV antibodies", "GENE_OR_GENE_PRODUCT", 125, 140], ["BPoV antibodies", "PROTEIN", 125, 140], ["BPoV", "SPECIES", 125, 129], ["some serum samples", "TEST", 3, 21], ["nonspecific inhibitors of BPoV hemagglutination", "PROBLEM", 23, 70], ["testing", "TEST", 113, 120], ["BPoV antibodies", "PROBLEM", 125, 140]]], ["The HI antibody titers corresponded well with results obtained through infectivity neutralization tests and other methods for the detection of antibodies (Hayder et al., 1983) .Virus infections of ruminantsRecently, a competitive ELISA was introduced for detection and titration of antibodies to BPoV.", [["Virus infections", "DISEASE", 177, 193], ["HI antibody", "GENE_OR_GENE_PRODUCT", 4, 15], ["Virus", "ORGANISM", 177, 182], ["ruminants", "ORGANISM", 197, 206], ["BPoV", "GENE_OR_GENE_PRODUCT", 296, 300], ["HI antibody", "PROTEIN", 4, 15], ["antibodies", "PROTEIN", 143, 153], ["antibodies", "PROTEIN", 282, 292], ["BPoV", "PROTEIN", 296, 300], ["The HI antibody titers", "TEST", 0, 22], ["infectivity neutralization tests", "TEST", 71, 103], ["the detection", "TEST", 126, 139], ["antibodies", "PROBLEM", 143, 153], ["Virus infections of ruminants", "PROBLEM", 177, 206], ["a competitive ELISA", "PROBLEM", 216, 235], ["titration of antibodies", "TREATMENT", 269, 292], ["infections", "OBSERVATION", 183, 193], ["ruminants", "OBSERVATION_MODIFIER", 197, 206]]], ["The antibodies, if present in the cattle sera, are competing in this assay with two monoclonal antibodies to the parvoviral hemagglutinin.", [["sera", "ANATOMY", 41, 45], ["cattle", "ORGANISM", 34, 40], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["parvoviral hemagglutinin", "ORGANISM", 113, 137], ["antibodies", "PROTEIN", 4, 14], ["monoclonal antibodies", "PROTEIN", 84, 105], ["parvoviral hemagglutinin", "PROTEIN", 113, 137], ["cattle", "SPECIES", 34, 40], ["cattle", "SPECIES", 34, 40], ["The antibodies", "TEST", 0, 14], ["this assay", "TEST", 64, 74], ["two monoclonal antibodies", "TREATMENT", 80, 105], ["the parvoviral hemagglutinin", "TREATMENT", 109, 137]]], ["The antibody titers determined in ELISA correlated with the titers in VN tests (N. Juntti, personal communication, 1987) .PROPHYLAXIS AND CONTROLA high percentage of cattle in the USA and other parts of the world has antibodies resulting from natural infections (Storz and Leary, 1979) .", [["infections", "DISEASE", 251, 261], ["cattle", "ORGANISM", 166, 172], ["antibodies", "PROTEIN", 217, 227], ["cattle", "SPECIES", 166, 172], ["cattle", "SPECIES", 166, 172], ["The antibody titers", "TEST", 0, 19], ["ELISA", "TEST", 34, 39], ["the titers", "TEST", 56, 66], ["VN tests", "TEST", 70, 78], ["PROPHYLAXIS", "TREATMENT", 122, 133], ["CONTROLA high percentage of cattle", "TREATMENT", 138, 172], ["antibodies", "PROBLEM", 217, 227], ["natural infections", "PROBLEM", 243, 261], ["natural", "OBSERVATION_MODIFIER", 243, 250], ["infections", "OBSERVATION", 251, 261]]], ["However, there are herds of seronegative cattle and thus without experience with this infection.", [["infection", "DISEASE", 86, 95], ["cattle", "ORGANISM", 41, 47], ["cattle", "SPECIES", 41, 47], ["cattle", "SPECIES", 41, 47], ["seronegative cattle", "PROBLEM", 28, 47], ["this infection", "PROBLEM", 81, 95], ["seronegative cattle", "OBSERVATION", 28, 47], ["infection", "OBSERVATION", 86, 95]]], ["Attempts to vaccinate cattle have not been described.", [["cattle", "ORGANISM", 22, 28], ["cattle", "SPECIES", 22, 28], ["cattle", "SPECIES", 22, 28]]], ["As we learn more about the infection and the pathogenic potential of BPoV, efforts to develop vaccines may be warranted, particularly for the prevention of reproductive disease problems.", [["infection", "DISEASE", 27, 36], ["the infection", "PROBLEM", 23, 36], ["BPoV", "PROBLEM", 69, 73], ["vaccines", "TREATMENT", 94, 102], ["reproductive disease problems", "PROBLEM", 156, 185], ["infection", "OBSERVATION", 27, 36]]], ["This approach would be of benefit in reducing parvovirus-induced disease during the neonatal period of calves.", [["parvovirus-induced disease", "DISEASE", 46, 72], ["parvovirus", "ORGANISM", 46, 56], ["calves", "ORGANISM", 103, 109], ["calves", "SPECIES", 103, 109], ["This approach", "TREATMENT", 0, 13], ["reducing parvovirus", "PROBLEM", 37, 56], ["induced disease", "PROBLEM", 57, 72], ["parvovirus", "OBSERVATION", 46, 56], ["disease", "OBSERVATION", 65, 72], ["calves", "ANATOMY", 103, 109]]]], "bef704b71f8e18fe6ea1632273c801db1226eb8b": [["The specimen remained in the Harvard Museum where it was seen by Professor Ralph Blanchard, Member of the Academy of Medicine and Past President of the French Society of the History of Medicine, in 1907.", [["specimen", "ANATOMY", 4, 12]]], ["He was cordially received by Dr. William F. Whitney, who was then the Curator of the Warren Anatomical Museum.", [["He", "ORGANISM", 0, 2]]], ["Blanchard reported that the wax model was exhibited under glass and that it was in good condition except for the fingers which had been damaged in a fall.", [["fingers", "ANATOMY", 113, 120], ["fingers", "ORGANISM_SUBDIVISION", 113, 120], ["the wax model", "PROBLEM", 24, 37], ["fingers", "ANATOMY", 113, 120]]]], "0d354b208fdfa2806bf33fd03e940e057b339de5": [[": Amodiaquine reduces cellular sensitivity to LF+PA83 and LF+PA63.", [["cellular", "ANATOMY", 22, 30], ["Amodiaquine", "CHEMICAL", 2, 13], ["Amodiaquine", "CHEMICAL", 2, 13], ["Amodiaquine", "SIMPLE_CHEMICAL", 2, 13], ["cellular", "CELL", 22, 30], ["PA83", "SIMPLE_CHEMICAL", 49, 53], ["LF+PA63", "GENE_OR_GENE_PRODUCT", 58, 65], ["LF", "PROTEIN", 46, 48], ["LF", "PROTEIN", 58, 60], ["Amodiaquine", "TREATMENT", 2, 13], ["cellular sensitivity", "TEST", 22, 42], ["LF", "TEST", 46, 48], ["PA83", "TEST", 49, 53], ["LF", "TEST", 58, 60], ["PA63", "TEST", 61, 65]]], ["RAW264.7 cells were pretreated either with DMSO or with AQ for 1 hour, and then treated with 500ng/ml of LF in the presence of 1.5 \u00b5g/ml of either of PA83 or PA63 for 6 hours a b Figure 3 : The effect of Amodiaquine, Chloroquine, and their metabolites on the activity of host cathepsin B. FRET assay showing the activity of cathepsin B without drugs, or with addition of AQ, DEAQ, CQ, or DECQ at 4, 8, 16, 33, or 66 \u00b5M.", [["RAW264.7 cells", "ANATOMY", 0, 14], ["DMSO", "CHEMICAL", 43, 47], ["AQ", "CHEMICAL", 56, 58], ["PA83", "CHEMICAL", 150, 154], ["PA63", "CHEMICAL", 158, 162], ["Amodiaquine", "CHEMICAL", 204, 215], ["Chloroquine", "CHEMICAL", 217, 228], ["AQ", "CHEMICAL", 371, 373], ["DEAQ", "CHEMICAL", 375, 379], ["CQ", "CHEMICAL", 381, 383], ["DECQ", "CHEMICAL", 388, 392], ["DMSO", "CHEMICAL", 43, 47], ["PA83", "CHEMICAL", 150, 154], ["PA63", "CHEMICAL", 158, 162], ["Amodiaquine", "CHEMICAL", 204, 215], ["Chloroquine", "CHEMICAL", 217, 228], ["DEAQ", "CHEMICAL", 375, 379], ["CQ", "CHEMICAL", 381, 383], ["DECQ", "CHEMICAL", 388, 392], ["RAW264.7 cells", "CELL", 0, 14], ["DMSO", "SIMPLE_CHEMICAL", 43, 47], ["AQ", "SIMPLE_CHEMICAL", 56, 58], ["PA83", "SIMPLE_CHEMICAL", 150, 154], ["PA63", "SIMPLE_CHEMICAL", 158, 162], ["Amodiaquine", "SIMPLE_CHEMICAL", 204, 215], ["Chloroquine", "SIMPLE_CHEMICAL", 217, 228], ["cathepsin B.", "GENE_OR_GENE_PRODUCT", 276, 288], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 324, 335], ["AQ", "SIMPLE_CHEMICAL", 371, 373], ["DEAQ", "SIMPLE_CHEMICAL", 375, 379], ["CQ", "SIMPLE_CHEMICAL", 381, 383], ["DECQ", "SIMPLE_CHEMICAL", 388, 392], ["RAW264.7 cells", "CELL_LINE", 0, 14], ["cathepsin B", "PROTEIN", 324, 335], ["DMSO", "TREATMENT", 43, 47], ["PA83", "TREATMENT", 150, 154], ["PA63", "TREATMENT", 158, 162], ["Amodiaquine", "TREATMENT", 204, 215], ["Chloroquine", "TREATMENT", 217, 228], ["host cathepsin B. FRET assay", "TEST", 271, 299], ["cathepsin B", "TREATMENT", 324, 335], ["drugs", "TREATMENT", 344, 349]]], ["RAW264.7 cells were treated with drugs for 1 hour prior to lysis and determination of cathepsin B activity (a), or untreated RAW264 cells were lysed, the lysate was treated with drugs, and then the activity of cathepsin B was assessed (b).Supplemental Materials and Methods:Screening Assays for Ebola virus (EBOV, Strain Kikwit).High Content Imaging virus infection assayCell Culture and infection HeLa cells (ATCC) were cultured for 3 days in T175 or T225 (Corning) flasks in culture media containing Minimum Essential Medium (MEM, Corning Cellgro) supplemented with 10% Fetal Bovine Serum (Hyclone), 1% L-Glutammine (Hyclone), 10 mM Hepes 7.0-7.6 (Sigma), 1% non-essential amino acids (Sigma).", [["RAW264.7 cells", "ANATOMY", 0, 14], ["RAW264 cells", "ANATOMY", 125, 137], ["lysate", "ANATOMY", 154, 160], ["HeLa cells", "ANATOMY", 398, 408], ["ATCC", "ANATOMY", 410, 414], ["T175", "ANATOMY", 444, 448], ["Ebola virus", "DISEASE", 295, 306], ["infection", "DISEASE", 356, 365], ["infection", "DISEASE", 388, 397], ["L-Glutammine", "CHEMICAL", 605, 617], ["amino acids", "CHEMICAL", 675, 686], ["L-Glutammine", "CHEMICAL", 605, 617], ["amino acids", "CHEMICAL", 675, 686], ["RAW264.7 cells", "CELL", 0, 14], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 86, 97], ["RAW264 cells", "CELL", 125, 137], ["lysate", "ORGANISM_SUBSTANCE", 154, 160], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 210, 221], ["Ebola virus", "ORGANISM", 295, 306], ["EBOV", "ORGANISM", 308, 312], ["HeLa cells", "CELL", 398, 408], ["ATCC", "CELL", 410, 414], ["Bovine", "ORGANISM", 578, 584], ["Serum", "ORGANISM_SUBSTANCE", 585, 590], ["Hyclone", "ORGANISM_SUBSTANCE", 592, 599], ["L-Glutammine", "SIMPLE_CHEMICAL", 605, 617], ["Hyclone", "ORGANISM_SUBSTANCE", 619, 626], ["amino acids", "AMINO_ACID", 675, 686], ["RAW264.7 cells", "CELL_LINE", 0, 14], ["cathepsin B", "PROTEIN", 86, 97], ["RAW264 cells", "CELL_LINE", 125, 137], ["cathepsin B", "PROTEIN", 210, 221], ["infection HeLa cells", "CELL_LINE", 388, 408], ["ATCC", "CELL_LINE", 410, 414], ["Ebola virus", "SPECIES", 295, 306], ["Bovine", "SPECIES", 578, 584], ["Ebola virus", "SPECIES", 295, 306], ["EBOV", "SPECIES", 308, 312], ["ATCC", "SPECIES", 410, 414], ["Bovine", "SPECIES", 578, 584], ["drugs", "TREATMENT", 33, 38], ["lysis", "TREATMENT", 59, 64], ["cathepsin B activity", "TREATMENT", 86, 106], ["untreated RAW264 cells", "PROBLEM", 115, 137], ["the lysate", "TREATMENT", 150, 160], ["drugs", "TREATMENT", 178, 183], ["cathepsin B", "TREATMENT", 210, 221], ["Supplemental Materials", "TREATMENT", 239, 261], ["Screening Assays", "TEST", 274, 290], ["Ebola virus", "PROBLEM", 295, 306], ["High Content Imaging virus infection", "PROBLEM", 329, 365], ["assayCell Culture", "TEST", 366, 383], ["infection HeLa cells", "PROBLEM", 388, 408], ["flasks in culture media", "TREATMENT", 467, 490], ["Minimum Essential Medium (MEM, Corning Cellgro)", "TREATMENT", 502, 549], ["Fetal Bovine Serum", "TEST", 572, 590], ["Hyclone", "TEST", 592, 599], ["mM Hepes", "TEST", 632, 640], ["virus infection", "OBSERVATION", 350, 365], ["amino acids", "OBSERVATION", 675, 686]]], ["Cells were lifted using Trypsin-EDTA (Sigma, T3974) and 2,000 cells/well were plated in 35\u00b5l of culture media into imaging 384 well assay plates (Aurora 384, IQ-EB, 384 IQ-EB/NB, 200mclear, #1052-11130) and incubated for about 20h before compound treatment.Compound treatmentTreatment of the cells with test and control compounds was done 2 h prior infection.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 292, 297], ["Trypsin-EDTA", "CHEMICAL", 24, 36], ["infection", "DISEASE", 349, 358], ["EDTA", "CHEMICAL", 32, 36], ["Cells", "CELL", 0, 5], ["Trypsin-EDTA", "SIMPLE_CHEMICAL", 24, 36], ["Sigma", "SIMPLE_CHEMICAL", 38, 43], ["cells", "CELL", 62, 67], ["cells", "CELL", 292, 297], ["Trypsin", "TEST", 24, 31], ["culture media", "TEST", 96, 109], ["imaging", "TEST", 115, 122], ["assay plates", "TEST", 132, 144], ["Aurora", "TEST", 146, 152], ["IQ", "TEST", 158, 160], ["IQ", "TEST", 169, 171], ["compound treatment", "TREATMENT", 238, 256], ["Compound treatment", "TREATMENT", 257, 275], ["test", "TEST", 303, 307], ["control compounds", "TREATMENT", 312, 329], ["prior infection", "PROBLEM", 343, 358], ["infection", "OBSERVATION", 349, 358]]], ["EC50 determination for test compound done with 2 fold step at least for 10 doses starting from highest concentration of 100uM (with stock concentration of 10mM) using HP D-300 digital dispenser.", [["HP D-300", "CHEMICAL", 167, 175], ["EC50 determination", "TEST", 0, 18], ["test compound", "TEST", 23, 36]]], ["Concentration of DMSO in all wells was normalized to 1%.", [["DMSO", "CHEMICAL", 17, 21], ["DMSO", "CHEMICAL", 17, 21], ["DMSO", "SIMPLE_CHEMICAL", 17, 21], ["Concentration of DMSO in all wells", "PROBLEM", 0, 34], ["DMSO", "OBSERVATION", 17, 21]]], ["Cells were pre-treated with serially diluted compounds for 2 hours before infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 74, 83], ["Cells", "CELL", 0, 5], ["serially diluted compounds", "TREATMENT", 28, 54], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["Each dose were repeated 4 times on one plate (n=4).InfectionInfection was done using Ebola virus (Kikwit) MOI = 0.5 (calculated for 4,000 cells/well, assuming one complete round of replication of HeLa cells at 15\u00b12 hrs after cell seeding) and 10ul of virus dilution was dispensed in each well except column 2, representing \"no infection control\".", [["cells", "ANATOMY", 138, 143], ["HeLa cells", "ANATOMY", 196, 206], ["cell", "ANATOMY", 225, 229], ["InfectionInfection", "DISEASE", 51, 69], ["infection", "DISEASE", 327, 336], ["Ebola virus", "ORGANISM", 85, 96], ["cells", "CELL", 138, 143], ["HeLa cells", "CELL", 196, 206], ["cell", "CELL", 225, 229], ["HeLa cells", "CELL_LINE", 196, 206], ["Ebola virus", "SPECIES", 85, 96], ["Ebola virus", "SPECIES", 85, 96], ["InfectionInfection", "PROBLEM", 51, 69], ["Ebola virus", "PROBLEM", 85, 96], ["MOI", "TEST", 106, 109], ["replication of HeLa cells", "TREATMENT", 181, 206], ["cell seeding", "TREATMENT", 225, 237], ["virus dilution", "TREATMENT", 251, 265], ["infection control\"", "PROBLEM", 327, 345], ["no", "UNCERTAINTY", 324, 326], ["infection", "OBSERVATION", 327, 336]]], ["Cells were incubated with the virus for 24 or 48h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the virus", "TREATMENT", 26, 35]]], ["Infection was terminated by fixing samples in formalin solution.Immuno-staining assayImmune-staining was used to visualize infected cells.", [["samples", "ANATOMY", 35, 42], ["cells", "ANATOMY", 132, 137], ["formalin", "CHEMICAL", 46, 54], ["formalin", "CHEMICAL", 46, 54], ["formalin", "SIMPLE_CHEMICAL", 46, 54], ["cells", "CELL", 132, 137], ["infected cells", "CELL_TYPE", 123, 137], ["Infection", "PROBLEM", 0, 9], ["fixing samples in formalin solution", "TREATMENT", 28, 63], ["Immuno-staining assayImmune", "TEST", 64, 91], ["infected cells", "PROBLEM", 123, 137], ["infected cells", "OBSERVATION", 123, 137]]], ["Cells were treated with anti-GP specific monoclonal antibody (6D8) (1 to 1000 dilution) followed by anti-mouse IgG conjugated with Dylight488 (Thermo) (1 to 1000 dilution) in blocking buffer containing 3% BSA in PBS.", [["Cells", "ANATOMY", 0, 5], ["Dylight488", "CHEMICAL", 131, 141], ["BSA", "CHEMICAL", 205, 208], ["Dylight488", "CHEMICAL", 131, 141], ["Cells", "CELL", 0, 5], ["anti-GP", "SIMPLE_CHEMICAL", 24, 31], ["Dylight488", "SIMPLE_CHEMICAL", 131, 141], ["BSA", "SIMPLE_CHEMICAL", 205, 208], ["anti-GP specific monoclonal antibody", "PROTEIN", 24, 60], ["6D8", "PROTEIN", 62, 65], ["anti-mouse IgG", "PROTEIN", 100, 114], ["anti-mouse", "SPECIES", 100, 110], ["anti-mouse", "SPECIES", 100, 110], ["anti-GP specific monoclonal antibody", "TREATMENT", 24, 60], ["blocking buffer", "TREATMENT", 175, 190], ["3% BSA in PBS", "TREATMENT", 202, 215]]], ["Nuclei were stained with Draq5 (Biostatus) diluted in PBS buffer.Image and Data analysis.Images were acquired on the Opera imaging instrument (Perkin Elmer) using 10x Air objective and four images/well were acquired.", [["Nuclei", "ANATOMY", 0, 6], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["Draq5", "SIMPLE_CHEMICAL", 25, 30], ["Draq5", "PROTEIN", 25, 30], ["Draq5 (Biostatus)", "TREATMENT", 25, 42], ["PBS buffer", "TREATMENT", 54, 64], ["Image and Data analysis", "TEST", 65, 88], ["Images", "TEST", 89, 95], ["the Opera imaging instrument", "TEST", 113, 141]]], ["Signal from anti-virus staining was detected at 488nm emission wavelength and Nuclei at 640nm.", [["Signal from anti-virus staining", "TEST", 0, 31]]], ["Image analysis was performed using PE Acapella algorithms.", [["Image analysis", "TEST", 0, 14], ["PE Acapella algorithms", "TEST", 35, 57], ["PE", "OBSERVATION", 35, 37]]], ["Several well-based output parameters were measured including: Number of Objects (Nuclei) and Positive Virus Number of Objects (Ave of Intensity for virus specific signal).", [["based output parameters", "TEST", 13, 36], ["Positive Virus", "PROBLEM", 93, 107], ["Positive Virus", "OBSERVATION", 93, 107]]], ["The % of Infected cells were calculated by Acapella directly asImage and Data analysis.% Viability.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["Infected cells", "CELL_TYPE", 9, 23], ["Infected cells", "PROBLEM", 9, 23], ["Data analysis", "TEST", 73, 86], ["Infected cells", "OBSERVATION", 9, 23]]], ["Number of objects represented the amount of cells in each treated well and was also used as indication of the cyto-toxic or cyto-static effect.", [["cells", "ANATOMY", 44, 49], ["cells", "CELL", 44, 49], ["the cyto-toxic or cyto-static effect", "PROBLEM", 106, 142], ["objects", "OBSERVATION", 10, 17], ["amount", "OBSERVATION_MODIFIER", 34, 40]]], ["The number of objects was converted by GeneData Condeseo to % Viability for with a compound dose response.Image and Data analysis.%!\"#%& !\"#%& !\"# !\"#$%& (!\") * 100% Dose response curve fitting analysis Analysis of dose response curve for % Inhibition and % Viability was used to determine EC 50 and CC 50 , and was applying GeneData Condoseo software with Levenberg-Marquardt algorithm (LMA) for curve fitting strategy.", [["EC", "ANATOMY", 290, 292], ["EC", "CELL", 290, 292], ["a compound dose response", "TREATMENT", 81, 105], ["Image", "TEST", 106, 111], ["Data analysis", "TEST", 116, 129], ["fitting analysis", "TEST", 186, 202], ["dose response curve", "TEST", 215, 234], ["% Inhibition", "TREATMENT", 239, 251], ["EC", "TEST", 290, 292], ["Levenberg-Marquardt algorithm (LMA", "TREATMENT", 357, 391], ["curve fitting strategy", "TREATMENT", 397, 419]]], ["The Curve-fitting applied validity criteria, such aschi 2 , SE logEC 50 , minimal number of valid data points, to indicate if curve fitting converging was successful and indicated in table with results.", [["SE", "DISEASE", 60, 62], ["validity criteria", "TEST", 26, 43], ["SE logEC", "TEST", 60, 68]]], ["R 2 value quantifies goodness of fit.", [["R 2", "GENE_OR_GENE_PRODUCT", 0, 3], ["fit", "OBSERVATION", 33, 36]]], ["Fitting strategy was considered acceptable if it gave conversion with R 2 >0.8.Screening Assays for Venezuelan equine encephalitis virus (VEEV, Strain TC-83).Primary cytopathic effect (CPE) reduction assay.", [["Venezuelan equine encephalitis", "DISEASE", 100, 130], ["Venezuelan equine encephalitis virus", "ORGANISM", 100, 136], ["VEEV", "ORGANISM", 138, 142], ["Venezuelan equine encephalitis virus", "SPECIES", 100, 136], ["Venezuelan equine encephalitis virus", "SPECIES", 100, 136], ["VEEV", "SPECIES", 138, 142], ["Screening Assays", "TEST", 79, 95], ["Venezuelan equine encephalitis virus", "PROBLEM", 100, 136], ["Strain TC", "TEST", 144, 153], ["Primary cytopathic effect (CPE) reduction assay", "PROBLEM", 158, 205], ["cytopathic effect", "OBSERVATION", 166, 183]]], ["Four-concentration CPE inhibition assays are performed.", [["Four-concentration CPE inhibition assays", "TEST", 0, 40]]], ["Confluent or near-confluent cell culture monolayers in 96-well disposable microplates are prepared.", [["Confluent", "ANATOMY", 0, 9], ["cell culture monolayers", "ANATOMY", 28, 51], ["Confluent", "CELL", 0, 9], ["cell culture monolayers", "CELL", 28, 51], ["near-confluent cell culture monolayers", "CELL_LINE", 13, 51], ["Confluent or near-confluent cell culture monolayers", "PROBLEM", 0, 51], ["well disposable microplates", "TREATMENT", 58, 85], ["confluent", "OBSERVATION_MODIFIER", 18, 27], ["cell culture monolayers", "OBSERVATION", 28, 51]]], ["Cells are maintained in MEM or DMEM supplemented with FBS as required for each cell line.", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 54, 57], ["cell line", "ANATOMY", 79, 88], ["Cells", "CELL", 0, 5], ["MEM", "ORGANISM_SUBSTANCE", 24, 27], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["cell line", "CELL", 79, 88], ["FBS", "TREATMENT", 54, 57], ["each cell line", "TREATMENT", 74, 88], ["cell line", "OBSERVATION", 79, 88]]], ["For antiviral assays the same medium is used but with FBS reduced to 2% or less and supplemented with 50 \u00b5g/ml gentamicin.", [["FBS", "ANATOMY", 54, 57], ["gentamicin", "CHEMICAL", 111, 121], ["gentamicin", "CHEMICAL", 111, 121], ["FBS", "ORGANISM_SUBSTANCE", 54, 57], ["gentamicin", "SIMPLE_CHEMICAL", 111, 121], ["antiviral assays", "TEST", 4, 20], ["FBS", "TEST", 54, 57], ["gentamicin", "TREATMENT", 111, 121]]], ["The test compound is prepared at four log 10 final concentrations, usually 0.1, 1.0, 10, and 100 \u00b5g/ml or \u00b5M.", [["The test compound", "TEST", 0, 17]]], ["The virus control and cell control wells are on every microplate.", [["cell", "ANATOMY", 22, 26], ["cell", "CELL", 22, 26], ["The virus control", "TREATMENT", 0, 17], ["cell control wells", "TREATMENT", 22, 40], ["virus", "OBSERVATION", 4, 9]]], ["In parallel, a known active drug is tested as a positive control drug using the same method as is applied for test compounds.", [["a positive control drug", "TREATMENT", 46, 69], ["the same method", "TREATMENT", 76, 91], ["test compounds", "TEST", 110, 124], ["active", "OBSERVATION_MODIFIER", 21, 27], ["drug", "OBSERVATION", 28, 32]]], ["The positive control is tested with each test run.", [["each test run", "TEST", 36, 49], ["positive control", "OBSERVATION", 4, 20]]], ["The assay is set up by first removing growth media from the 96-well plates of cells.", [["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["The assay", "TEST", 0, 9]]], ["Then the test compound is applied in 0.1 ml volume to wells at 2X concentration.", [["the test compound", "TREATMENT", 5, 22]]], ["Virus, normally at <100 50% cell culture infectious doses (CCID50) in 0.1 ml volume, is placed in those wells designated for virus infection.", [["cell", "ANATOMY", 28, 32], ["infection", "DISEASE", 131, 140], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 28, 32], ["Virus", "PROBLEM", 0, 5], ["CCID50)", "TREATMENT", 59, 66], ["virus infection", "PROBLEM", 125, 140], ["infection", "OBSERVATION", 131, 140]]], ["Medium devoid of virus is placed in toxicity control wells and cell control wells.", [["cell", "ANATOMY", 63, 67], ["toxicity", "DISEASE", 36, 44], ["cell", "CELL", 63, 67], ["Medium devoid of virus", "PROBLEM", 0, 22], ["toxicity control wells", "TREATMENT", 36, 58], ["cell control wells", "TREATMENT", 63, 81], ["virus", "OBSERVATION", 17, 22]]], ["Virus control wells are treated similarly with virus.", [["Virus", "ORGANISM", 0, 5], ["Virus control wells", "TREATMENT", 0, 19], ["virus", "PROBLEM", 47, 52]]], ["Plates are incubated at 37 o C with 5% CO 2 until maximum CPE is observed in virus control wells.", [["CO 2", "CHEMICAL", 39, 43], ["5% CO", "TREATMENT", 36, 41], ["maximum CPE", "PROBLEM", 50, 61]]], ["The plates are then stained with 0.011% neutral red for approximately two hours at 37 o C in a 5% CO 2 incubator.", [["CO 2", "CHEMICAL", 98, 102], ["a 5% CO 2 incubator", "TREATMENT", 93, 112], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The neutral red medium is removed by complete aspiration, and the cells may be rinsed 1X with phosphate buffered solution (PBS) to remove residual dye.", [["cells", "ANATOMY", 66, 71], ["phosphate", "CHEMICAL", 94, 103], ["phosphate", "CHEMICAL", 94, 103], ["cells", "CELL", 66, 71], ["phosphate buffered solution", "SIMPLE_CHEMICAL", 94, 121], ["The neutral red medium", "TREATMENT", 0, 22], ["complete aspiration", "PROBLEM", 37, 56], ["the cells", "TREATMENT", 62, 71], ["phosphate buffered solution (PBS", "TREATMENT", 94, 126], ["residual dye", "PROBLEM", 138, 150], ["neutral", "OBSERVATION_MODIFIER", 4, 11], ["red medium", "OBSERVATION_MODIFIER", 12, 22], ["aspiration", "OBSERVATION", 46, 56]]], ["The PBS is completely removed and the incorporated neutral red is eluted with 50% Sorensen's citrate buffer/50% ethanol (pH 4.2) for at least 30 minutes.", [["Sorensen's citrate", "CHEMICAL", 82, 100], ["ethanol", "CHEMICAL", 112, 119], ["citrate", "CHEMICAL", 93, 100], ["ethanol", "CHEMICAL", 112, 119], ["Sorensen", "SIMPLE_CHEMICAL", 82, 90], ["citrate", "SIMPLE_CHEMICAL", 93, 100], ["ethanol", "SIMPLE_CHEMICAL", 112, 119], ["The PBS", "TREATMENT", 0, 7], ["50% Sorensen's citrate buffer", "TREATMENT", 78, 107], ["pH", "TEST", 121, 123], ["completely", "OBSERVATION_MODIFIER", 11, 21], ["removed", "OBSERVATION", 22, 29]]], ["Neutral red dye penetrates into living cells, thus, the more intense the red color, the larger the number of viable cells present in the wells.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 116, 121], ["Neutral red dye", "SIMPLE_CHEMICAL", 0, 15], ["cells", "CELL", 39, 44], ["cells", "CELL", 116, 121], ["living cells", "CELL_TYPE", 32, 44], ["Neutral red dye penetrates into living cells", "PROBLEM", 0, 44], ["red color", "TEST", 73, 82], ["dye penetrates", "OBSERVATION", 12, 26], ["living cells", "OBSERVATION", 32, 44], ["intense", "OBSERVATION_MODIFIER", 61, 68], ["red color", "OBSERVATION", 73, 82], ["larger", "OBSERVATION_MODIFIER", 88, 94], ["number", "OBSERVATION_MODIFIER", 99, 105], ["viable cells", "OBSERVATION", 109, 121]]], ["The dye content in each well is quantified using a 96-well spectrophotometer at 540 nm wavelength.", [["dye", "SIMPLE_CHEMICAL", 4, 7], ["dye content", "OBSERVATION", 4, 15]]], ["The dye content in each set of wells is converted to a percentage of dye present in untreated control wells using a Microsoft Excel computer-based spreadsheet.", [["dye", "SIMPLE_CHEMICAL", 4, 7], ["The dye content", "PROBLEM", 0, 15], ["a percentage of dye", "TREATMENT", 53, 72], ["dye content", "OBSERVATION", 4, 15]]], ["The 50% effective (EC 50 , virus-inhibitory) concentrations and 50% cytotoxic (CC 50 , cellinhibitory) concentrations are then calculated by linear regression analysis.", [["CC", "CHEMICAL", 79, 81], ["virus-inhibitory) concentrations", "TREATMENT", 27, 59], ["50% cytotoxic (CC 50 , cellinhibitory) concentrations", "TREATMENT", 64, 117], ["linear regression analysis", "TEST", 141, 167]]], ["The quotient of CC 50 divided by EC 50 gives the selectivity index (SI) value.Screening Assays for Herpes Simplex Virus 1 (HSV-1, Strain E-377) and Human Cytomegalovirus (CMV, Strain AD169).Human foreskin fibroblast (HFF) cells were prepared from human foreskin tissue.", [["foreskin fibroblast (HFF) cells", "ANATOMY", 196, 227], ["foreskin tissue", "ANATOMY", 253, 268], ["CC", "CHEMICAL", 16, 18], ["Herpes Simplex Virus", "DISEASE", 99, 119], ["EC", "CELL", 33, 35], ["Herpes Simplex Virus 1", "ORGANISM", 99, 121], ["HSV-1", "ORGANISM", 123, 128], ["Strain E-377", "ORGANISM", 130, 142], ["Human", "ORGANISM", 148, 153], ["Cytomegalovirus", "ORGANISM", 154, 169], ["CMV", "ORGANISM", 171, 174], ["Human", "ORGANISM", 190, 195], ["foreskin fibroblast", "CELL", 196, 215], ["HFF) cells", "CELL", 217, 227], ["human", "ORGANISM", 247, 252], ["foreskin tissue", "TISSUE", 253, 268], ["Human foreskin fibroblast (HFF) cells", "CELL_LINE", 190, 227], ["Herpes Simplex Virus 1", "SPECIES", 99, 121], ["HSV-1", "SPECIES", 123, 128], ["Human", "SPECIES", 148, 153], ["Human", "SPECIES", 190, 195], ["human", "SPECIES", 247, 252], ["Herpes Simplex Virus 1", "SPECIES", 99, 121], ["HSV-1", "SPECIES", 123, 128], ["Human Cytomegalovirus", "SPECIES", 148, 169], ["CMV", "SPECIES", 171, 174], ["Human", "SPECIES", 190, 195], ["human", "SPECIES", 247, 252], ["The quotient of CC", "TREATMENT", 0, 18], ["Screening Assays", "TEST", 78, 94], ["Herpes Simplex Virus", "TEST", 99, 119], ["HSV", "TEST", 123, 126], ["Strain E", "TEST", 130, 138], ["Human Cytomegalovirus (CMV", "PROBLEM", 148, 174], ["Human foreskin fibroblast (HFF) cells", "TREATMENT", 190, 227], ["Cytomegalovirus", "OBSERVATION", 154, 169], ["foreskin fibroblast", "OBSERVATION", 196, 215], ["foreskin tissue", "OBSERVATION", 253, 268]]], ["The tissue was incubated at 4\u00b0C for 4 h in Clinical Medium and then placed in phosphate buffered saline (PBS) to remove the red blood cells, and resuspended in trypsin/EDTA solution.", [["tissue", "ANATOMY", 4, 10], ["red blood cells", "ANATOMY", 124, 139], ["phosphate", "CHEMICAL", 78, 87], ["phosphate", "CHEMICAL", 78, 87], ["EDTA", "CHEMICAL", 168, 172], ["tissue", "TISSUE", 4, 10], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 78, 103], ["red blood cells", "CELL", 124, 139], ["trypsin", "SIMPLE_CHEMICAL", 160, 167], ["EDTA", "SIMPLE_CHEMICAL", 168, 172], ["red blood cells", "CELL_TYPE", 124, 139], ["trypsin", "PROTEIN", 160, 167], ["Clinical Medium", "TREATMENT", 43, 58], ["phosphate buffered saline (PBS", "TREATMENT", 78, 108], ["the red blood cells", "TEST", 120, 139], ["trypsin/EDTA solution", "TREATMENT", 160, 181], ["tissue", "ANATOMY", 4, 10], ["blood cells", "ANATOMY", 128, 139]]], ["The tissue suspension was incubated at 37\u00b0C and gently agitated to disperse the cells, which were collected by centrifugation.", [["tissue", "ANATOMY", 4, 10], ["cells", "ANATOMY", 80, 85], ["tissue", "TISSUE", 4, 10], ["C", "SIMPLE_CHEMICAL", 42, 43], ["cells", "CELL", 80, 85], ["The tissue suspension", "TREATMENT", 0, 21], ["gently agitated", "PROBLEM", 48, 63], ["tissue", "ANATOMY", 4, 10], ["suspension", "OBSERVATION_MODIFIER", 11, 21]]], ["Cells were resuspended in 4 ml Clinical Medium and placed in a flask and incubated at 37\u00b0C in a humidified CO 2 incubator for 24 h.", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 107, 111], ["Cells", "CELL", 0, 5], ["a humidified CO 2 incubator", "TREATMENT", 94, 121]]], ["The media was then replaced with fresh Clinical Medium and the cell growth was monitored daily until a confluent monolayer has formed.", [["cell", "ANATOMY", 63, 67], ["monolayer", "ANATOMY", 113, 122], ["cell", "CELL", 63, 67], ["monolayer", "CELL", 113, 122], ["fresh Clinical Medium", "TREATMENT", 33, 54], ["the cell growth", "TEST", 59, 74], ["a confluent monolayer", "PROBLEM", 101, 122], ["confluent", "OBSERVATION_MODIFIER", 103, 112], ["monolayer", "OBSERVATION_MODIFIER", 113, 122]]], ["The HFF cells were then expanded through serial passages in standard growth medium of MEM with Earl's salts supplemented with 10% FBS and antibiotics.", [["HFF cells", "ANATOMY", 4, 13], ["HFF cells", "CELL", 4, 13], ["FBS", "ORGANISM_SUBSTANCE", 130, 133], ["HFF cells", "CELL_LINE", 4, 13], ["The HFF cells", "TREATMENT", 0, 13], ["serial passages", "TEST", 41, 56], ["Earl's salts", "TREATMENT", 95, 107], ["10% FBS", "TREATMENT", 126, 133], ["antibiotics", "TREATMENT", 138, 149], ["HFF cells", "OBSERVATION", 4, 13]]], ["The cells were passaged routinely and used for assays at or below passage 10.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9], ["assays", "TEST", 47, 53]]], ["Primary Cytopathic Effect (CPE) Reduction Assay.", [["Primary Cytopathic Effect", "PROBLEM", 0, 25], ["Reduction Assay", "TEST", 32, 47], ["Cytopathic Effect", "OBSERVATION", 8, 25]]], ["Low passage (3-10) HFF cells were trypsinized, counted, and seeded into 96 well tissue culture plates in 0.1 ml of MEM supplemented with 10% FBS.", [["HFF cells", "ANATOMY", 19, 28], ["FBS", "ANATOMY", 141, 144], ["MEM", "CHEMICAL", 115, 118], ["HFF cells", "CELL", 19, 28], ["FBS", "ORGANISM_SUBSTANCE", 141, 144], ["HFF cells", "CELL_LINE", 19, 28], ["Low passage", "PROBLEM", 0, 11], ["10% FBS", "TREATMENT", 137, 144], ["passage", "OBSERVATION_MODIFIER", 4, 11]]], ["The cells were then incubated for 24 h at 37 o C. The media was then removed and 100 \u00b5l of MEM containing 2% FBS was added to all but the first row.", [["cells", "ANATOMY", 4, 9], ["FBS", "ANATOMY", 109, 112], ["MEM", "CHEMICAL", 91, 94], ["cells", "CELL", 4, 9], ["FBS", "ORGANISM_SUBSTANCE", 109, 112], ["MEM containing 2% FBS", "TREATMENT", 91, 112]]], ["In the first row, 125 \u00b5l of media containing the experimental drug was added in triplicate wells.", [["media", "TREATMENT", 28, 33], ["the experimental drug", "TREATMENT", 45, 66]]], ["Media alone was added to both cell and virus control wells.", [["cell", "ANATOMY", 30, 34], ["cell", "CELL", 30, 34], ["Media", "TREATMENT", 0, 5], ["virus control wells", "TREATMENT", 39, 58]]], ["The plates were then incubated for 60 min and 100 \u00b5l of a virus suspension was added to each well, excluding cell control wells which received 100 \u00b5l of MEM.", [["cell", "ANATOMY", 109, 113], ["MEM", "CHEMICAL", 153, 156], ["cell", "CELL", 109, 113], ["The plates", "TREATMENT", 0, 10], ["a virus suspension", "TREATMENT", 56, 74], ["cell control wells", "TREATMENT", 109, 127]]], ["The plates were then incubated at 37 o C in a CO 2 incubator for three days for HSV-1, or 14 d for CMV.", [["CO 2", "CHEMICAL", 46, 50], ["HSV", "ORGANISM", 80, 83], ["CMV", "ORGANISM", 99, 102], ["HSV-1", "SPECIES", 80, 85], ["CMV", "SPECIES", 99, 102], ["a CO 2 incubator", "TREATMENT", 44, 60], ["HSV", "TEST", 80, 83], ["CMV", "PROBLEM", 99, 102]]], ["After the incubation period, media was aspirated and the cells stained with crystal violet in formalin for 4h.", [["cells", "ANATOMY", 57, 62], ["formalin", "CHEMICAL", 94, 102], ["formalin", "CHEMICAL", 94, 102], ["cells", "CELL", 57, 62], ["formalin", "SIMPLE_CHEMICAL", 94, 102], ["media", "TREATMENT", 29, 34], ["the cells", "PROBLEM", 53, 62], ["crystal violet in formalin", "TREATMENT", 76, 102], ["crystal violet", "OBSERVATION", 76, 90]]], ["The stain was then removed and the plates were rinsed until all excess stain was removed.", [["The stain", "TEST", 0, 9], ["the plates", "TREATMENT", 31, 41], ["all excess stain", "TEST", 60, 76]]], ["The plates were allowed to dry for 24 h and the amount of CPE in each row determined using a BioTek Multiplate Autoreader.", [["CPE", "CHEMICAL", 58, 61], ["The plates", "TREATMENT", 0, 10], ["a BioTek Multiplate Autoreader", "TREATMENT", 91, 121], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["EC 50 and CC 50 values were determined by comparing drug treated and untreated cells using a computer program.Screening Assays for Rabies (Strain Flury).Confluent BHK-21 cells were prepared in T-150 flask.", [["EC", "ANATOMY", 0, 2], ["cells", "ANATOMY", 79, 84], ["BHK-21 cells", "ANATOMY", 163, 175], ["CC", "CHEMICAL", 10, 12], ["Rabies", "DISEASE", 131, 137], ["EC", "CELL", 0, 2], ["cells", "CELL", 79, 84], ["BHK-21 cells", "CELL", 163, 175], ["untreated cells", "CELL_TYPE", 69, 84], ["BHK-21 cells", "CELL_LINE", 163, 175], ["EC", "TEST", 0, 2], ["Screening Assays", "TEST", 110, 126], ["Confluent BHK", "TEST", 153, 166], ["21 cells", "OBSERVATION_MODIFIER", 167, 175]]], ["Cells were Trypsinized cells and made as cell suspensions.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 23, 28], ["cell", "ANATOMY", 41, 45], ["Cells", "CELL", 0, 5], ["Trypsinized cells", "CELL", 11, 28], ["cell", "CELL", 41, 45], ["Trypsinized cells", "CELL_LINE", 11, 28], ["cell suspensions", "TREATMENT", 41, 57]]], ["50 \u00b5l of 5x10 5 cells/ml cell suspension (25,000 cells/well) were added into each well of the 96 well plates, except row H. 2X concentration of antivirals were made (Isoprinosine and test drug(s)).", [["cells", "ANATOMY", 16, 21], ["cell", "ANATOMY", 25, 29], ["cells", "ANATOMY", 49, 54], ["Isoprinosine", "CHEMICAL", 166, 178], ["Isoprinosine", "CHEMICAL", 166, 178], ["cells", "CELL", 16, 21], ["cell", "CELL", 25, 29], ["cells", "CELL", 49, 54], ["Isoprinosine", "SIMPLE_CHEMICAL", 166, 178], ["5x10 5 cells/ml cell suspension", "TREATMENT", 9, 40], ["antivirals", "TREATMENT", 144, 154], ["Isoprinosine", "TREATMENT", 166, 178]]], ["100\u00b5l per well that will be tested for effective concentration (drug wells) and cytotoxic concentration (tox wells) were added.", [["effective concentration (drug wells", "TREATMENT", 39, 74], ["cytotoxic concentration (tox wells", "TREATMENT", 80, 114]]], ["The rabies virus was diluted 1:1000.", [["rabies virus", "ORGANISM", 4, 16], ["rabies virus", "SPECIES", 4, 16], ["The rabies virus", "PROBLEM", 0, 16]]], ["50\u00b5l was added per well in the drug wells and virus control wells.", [["virus control wells", "TREATMENT", 46, 65]]], ["The final volume was 200\u00b5l.", [["The final volume", "TEST", 0, 16], ["volume", "OBSERVATION_MODIFIER", 10, 16]]], ["Additional media was added to fill up wells, ie: Tox wells were 100\u00b5l 2x drug, 50\u00b5l cells (5e5 cells/ml), and 50\u00b5l media.", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 95, 100], ["cells", "CELL", 84, 89], ["5e5 cells", "CELL", 91, 100], ["Additional media", "TREATMENT", 0, 16], ["Tox wells", "TEST", 49, 58]]], ["Plates were covered and incubated (37\u00b0C; 5 % CO 2 ) for 5 days.", [["CO 2", "CHEMICAL", 45, 49], ["Plates", "TEST", 0, 6]]], ["After 5 days the Promega CellTiter-Glo Luminescent Cell Viability Assay was run using the Fluoroskan FL to scan for luminescence.", [["Cell", "ANATOMY", 51, 55], ["CellTiter-Glo", "CHEMICAL", 25, 38], ["Cell", "CELL", 51, 55], ["the Promega CellTiter", "TREATMENT", 13, 34], ["Glo Luminescent Cell Viability Assay", "TEST", 35, 71], ["luminescence", "PROBLEM", 116, 128]]]], "b97e7e044c19bb1bbb82b89a8fb91339c974e642": [["Background and OverviewIn this study, we analyze the impact of social distancing measures and testing capacity on the evolution of COVID-19 in New York City.", [["this study", "TEST", 26, 36], ["social distancing measures", "TREATMENT", 63, 89], ["testing capacity", "TEST", 94, 110], ["COVID", "TEST", 131, 136]]], ["On March 22, the New York State on Pause executive order came into effect to ensure adequate social distancing and it has been helpful in controlling the spread of the disease and preventing healthcare resources from stretching too thin.", [["the disease", "PROBLEM", 164, 175], ["stretching too thin", "PROBLEM", 217, 236]]], ["Pause will remain in effect in the City in some form until early June.", [["Pause", "PROBLEM", 0, 5]]], ["Testing, particularly together with contact tracing, could help relax social distancing measures, facilitating the partial reopening of the economy while keeping the spread of the disease under control.", [["Testing", "TEST", 0, 7], ["contact tracing", "TEST", 36, 51], ["social distancing measures", "TREATMENT", 70, 96], ["the partial reopening of the economy", "TREATMENT", 111, 147], ["the disease under control", "PROBLEM", 176, 201], ["partial", "OBSERVATION_MODIFIER", 115, 122], ["reopening", "OBSERVATION", 123, 132], ["disease", "OBSERVATION", 180, 187]]], ["However, the level of testing capacity necessary to allow noticeable relaxation in the social distancing norms and to help reopen the economy is not yet clear.", [["testing capacity", "TEST", 22, 38]]], ["We consider various possibilities regarding the social distancing measures and testing capacity availability in the immediate post-Pause period.", [["the social distancing measures", "TREATMENT", 44, 74], ["testing capacity", "TEST", 79, 95]]], ["We project the evolution of the pandemic in the City until the end of September.", [["pandemic", "OBSERVATION_MODIFIER", 32, 40]]], ["To make our projections, we use a compartmentalized model that captures the limited availability of testing capacity, while allowing some contact tracing to identify, test, and isolate individuals at risk.Background and OverviewWe find that testing capacity must increase dramatically if it is to counterbalance somewhat small levels of relaxation in the social distancing measures in the post-Pause period.", [["testing capacity", "TEST", 100, 116], ["some contact tracing", "TEST", 133, 153], ["test", "TEST", 167, 171], ["testing capacity", "PROBLEM", 241, 257]]], ["If the social distancing measures in the post-Pause period are relaxed to pre-Pause norms and the City continues to perform 20,000 tests per day, then the number of deaths by the end of September can reach 250,000.", [["deaths", "DISEASE", 165, 171]]], ["If the social distancing norms are fully relaxed, then even with a testing capacity of 100,000 per day, the City still faces a second wave of the pandemic that would likely supersede the one it experienced in April.", [["a testing capacity", "TEST", 65, 83]]], ["By keeping the social distancing measures halfway between the preand in-Pause levels and performing 100,000 tests per day in the post-Pause period, the number of deaths by the end of September can be kept at around 27,000.", [["deaths", "DISEASE", 162, 168]]], ["If the City is to go back to pre-Pause social distancing norms and keep the number of deaths by the end of September under 35,000, then it should be performing 500,000 tests per day.", [["deaths", "DISEASE", 86, 92]]], ["The message is clear.", [["clear", "OBSERVATION", 15, 20]]], ["If one considers for a moment going back to the pre-Pause life quickly in the post-Pause period, then the City should be ramping up its testing capacity to 500,000, but even then, there will be a price to pay.Compartmentalized ModelOur model follows the standard susceptible-infected-recovered paradigm with compartments capturing individuals classified along the dimensions of infected, noninfected, and recovered, as well as symptomatic-isolated, asymptomatic-isolated, and asymptomatic-nonisolated.", [["dimensions", "OBSERVATION_MODIFIER", 364, 374], ["infected", "OBSERVATION", 378, 386], ["noninfected", "OBSERVATION_MODIFIER", 388, 399]]], ["Once an individual is tested positive, a certain number of individuals who are expected to have been in close contact with the positive individual are transferred to a certain isolated compartment.", [["individuals", "ORGANISM", 59, 70]]], ["In the appendix, we give a discussion of our model and provide comparisons of its output with the actual trajectory of the pandemic.A Close Look at Two Testing ScenariosIn the top and bottom panels of Figure 1 , we give the trajectory of projected daily deaths under two testing capacity scenarios of 20,000 and 100,000 tests per day.", [["deaths", "DISEASE", 254, 260], ["appendix", "ORGAN", 7, 15], ["its output", "TEST", 78, 88], ["two testing capacity scenarios", "TEST", 267, 297], ["appendix", "ANATOMY", 7, 15]]], ["Each data series in the two panels corresponds to a different level of social distancing practiced in the post-Pause period, expressed as a percentage relaxation in the in-Pause social distancing norms.", [["Each data series", "TEST", 0, 16]]], ["Specifically, 0% is no relaxation, corresponding to the strictest level of social distancing that was implemented in the in-Pause period, whereas 100% is full relaxation, corresponding to no social distancing, as in life in the pre-Pause period.", [["relaxation", "PROBLEM", 23, 33], ["no", "UNCERTAINTY", 20, 22], ["relaxation", "OBSERVATION", 23, 33]]], ["Other percentages reflect different levels of relaxation the City may consider, each with a certain R-naught value between the two extremes.", [["different", "OBSERVATION_MODIFIER", 26, 35], ["levels", "OBSERVATION_MODIFIER", 36, 42]]], ["All newly-imposed social distancing measures come into effect on June 1, the beginning of the post-Pause period.", [["social distancing measures", "TREATMENT", 18, 44]]], ["The testing capacities of 20,000 and 100,000 tests per day represent the current situation and an order of magnitude bump.A Close Look at Two Testing ScenariosNoting the purple data series in the figure, fully relaxing the social distancing measures immediately in the post-Pause period and going back to pre-Pause practices will lead to another wave peaking in late August, regardless of whether the City has 20,000 or 100,000 per day testing capacity.", [["The testing capacities", "TEST", 0, 22], ["magnitude bump", "PROBLEM", 107, 121], ["the purple data series", "PROBLEM", 166, 188], ["pre-Pause practices", "TREATMENT", 305, 324], ["purple", "OBSERVATION_MODIFIER", 170, 176]]], ["Testing capacity will surely have an impact on the size of the next wave.", [["Testing capacity", "TEST", 0, 16], ["size", "OBSERVATION_MODIFIER", 51, 55]]], ["Under 20,000 per day testing capacity, full relaxation of social distancing measures will result in 252,000 deaths by the end of September.", [["deaths", "DISEASE", 108, 114], ["social distancing measures", "TREATMENT", 58, 84]]], ["Note that the labels on the right end of each panel give the total number of deaths by the end of September.", [["deaths", "DISEASE", 77, 83], ["right", "ANATOMY_MODIFIER", 28, 33]]], ["Even with 100,000 per day testing capacity, if the social distancing norms are fully relaxed in the post-Pause period, then the next wave in August will be significantly larger than what the City already experienced in April, ultimately resulting in 109,000 deaths by the end of September. social distancing measures somewhere halfway between the pre-and in-Pause levels, corresponding to the green data series in the figure.", [["deaths", "DISEASE", 258, 264], ["testing capacity", "TEST", 26, 42], ["distancing", "OBSERVATION", 297, 307]]], ["In this case, if the City keeps on performing 20,000 tests per day in the post-Pause period, then the number of deaths by the end of September adds up to 30,000.", [["deaths", "DISEASE", 112, 118]]], ["Increasing the testing capacity to 100,000 per day reduces the number of deaths by the end of September to 27,000, but even in this case, the daily deaths demonstrate a slightly increasing trend at the end of September.A Close Look at Two Testing ScenariosBeing more liberal with the social distancing measures in the post-Pause period and relaxing them even more than halfway between the pre-and in-Pause levels will be problematic.", [["deaths", "DISEASE", 73, 79], ["deaths", "DISEASE", 148, 154], ["Increasing the testing capacity", "PROBLEM", 0, 31], ["a slightly increasing trend", "PROBLEM", 167, 194], ["the social distancing measures", "TREATMENT", 280, 310], ["slightly", "OBSERVATION_MODIFIER", 169, 177], ["increasing", "OBSERVATION_MODIFIER", 178, 188], ["liberal", "OBSERVATION_MODIFIER", 267, 274]]], ["Consider relaxing the social distancing measures by 75%, corresponding to the red data series in the figure.A Close Look at Two Testing ScenariosUnder both testing capacities of 20,000 and 100,000 per day, a second wave picks up at the end of September.", [["testing capacities", "TEST", 156, 174]]], ["The testing capacity will affect the magnitude of the wave, but the number of deaths by the end of August reaches 52,000 even with a testing capacity of 100,000 per day.A Close Look at Two Testing ScenariosIn Figure 1 , full (100%) and no (0%) relaxation in social distancing practices correspond to life before and after March 22.", [["deaths", "DISEASE", 78, 84], ["The testing capacity", "TEST", 0, 20], ["a testing capacity", "TEST", 131, 149]]], ["We emphasize that the interpretation of other levels of social distancing measures requires more care.", [["social distancing measures", "TREATMENT", 56, 82]]], ["In particular, the other levels of social distancing measures correspond to different R-naught values between the two extremes and they should not be interpreted as a suggested level of occupancy in business establishments.", [["social distancing", "OBSERVATION", 35, 52]]], ["There is work to be done to convert these social distancing levels into public health policy.What Level of Testing Capacity Allows for ReopeningThe discussion in the previous section indicates there are risks if the City quickly relaxes the social distancing norms in the post-Pause period.", [["Testing Capacity", "TEST", 107, 123], ["Reopening", "TREATMENT", 135, 144]]], ["A natural question is what testing capacity would likely be sufficient to keep the risk of a second wave at bay while relaxing the social distancing measures to a degree that the economy can start functioning.What Level of Testing Capacity Allows for ReopeningIn the top panel of Figure 2 , we show the tradeoff between the total number of deaths by the end of September and the level of social distancing practiced, under different testing capacities.", [["deaths", "DISEASE", 340, 346], ["the social distancing measures", "TREATMENT", 127, 157], ["Testing Capacity", "TEST", 223, 239], ["Reopening", "TREATMENT", 251, 260]]], ["The horizontal axis shows the level of social distancing, expressed, as before, as a percentage relaxation in the in-Pause social distancing norms.", [["a percentage relaxation", "TREATMENT", 83, 106], ["horizontal axis", "OBSERVATION", 4, 19], ["social distancing", "OBSERVATION", 39, 56]]], ["Thus, 0% is no relaxation, corresponding to the strictest level of social distancing observed during Pause, whereas 100% is full relaxation, corresponding to the loosest level of social distancing that was in the pre-Pause period.", [["relaxation", "PROBLEM", 15, 25]]], ["The vertical axis shows the total number of projected deaths by the end of September.", [["deaths", "DISEASE", 54, 60], ["vertical axis", "OBSERVATION", 4, 17], ["total", "OBSERVATION_MODIFIER", 28, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["projected", "OBSERVATION_MODIFIER", 44, 53], ["deaths", "OBSERVATION", 54, 60]]], ["Each data series corresponds to a different level of testing capacity.", [["Each data series", "TEST", 0, 16], ["testing capacity", "TEST", 53, 69]]], ["In the bottom panel of Figure 2 , we give the same information but zoom in on the more relevant region of social distancing measures.", [["social distancing measures", "TREATMENT", 106, 132]]], ["In our model, all new testing capacity and social distancing norms become effective on June 1.", [["all new testing capacity", "TEST", 14, 38]]], ["Before May 1, we use the actual number of tests performed by the City and extrapolate between early-May and June 1.What Level of Testing Capacity Allows for ReopeningA good starting point is to consider the case where the City relaxes the social distancing measures halfway between the pre-and in-Pause norms, corresponding to 50% on the horizontal axis in the figure.", [["tests", "TEST", 42, 47], ["Testing Capacity", "TEST", 129, 145], ["ReopeningA", "TREATMENT", 157, 167]]], ["We observe that keeping a testing capacity of 20,000 per day results in a total of 30,000 deaths by the end of September.", [["deaths", "DISEASE", 90, 96], ["a testing capacity", "TEST", 24, 42]]], ["Raising the testing capacity to 100,000 per day reduces the number of deaths by the end of September to 27,000.", [["deaths", "DISEASE", 70, 76], ["the testing capacity", "TEST", 8, 28]]], ["Even by performing 250,000 tests per day, the total number of deaths by the end of September can only be kept at 34,000.", [["deaths", "DISEASE", 62, 68]]], ["Even then, there will be a price to pay and testing is far from being a perfect substitute for social distancing.Discussion and Next StepsThe analysis in this study puts all new social distancing measures and testing capacities into effect immediately on June 1.", [["The analysis", "TEST", 138, 150], ["this study", "TEST", 154, 164], ["social distancing measures", "TREATMENT", 178, 204], ["testing capacities", "TEST", 209, 227]]], ["An analysis along these lines will be our next line of attack.", [["An analysis", "TEST", 0, 11], ["these lines", "TREATMENT", 18, 29], ["attack", "PROBLEM", 55, 61]]], ["Moreover, as discussed in the appendix, we have a contact tracing mechanism in our model, where close contacts of every positive case are put into isolation.", [["appendix", "ORGAN", 30, 38], ["appendix", "ANATOMY", 30, 38]]], ["In other words, our model implicitly assumes that the bottleneck is the testing capacity, not the contract tracing capacity.", [["the testing capacity", "TEST", 68, 88]]], ["We plan to use our model to estimate the number of contact tracers needed to keep up with the increasing testing capacity and new cases.", [["the increasing testing capacity", "TEST", 90, 121]]], ["The interpretation of the pre-and in-Pause social distancing measures are somewhat clear, each corresponding to life before and after March 22.", [["somewhat", "OBSERVATION_MODIFIER", 74, 82], ["clear", "OBSERVATION", 83, 88]]], ["Lastly, we believe that the death projections from our model are on the optimistic side, because our model assumes the presence of a streamlined tracing mechanism and individuals in certain compartments are willing to isolate themselves, infecting others minimally.", [["death", "DISEASE", 28, 33], ["a streamlined tracing mechanism", "PROBLEM", 131, 162]]], ["Such optimistic behavior of our model should be taken into consideration when interpreting our results.AppendixThe appendix is organized as follows.", [["appendix", "ORGAN", 115, 123], ["appendix", "ANATOMY", 115, 123], ["organized", "OBSERVATION", 127, 136]]], ["In Appendix A, we discuss our model at a high level.", [["Appendix", "ANATOMY", 3, 11]]], ["In Appendix B, we provide the full mathematical details of our model.", [["Appendix B", "CELL", 3, 13], ["Appendix", "ANATOMY", 3, 11]]], ["In Appendix C, we elaborate on the parameters of our model and how they are estimated.", [["Appendix", "ANATOMY", 3, 11]]], ["We borrow some of the parameters from the literature and derive others based off of problem primitives.", [["problem primitives", "PROBLEM", 84, 102]]], ["In Appendix D, we compare the output of our model with the trajectory of the pandemic in the City until early May and demonstrate that our model does a reasonably good job of predicting the trajectory that has been observed so far.A. Model at a High LevelIn our model, we capture the two benefits of testing, which are isolating the specific individual tested positive and tracing the contacts of the positive individual.", [["the output", "TEST", 26, 36], ["testing", "TEST", 300, 307], ["Appendix", "ANATOMY", 3, 11]]], ["In particular, our model distinguishes the infected individuals who know that they are infected from the infected individuals who do not know whether they are infected.", [["individuals", "ORGANISM", 52, 63], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["infected", "OBSERVATION", 159, 167]]], ["Once a person is tested positive, this person is an infected individual who knows that she is infected.", [["person", "ORGANISM", 39, 45], ["person", "SPECIES", 7, 13], ["person", "SPECIES", 39, 45], ["infected", "PROBLEM", 94, 102], ["infected", "OBSERVATION", 94, 102]]], ["Such a person minimally infects others.", [["person", "SPECIES", 7, 13]]], ["Moreover, considering the individuals who do not know whether they are infected, we classify them as symptomatic-isolated, asymptomatic-isolated, or asymptomatic-nonisolated.", [["symptomatic", "PROBLEM", 101, 112], ["asymptomatic", "PROBLEM", 123, 135], ["asymptomatic", "PROBLEM", 149, 161], ["infected", "OBSERVATION", 71, 79]]], ["Once an individual is tested positive, a certain number of people around this person are classified as asymptomatic-isolated people, so these individuals reduce their contact with the general population, preventing them from infecting others to some extent.A. Model at a High LevelOur model follows the standard susceptible-infected-recovered modeling paradigm.", [["people", "ORGANISM", 59, 65], ["people", "ORGANISM", 125, 131], ["individuals", "ORGANISM", 142, 153], ["people", "SPECIES", 59, 65], ["person", "SPECIES", 78, 84], ["people", "SPECIES", 125, 131], ["infected", "OBSERVATION", 324, 332]]], ["The boxes represent the compartments.", [["compartments", "OBSERVATION_MODIFIER", 24, 36]]], ["The arrows represent the possible flows between the compartments.", [["The arrows", "PROBLEM", 0, 10], ["possible", "UNCERTAINTY", 25, 33], ["flows", "OBSERVATION", 34, 39], ["compartments", "ANATOMY_MODIFIER", 52, 64]]], ["The three compartments on the right of the figure capture the individuals who know that they are infected.", [["three", "OBSERVATION_MODIFIER", 4, 9], ["compartments", "OBSERVATION_MODIFIER", 10, 22], ["right", "ANATOMY_MODIFIER", 30, 35], ["infected", "OBSERVATION", 97, 105]]], ["In particular, the compartment labeled \"KI\" corresponds to the infected individuals who know that they are infected and not (yet) hospitalized.", [["compartment", "ANATOMY_MODIFIER", 19, 30], ["infected", "OBSERVATION", 63, 71], ["infected", "OBSERVATION", 107, 115]]], ["The compartment labeled \"H\" captures the infected individuals who are hospitalized.", [["individuals", "ORGANISM", 50, 61], ["compartment", "ANATOMY_MODIFIER", 4, 15], ["infected", "OBSERVATION_MODIFIER", 41, 49]]], ["The individuals in the latter compartment also know that they are infected.", [["infected", "PROBLEM", 66, 74], ["infected", "OBSERVATION", 66, 74]]], ["The compartment labeled \"KR\" captures the recovered individuals who knew that they were infected.", [["KR", "GENE_OR_GENE_PRODUCT", 25, 27], ["compartment", "ANATOMY_MODIFIER", 4, 15], ["infected", "OBSERVATION", 88, 96]]], ["Perhaps optimistically, in our model, the individuals in all of these three compartments minimally infect others, since they are aware that they were infected.A. Model at a High LevelThe nine compartments on the left side of the figure capture the individuals who do not know whether they are infected.", [["infected", "PROBLEM", 150, 158], ["infect", "OBSERVATION", 99, 105], ["infected", "OBSERVATION", 150, 158], ["left", "ANATOMY_MODIFIER", 212, 216], ["infected", "OBSERVATION", 293, 301]]], ["Some of these individuals will, in actuality, be infected, some will be noninfected, and some will even have recovered without knowing they had been infected.", [["individuals", "ORGANISM", 14, 25], ["infected", "PROBLEM", 49, 57], ["infected", "OBSERVATION", 49, 57], ["infected", "OBSERVATION", 149, 157]]], ["We classify the individuals who do not know whether they are infected along two dimensions.", [["infected", "OBSERVATION", 61, 69]]], ["In the first dimension, any such individual could be symptomatic-isolated, asymptomatic-isolated, or asymptomatic-nonisolated.", [["symptomatic", "PROBLEM", 53, 64], ["asymptomatic", "PROBLEM", 75, 87], ["asymptomatic", "PROBLEM", 101, 113], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["Asymptomatic-nonisolated individuals do not show symptoms of the disease and do not make an effort to reduce their contact.", [["individuals", "ORGANISM", 25, 36], ["Asymptomatic", "PROBLEM", 0, 12], ["nonisolated individuals", "PROBLEM", 13, 36], ["symptoms", "PROBLEM", 49, 57], ["the disease", "PROBLEM", 61, 72], ["disease", "OBSERVATION", 65, 72]]], ["Asymptomatic-isolated individuals make a conscious effort to reduce their contact, mainly because they have been in touch with a person who tested positive.", [["individuals", "ORGANISM", 22, 33], ["person", "SPECIES", 129, 135], ["Asymptomatic", "PROBLEM", 0, 12]]], ["Symptomatic-isolated individuals show symptoms but do not know whether they are infected.", [["individuals", "ORGANISM", 21, 32], ["isolated individuals", "PROBLEM", 12, 32], ["symptoms", "PROBLEM", 38, 46], ["infected", "PROBLEM", 80, 88], ["infected", "OBSERVATION", 80, 88]]], ["Their symptoms may be due to other diseases.A. Model at a High LevelOnce again, perhaps optimistically, in our model, all symptomatic individuals isolate themselves, so we do not have a compartment for symptomatic-nonisolated people.", [["individuals", "ORGANISM", 134, 145], ["people", "ORGANISM", 226, 232], ["people", "SPECIES", 226, 232], ["Their symptoms", "PROBLEM", 0, 14], ["other diseases", "PROBLEM", 29, 43], ["may be due to", "UNCERTAINTY", 15, 28], ["diseases", "OBSERVATION", 35, 43]]], ["Symptomatic-isolated and asymptomatic-isolated individuals infect others with a smaller rate, when compared with asymptomatic-nonisolated people.", [["individuals", "ORGANISM", 47, 58], ["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["Symptomatic-isolated and asymptomatic", "PROBLEM", 0, 37], ["isolated individuals infect", "PROBLEM", 38, 65], ["asymptomatic", "OBSERVATION_MODIFIER", 25, 37], ["smaller", "OBSERVATION_MODIFIER", 80, 87]]], ["When stricter social distancing norms are enforced, all individuals will reduce their contact with the general population, but we follow the assumption that asymptomatic-nonisolated individuals will still maintain a higher contact rate with the rest of the population than asymptomatic-isolated and symptomatic-isolated individuals.A. Model at a High LevelConsidering the individuals who do not know whether they are infected, we classify them along another dimension.", [["individuals", "ORGANISM", 182, 193], ["asymptomatic", "PROBLEM", 157, 169], ["asymptomatic", "PROBLEM", 273, 285], ["symptomatic", "PROBLEM", 299, 310], ["isolated individuals", "PROBLEM", 311, 331], ["infected", "OBSERVATION", 417, 425]]], ["In this second dimension, an individual who does not know whether she is infected could be infected, noninfected, or recovered.", [["infected", "PROBLEM", 73, 81], ["infected", "PROBLEM", 91, 99], ["infected", "OBSERVATION", 73, 81], ["infected", "OBSERVATION", 91, 99]]], ["Thus, considering the nine compartments on the left side of Figure 3 , the compartment labeled \"I An ,\" for example, captures the infected and asymptomatic-nonisolated individuals who do not know whether they are infected.", [["individuals", "ORGANISM", 168, 179], ["infected", "PROBLEM", 213, 221], ["left", "ANATOMY_MODIFIER", 47, 51], ["infected", "OBSERVATION", 130, 138], ["infected", "OBSERVATION", 213, 221]]], ["Note that these individuals are infected in actuality, but they do not know that they are infected and they maintain a high contract rate with the rest of the population, being nonisolated.", [["individuals", "ORGANISM", 16, 27], ["infected", "OBSERVATION", 32, 40], ["infected", "OBSERVATION", 90, 98]]], ["When we perform tests on a segment of a population, the proportion of positive tests is given by the fraction of the infected individuals in the segment relative to the size of the whole segment.", [["tests", "TEST", 16, 21], ["positive tests", "PROBLEM", 70, 84], ["positive", "OBSERVATION", 70, 78], ["infected", "OBSERVATION", 117, 125], ["segment", "ANATOMY_MODIFIER", 145, 152], ["size", "OBSERVATION_MODIFIER", 169, 173], ["whole segment", "ANATOMY_MODIFIER", 181, 194]]], ["For example, using the label of a compartment to also denote the number of individuals in the compartment, since there are N An + R An + I An asymptomatic-nonisolated individuals, if we test T asymptomatic-nonisolated individuals, then the number of positive tests is T \u00d7 I An N An +R An +I An .", [["individuals", "ORGANISM", 218, 229], ["nonisolated individuals", "PROBLEM", 206, 229], ["positive tests", "TEST", 250, 264], ["compartment", "ANATOMY", 94, 105]]], ["In other words, our model implicitly assumes that the bottleneck is the testing capacity, not contact tracing capacity.", [["the testing capacity", "TEST", 68, 88]]], ["It is important to note that growing the testing capacity in the City beyond a certain level without growing the contact tracing capacity will not be of much benefit, so any decision regarding how much to grow the contact tracing capacity should be directly informed by the plans to grow the testing capacity.B. Mathematical Description of the System DynamicsIn this section, we provide a detailed description of the system dynamics of our model.", [["the testing capacity", "TEST", 37, 57], ["the testing capacity", "TEST", 288, 308]]], ["Mathematical Description of the System Dynamicswhere the variables I tB.", [["I tB", "PROTEIN", 67, 71]]], ["Mathematical Description of the System DynamicsAn denote the states associated with the nine compartments on the left side of Figure 3 .", [["left", "ANATOMY_MODIFIER", 113, 117]]], ["These nine compartments correspond to individuals whose COVID-19 status is unknown.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 56, 64], ["COVID", "PROTEIN", 56, 61], ["COVID", "TEST", 56, 61]]], ["The variable KI t captures the number of individuals who have been confirmed to have COVID-19 and are currently infected in period t.", [["COVID", "TEST", 85, 90], ["infected", "OBSERVATION", 112, 120]]], ["The variable KR t captures the number of individuals who have been confirmed to have COVID-19 and recovered by period t.B. Mathematical Description of the System DynamicsDescription of Sub-compartments: For our state variables, we use regular font to denote scalars and bold font to denote vectors.", [["KR t", "DNA", 13, 17], ["COVID", "TEST", 85, 90], ["scalars", "TREATMENT", 258, 265]]], ["We use vector notation when a compartment has multiple sub-compartments representing different subgroups of the population.", [["vector notation", "TREATMENT", 7, 22]]], ["Here are the descriptions of the sub-compartments.B. Mathematical Description of the System Dynamics\u2022 Sub-compartments within the I Si compartment: The I Si compartment has 3 sub-compartments:B. Mathematical Description of the System Dynamics(a) those who will recover naturally without requiring any hospitalization, (b) those who will require hospitalization, and (c) those who will die without access to a COVID-19 diagnostic test.", [["Sub-compartments", "ANATOMY", 102, 118], ["Si", "CHEMICAL", 132, 134], ["Si", "CHEMICAL", 154, 156], ["a COVID", "TEST", 407, 414], ["diagnostic test", "TEST", 418, 433], ["sub", "OBSERVATION_MODIFIER", 33, 36], ["compartments", "ANATOMY_MODIFIER", 106, 118]]], ["Thus,B. Mathematical Description of the System Dynamicsto denote the total number of individuals in the I Si compartment.", [["Si", "CHEMICAL", 106, 108], ["total", "OBSERVATION_MODIFIER", 69, 74], ["number", "OBSERVATION_MODIFIER", 75, 81]]], ["The trick we use here is that when an individual is infected, we immediately decide whether this person will recover, will be hospitalized, or will die.", [["person", "SPECIES", 97, 103]]], ["We keep the identity of the individual accordingly throughout the simulation.B. Mathematical Description of the System Dynamics\u2022 Sub-compartments within the I Ai compartment: The I Ai compartment has 2 sub-compartments:B. Mathematical Description of the System Dynamics(a) those who will never develop COVID-19 symptoms, and (b) those who will show COVID-19 symptoms but are currently pre-symptomatic.", [["Sub-compartments", "ANATOMY", 129, 145], ["COVID-19 symptoms", "PROBLEM", 302, 319], ["COVID-19 symptoms", "PROBLEM", 349, 366], ["pre-symptomatic", "PROBLEM", 385, 400], ["compartments", "ANATOMY_MODIFIER", 133, 145]]], ["Thus,B. Mathematical Description of the System Dynamicsand we let\u012a t Ai = I t Ai (recovered) + I t Ai (show symptom) denote the total number of individuals in the I Ai compartment.B. Mathematical Description of the System Dynamics\u2022 Sub-compartments within the I An compartments: Similar to the I Ai compartment, the I An compartment has 2 sub-compartments: (a) those who will never develop COVID-19 symptoms, and (b) those who will show COVID-19 symptoms but are currently pre-symptomatic.", [["Sub-compartments", "ANATOMY", 232, 248], ["symptom", "PROBLEM", 108, 115], ["COVID-19 symptoms", "PROBLEM", 390, 407], ["COVID-19 symptoms", "PROBLEM", 437, 454], ["pre-symptomatic", "PROBLEM", 473, 488], ["compartments", "ANATOMY_MODIFIER", 236, 248]]], ["Thus,B. Mathematical Description of the System Dynamicsand as before, we let\u012a t An = I t An (recovered) + I t An (show symptom) denote the total number of individuals in the I An compartment.B. Mathematical Description of the System Dynamics\u2022 Sub-compartments within the H compartment: The H compartment consists of two types of individuals: (a) those who will die and (b) those who will eventually recover.", [["Sub-compartments", "ANATOMY", 243, 259], ["H compartment", "ANATOMY", 271, 284], ["H compartment", "ANATOMY", 290, 303], ["symptom", "PROBLEM", 119, 126], ["compartments", "ANATOMY_MODIFIER", 247, 259]]], ["Therefore, we have that KI t = KI t (hospitalized), KI t (recovered) .Impact of Testing:We assume that the diagnostic test is 100% accurate and the result is obtained instantaneously.", [["KI t", "TEST", 52, 56], ["the diagnostic test", "TEST", 103, 122]]], ["However when we perform the test, we cannot differentiate between unknown infected, unknown non-infected, and recovered people.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["the test", "TEST", 24, 32], ["infected", "OBSERVATION", 74, 82]]], ["We can only test people based on their observable characteristics.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["At the beginning of each period, we test T Si symptomatic-isolated individuals, T Ai asymptomatic-isolated individuals, and T An asymptomatic-nonisolated individuals.", [["Si", "CHEMICAL", 43, 45], ["individuals", "ORGANISM", 67, 78], ["T Ai", "CELL", 80, 84], ["individuals", "ORGANISM", 107, 118], ["T", "CELL", 124, 125], ["individuals", "ORGANISM", 154, 165], ["nonisolated individuals", "PROBLEM", 142, 165]]], ["We assume that the tests are administered at random within each of these populations.", [["the tests", "TEST", 15, 24]]], ["Let \u03c0 Si , \u03c0 Ai , and \u03c0 An denote the fraction of symptomatic isolated, asymptomatic isolated, and asymptomatic non-isolated individuals, respectively, who receive diagnostic tests.", [["Si", "CHEMICAL", 6, 8], ["\u03c0", "CHEMICAL", 11, 12], ["Let \u03c0 Si", "GENE_OR_GENE_PRODUCT", 0, 8], ["symptomatic isolated", "PROBLEM", 50, 70], ["asymptomatic", "PROBLEM", 72, 84], ["asymptomatic non-isolated individuals", "PROBLEM", 99, 136], ["diagnostic tests", "TEST", 164, 180], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61]]], ["Then,Impact of Testing:The above fractions drive the dynamics across compartments, which are described below based on the events that can occur in our model.", [["The above fractions", "TREATMENT", 23, 42]]], ["In the fraction \u03c0 Si , we assume that the infected symptomatic-isolated individuals from the death sub-compartment are inaccessible for testing.Description of Dynamics Between Compartments:Our description below is organized by the compartments.", [["death", "DISEASE", 93, 98], ["Si", "CHEMICAL", 18, 20], ["\u03c0 Si", "CELL_LINE", 16, 20], ["the infected symptomatic-isolated individuals", "PROBLEM", 38, 83], ["testing", "TEST", 136, 143], ["infected", "OBSERVATION_MODIFIER", 42, 50], ["symptomatic", "OBSERVATION_MODIFIER", 51, 62]]], ["For each compartment, we describe the inflows, outflows, and the new state at time period t + 1.Description of Dynamics Between Compartments:\u2022 Infected Symptomatic-Isolated Compartment (I Si ): As noted earlier, the I Si compartment has 3 subgroups of individuals: (a) those who will recover naturally without requiring any hospitalization, (b) those who require hospitalization, and (c) those who die without access to a COVID-19 diagnostic test.", [["Si", "CHEMICAL", 218, 220], ["a COVID", "TEST", 420, 427], ["diagnostic test", "TEST", 431, 446], ["inflows", "OBSERVATION", 38, 45], ["outflows", "OBSERVATION_MODIFIER", 47, 55], ["new", "OBSERVATION_MODIFIER", 65, 68]]], ["Thus,Description of Dynamics Between Compartments:denotes the total number of individuals across the three sub-compartments.Description of Dynamics Between Compartments:Inflow: The inflow to the I Si compartment consists of 3 sources given by:Description of Dynamics Between Compartments:-Non-infected symptomatic-isolated (N Si ) individuals who did not get tested and were newly infected during period t.", [["Si", "CHEMICAL", 197, 199], ["Si", "CHEMICAL", 326, 328], ["Non-infected symptomatic", "PROBLEM", 289, 313], ["infected", "OBSERVATION", 381, 389]]], ["The number of such individuals is given byDescription of Dynamics Between Compartments:represents the infected population who remains untested, and \u03b2 represents the effective contact rate among isolated individuals.", [["infected", "OBSERVATION_MODIFIER", 102, 110], ["population", "OBSERVATION", 111, 121]]], ["At the start of our simulation, we set \u03b2 = 1.8823 \u00d7 10 \u22128 , and starting on March 22, we reduce \u03b2 by a third, to a new value of 6.2742 \u00d7 10 \u22129 ; see Section C for more details.Description of Dynamics Between Compartments:-Infected asymptomatic-nonisolated (I An ) individuals who become symptomatic.", [["\u03b2", "PROTEIN", 96, 97], ["Infected asymptomatic", "PROBLEM", 222, 243], ["symptomatic", "PROBLEM", 287, 298], ["symptomatic", "OBSERVATION", 287, 298]]], ["The total inflow of such individuals is given byDescription of Dynamics Between Compartments:where infToSympTime represents the average number of days until an infected person displays symptoms.", [["person", "SPECIES", 169, 175], ["symptoms", "PROBLEM", 185, 193], ["total", "OBSERVATION_MODIFIER", 4, 9], ["inflow", "OBSERVATION_MODIFIER", 10, 16], ["infected", "OBSERVATION", 160, 168]]], ["In our model, we set infToSympTime to be 5 days; see Section C for more details.Description of Dynamics Between Compartments:-Infected asymptomatic-isolated (I Ai ) individuals who become symptomatic.", [["Infected asymptomatic", "PROBLEM", 126, 147], ["symptomatic", "PROBLEM", 188, 199], ["symptomatic", "OBSERVATION_MODIFIER", 188, 199]]], ["Using a similar logic as above, the total amount of such inflow is given byDescription of Dynamics Between Compartments:We assume that a fraction hospOutOfSympFrac, currently set at 20%, of the total inflow to the I Si compartment will require hospitalization, and a fraction deathOutOfSympFrac (2%) will die without being tested.", [["Si", "CHEMICAL", 216, 218], ["such inflow", "TREATMENT", 52, 63], ["a fraction hospOutOfSympFrac", "TREATMENT", 135, 163], ["a fraction deathOutOfSympFrac", "TREATMENT", 265, 294]]], ["The remaining 1 \u2212 hospOutOfSympFrac \u2212 deathOutOfSympFrac = 78% will recover at home.", [["deathOutOfSympFrac", "TEST", 38, 56]]], ["Justifications for these fractions are given in Section C.Description of Dynamics Between Compartments:Outflow: There are four destinations for the outflow from the I Si compartment.Description of Dynamics Between Compartments:-Individuals in the \"recovered\" sub-compartment, I t Si (recovered), will move to the recovered asymptomatic-nonisolated (R An ) compartment at the rate of 1/sympToRecoveryTime, where sympToRecoveryTime represents the average time for a symptomatic individual to recover from the disease.", [["Si", "CHEMICAL", 167, 169], ["Si", "CHEMICAL", 280, 282], ["these fractions", "TREATMENT", 19, 34], ["a symptomatic individual", "PROBLEM", 462, 486], ["the disease", "PROBLEM", 503, 514], ["Outflow", "ANATOMY", 103, 110], ["outflow", "ANATOMY_MODIFIER", 148, 155], ["disease", "OBSERVATION", 507, 514]]], ["Currently, sympToRecoveryTime is set at 14 days.Description of Dynamics Between Compartments:-Individuals in the \"hospitalized\" sub-compartment, I t Si (hospitalized), will move to the H compartment at the rate of 1/sympToHospTime, where sympToHospTime (5 days) represents the average number of days from symptom onset until hospitalization.Description of Dynamics Between Compartments:-Individuals in the \"death\" sub-compartment, I t Si (death), will move to the death compartment (D) at the rate of 1/sympToDeathTime, where sympToDeathTime (14 days) denotes the average time from symptoms onset to death.Description of Dynamics Between Compartments:-Finally, a fraction \u03c0 Si in every sub-compartment will move to the known infected (KI) compartment due to testing.Description of Dynamics Between Compartments:Update Equations: Let recoverOutOfSympFrac = 1\u2212hospOutOfSympFrac\u2212deathOutOfSympFrac.Description of Dynamics Between Compartments:We have the following update equations.Description of Dynamics Between Compartments:infToSympTime .Description of Dynamics Between Compartments:\u2022 Infected Asymptomatic-Isolated Compartment (I Ai ): We have two sub-compartments with I t Ai = I t Ai (recovered), I t Ai (show symptom) , and\u012a t Ai = I t Ai (recovered) + I t Ai (show symptom) denotes the total number of individuals across the two sub-compartments.Description of Dynamics Between Compartments:Inflow: The inflow to the I Ai compartment has two sources:Description of Dynamics Between Compartments:-Non-infected asymptomatic-isolated (N Ai ) individuals who were not tested and became newly infected during period t.", [["sub-compartment", "ANATOMY", 686, 701], ["death", "DISEASE", 407, 412], ["death", "DISEASE", 439, 444], ["death", "DISEASE", 464, 469], ["death", "DISEASE", 600, 605], ["Si", "CHEMICAL", 674, 676], ["Si", "CHEMICAL", 674, 676], ["I t Ai", "PROTEIN", 1258, 1264], ["symptoms", "PROBLEM", 582, 590], ["death", "PROBLEM", 600, 605], ["testing", "TEST", 758, 765], ["symptom", "PROBLEM", 1214, 1221], ["symptom", "PROBLEM", 1271, 1278], ["Non-infected asymptomatic", "PROBLEM", 1502, 1527], ["newly infected", "PROBLEM", 1588, 1602], ["compartment", "ANATOMY", 418, 429], ["infected", "OBSERVATION", 725, 733], ["sub", "OBSERVATION_MODIFIER", 1150, 1153], ["total", "OBSERVATION_MODIFIER", 1292, 1297], ["infected", "OBSERVATION", 1594, 1602]]], ["The number of such individuals is given byDescription of Dynamics Between Compartments:where \u03b2 denotes the effective contact rate for isolated individuals.Description of Dynamics Between Compartments:-Infected asymptomatic-nonisolated (I An ) individuals who were not tested but were identified as a close contact of a positive case.", [["\u03b2", "PROTEIN", 93, 94], ["isolated individuals", "PROBLEM", 134, 154], ["Infected asymptomatic", "PROBLEM", 201, 222]]], ["The number of such individuals is given byDescription of Dynamics Between Compartments:where contactPerPosCase is the average number of contacts per positive case, currently set at 4, whereas\u012a t Si \u03c0 Si +\u012a t Ai \u03c0 Ai +\u012a t An \u03c0 An denotes the number of positive cases identified that time period andH is given b\u0233Description of Dynamics Between Compartments:where the parameter likOfBeingInfected measures the likelihood that a contacted individual is in the infected population as compared to the non-infected and recovered populations.", [["Si", "CHEMICAL", 195, 197], ["Si", "CHEMICAL", 200, 202], ["contactPerPosCase", "PROTEIN", 93, 110], ["\u03c0", "DNA", 224, 225], ["Ai", "TEST", 213, 215], ["the infected population", "PROBLEM", 452, 475], ["Infected", "OBSERVATION", 385, 393], ["infected", "OBSERVATION_MODIFIER", 456, 464], ["population", "OBSERVATION", 465, 475]]], ["We set likOfBeingInfected at 5.5.Description of Dynamics Between Compartments:We assume that a fraction symptomFrac, currently set at 50%, of the total inflow to the I Ai compartment will develop symptoms, and the remaining 1\u2212symptomFrac = 50% will not develop any symptoms.Description of Dynamics Between Compartments:Outflow: There are three destinations for the outflow from the I Ai compartment.Description of Dynamics Between Compartments:-The individuals in the \"recovered\" sub-compartment, I t Ai (recovered), will move to the R An compartment at the rate of 1/asympToRecoveryTime.", [["a fraction symptomFrac", "TEST", 93, 115], ["the total inflow", "TREATMENT", 142, 158], ["symptoms", "PROBLEM", 196, 204], ["any symptoms", "PROBLEM", 261, 273], ["Outflow", "ANATOMY", 319, 326], ["outflow", "ANATOMY_MODIFIER", 365, 372]]], ["The parameter asympToRecoveryTime represents the average time that an asymptomatic infected person self-isolates after being identified as a close contact.", [["person", "SPECIES", 92, 98], ["asymptomatic", "OBSERVATION_MODIFIER", 70, 82], ["infected", "OBSERVATION", 83, 91]]], ["We currently set this value to 10 days.Description of Dynamics Between Compartments:-The \"show symptom\" sub-compartment, I t Ai (show symptom), will move to the I Si compartment at the rate of 1/infToSympTime, where infToSympTime (5 days) is the average time until symptom onset.Description of Dynamics Between Compartments:-A fraction \u03c0 Ai of individuals who are tested will move to the known infected (KI) compartment.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Infected Asymptomatic-Nonisolated Compartment (I An ):Description of Dynamics Between Compartments:We have two subcompartments, I t An = I t An (recovered), I t An (show symptom) , and we denote the total number of individuals across the two sub-compartments as\u012a t An = I t An (recovered) + I t An (show symptom).Description of Dynamics Between Compartments:Inflow: The inflow to the I An compartment comes from non-infected asymptomatic-nonisolated N An individuals who become newly infected during period t.", [["Si", "CHEMICAL", 163, 165], ["individuals", "ORGANISM", 344, 355], ["symptom", "PROBLEM", 95, 102], ["symptom", "PROBLEM", 134, 141], ["symptom", "PROBLEM", 739, 746], ["infected", "OBSERVATION", 394, 402], ["infected", "OBSERVATION", 1053, 1061]]], ["We assume that a fraction symptomFrac, currently set at 50%, of the total inflow to the I An compartment will develop symptom, and the remaining 1 \u2212 symptomFrac = 50% will not develop any symptoms.Description of Dynamics Between Compartments:Outflow: The outflow from the I An compartment has four destinations.Description of Dynamics Between Compartments:-Individuals leave self-quarantine at a rate of 1/selfQuarTime, where selfQuarTime is the average time that an individual self-isolates.", [["a fraction symptomFrac", "TEST", 15, 37], ["the total inflow", "TREATMENT", 64, 80], ["symptom", "PROBLEM", 118, 125], ["any symptoms", "PROBLEM", 184, 196], ["Outflow", "ANATOMY_MODIFIER", 242, 249], ["outflow", "ANATOMY_MODIFIER", 255, 262]]], ["The number of such individuals is given byDescription of Dynamics Between Compartments:where contactPerPosCase is the average number of contacts per positive case, currently set at 4, andH denotes the total number of high-contact individuals; see the discussion in the I Ai compartment.Description of Dynamics Between Compartments:Outflow: The outflow from the N Ai compartment has four destinations.Description of Dynamics Between Compartments:-Individuals who are tested will test negative and move to the N An compartment, end their self-isolation, and increase their contacts.Description of Dynamics Between Compartments:-Untested individuals leave self-isolation at a rate of 1/selfQuarTime.Description of Dynamics Between Compartments:-Some individuals will become infected and move to the I Ai compartment.Description of Dynamics Between Compartments:-Some individuals will develop flu-like symptoms but not COVID-19, at the rate of nonCOVIDSymptRate.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Non-infected Asymptomatic-Nonisolated Compartment (N An ):Description of Dynamics Between Compartments:Inflow: The inflow to the N An compartment comes from three sources.", [["flu", "DISEASE", 889, 892], ["individuals", "ORGANISM", 635, 646], ["individuals", "ORGANISM", 747, 758], ["individuals", "ORGANISM", 864, 875], ["contactPerPosCase", "PROTEIN", 93, 110], ["Some individuals", "PROBLEM", 742, 758], ["infected", "PROBLEM", 771, 779], ["Some individuals", "PROBLEM", 859, 875], ["flu-like symptoms", "PROBLEM", 889, 906], ["COVID", "TEST", 915, 920], ["The inflow", "TREATMENT", 1218, 1228], ["Outflow", "ANATOMY_MODIFIER", 331, 338], ["outflow", "ANATOMY_MODIFIER", 344, 351], ["infected", "OBSERVATION", 771, 779], ["Inflow", "OBSERVATION", 1210, 1216], ["compartment", "OBSERVATION", 1241, 1252]]], ["First, individuals from the N Si compartment recover from non-COVID-19 symptoms at a rate of 1 selfQuarTimeDescription of Dynamics Between Compartments:.", [["Si", "CHEMICAL", 30, 32], ["non-COVID-19 symptoms", "PROBLEM", 58, 79]]], ["Second, individuals from the N Ai compartment leave self-isolation and increase their contact with others at a rate of 1 selfQuarTimeDescription of Dynamics Between Compartments:.", [["the N Ai compartment", "TREATMENT", 25, 45], ["self-isolation", "TREATMENT", 52, 66]]], ["Third, individuals from the N Si and N Ai compartments who test negative will also increase their contact rates.Description of Dynamics Between Compartments:Outflow: The outflow from the N An compartment has three destinations.", [["Si", "CHEMICAL", 30, 32], ["Outflow", "ANATOMY_MODIFIER", 157, 164], ["outflow", "ANATOMY_MODIFIER", 170, 177]]], ["Second, other individuals will develop flu-like symptoms independent of COVID and move to the N Si compartment at the rate of nonCOVIDSymptRate.", [["flu", "DISEASE", 39, 42], ["Si", "CHEMICAL", 96, 98], ["flu", "PROBLEM", 39, 42], ["symptoms", "PROBLEM", 48, 56], ["COVID", "TREATMENT", 72, 77]]], ["Third, some individuals will become infected and move to the I An compartment.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Recovered Symptomatic-Isolated Compartment (R Si ):Description of Dynamics Between Compartments:Inflow: The inflow to the R Si compartment has two sources.", [["Si", "CHEMICAL", 351, 353], ["individuals", "ORGANISM", 12, 23], ["some individuals", "PROBLEM", 7, 23], ["infected", "PROBLEM", 36, 44], ["infected", "OBSERVATION", 36, 44], ["Inflow", "OBSERVATION", 323, 329], ["inflow", "OBSERVATION", 335, 341]]], ["Recovered asymptomatic-nonisolated (R An ) and recovered asymptomatic-isolated (R Ai ) individuals, who did not get tested, can develop flu-like symptoms independent of COVID-19, at the rate of nonCOVIDSymptRate.Description of Dynamics Between Compartments:Outflow: The outflow from the R Si compartment occurs from individuals who recover from non-COVID-19 symptoms at the rate of 1/selfQuarTime.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Recovered Asymptomatic-Isolated Compartment (R Ai ):Description of Dynamics Between Compartments:Inflow: The inflow to the R Ai compartment comes from individuals in the R An compartment who reduce their exposure to other individuals after being identified as a close contact.", [["flu", "DISEASE", 136, 139], ["Si", "CHEMICAL", 289, 291], ["asymptomatic", "PROBLEM", 10, 22], ["nonisolated", "PROBLEM", 23, 34], ["asymptomatic", "PROBLEM", 57, 69], ["flu", "PROBLEM", 136, 139], ["symptoms", "PROBLEM", 145, 153], ["COVID", "TEST", 169, 174], ["nonCOVIDSymptRate", "TREATMENT", 194, 211], ["non-COVID-19 symptoms", "PROBLEM", 345, 366], ["Asymptomatic", "PROBLEM", 556, 568], ["Outflow", "ANATOMY_MODIFIER", 257, 264], ["outflow", "ANATOMY_MODIFIER", 270, 277]]], ["The number of such individuals is given byDescription of Dynamics Between Compartments:Outflow: The outflow from the R Ai compartment has two destinations.", [["Outflow", "ANATOMY_MODIFIER", 87, 94], ["outflow", "ANATOMY_MODIFIER", 100, 107], ["R", "ANATOMY_MODIFIER", 117, 118], ["Ai", "ANATOMY", 119, 121], ["two destinations", "OBSERVATION", 138, 154]]], ["First, untested individuals leave isolation at the rate of 1/selfQuarTime.", [["individuals", "ORGANISM", 16, 27]]], ["Second, other individuals will develop symptoms independent of COVID-19, at the rate of nonCOVIDSymptRate.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Recovered Asymptomatic-Nonisolated Compartment (R An ):Description of Dynamics Between Compartments:Inflow: The inflow to the R An compartment has six sources:Description of Dynamics Between Compartments:-Untested people from the I Si compartment who recovered naturally.Description of Dynamics Between Compartments:-Untested people from the I Ai compartment who recovered naturally.Description of Dynamics Between Compartments:-Untested people from the I An compartment who recovered naturally.Description of Dynamics Between Compartments:-People from the R Ai and R Si compartments who test negative.Description of Dynamics Between Compartments:-People from the R Ai compartment who leave self-quarantine.Description of Dynamics Between Compartments:-People from the R Si compartment whose non-COVID-19 symptoms disappeared.Description of Dynamics Between Compartments:Outflow: The outflow from the R An compartment occurs in two ways.", [["Si", "CHEMICAL", 487, 489], ["Si", "CHEMICAL", 823, 825], ["Si", "CHEMICAL", 1026, 1028], ["individuals", "ORGANISM", 14, 25], ["people", "ORGANISM", 469, 475], ["people", "ORGANISM", 581, 587], ["people", "ORGANISM", 693, 699], ["people", "SPECIES", 469, 475], ["people", "SPECIES", 581, 587], ["people", "SPECIES", 693, 699], ["People", "SPECIES", 796, 802], ["People", "SPECIES", 903, 909], ["People", "SPECIES", 1008, 1014], ["symptoms", "PROBLEM", 39, 47], ["COVID", "TEST", 63, 68], ["nonCOVIDSymptRate", "TREATMENT", 88, 105], ["Asymptomatic", "PROBLEM", 265, 277], ["non-COVID", "TEST", 1047, 1056], ["symptoms", "PROBLEM", 1060, 1068], ["Outflow", "ANATOMY_MODIFIER", 1126, 1133], ["outflow", "ANATOMY_MODIFIER", 1139, 1146], ["R", "ANATOMY_MODIFIER", 1156, 1157], ["compartment", "OBSERVATION", 1161, 1172]]], ["Second, some individuals will develop symptoms independent of COVID-19, at the rate of nonCOVIDSymptRate.Description of Dynamics Between Compartments:Update Equations: We have the following update equations.Description of Dynamics Between Compartments:\u2022 Known Infected Compartment (KI): This compartment has two sub-compartments, with KI t = KI t (hospitalized), H t (recovered) and we have the following dynamics.Description of Dynamics Between Compartments:Inflow: There are three sources of inflow.", [["individuals", "ORGANISM", 13, 24], ["symptoms", "PROBLEM", 38, 46], ["COVID", "TEST", 62, 67], ["nonCOVIDSymptRate", "TREATMENT", 87, 104], ["Infected", "OBSERVATION", 260, 268], ["inflow", "OBSERVATION", 494, 500]]], ["The infected individuals in I Si , I Ai , and I An compartments who are tested.", [["infected", "OBSERVATION_MODIFIER", 4, 12], ["individuals", "OBSERVATION", 13, 24], ["I Si", "OBSERVATION_MODIFIER", 28, 32]]], ["We assume that individuals from the I Si (hospitalized) subcompartment flow into the KI t (hospitalized) sub-compartment, and that individuals from the I Si (recovered) sub-compartment flow into the KI t (recovered) sub-compartment.", [["Si", "CHEMICAL", 38, 40], ["Si", "CHEMICAL", 154, 156], ["compartment", "ANATOMY", 109, 120], ["flow", "OBSERVATION", 185, 189]]], ["We assume that hospOutOfSymptFrac (20%) of the individuals from the I Ai and I An compartments require hospitalization, while the remaining 1 -hospOutOfSymptFrac = 80% will recover naturally.Description of Dynamics Between Compartments:Outflow: Individuals who require hospitalization move to the H compartment at the rate of 1/infToHospTime, where infToHospTime represents the average time until an infected person requires hospitalization.", [["person", "SPECIES", 409, 415], ["hospitalization", "TREATMENT", 269, 284], ["Outflow", "ANATOMY", 236, 243], ["infected", "OBSERVATION", 400, 408]]], ["Then,Description of Dynamics Between Compartments:\u2022 Hospitalization Compartment (H): This compartment has two sub-compartments, with H t = H t (die), H t (recovered) .Description of Dynamics Between Compartments:Inflow: There are two sources of inflow to the hospitalization compartment: the infected individuals from the I Si and KI compartments who require hospitalization.", [["Si", "CHEMICAL", 324, 326], ["the infected individuals", "PROBLEM", 288, 312], ["inflow", "OBSERVATION", 245, 251], ["infected", "OBSERVATION", 292, 300]]], ["We assume that a fraction deathFrac, currently set at 1/3, of the inflow to the hospitalization compartment will die.", [["a fraction deathFrac", "TEST", 15, 35]]], ["We assume the remaining 1 \u2212 deathFrac = 2/3 will recover.Description of Dynamics Between Compartments:Outflow: Individuals who die leave the hospital at the rate of 1/hospToDeathTime, where hospToDeathTime is the average time between hospitalization and death.", [["death", "DISEASE", 254, 259], ["death", "PROBLEM", 254, 259], ["Outflow", "ANATOMY", 102, 109]]], ["We have the following update equations.Description of Dynamics Between Compartments:\u2022 Known Recovery Compartment (KR):Description of Dynamics Between Compartments:Update Equations: Let recoverOutOfSymptFrac = 1 \u2212 hospOutOfSymptFrac = 80%.", [["hospOutOfSymptFrac", "TEST", 213, 231]]], ["We have the following update equations.Description of Dynamics Between Compartments:\u2022 Death Compartment (D):Description of Dynamics Between Compartments:Update Equations: We have the following update equations.C. Model Parameters and Their Estimated ValuesIn this section, we discuss how we obtain the estimates for different model parameters.Estimating Flow Rates Between Compartments:We assume an incubation period of 5 days [8] .", [["Death", "DISEASE", 86, 91], ["Flow", "OBSERVATION", 354, 358]]], ["After an individual develops symptoms, we assume it takes another 5 days for the individual to become hospitalized [16] .", [["symptoms", "PROBLEM", 29, 37]]], ["Specifically, we set infToSympTime = infToHospTime = sympToHospTime = 5.Estimating Flow Rates Between Compartments:We set the recovery time for symptomatic individuals to be 14 days.", [["symptomatic individuals", "PROBLEM", 144, 167], ["Flow", "OBSERVATION", 83, 87]]], ["Similar to the recovery time, we do not differentiate between deaths at home versus at the hospital and set both sympToDeathTime = hospToDeathTime = 14 [8] .Estimating Flow Rates Between Compartments:We assume that individuals who self-isolate after being identified as a close-contact or develop symptoms from a non-COVID-19 illness spend an average of 10 days reducing their contact with others.", [["deaths", "DISEASE", 62, 68], ["symptoms", "PROBLEM", 297, 305], ["Flow", "OBSERVATION", 168, 172]]], ["We set selfQuarTime = asympToRecoveryTime = 10.Estimating Flow Rates Between Compartments:In our model, non-infected and recovered individuals develop symptoms due to non-COVID-19 diseases at a rate of nonCOVIDSymptRate = 1 1200 .", [["symptoms", "PROBLEM", 151, 159], ["non-COVID-19 diseases", "PROBLEM", 167, 188], ["Flow", "OBSERVATION", 58, 62]]], ["This rate is based on the assumption that 10% of the population is infected over the course of 4 months.", [["infected", "OBSERVATION", 67, 75]]], ["This is roughly estimated using the flu symptom rate in past years as reported by the CDC [3] .", [["the flu symptom rate", "PROBLEM", 32, 52]]], ["We also assume that 28, 000 individuals, corresponding to roughly 3% of the population, initially has symptoms due to the seasonal flu.", [["flu", "DISEASE", 131, 134], ["symptoms", "PROBLEM", 102, 110], ["the seasonal flu", "PROBLEM", 118, 134], ["flu", "OBSERVATION", 131, 134]]], ["This is calculated assuming that flu symptoms last for an average of 4 days.Estimating Disease Dynamics:We use sympOutOfInfFrac to denote the fraction of COVID-19 infected individuals who develop symptoms.", [["flu", "DISEASE", 33, 36], ["individuals", "ORGANISM", 172, 183], ["sympOutOfInfFrac", "PROTEIN", 111, 127], ["flu symptoms", "PROBLEM", 33, 45], ["COVID", "TEST", 154, 159], ["symptoms", "PROBLEM", 196, 204]]], ["We set sympOutOfInfFrac = 50%.Estimating Disease Dynamics:The parameter hospOutOfSympFrac denotes the fraction of symptomatic individuals who need hospitalization.", [["sympOutOfInfFrac", "TEST", 7, 23], ["Estimating Disease Dynamics", "PROBLEM", 30, 57], ["The parameter hospOutOfSympFrac", "TEST", 58, 89], ["symptomatic individuals", "PROBLEM", 114, 137], ["Disease", "OBSERVATION", 41, 48]]], ["Both of these values are roughly estimated using historical hospitalization and death numbers as reported by New York City [10] .", [["death", "DISEASE", 80, 85]]], ["Finally, we assume that some portion of the infected population die at home without hospitalization.", [["infected", "OBSERVATION_MODIFIER", 44, 52], ["population", "OBSERVATION", 53, 63]]], ["We estimate this value using the number of probable deaths as reported by the City.Infection Dynamics and Estimating Contact Rates:The basic reproductive number, R 0 , captures the average number of new infections produced by each infected individual.", [["deaths", "DISEASE", 52, 58], ["infections", "DISEASE", 203, 213], ["new infections", "PROBLEM", 199, 213], ["probable", "UNCERTAINTY", 43, 51], ["deaths", "OBSERVATION", 52, 58], ["average", "OBSERVATION_MODIFIER", 181, 188], ["number", "OBSERVATION_MODIFIER", 189, 195], ["new", "OBSERVATION_MODIFIER", 199, 202], ["infections", "OBSERVATION", 203, 213]]], ["There are numerous recent studies estimating the value of R 0 for COVID-19.", [["COVID", "TEST", 66, 71], ["numerous", "OBSERVATION_MODIFIER", 10, 18]]], ["These estimates vary widely, from anywhere between 2.2 [6] and 5.7 [15] .", [["vary", "OBSERVATION_MODIFIER", 16, 20], ["widely", "OBSERVATION_MODIFIER", 21, 27]]], ["Furthermore, it is possible that R 0 varies across different countries and cities due to climate, environmental, and sociological differences.", [["R 0", "GENE_OR_GENE_PRODUCT", 33, 36]]], ["As a result, we set R 0 = 3.38 according to a tuning procedure using historical hospitalization and death statistics as reported by New York City.", [["death", "DISEASE", 100, 105], ["a tuning procedure", "TREATMENT", 44, 62], ["historical hospitalization", "TREATMENT", 69, 95]]], ["We briefly discuss the details of this procedure in Section D.Infection Dynamics and Estimating Contact Rates:The rate of new infections is controlled by \u03b2, the contact rate between infected and non-infected populations.", [["infections", "DISEASE", 126, 136], ["\u03b2", "GENE_OR_GENE_PRODUCT", 154, 155], ["this procedure", "TREATMENT", 34, 48], ["new infections", "PROBLEM", 122, 136], ["infected and non-infected populations", "PROBLEM", 182, 219], ["new", "OBSERVATION_MODIFIER", 122, 125], ["infections", "OBSERVATION", 126, 136], ["non-infected populations", "OBSERVATION", 195, 219]]], ["In a standard compartmentalized model, the number of new infections during any time period is captured byInfection Dynamics and Estimating Contact Rates:In our model, we have a similar term for every pair of infected and non-infected compartments.", [["compartments", "ANATOMY", 234, 246], ["infections", "DISEASE", 57, 67], ["new infections", "PROBLEM", 53, 67], ["infected and non-infected compartments", "PROBLEM", 208, 246], ["new", "OBSERVATION_MODIFIER", 53, 56], ["infections", "OBSERVATION", 57, 67], ["infected", "OBSERVATION", 208, 216], ["non-infected compartments", "OBSERVATION", 221, 246]]], ["We employ two different contact rates \u03b2 h and \u03b2 , so we differentiate their usage according to whether we are considering isolating or non-isolating compartments.Infection Dynamics and Estimating Contact Rates:We set \u03b2 h = R 0 N \u00d7sympToRecoveryTime and use this as the contact rate between infected and non-infected compartments that are both non-isolating.", [["isolating or non-isolating compartments", "PROBLEM", 122, 161], ["Infection Dynamics", "PROBLEM", 162, 180], ["infected and non-infected compartments", "PROBLEM", 290, 328], ["infected", "OBSERVATION", 290, 298], ["non-infected compartments", "OBSERVATION", 303, 328]]], ["When at least one of the compartments is isolating or symptomatic, we assume that contact between these populations is reduced by one third and use the contact rate \u03b2 = 2 3 \u00d7 R 0 N \u00d7sympToRecoveryTime .", [["symptomatic", "PROBLEM", 54, 65], ["the contact rate", "TEST", 148, 164], ["symptomatic", "OBSERVATION_MODIFIER", 54, 65]]], ["Beginning on March 22, we reduce both \u03b2 h and \u03b2 by a factor of 1/3.", [["\u03b2", "PROTEIN", 46, 47]]], ["This reduction is due to social distancing measures associated with the start of NY Pause.", [["This reduction", "TREATMENT", 0, 14], ["social distancing measures", "TREATMENT", 25, 51]]], ["We set this reduction to 1/3 according to a report by SafeGraph which used smartphone location data to estimate the reduction in foot traffic due to social distancing measures across the United States.", [["foot", "ORGANISM_SUBDIVISION", 129, 133], ["this reduction", "TREATMENT", 7, 21], ["the reduction in foot traffic", "PROBLEM", 112, 141], ["foot", "ANATOMY", 129, 133]]], ["Their study shows that starting March 22, foot traffic in the New York region is at roughly one third of the activity level recorded in previous years over the same time period [14] .Dynamics of Contact Tracing:The parameter contactPerPosCase denotes the average number of close contacts that are identified via tracing for each COVID-19 positive individual.", [["Their study", "TEST", 0, 11], ["each COVID", "TEST", 324, 334], ["foot", "ANATOMY", 42, 46]]], ["The parameter likOfBeingInfected is a multiplier that captures how much more likely an infected individual will be identified as a close contact as compared to a non-infected individual.", [["Infected", "OBSERVATION", 24, 32], ["infected", "OBSERVATION", 87, 95]]], ["Specifically,Dynamics of Contact Tracing:which can be shown to be equal toDynamics of Contact Tracing:.Dynamics of Contact Tracing:Thus, we need estimates for the proportion of infected versus non-infected individuals within the non-isolating population as well as the proportion of infected versus non-infected individuals among people identified as close contacts.", [["people", "ORGANISM", 330, 336], ["people", "SPECIES", 330, 336], ["infected versus non-infected individuals", "PROBLEM", 177, 217], ["infected", "OBSERVATION", 177, 185], ["infected", "OBSERVATION", 283, 291]]], ["Wuhan has a population of approximately 11 million people and is comparable in size to New York City.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["population", "OBSERVATION_MODIFIER", 12, 22], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["It experienced a surge of COVID-19 cases similar to that of New York City.Dynamics of Contact Tracing:To estimate contactPerPosCase and the proportion of infected and non-infected individuals within the close-contact group, we use the results of [1] , a comprehensive study on contact tracing.", [["COVID", "TEST", 26, 31], ["infected and non-infected individuals", "PROBLEM", 154, 191], ["a comprehensive study", "TEST", 252, 273], ["contact tracing", "TEST", 277, 292], ["infected", "OBSERVATION", 154, 162]]], ["This study reports the results of contact tracing in Shenzhen, China but the index cases are mostly travelers arriving from Hubei province.", [["This study", "TEST", 0, 10], ["contact tracing", "TEST", 34, 49]]], ["In this study, the authors identified 1,286 close contacts based on 292 COVID-positive cases.", [["COVID", "GENE_OR_GENE_PRODUCT", 72, 77], ["this study", "TEST", 3, 13]]], ["This suggests an average close contact group size of 1286/292 = 4.4 for each COVID-positive individual identified.", [["COVID", "CANCER", 77, 82], ["COVID", "PROTEIN", 77, 82], ["each COVID", "TEST", 72, 82], ["average", "OBSERVATION_MODIFIER", 17, 24]]], ["Therefore, we set the parameter contactPerPosCase to 4 in our model.", [["the parameter contactPerPosCase", "TREATMENT", 18, 49]]], ["Thus, we estimated the proportion of the infected to non-infected within the close contact group to be P (infected|close-contact)/P (non-infected|close-contact) = 98/1188 = 0.082.Dynamics of Contact Tracing:To estimate P (infected)/P (non-infected), the proportion of infected to non-infected in the general non-isolating population, we used the following approach.", [["infected", "OBSERVATION", 41, 49], ["infected", "OBSERVATION", 268, 276]]], ["According to a recent study, in Wuhan, the probability of death after developing symptoms was 1.4% [5] .", [["death", "DISEASE", 58, 63], ["a recent study", "TEST", 13, 27], ["death", "PROBLEM", 58, 63], ["developing symptoms", "PROBLEM", 70, 89]]], ["Using this estimate and the number of deaths in Wuhan, which is reported as 4,512 by the Johns Hopkins Coronavirus Resource Center [4], we can estimate the total number of infected individuals in Wuhan to be 322,286.", [["deaths", "DISEASE", 38, 44], ["infected", "OBSERVATION", 172, 180]]], ["This estimates the total number of infected individuals over the entire course of the pandemic in Wuhan.", [["infected individuals", "PROBLEM", 35, 55], ["total", "OBSERVATION_MODIFIER", 19, 24], ["number", "OBSERVATION_MODIFIER", 25, 31], ["infected", "OBSERVATION", 35, 43]]], ["In order to estimate the total number of infected individuals at some random time between mid-January and mid-February, we divide this by two and use 161,143 as the average number of infected individuals at a given time.", [["infected individuals", "PROBLEM", 41, 61], ["infected individuals", "PROBLEM", 183, 203], ["infected", "OBSERVATION", 41, 49], ["infected", "OBSERVATION", 183, 191]]], ["This approximation implicitly assumes a linear build-up of new COVID-positive cases, which is not true for infection spread within a population, but nevertheless serves as a reasonable rough estimate.", [["infection", "DISEASE", 107, 116], ["COVID", "GENE_OR_GENE_PRODUCT", 63, 68], ["COVID", "PROTEIN", 63, 68], ["new COVID-positive cases", "PROBLEM", 59, 83], ["infection spread", "PROBLEM", 107, 123], ["linear", "OBSERVATION_MODIFIER", 40, 46], ["new", "OBSERVATION_MODIFIER", 59, 62], ["positive cases", "OBSERVATION_MODIFIER", 69, 83], ["not true for", "UNCERTAINTY", 94, 106], ["infection", "OBSERVATION", 107, 116]]], ["These two parameters are the R 0 value and the initial number of infected asymptomatic-nonisolated individuals on March 2.", [["the R 0 value", "TEST", 25, 38], ["infected asymptomatic", "PROBLEM", 65, 86], ["infected", "OBSERVATION_MODIFIER", 65, 73], ["asymptomatic", "OBSERVATION", 74, 86]]], ["We ended up with an R 0 value of 3.38 and an initial infected asymptomatic-nonisolated population of about 10,000.", [["an R 0 value", "TEST", 17, 29], ["an initial infected asymptomatic-nonisolated population", "PROBLEM", 42, 97], ["infected", "OBSERVATION_MODIFIER", 53, 61], ["asymptomatic", "OBSERVATION", 62, 74]]], ["These starting parameters are tuned based on hospitalization, death, and test data up to April 15.", [["death", "DISEASE", 62, 67], ["test data", "TEST", 73, 82]]], ["We assume that the tests are conducted daily on people in the order of symptomatic, isolated, and finally non-isolated people.D. Model ValidationThe plots in Figure 4 show the epidemic trajectory as predicted by our model.", [["people", "ORGANISM", 48, 54], ["people", "ORGANISM", 119, 125], ["people", "SPECIES", 48, 54], ["people", "SPECIES", 119, 125], ["the tests", "TEST", 15, 24], ["symptomatic", "PROBLEM", 71, 82]]], ["In particular, Figure 4a shows the total number of currently hospitalized, symptomatic infected, asymptomatic infected and known infected people on each day as projected by the model.", [["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["symptomatic infected", "PROBLEM", 75, 95], ["asymptomatic infected", "PROBLEM", 97, 118], ["symptomatic", "OBSERVATION_MODIFIER", 75, 86], ["infected", "OBSERVATION", 87, 95], ["asymptomatic", "OBSERVATION_MODIFIER", 97, 109], ["infected", "OBSERVATION_MODIFIER", 110, 118], ["infected", "OBSERVATION_MODIFIER", 129, 137]]], ["In Figure 4b , we compare the cumulative number of deaths predicted by our model with the actual cumulative number of deaths.", [["deaths", "DISEASE", 51, 57], ["deaths", "DISEASE", 118, 124]]], ["The data set from NYC Health includes confirmed and probable deaths due to COVID-19.", [["deaths", "DISEASE", 61, 67], ["COVID-19", "CHEMICAL", 75, 83], ["COVID", "TEST", 75, 80]]], ["A death is classified as probable if the decedent was a New York City resident who had no known positive laboratory test for COVID-19 but the death certificate lists as a cause of death \"COVID-19\" or equivalent.", [["death", "DISEASE", 2, 7], ["death", "DISEASE", 142, 147], ["death", "DISEASE", 180, 185], ["A death", "PROBLEM", 0, 7], ["COVID", "TEST", 125, 130], ["death", "PROBLEM", 180, 185]]], ["We show both confirmed deaths and probable deaths in our plots.", [["deaths", "DISEASE", 23, 29], ["deaths", "DISEASE", 43, 49], ["probable", "UNCERTAINTY", 34, 42]]], ["In Figure 4c , we plot the actual daily number of tests conducted and positive cases found in the City.", [["tests", "TEST", 50, 55], ["positive cases", "PROBLEM", 70, 84]]], ["We set the testing capacity to 20,000 in the City for future projections in this plot.", [["the testing capacity", "TEST", 7, 27]]], ["Note that the daily number of positive tests in our model fluctuates because we use the actual number of tests performed in the City until early May as the number of tests performed in our model.", [["positive tests", "TEST", 30, 44], ["tests", "TEST", 105, 110], ["tests", "TEST", 166, 171]]], ["However, the number of positive cases identified in our model emerges from the internal behavior of our model.", [["positive", "OBSERVATION_MODIFIER", 23, 31], ["cases", "OBSERVATION", 32, 37]]], ["Figure 4e plots the daily deaths projected by our model against the daily deaths reported by NYC Health, including probable deaths.", [["deaths", "DISEASE", 26, 32], ["deaths", "DISEASE", 74, 80], ["deaths", "DISEASE", 124, 130]]]], "299d71dfb14e47a63024dea292f2ecf6b94bd8fd": [["Redistributing income support from already profitable farming regions to other goals of the CAP could unlock some of the policy's untapped potential.", [["Redistributing income support", "TREATMENT", 0, 29], ["the CAP", "PROBLEM", 88, 95]]], ["Result-based payments and better monitoring and evaluation are also necessary.INTRODUCTIONTransforming agriculture to support both human and environmental health is recognized as critical to achieving the shared international agenda for social development and environmental protection 1 found in the United Nations' Sustainable Development Goals (SDGs).", [["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["better monitoring", "TEST", 26, 43], ["evaluation", "TEST", 48, 58]]], ["2 Agriculture is crucial to providing good nutrition for human health, but the driving role of agriculture for biodiversity loss, water use and pollution, air pollution, and climate change must also be addressed.", [["biodiversity loss", "DISEASE", 111, 128], ["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["biodiversity loss", "PROBLEM", 111, 128], ["air pollution", "TREATMENT", 155, 168], ["air pollution", "OBSERVATION", 155, 168]]], ["[3] [4] [5] European agriculture is a key case study to this end because the European Union (EU) is committed to being a world leader in achieving the SDGs.", [["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10]]], ["The Green Deal recognizes the importance of a fair, healthy, and environmentally friendly food system in its ''Farm to Fork'' strategy, and claims at least 40% of the CAP budget for 2021-2027 would contribute to climate action.", [["2021-2027", "CHEMICAL", 182, 191]]], ["The Green Deal also recognizes that the EU is not meeting its objective to halt biodiversity loss, mainly driven by unsustainable land use.", [["halt biodiversity loss", "PROBLEM", 75, 97], ["biodiversity loss", "OBSERVATION", 80, 97]]], ["The CAP will be reformed after 2020, and we reveal the untapped potential for vast spending under the policy to contribute to sustainable agriculture in Europe.", [["The CAP", "TEST", 0, 7], ["CAP", "OBSERVATION_MODIFIER", 4, 7]]], ["To do so, CAP payments will need to be redistributed from supporting income in regions where farming is already profitable to supporting farmers to implement environment-and climate-friendly practices.", [["CAP payments", "TREATMENT", 10, 22]]], ["In light of the urgent need to reconcile food production with sustainable development and make effective use of limited public funds, agricultural subsidies that support overproduction of unhealthy foods in environmentally damaging ways are coming under increasing scrutiny.", [["limited public funds", "TREATMENT", 112, 132], ["agricultural subsidies", "TREATMENT", 134, 156]]], ["A new report 8 finds global agricultural subsidies total over $700 billion (~V640 billion) per year, with many driving unsustainable production practices and environmental damage.", [["environmental damage", "PROBLEM", 158, 178]]], ["If applied more prudently, such subsidies could be a powerful tool to leverage agriculture's contribution to achieving the SDGs.OPEN ACCESSThe Common Agricultural Policy (CAP) is the guiding agricultural policy of the EU, and the European Commission has communicated that the future CAP (i.e., after 2020) should evolve in line with the SDGs.", [["the SDGs", "PROBLEM", 119, 127]]], ["13 The CAP was founded in 1962 with the original goals to increase agricultural productivity, ensure a fair standard of living for the agricultural community, and ensure market stability, as established in the Treaty on the Functioning of the European Union.", [["The CAP", "TEST", 3, 10], ["CAP", "OBSERVATION_MODIFIER", 7, 10], ["agricultural productivity", "OBSERVATION", 67, 92]]], ["Its original focus has been expanded over the decades from being farmer-, production-, and consumer-orientated to nine modern objectives encompassing a broad range of societal concerns, proposed in 2018 to 14 (a) support viable farm income and resilience; (b) enhance market orientation and increase competitiveness; (c) improve farmers' position in the value chain; (d) contribute to climate change mitigation and adaptation; (e) foster sustainable and efficient management of natural resources; (f) protect biodiversity, enhance ecosystem services, and preserve habitats and landscapes; (g) attract young farmers and facilitate rural business development; (h) promote employment, growth, social inclusion, and local development in rural areas; (i) respond to societal demands on food and health quality, and animal welfare.OPEN ACCESSHowever, the original objectives are still in place, and the two sets of objectives are in stark contrast to each other.", [["OPEN ACCESSHowever", "TREATMENT", 825, 843], ["focus", "OBSERVATION_MODIFIER", 13, 18], ["expanded", "OBSERVATION_MODIFIER", 28, 36]]], ["15 Currently, the CAP is organized under two ''pillars,'' where Pillar I contains market management (5% of CAP budget) and direct payments to farmers (72% of CAP budget), and Pillar II contains schemes related to rural development, the environment, and climate action (23% of CAP budget) (from here on italicized terms in the text are defined in Table 1 ).OPEN ACCESSThe CAP has a decades-long history of reform successively aiming to address overproduction, inequality, and environmental concerns with the structure of payments (Note S1).", [["market management", "TREATMENT", 82, 99], ["CAP budget", "TREATMENT", 107, 117], ["direct payments", "TREATMENT", 123, 138], ["CAP budget", "TREATMENT", 158, 168], ["overproduction", "PROBLEM", 443, 457], ["CAP", "OBSERVATION_MODIFIER", 18, 21], ["pillars", "OBSERVATION_MODIFIER", 47, 54], ["Pillar", "ANATOMY", 175, 181], ["CAP", "OBSERVATION_MODIFIER", 371, 374]]], ["In its first three decades, CAP support to farmers through guaranteed minimum prices for products ultimately resulted in extreme levels of overproduction described as ''lakes of milk and beef mountains'' 16 in the 1970s and 1980s.", [["milk", "ANATOMY", 178, 182], ["milk", "ORGANISM_SUBSTANCE", 178, 182], ["milk", "SPECIES", 178, 182], ["beef", "SPECIES", 187, 191], ["CAP support", "TREATMENT", 28, 39], ["guaranteed minimum prices", "TREATMENT", 59, 84], ["products", "TREATMENT", 89, 97], ["extreme levels of overproduction", "PROBLEM", 121, 153]]], ["To address this problem, the MacSharry reform in 1992 replaced market support with socalled direct payments to farmers, which were coupled to production based on areas of eligible crops and numbers of eligible livestock.", [["market support", "TREATMENT", 63, 77]]], ["17 Since 2005, farmers receive the majority of their support as decoupled direct payments based on their agricultural area.", [["their support", "TREATMENT", 47, 60], ["direct payments", "TREATMENT", 74, 89]]], ["This area-based support is contingent on farmers keeping their land in ''good agricultural and environmental condition'' and complying with Statutory Management Requirements including meeting minimum standards for protection of the environment, animal health and welfare, and food safety (Table 1) .", [["Statutory Management", "TREATMENT", 140, 160]]], ["Three remaining problems with direct payments after the 2003 reforms, however, were that (1) rates of decoupled payments varied substantially both within and among the Member States, 18 (2) payments were concentrated among few farmers, and (3) the CAP still failed to adequately address citizens' concerns regarding the sustainability of farming, the environment, and climate change.", [["the CAP", "PROBLEM", 244, 251]]], ["19 Reforms undertaken to date to address each of these problems have so far proven ineffective, despite the introduction of internal and external convergence, capping and redistribution of payments, and green direct payments (Table 1 and Note S1).OPEN ACCESSIf direct payments contributed to improving income distribution and achieving the SDGs (beyond what would be achieved through market forces alone), then they could be said to be increasing societal welfare.", [["internal and external convergence", "TREATMENT", 124, 157], ["capping and redistribution of payments", "TREATMENT", 159, 197], ["OPEN ACCESSIf direct payments", "TREATMENT", 247, 276], ["the SDGs", "PROBLEM", 336, 344], ["redistribution", "OBSERVATION_MODIFIER", 171, 185]]], ["Otherwise these payments could be better used in the pursuit of other goals by providing the necessary support to farm systems that provide public goods in the form of rural, cultural, and environmental benefits that are not sufficiently rewarded on the market, such as in marginal and low-income areas characterized by climate-friendly agriculture and extensively managed grasslands with high biodiversity and social and cultural values.", [["cultural values", "TEST", 422, 437]]], ["20 The CAP is currently undergoing reform, with a new policy being proposed for 2021-2027, 14 so analysis of its contribution to multiple social and environmental goals is timely.OPEN ACCESSHere, we analyze the potential for CAP spending to contribute to achieving its nine modern objectives (as listed in the Commission's June 2018 proposal 14 ) and the SDGs in rural Europe.", [["CAP", "PROBLEM", 225, 228], ["CAP", "OBSERVATION_MODIFIER", 7, 10]]], ["We first expand on recent evaluations of the CAP and SDGs based on expert judgment 15 by quantifying the alignment between CAP payment instruments (referred to in EU legislation as measures), its modern objectives, the SDGs, and CAP monitoring and evaluation indicators.", [["recent evaluations", "TEST", 19, 37], ["the CAP", "PROBLEM", 41, 48], ["expert judgment", "TEST", 67, 82], ["CAP payment instruments", "TREATMENT", 123, 146], ["the SDGs", "TEST", 215, 223], ["CAP monitoring", "TEST", 229, 243], ["evaluation indicators", "TEST", 248, 269], ["CAP", "OBSERVATION_MODIFIER", 45, 48]]], ["We then scrutinize the distribution of recent CAP payments against social and environmental needs and the provision of public goods through CAP spending.", [["recent CAP payments", "TREATMENT", 39, 58], ["CAP", "OBSERVATION_MODIFIER", 46, 49]]], ["We argue that this imbalance Cross-compliance Mandatory conditions that must be met before a farmer receives any decoupled direct payments.", [["this imbalance", "PROBLEM", 14, 28]]], ["These include both complying with regulations related to agriculture (see SMR) as well as land maintenance requirements (see GAEC)OPEN ACCESSInternal convergence (internal equalization) The mandatory CAP mechanism for equalizing decoupled direct payments to a uniform hectare payment within each Member State.", [["land maintenance requirements", "TREATMENT", 90, 119], ["OPEN ACCESSInternal convergence", "TREATMENT", 130, 161], ["internal equalization)", "TREATMENT", 163, 185]]], ["The need for this mechanism emerged due to substantial variation in the hectare payment rates among farms following the introduction of decoupled direct payments in 2005, when many Member States elected to convert portions of previous livestock payments to farm-specific decoupled area payments.", [["this mechanism", "TREATMENT", 13, 27], ["substantial variation", "PROBLEM", 43, 64]]], ["Even farms that ceased livestock production after 2005 retained the right to their farm-specific payments limits the CAP's potential contribution to achieving its own objectives as well as the SDGs as claimed by the Commission.", [["right", "ANATOMY_MODIFIER", 68, 73]]], ["We suggest equitability (i.e., needs-based income support) is essential for the future CAP to achieve its modern objectives and contribute to the SDGs, as are payments targeted toward the objectives using clearly aligned instruments (measures) and monitored with supporting impact indicators.Alignment of CAP with the SDGsWe find that many connections between the CAP and the SDGs exist, but their full potential is currently limited because of the inequitable distribution of CAP spending among its objectives.", [["SDGsWe", "DNA", 318, 324], ["SDGs", "DNA", 376, 380], ["the CAP", "TREATMENT", 360, 367], ["CAP", "PROBLEM", 477, 480], ["CAP", "OBSERVATION_MODIFIER", 305, 308], ["CAP", "OBSERVATION_MODIFIER", 364, 367], ["CAP", "OBSERVATION_MODIFIER", 477, 480]]], ["More than 60% of the current CAP budget goes to supporting only one of the CAP objectives 15 -viable farm income (objective (a)), which aligns with targets for only two of the 17 SDGs (building resilience of the vulnerable [SDG1] and increasing incomes of small-scale food producers [SDG2]) ( Figure 1 ).", [["the CAP objectives", "TEST", 71, 89], ["small", "OBSERVATION_MODIFIER", 256, 261]]], ["These objectives with high potential for the SDGs are supported almost exclusively by the smaller Pillar II funding and include environmental care (e), 2% of CAP budget; preserving landscapes and biodiversity (f), 9%; generational renewal (g), less than 1%; vibrant rural areas (h), 6%; and protecting food and health quality (i), 2% ( Figure 1 ).", [["the SDGs", "PROBLEM", 41, 49], ["CAP budget", "TREATMENT", 158, 168], ["smaller", "OBSERVATION_MODIFIER", 90, 97], ["Pillar", "OBSERVATION_MODIFIER", 98, 104]]], ["In addition, there is currently low ability to monitor how the CAP contributes to the SDGs, because appropriate indicators aligned with the SDGs are insufficient (Figure 1 ), which limits follow-up and review of the policy.", [["the SDGs", "PROBLEM", 82, 90]]], ["The most relevant set of CAP indicators for the SDGs are the Target indicators, where nearly all can be linked with SDGs, but the majority of indicators do not align with any SDGs (gray box ''not aligned'' in Figure 1 ); this makes it difficult to monitor and evaluate progress or policy contributions toward desired social or environmental goals (see also Scown and Nicholas 23 (Figure 1 ).CAP Payments Compared with Social and Environmental NeedsOur results show that CAP area-based decoupled direct payments are not well aligned with the goal of supporting fair farm incomes (CAP objective (a) and linked to SDGs 1 and 2).", [["the SDGs", "PROBLEM", 44, 52], ["CAP area", "PROBLEM", 470, 478]]], ["We found average farm incomes in 65% of regions are at or above the 2015 EU median, but most agricultural jobs are in the lowest-paid regions ( Figure 2A ).", [["average", "OBSERVATION_MODIFIER", 9, 16], ["farm", "OBSERVATION_MODIFIER", 17, 21], ["incomes", "OBSERVATION_MODIFIER", 22, 29], ["agricultural jobs", "OBSERVATION", 93, 110]]], ["The intention is to increase synergies between income support and rural development goalsCAP Payments Compared with Social and Environmental NeedsTerms are listed as mentioned chronologically in the text and in Note S1.OPEN ACCESSArticle EU's full-time farm labor-work in the lowest-paid 20% of regions grouped by average farm-labor income ( Figure 2A ).", [["income support", "TREATMENT", 47, 61], ["rural development goalsCAP Payments", "TREATMENT", 66, 101], ["farm labor", "PROBLEM", 253, 263]]], ["Meanwhile, the regions with the highest farm incomes support the fewest jobs, with more than ten times more farm jobs located in the lowest compared with the highest income deciles (Figure 2A ).", [["regions", "ANATOMY_MODIFIER", 15, 22], ["highest", "OBSERVATION_MODIFIER", 32, 39], ["fewest", "OBSERVATION_MODIFIER", 65, 71], ["jobs", "OBSERVATION", 72, 76]]], ["According to our analysis, richer farming regions receive substantial CAP payments that bring them further above the EU median income, on average, while CAP payments to the poorest 40% of regions are not sufficient to make farm income reach the EU median disposable income.", [["our analysis", "TEST", 13, 25], ["substantial CAP payments", "TREATMENT", 58, 82], ["CAP payments", "TREATMENT", 153, 165]]], ["Thus, current payments increase income inequality within agriculture (exacerbating income differences between rich and poor farmers), so the necessity of income support in farming regions already above the EU median income across sectors must be questioned.OPEN ACCESSIn terms of farming providing benefits related to other SDGs, we assessed CAP payments related to farming practices of climate-friendly agriculture (SDG 13) and maintenance of high nature value (HNV) farmland to support biodiversity (SDG 15).", [["SDG", "CHEMICAL", 417, 420], ["HNV", "SPECIES", 463, 466], ["income support", "TREATMENT", 154, 168], ["other SDGs", "PROBLEM", 318, 328], ["CAP payments", "TREATMENT", 342, 354], ["high nature", "OBSERVATION_MODIFIER", 444, 455]]], ["We found that the most climate-and biodiversity-friendly farming regions, those with low greenhouse gas (GHG) emissions and a large proportion of HNV farmland, often generate less income than the most climate polluting and least biodiverse regions with high GHG emissions and low fractions of HNV farmland ( Figures 2C and 2E ).", [["GHG", "CHEMICAL", 105, 108], ["low greenhouse gas (GHG) emissions", "PROBLEM", 85, 119], ["a large proportion of HNV farmland", "PROBLEM", 124, 158], ["high GHG emissions", "PROBLEM", 253, 271], ["low fractions of HNV farmland", "PROBLEM", 276, 305], ["large", "OBSERVATION_MODIFIER", 126, 131], ["HNV farmland", "OBSERVATION", 146, 158], ["high", "OBSERVATION_MODIFIER", 253, 257], ["GHG emissions", "OBSERVATION", 258, 271], ["low fractions", "OBSERVATION_MODIFIER", 276, 289]]], ["These regions providing public goods also tend to receive the same or less income support per worker, Box height for CAP funding instruments reflects the share of the 2014-2020 CAP budget.", [["CAP funding instruments", "TREATMENT", 117, 140]]], ["Box height for CAP objectives reflects the proportion of funding support each objective receives or the number of SDG targets each objective aligns with, whichever is greater.", [["Box height", "TEST", 0, 10], ["CAP objectives", "TEST", 15, 29], ["funding support", "TREATMENT", 57, 72], ["greater", "OBSERVATION_MODIFIER", 167, 174]]], ["Box height for SDGs reflects the number of targets that align with CAP objectives plus the number of CAP indicators that monitor progress toward each goal.", [["Box height", "TEST", 0, 10], ["SDGs", "PROBLEM", 15, 19], ["CAP objectives", "TREATMENT", 67, 81]]], ["Box size for CAP indicators reflects the number of indicators in each set.", [["CAP indicators", "TEST", 13, 27], ["size", "OBSERVATION_MODIFIER", 4, 8], ["CAP", "OBSERVATION_MODIFIER", 13, 16]]], ["Data sources: current CAP funding instruments (V) and contribution to achieving CAP objectives (Pe'er et al. 15 because decoupled direct payments are area-based.", [["CAP objectives", "TEST", 80, 94], ["Pe", "PROBLEM", 96, 98], ["Pe", "OBSERVATION", 96, 98]]], ["Based on our analysis, average farm incomes across the upper half of regions with the highest agricultural GHG emissions are almost 60% higher than those in the lower half of emitting regions (Figure 2C) .", [["our analysis", "TEST", 9, 21], ["upper half", "ANATOMY_MODIFIER", 55, 65], ["highest", "OBSERVATION_MODIFIER", 86, 93], ["GHG emissions", "OBSERVATION", 107, 120], ["almost", "OBSERVATION_MODIFIER", 125, 131], ["60%", "OBSERVATION_MODIFIER", 132, 135], ["higher", "OBSERVATION_MODIFIER", 136, 142], ["lower", "ANATOMY_MODIFIER", 161, 166]]], ["Similarly, while HNV farmland is important for biodiversity, the average farm income across the 30% of regions supporting the least HNV farmland is more than twice that of other regions ( Figure 2E ).", [["HNV", "SPECIES", 17, 20], ["HNV", "SPECIES", 132, 135], ["farmland", "OBSERVATION", 136, 144]]], ["The highest GHG-emitting regions are largely in the Netherlands, Belgium, Denmark, United Kingdom, and Ireland with intensive livestock production systems (particularly cattle and pigs), as well as northern Italy where rice is produced ( Figure 2D ; please see open database of Scown et al. 24 for these and other variables by NUTS2 regions).", [["pigs", "ORGANISM", 180, 184], ["NUTS2 regions", "PROTEIN", 327, 340], ["cattle", "SPECIES", 169, 175], ["pigs", "SPECIES", 180, 184], ["rice", "SPECIES", 219, 223], ["cattle", "SPECIES", 169, 175], ["pigs", "SPECIES", 180, 184], ["rice", "SPECIES", 219, 223], ["intensive livestock production systems", "TREATMENT", 116, 154], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["GHG", "OBSERVATION_MODIFIER", 12, 15], ["emitting regions", "OBSERVATION", 16, 32], ["largely", "OBSERVATION_MODIFIER", 37, 44]]], ["HNV farmland is relatively abundant in mountain regions of Austria and Italy, Scotland, Croatia, and parts of France and Spain ( Figure 2F) , where farm incomes are relatively low ( Figure 2B ).", [["HNV", "SPECIES", 0, 3], ["farmland", "OBSERVATION", 4, 12], ["relatively", "OBSERVATION_MODIFIER", 16, 26], ["abundant", "OBSERVATION_MODIFIER", 27, 35], ["mountain", "OBSERVATION_MODIFIER", 39, 47], ["Austria", "OBSERVATION", 59, 66]]], ["These results suggest CAP payments are biased against, rather than in favor of, marginal regions that provide public goods in the form of climate-and biodiversity-friendly agriculture, which are not rewarded on the market.", [["CAP payments", "TREATMENT", 22, 34], ["CAP payments", "OBSERVATION", 22, 34]]], ["Thus, the current distribution of CAP payments is not supporting the CAP objective of fair farm income in environmentally friendly farming regions or the interacting social and environmental SDGs related to agriculture throughout the EU.OPEN ACCESSMore than V24.2 billion in income support in our data were paid to regions whose average annual farm income is at or above the EU median disposable income without these payments (orange bars in Figure 3A ).", [["CAP payments", "TREATMENT", 34, 46], ["income support", "TREATMENT", 275, 289]]], ["Nonetheless, income support payments made to regions with incomes below the EU median (blue regions in Figure 3D ) indicate a more prudent use of CAP direct payments.", [["income support payments", "TREATMENT", 13, 36], ["CAP direct payments", "TREATMENT", 146, 165]]], ["We analyzed where the average excess income support was distributed in terms of regional environmental performance, based on GHG emissions and HNV farmland.", [["the average excess income support", "TREATMENT", 18, 51], ["GHG emissions", "TEST", 125, 138]]], ["Almost 70% of the V24.2 billion (V16.9 billion) was paid to the highest 50% of GHG-emitting regions (orange bars in Figure 3B ) and almost 58% (V14.0 billion) was paid to the 40% of regions maintaining the lowest fraction of HNV farmland (Greece is excluded from the HNV calculation).", [["HNV", "SPECIES", 225, 228], ["the HNV calculation", "TEST", 263, 282], ["HNV farmland", "OBSERVATION", 225, 237]]], ["The data show CAP income support payments are 1.5 times higher in farming regions producing the most climate pollution than in the lowest-polluting farms, and most of this income support in high-emitting regions also goes to regions with high farm incomes ( Figure 3B ).", [["The data", "TEST", 0, 8], ["CAP income support payments", "TREATMENT", 14, 41], ["CAP", "OBSERVATION_MODIFIER", 14, 17], ["polluting farms", "OBSERVATION", 138, 153], ["high", "OBSERVATION_MODIFIER", 190, 194], ["high", "OBSERVATION_MODIFIER", 238, 242]]], ["Similarly, almost 58% of income support payments made to already market-profitable farming regions (orange bars) also flow to the 40% of regions supporting the least HNV farmland ( Figure 3C ).", [["income support payments", "TREATMENT", 25, 48]]], ["These results show that V24.2 billion of CAP income support did not go to regions in obvious need of income support, nor does much of this flow to regions performing well in terms of environmental goals.OPEN ACCESSWe next investigated the aim of the CAP to support rural development, particularly through CAP objective (e) vibrant rural areas, which has the potential to contribute to many SDGs (Figure 1 ).", [["CAP income support", "TREATMENT", 41, 59], ["income support", "TREATMENT", 101, 115], ["the CAP", "TREATMENT", 246, 253], ["rural development", "TREATMENT", 265, 282], ["vibrant rural areas", "PROBLEM", 323, 342]]], ["We assessed where V50.3 billion of CAP funding is geographically allocated by NUTS3 regions (we were able to allocate 85% of the total V59.4 billion payments to a NUTS3 geographic region; see Experimental Procedures), finding only around 38% of this goes to predominantly rural areas ( Figure 4 ).OPEN ACCESSAnother 42% goes to intermediate (urban fringe) areas, which may still support rural development ( Figure 4 ).", [["CAP funding", "TREATMENT", 35, 46], ["the total V59.4 billion payments", "TREATMENT", 125, 157], ["OPEN ACCESSAnother", "TREATMENT", 297, 315], ["CAP", "OBSERVATION_MODIFIER", 35, 38], ["funding", "OBSERVATION", 39, 46], ["geographically", "OBSERVATION_MODIFIER", 50, 64], ["predominantly", "OBSERVATION_MODIFIER", 258, 271], ["rural", "OBSERVATION_MODIFIER", 272, 277]]], ["The final 20% (V9.9 billion) goes to predominantly urban areas (e.g., Greater London [all NUTS3 codes within UKI-], which received V64 million in CAP subsidies in 2015).", [["UKI", "TEST", 109, 112], ["predominantly", "OBSERVATION_MODIFIER", 37, 50], ["urban", "OBSERVATION_MODIFIER", 51, 56]]], ["Within the total subsidies for each NUTS3 region, the majority are area-based from Pillar I (dark bars in Figure 4 ).", [["NUTS3 region", "DNA", 36, 48], ["each NUTS3 region", "PROBLEM", 31, 48], ["total", "OBSERVATION_MODIFIER", 11, 16], ["majority", "OBSERVATION_MODIFIER", 54, 62], ["area", "OBSERVATION_MODIFIER", 67, 71], ["Pillar", "OBSERVATION_MODIFIER", 83, 89]]], ["However, intermediate areas and landowners living in urban areas receive substantial funding from Pillar II for rural development ( Figure 4 ).", [["Pillar II", "CHEMICAL", 98, 107], ["substantial funding from Pillar II", "TREATMENT", 73, 107], ["intermediate", "OBSERVATION_MODIFIER", 9, 21], ["areas", "OBSERVATION_MODIFIER", 22, 27], ["substantial", "OBSERVATION_MODIFIER", 73, 84], ["funding", "OBSERVATION", 85, 92]]], ["This rural development funding constitutes 28% (V5.4 billion) of the funding in rural areas, 23% (V4.9 billion) in intermediate areas, and 25% (V2.5 billion) in urban regions ( Figure 4 ).", [["rural", "ANATOMY_MODIFIER", 80, 85], ["intermediate", "OBSERVATION_MODIFIER", 115, 127], ["areas", "OBSERVATION_MODIFIER", 128, 133]]], ["The V2.5 billion in Pillar II payments to urban areas are additional to the V24.2 billion in income support above the EU median.", [["The V2.5 billion in Pillar II payments", "TREATMENT", 0, 38], ["Pillar", "OBSERVATION_MODIFIER", 20, 26]]], ["While Pillar II payments to urban areas may represent payment for value-added in a rural area (e.g., if a landowner invested in farmer training programs), it is difficult to demonstrate the intended benefit for rural development from these subsidies.DISCUSSIONThe Same Old CAP Will Not Promote the SDGs Assessments of the CAP's contribution to the SDGs are few; however, the existing consensus suggests that the CAP's potential can only be realized with significant reallocation of funding among CAP objectives, 15 as well as substantially improving monitoring and evaluation.", [["Pillar II payments", "TREATMENT", 6, 24], ["value", "TEST", 66, 71], ["the CAP's", "PROBLEM", 318, 327], ["the SDGs", "PROBLEM", 344, 352], ["the CAP's", "PROBLEM", 408, 417], ["evaluation", "TEST", 565, 575]]], ["23, 26 We assessed the potential for the CAP to contribute to achieving its own objectives and, with those, the SDGs by analyzing how well the modern CAP objectives align with SDG targets, and which SDGs are covered by the current CAP monitoring and evaluation indicators (see Experimental Procedures).", [["SDG", "SIMPLE_CHEMICAL", 176, 179], ["the CAP", "PROBLEM", 37, 44], ["SDG targets", "TREATMENT", 176, 187], ["the current CAP monitoring", "TEST", 219, 245], ["evaluation indicators", "TEST", 250, 271]]], ["Our quantitative results, based on the number of CAP objectives and indicators that align with SDG targets and indicators, support the conclusion of other analyses based on expert judgment 15, 22 and communication from the European Commission 9 that the CAP has the potential to contribute to most of the SDGs, but our analysis indicates that actually doing so would require substantial reallocation of payments among goals.DISCUSSIONThe nine modern objectives for the 2021-2027 CAP 14 have the potential to contribute to many SDGs for European societies and the environment; however, a recent analysis by Pe'er et al. 15 shows that the distribution of current funding is highly unbalanced among these nine objectives.", [["SDG targets", "TREATMENT", 95, 106], ["other analyses", "TEST", 149, 163], ["expert judgment", "TEST", 173, 188], ["the CAP", "PROBLEM", 250, 257], ["the SDGs", "PROBLEM", 301, 309], ["our analysis", "TEST", 315, 327], ["substantial reallocation of payments", "TREATMENT", 375, 411], ["a recent analysis", "TEST", 585, 602], ["Pe", "OBSERVATION", 606, 608]]], ["Similarly, monitoring and evaluation of the CAP based on the current set of indicators is not optimized to determine whether or not payments are actually contributing to SDGs, because CAP indicators are lacking for many SDGs.", [["SDGs", "PATHOLOGICAL_FORMATION", 220, 224], ["evaluation", "TEST", 26, 36], ["the CAP", "TEST", 40, 47], ["SDGs", "PROBLEM", 170, 174], ["many SDGs", "PROBLEM", 215, 224]]], ["23 Our findings show that while the CAP indeed has the potential to promote many SDGs in Europe, 9 excessive CAP payments are currently being made to regions that would be relatively well-off anyway (i.e., income support in highly productive farming regions).", [["SDGs", "DISEASE", 81, 85], ["9 excessive CAP payments", "TREATMENT", 97, 121], ["highly", "OBSERVATION_MODIFIER", 224, 230], ["productive", "OBSERVATION_MODIFIER", 231, 241]]], ["Further, a substantial fraction of CAP payments are supporting already high-income agriculture with high GHG emissions; these payments could be better used (reallocated) to finance environmental and climate measures (AECMs, or the proposed post-2020 ecoschemes 14 ) .", [["CAP payments", "TREATMENT", 35, 47], ["high GHG emissions", "PROBLEM", 100, 118], ["substantial", "OBSERVATION_MODIFIER", 11, 22], ["fraction", "OBSERVATION_MODIFIER", 23, 31], ["CAP payments", "OBSERVATION", 35, 47], ["GHG emissions", "OBSERVATION", 105, 118]]], ["Similarly, we found a substantial portion of Pillar II funding (the Rural Development Program) actually goes to recipients in predominantly urban areas of the EU, likely having limited if any benefit for rural development.", [["Pillar II funding", "TREATMENT", 45, 62], ["substantial", "OBSERVATION_MODIFIER", 22, 33], ["portion", "OBSERVATION_MODIFIER", 34, 41], ["Pillar II funding", "OBSERVATION", 45, 62], ["predominantly", "OBSERVATION_MODIFIER", 126, 139], ["urban", "OBSERVATION_MODIFIER", 140, 145]]], ["These results suggest that the current distribution of CAP funding is inequitable in terms of needs in different EU regions and in terms of supporting the multiple social and environmental SDGs.DISCUSSIONReallocation of CAP funding from Pillar I to Pillar II and among instruments is therefore needed to increase the likelihood of the policy promoting multiple SDGs while simultaneously fulfilling its own objectives, as opposed to its current focus on a single objective: ensuring farm income.", [["CAP funding", "TREATMENT", 55, 66], ["CAP funding", "TREATMENT", 220, 231], ["Pillar I to Pillar II and among instruments", "TREATMENT", 237, 280], ["multiple SDGs", "PROBLEM", 352, 365], ["CAP", "OBSERVATION_MODIFIER", 55, 58], ["funding", "OBSERVATION", 59, 66]]], ["Our analysis supports previous findings that the CAP does not currently achieve additionality for the SDGs or broader societal goals, 15, [27] [28] [29] and further reveals that at least V24 billion per year could be reallocated to help realize multiple agreed societal goals.", [["Our analysis", "TEST", 0, 12]]], ["This excess income support also more than covers the V20 billion per year that is required to support the commitments of the EU's Biodiversity Strategy, 30 released in May 2020.Future CAP Unlikely to Realize Substantive ImprovementsThe details of the post-2020 CAP are currently being wrangled with the Member States.", [["Future CAP", "PROBLEM", 177, 187]]], ["The European Commission claims that the new CAP will bring a fairer distribution of payments among farmers, support action on environmental degradation and climate change, and boost the development of rural areas.", [["the new CAP", "PROBLEM", 36, 47], ["environmental degradation", "TREATMENT", 126, 151]]], ["14 The pressing question is whether the new CAP is likely to live up to these claims.", [["the new CAP", "PROBLEM", 36, 47], ["new", "OBSERVATION_MODIFIER", 40, 43], ["CAP", "OBSERVATION", 44, 47]]], ["In fact, the instrument ensuring that the majority of payments go to a minority of farmers as income support-the Basic Payment Scheme-will remain as the primary distributive mechanism for the majority of CAP payments.Future CAP Unlikely to Realize Substantive ImprovementsThe Commission claims it is implementing measures to remedy the weaknesses of the income support system.", [["CAP payments", "TREATMENT", 204, 216], ["Future CAP", "PROBLEM", 217, 227]]], ["However, it is highly unlikely that these measures will produce a substantial reallocation of payments, because it is, once again, relying on capping and redistribution to redress the unfair distribution of decoupled direct payments that is based on farm size.", [["capping", "TREATMENT", 142, 149], ["highly unlikely", "UNCERTAINTY", 15, 30], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["redistribution", "OBSERVATION_MODIFIER", 154, 168], ["size", "OBSERVATION_MODIFIER", 255, 259]]], ["These measures are identical to those used in the 2013 reform, but with token changes in capping levels.", [["token changes in capping levels", "PROBLEM", 72, 103], ["capping levels", "OBSERVATION", 89, 103]]], ["Capping has failed to substantively reduce payments to large farms, as most farms fall under the maximum payment ceiling of V100,000 per farm given the allowance for large farms to deduct their labor costs prior to capping, because average labor costs per hectare are generally higher than payment rates.", [["Capping", "TREATMENT", 0, 7], ["capping", "TREATMENT", 215, 222], ["average labor", "PROBLEM", 232, 245], ["large", "OBSERVATION_MODIFIER", 55, 60], ["farms", "OBSERVATION", 61, 66]]], ["31 Further, the potential redistribution to small farms is based on at best a moderate increase in the basic payment per hectare to these farms, which is inherently limited in its income potential for small farms.", [["the potential redistribution to small farms", "PROBLEM", 12, 55], ["small farms", "PROBLEM", 201, 212], ["redistribution", "OBSERVATION_MODIFIER", 26, 40], ["small", "OBSERVATION_MODIFIER", 44, 49], ["farms", "OBSERVATION", 50, 55], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["small", "OBSERVATION_MODIFIER", 201, 206], ["farms", "OBSERVATION", 207, 212]]], ["Consequently, large farms will, in all likelihood, continue to receive the lion's share of direct payments and small farms the leftovers, because they have respectively large and small farm areas.", [["direct payments", "TREATMENT", 91, 106], ["large", "OBSERVATION_MODIFIER", 14, 19], ["farms", "OBSERVATION", 20, 25], ["small", "OBSERVATION_MODIFIER", 111, 116], ["large", "OBSERVATION_MODIFIER", 169, 174], ["small", "OBSERVATION_MODIFIER", 179, 184], ["farm", "OBSERVATION_MODIFIER", 185, 189]]], ["Such a result will be a failure of the CAP's attempt to equitably distribute payments among farms and reduce inequalities (SDG 10).", [["the CAP's attempt", "TREATMENT", 35, 52]]], ["We therefore argue that if CAP payments are to serve CAP income support payments are made to regions where average farm incomes without income support are above (orange) or below (blue) the EU median.", [["CAP payments", "TREATMENT", 27, 39], ["CAP income support payments", "TREATMENT", 53, 80]]], ["Note: excluded from all panels are NUTS2 regions UKI3, UKI4, CH01, ES63, and ES64, which did not have all the data necessary to perform decile analyses; excluded from (C) are all NUTS2 regions in Greece, which did not have HNV data (please see Experimental Procedures for full details and data sources).OPEN ACCESSArticle the purpose of making farming a tenable enterprise (SDG 2), income support payments should only be made to those who have very low incomes by EU standards (recall that presently 82% of direct payments rain down on 20% of farmers).", [["NUTS2 regions", "DNA", 35, 48], ["UKI4", "DNA", 55, 59], ["CH01", "DNA", 61, 65], ["ES63", "DNA", 67, 71], ["ES64", "DNA", 77, 81], ["NUTS2 regions", "DNA", 179, 192], ["all panels", "TEST", 20, 30], ["UKI3", "TEST", 49, 53], ["UKI4", "TEST", 55, 59], ["CH01", "TEST", 61, 65], ["ES63", "TEST", 67, 71], ["ES64", "TEST", 77, 81], ["decile analyses", "TEST", 136, 151], ["HNV data", "TEST", 223, 231], ["income support payments", "TREATMENT", 382, 405]]], ["12 As a result, the V24.2 billion of redundant payments currently made to the highincome group of regions could be more productively redirected to support other goals.OPEN ACCESSIn addition, direct payments have been criticized by economists because they can capitalize into land values (i.e., result in higher land and/or land-rental prices) in which case they will benefit landowners and landlords, and not farmers as intended.", [["redundant payments", "TREATMENT", 37, 55], ["direct payments", "TREATMENT", 191, 206]]], ["33 National-level studies indicate a range from almost complete capitalization in some regions of Germany, 25 to limited capitalization in Italy.", [["National-level studies", "TEST", 3, 25]]], ["34 Our results are consistent with these findings in that Figure 2A shows great variation in agricultural incomes across the EU: much of Germany lies within the highest income deciles, while Italy lies around the median.", [["great variation", "PROBLEM", 74, 89], ["consistent with", "UNCERTAINTY", 19, 34], ["great", "OBSERVATION_MODIFIER", 74, 79], ["variation", "OBSERVATION_MODIFIER", 80, 89], ["highest", "OBSERVATION_MODIFIER", 161, 168]]], ["Capitalization would be expected to occur to a lesser extent, if at all, in low-income deciles where farming has low profitability or it is not otherwise profitable to maintain agricultural land in good condition.", [["Capitalization", "TREATMENT", 0, 14], ["low profitability", "PROBLEM", 113, 130], ["lesser extent", "OBSERVATION_MODIFIER", 47, 60], ["low profitability", "OBSERVATION_MODIFIER", 113, 130], ["good condition", "OBSERVATION", 198, 212]]], ["However, conditionality is a new term rather than a new measure, because it merges existing measures from the 2013 reform currently contained under two instruments-cross-compliance and the requirement for Ecological Focus Areas, and crop diversification associated with green direct payments (Table 1 )-into a single conditionality obligation.", [["cross-compliance", "TREATMENT", 164, 180], ["crop diversification", "TREATMENT", 233, 253], ["green direct payments", "TREATMENT", 270, 291], ["a single conditionality obligation", "TREATMENT", 308, 342]]], ["Cross-compliance is intended to ensure that if minimum levels of environmental care and other statutory obligations are not respected, then farmers' payments can be reduced.", [["environmental care", "TREATMENT", 65, 83], ["other statutory obligations", "TREATMENT", 88, 115]]], ["The green direct payment, in turn, has failed to generate significant environmental benefits, due to its flaws as an environmental policy instrument (e.g., high levels of exceptions and lack of potential for spatial targeting).", [["its flaws", "PROBLEM", 101, 110]]], ["35, 36 In addition, insufficient monitoring and low sanctioning levels have historically hampered conditionality, but the Commission has not addressed these flaws.", [["insufficient monitoring", "TEST", 20, 43], ["low sanctioning levels", "PROBLEM", 48, 70]]], ["Consequently, it is unrealistic to expect conditionality to greatly improve the environment, but it may provide some simplification for administrators.OPEN ACCESSA new environmental initiative is eco-schemes, whereby the Commission has made it mandatory for Member States to offer their farmers more flexible Pillar II-type agri-environment-climate measures as part of Pillar I. In theory, ecoschemes create the opportunity to reallocate direct payments to dedicated environmental and climate measures, with the flexibility to adapt these to local environmental needs and implement results-orientated payment instruments.", [["climate measures", "TREATMENT", 341, 357], ["climate measures", "TREATMENT", 485, 501]]], ["Tellingly, Member States are permitted to reallocate up to 15% of their Pillar II payments to finance ecoschemes, indicating the potential for the reshuffling of payments for existing agri-environment and climate measures between Pillars, rather than increasing total payments to environmental and climate measuresand thereby generating environmental additionality.", [["existing agri-environment", "TREATMENT", 175, 200], ["increasing total payments", "TREATMENT", 251, 276]]], ["Since eco-schemes are voluntary for farmers and there is no obligation to reallocate funding from the Basic Payment Scheme to support them, there is nothing in the proposal to ensure that eco-schemes will generate substantial, additional environmental benefits.", [["no", "UNCERTAINTY", 57, 59]]], ["Rather, eco-schemes risk taking budgets away from other agri-environment and climate measures that are well established and potentially better instruments.", [["climate measures", "TREATMENT", 77, 93]]], ["Since Member States face strong political pressure from farmers' organizations to maintain the status quo distribution of payments among farmers and CAP goals, 38 eco-schemes risk continuing the green-washing that characterized the 2013 25 Predominantly urban areas received V9.9 billion of the payments we analyzed, including V2.5 billion designated for rural development under Pillar II.", [["CAP goals", "TEST", 149, 158], ["the payments", "TREATMENT", 291, 303], ["pressure", "OBSERVATION_MODIFIER", 42, 50]]], ["''Country-level data'' means payments could not be allocated to a NUTS3 region due to missing spatial information (n = 9 countries, representing 15% of total payments in our data), thus it is not possible to attribute them to an urban-rural typology.", [["NUTS3 region", "DNA", 66, 78]]], ["Note: ''Pillar unknown'' payment for the country-level data was negative in this period, indicating a net repayment from Member States to the EU of V0.2 billion, and so is not shown here.ArticleOne Earth 3, 237-250, August 21, 2020 245 reform, limiting the realization of the new CAP's potential to contribute to the environmental SDGs.ArticleRural areas are central to achieving the agriculture-and environment-related SDGs, but what are the chances that the CAP post 2020 will boost development in rural areas?", [["CAP", "CHEMICAL", 280, 283], ["the country-level data", "TEST", 37, 59], ["the environmental SDGs", "PROBLEM", 313, 335], ["the CAP", "PROBLEM", 456, 463], ["central", "OBSERVATION_MODIFIER", 359, 366]]], ["According to the Commission's February 14, 2020, proposal for the EU's 2021-2027 Multiannual Financial Framework, ordinary spending on the Rural Development Program (Pillar II) will be reduced by 24%, while that to Pillar I by only 10% (in constant 2018 prices), which although driven by the UK leaving the EU, is indicative of the political priorities concerning future CAP spending.ArticleExtraordinary funding was proposed on May 27, 2020, to bolster primarily Pillar II by V20 billion for 2021-2027, of which the majority (V15 billion) is sourced from the European Recovery Instrument with the intention ''. to address the consequences of the COVID-19 pandemic or the immediate funding needs to avoid a re-emergence of the COVID-19 pandemic.'' 39 While this funding increases the previous program period funding for Pillar II, the new money is not intended to bolster financing of existing Pillar II measures; the Commission specifies it is emergency aid targeted to support a new, but short-term goal, to ''repair the economic and social damage brought by the coronavirus pandemic''.ArticleSince the new money does not affect the distribution of the old money between Pillars and measures, it does not affect the conclusions stemming from our analysis: spending imbalances among CAP's modern goals are undermining the CAP's potential to support the SDGs, and hence the goals of the recently communicated European Green Deal 7 and Farm to Fork Strategy.", [["coronavirus", "DISEASE", 1065, 1076], ["coronavirus", "ORGANISM", 1065, 1076], ["the COVID", "TEST", 643, 652], ["the COVID", "TEST", 723, 732], ["existing Pillar II measures", "TREATMENT", 885, 912], ["repair", "TREATMENT", 1012, 1018], ["social damage", "PROBLEM", 1036, 1049], ["our analysis", "TEST", 1244, 1256], ["CAP's", "TREATMENT", 1284, 1289], ["Pillar II", "OBSERVATION_MODIFIER", 894, 903]]], ["Crucially, the potential for CAP post 2020 to ''do more'' is in the hands of the individual Member States to reallocate CAP funding, because the Commission has created the flexibility to reallocate funding among Pillars and goals/measures if Member States choose to reallocate from the Basic Payment Scheme to eco-schemes.ArticleAlthough the measures available to Member States in Pillar II will remain largely unchanged, the Commission is hoping that the new national strategic plans will leverage development potential.", [["CAP", "PROBLEM", 29, 32], ["unchanged", "OBSERVATION_MODIFIER", 411, 420]]], ["To what extent this is merely an administrative innovation rather than supporting coherence between the Pillars and thereby promoting sustainable development, remains to be seen.", [["Pillars", "OBSERVATION_MODIFIER", 104, 111], ["sustainable", "OBSERVATION_MODIFIER", 134, 145]]], ["Therefore, given the down prioritizing of Pillar II through the relatively large reduction in funding to its ordinary measures and the absence of new measures (besides the European Recovery Instrument funding that is for extraordinary measures), the Commission is placing a lot of faith in the capacity of the national plans in themselves to boost rural development.", [["Pillar II", "CHEMICAL", 42, 51], ["Pillar II", "TREATMENT", 42, 51], ["relatively", "OBSERVATION_MODIFIER", 64, 74], ["large", "OBSERVATION_MODIFIER", 75, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["new", "OBSERVATION_MODIFIER", 146, 149]]], ["Nonetheless, since CAP post 2020 is not likely to generate a significant reallocation of funding from Pillar I to Pillar II, it is also unlikely that it will boost rural development.ArticleRealizing the CAP's Potential for the SDGs Reforming the future CAP to contribute positively to more SDGs and to optimize trade-offs among potentially conflicting goals requires increased equitability in terms of needs-based spending.", [["CAP", "TEST", 19, 22], ["the SDGs", "PROBLEM", 223, 231], ["increased equitability", "PROBLEM", 367, 389], ["not likely", "UNCERTAINTY", 36, 46], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["reallocation", "OBSERVATION", 73, 85], ["is also unlikely", "UNCERTAINTY", 128, 144]]], ["Scholars have suggested that in high-income countries (sensu the World Bank 41 ), such as the majority of the EU, actions to reduce gender and income inequalities (SDGs 5 and 10) have the most synergistic benefits for other SDGs.", [["other SDGs", "PROBLEM", 218, 228]]], ["43 Thus, increasing equitability in CAP payments among recipients in economic need, and among under-supported objectives, is necessary for the CAP to successfully contribute to the SDGs.", [["CAP payments", "TREATMENT", 36, 48], ["the CAP", "TREATMENT", 139, 146], ["the SDGs", "PROBLEM", 177, 185], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["equitability", "OBSERVATION_MODIFIER", 20, 32], ["CAP", "OBSERVATION_MODIFIER", 36, 39]]], ["The current CAP rewards land owners for owning land (a purely private good) and does not provide effective remuneration for providing public goods (e.g., climate mitigation, conservation of biodiversity and landscapes).", [["climate mitigation", "TREATMENT", 154, 172]]], ["44 Also necessary to ensure the CAP will make a valuable contribution to the SDGs in Europe is strategic alignment of objectives, measures, and indicators for monitoring and evaluating the success of the policy.", [["monitoring", "TEST", 159, 169]]], ["23, 26 Currently, CAP monitoring and evaluation indicators focus on accounting for spending under the policy, rather than assessing the real-world outcomes and impacts relating to its objectives.", [["CAP monitoring", "TEST", 18, 32], ["evaluation", "TEST", 37, 47]]], ["15, 23 The lack of alignment ( Figure 1 ) between CAP objectives, measures, and indicators weakens monitoring, assessment, follow-up, and review of policies for the SDGs.", [["CAP objectives", "TEST", 50, 64], ["assessment", "TEST", 111, 121], ["the SDGs", "PROBLEM", 161, 169], ["alignment", "OBSERVATION_MODIFIER", 19, 28]]], ["26, 45 Difficulties in evaluating CAP impacts on sustainability arise from the many different perspectives and priorities in agriculture, 46,47 as well as limited or inaccessible data for monitoring and evaluation; 48 thus, monitoring frameworks require more strategic design.", [["monitoring", "TEST", 188, 198], ["evaluation", "TEST", 203, 213]]], ["Under the new CAP proposal, Member States would be required to submit their national strategic plans, including a monitoring and evaluation framework.", [["a monitoring", "TEST", 112, 124], ["evaluation framework", "TEST", 129, 149]]], ["A more prudent solution would be to redirect some CAP budget from redundant income support to national CAP monitoring offices, because complex challenges such as the sustainability of agriculture cannot be managed without effective monitoring and evaluation, and adaptation of plans and actions where needed.", [["A more prudent solution", "TREATMENT", 0, 23], ["effective monitoring", "TEST", 222, 242], ["evaluation", "TEST", 247, 257]]], ["49 Payments that are based on evidence of outcomes would also, by design, require that monitoring and evaluation focused on real impacts of CAP payments for social and environmental rather than administrative goals.ArticleRealizing the CAP's untapped potential to support the SDGs requires transparency in how payments are being spent (SDG 16, good governance).", [["that monitoring", "TEST", 82, 97], ["evaluation", "TEST", 102, 112], ["CAP payments", "TREATMENT", 140, 152], ["CAP", "OBSERVATION_MODIFIER", 236, 239]]], ["Currently, despite EU principles and laws on transparency in reporting these data, basic gaps in data reporting by Member States and a lack of centralized data make it extremely difficult to evaluate what benefits CAP payments provide, but also important, whether benefits are achieved through judicious use of public funds.", [["these data", "TEST", 71, 81], ["CAP payments", "TREATMENT", 214, 226], ["public funds", "TREATMENT", 311, 323]]], ["50 Please see Nicholas et al. 21 for a full description of the spatial database ll OPEN ACCESS Article we used and recommendations for improving the availability of data on CAP payments.ArticleOur analysis focused on three CAP objectives and SDGs: fair farm income, climate action, and protecting biodiversity; but many other SDGs are critical in agriculture 1,51,52 within the broader importance of sustainable food systems.", [["CAP payments", "TREATMENT", 173, 185], ["ArticleOur analysis", "TEST", 186, 205]]], ["3, 53, 54 Good health and well-being of farmers (including mental health 55, 56 ) are central to agriculture's contribution to the SDGs, but are largely overlooked by the CAP, where the health focus is on consumer demand for healthy food.", [["the SDGs", "PROBLEM", 127, 135]]], ["Similarly, gender equality in agriculture will be key to the sector's contribution to the SDGs, 57 as well as shortening value chains (CAP objective (c)), yet no CAP instruments are dedicated to these issues.", [["the SDGs", "TEST", 86, 94], ["shortening value chains", "PROBLEM", 110, 133], ["CAP instruments", "PROBLEM", 162, 177]]], ["15 These and other SDGs could all benefit from more equitable distribution of CAP spending to ensure all objectives are covered and farmers engaged in sustainable farming are adequately supported.ArticleOverall, we need better ways to achieve food security, landscape stewardship, and rural development with less environmental and climate damage.", [["ArticleOverall", "TREATMENT", 196, 210], ["CAP", "OBSERVATION_MODIFIER", 78, 81]]], ["If the EU is committed to being a global leader for the SDGs, as flagged by the Green Deal, then it should start by redirecting these existing resources toward achieving its stated goals.EXPERIMENTAL PROCEDURESResource Availability Lead Contact Further information and reasonable requests for resources should be directed to and will be fulfilled by the Lead Contact, Murray Scown.Materials AvailabilityThis study did not generate new unique materials.Aligning CAP Payments, Objectives, Indicators, and SDGsTo evaluate how well the CAP aligns with SDGs in terms of (1) current spending, (2) modern CAP objectives, and (3) monitoring and evaluation indicators, we used a combination of previously published analyses and our own alignment based on keywords in officially stated CAP objectives and SDG targets.", [["SDG", "SIMPLE_CHEMICAL", 795, 798], ["This study", "TEST", 403, 413], ["modern CAP objectives", "TEST", 591, 612], ["monitoring and evaluation indicators", "TEST", 622, 658], ["previously published analyses", "TEST", 685, 714]]], ["The results were visualized in a Sankey diagram (Figure 1) , showing: (1) the relative share of current CAP spending aligned with CAP objectives (based on Pe'er et al. 15 ); (2) the relative number of SDG targets within each goal aligning with the CAP objectives (our own analysis); and (3) the relative number of CAP indicators aligned with each SDG (from Scown and Nicholas 23 ).", [["SDG", "CHEMICAL", 201, 204], ["a Sankey diagram", "TEST", 31, 47], ["CAP objectives", "TEST", 130, 144], ["Pe", "TEST", 155, 157], ["the CAP objectives", "TEST", 244, 262], ["our own analysis", "TEST", 264, 280], ["Pe", "OBSERVATION", 155, 157], ["CAP", "OBSERVATION_MODIFIER", 314, 317]]], ["First, the relative share of current CAP spending aligned with the CAP objectives was taken from Figure S2 .3 and Table S2 .3 of Pe'er et al. 15 Second, the number of SDG targets aligned with new CAP objectives was determined by analyzing the official wording of CAP objectives 14 and SDG targets.", [["SDG", "SIMPLE_CHEMICAL", 285, 288], ["the CAP objectives", "TEST", 63, 81], ["Figure S2", "TEST", 97, 106], ["Pe", "PROBLEM", 129, 131], ["new CAP objectives", "PROBLEM", 192, 210], ["CAP objectives", "TEST", 263, 277], ["Pe", "OBSERVATION", 129, 131], ["new", "OBSERVATION_MODIFIER", 192, 195], ["CAP", "OBSERVATION_MODIFIER", 196, 199]]], ["2 Following the method of Scown and Nicholas, 23 we used keywords, shown in Table S1 , to count the number of SDG targets that could potentially be achieved in Europe through action toward stated CAP objectives (i.e., co-benefits for SDGs through CAP objectives).", [["SDG", "SIMPLE_CHEMICAL", 110, 113], ["SDGs through CAP objectives", "TREATMENT", 234, 261]]], ["We assumed that if similar themes (reflected in the keywords) appeared in an SDG target and a CAP objective, that target was aligned with that objective.", [["SDG", "OBSERVATION", 77, 80]]], ["Finally, the relative number of CAP indicators aligned with each SDG was taken from the analysis of Scown and Nicholas, 23 who aligned the CAP monitoring and evaluation indicators (Context, Output, Target, Result, and Impact indicator sets), 58 the Agri-Environmental Indicators used by the European Environment Agency to incorporate environmental con-cerns into the CAP, 59and the list of EU SDG indicators used by Eurostat to translate the global SDGs into an EU context.", [["the CAP monitoring", "TEST", 135, 153], ["evaluation indicators", "TEST", 158, 179], ["Output", "TEST", 190, 196], ["CAP", "OBSERVATION_MODIFIER", 32, 35]]], ["60Analyzing CAP Payments against SDG Needs To analyze how CAP payments are distributed relative to social and environmental needs relating to the SDGs, we utilized a public dataset of CAP payments centered around 2015, drawn from farmsubsidy.org and made spatially explicit.", [["CAP payments", "TREATMENT", 184, 196], ["org", "PROBLEM", 242, 245]]], ["21 The distribution of these CAP payments was compared with farm income from Eurostat, agricultural GHG emissions from the Joint Research Centre's EDGAR v4 database, 61 and HNV farmland from the Joint Research Centre and European Environment Agency, 62 using the regions delineated in the Nomenclature of Territorial Units for Statistics (NUTS; 2013 version).", [["Eurostat", "CHEMICAL", 77, 85], ["these CAP payments", "PROBLEM", 23, 41], ["agricultural GHG emissions", "TEST", 87, 113], ["distribution", "OBSERVATION_MODIFIER", 7, 19], ["CAP", "OBSERVATION_MODIFIER", 29, 32], ["GHG emissions", "OBSERVATION", 100, 113], ["Joint", "ANATOMY", 123, 128], ["Joint", "ANATOMY", 195, 200]]], ["63 No CAP payment data were available for Finland, so it was excluded from all analyses.", [["CAP payment data", "TEST", 6, 22]]], ["60First, CAP payment data from Nicholas et al. 21 was aggregated from NUTS3 to NUTS2 level (approximately 260 regions; please see Eurostat 63 for details) in order to align with the resolution of Eurostat data.", [["NUTS3", "GENE_OR_GENE_PRODUCT", 70, 75], ["NUTS2", "DNA", 79, 84], ["Eurostat data", "TEST", 196, 209]]], ["CAP payments in the original database for ten countries (BG, CZ, EE, EL, IE, LT, LU, LV, RO, SI) were not disaggregated below the country level (NUTS0), so these were manually allocated to a NUTS2 region based on the share of national utilized agricultural area (UAA) within each NUTS2.", [["EE", "CHEMICAL", 65, 67], ["NUTS2 region", "DNA", 191, 203], ["NUTS2", "DNA", 280, 285], ["CAP payments", "TREATMENT", 0, 12], ["BG", "TEST", 57, 59], ["CZ", "TEST", 61, 63], ["EE", "TEST", 65, 67], ["EL", "TEST", 69, 71], ["LT", "TEST", 77, 79], ["a NUTS2 region", "TREATMENT", 189, 203], ["LT", "ANATOMY", 77, 79], ["LV", "ANATOMY", 85, 87]]], ["The use of UAA to manually allocate CAP payments from NUTS0 to NUTS2 was justified because the vast majority of CAP payments are area-based.", [["UAA", "TREATMENT", 11, 14], ["CAP payments", "TREATMENT", 36, 48], ["NUTS2", "TREATMENT", 63, 68], ["CAP payments", "TREATMENT", 112, 124]]], ["For EE, LT, LU, and LV, NUTS0 and NUTS2 in the 2013 version are equivalent.", [["EE", "CHEMICAL", 4, 6], ["LT", "PROTEIN", 8, 10], ["NUTS0", "PROTEIN", 24, 29], ["NUTS2", "PROTEIN", 34, 39], ["EE", "TEST", 4, 6], ["LV", "TEST", 20, 22], ["NUTS0", "TEST", 24, 29], ["NUTS2", "TEST", 34, 39], ["LT", "ANATOMY", 8, 10], ["LU", "ANATOMY", 12, 14], ["LV", "ANATOMY", 20, 22]]], ["For the remaining six countries (BG, CZ, EL, IE, RO, SI), the method of manual allocation of CAP payments to NUTS2 was validated by performing the same allocation from NUTS0 to NUTS2 for all countries that did have disaggregated data, then comparing the results between original and manually allocated NUTS2 data.", [["NUTS2", "DNA", 109, 114], ["NUTS2", "DNA", 177, 182], ["NUTS2", "DNA", 302, 307], ["BG", "TEST", 33, 35], ["manual allocation of CAP payments", "TREATMENT", 72, 105]]], ["This validation showed that manual allocation based on UAA had a mean absolute error of V43 million (less than 0.1% of the total payments), which was inflated by only eight outliers that had an absolute error over V200 million ( Figure S1 ).", [["UAA", "DNA", 55, 58], ["This validation", "TEST", 0, 15], ["UAA", "TEST", 55, 58], ["absolute error", "OBSERVATION", 194, 208]]], ["Overall, more than 79% of NUTS2 regions had a manually allocated value within 30% of the true value.", [["NUTS2", "GENE_OR_GENE_PRODUCT", 26, 31], ["NUTS2 regions", "DNA", 26, 39]]], ["Furthermore, the final NUTS0 to NUTS2 manual allocation using UAA was only applied to six countries, representing less than 12% of the total payments.", [["NUTS0", "DNA", 23, 28], ["NUTS2", "DNA", 32, 37], ["UAA", "DNA", 62, 65], ["UAA", "TREATMENT", 62, 65], ["the total payments", "TREATMENT", 131, 149]]], ["The 18 countries with CAP payments at the NUTS3 level also had small proportions of payments not disaggregated below the NUTS0 level (V1.2 billion or 2% of total payments), and these were excluded from the analyses to not introduce further uncertainty where NUTS3 data were available.and the list of EU SDG indicators used by Eurostat to translate the global SDGs into an EU context.", [["CAP payments", "TREATMENT", 22, 34], ["total payments", "TREATMENT", 156, 170], ["NUTS3 data", "TEST", 258, 268], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["60Next, we grouped NUTS2 regions into deciles (approximately 26 regions per decile, reflecting the approximately 260 NUTS2 regions) based on farm income, GHG emission rates, and HNV farmland, then analyzed payments by these deciles.", [["NUTS2 regions", "DNA", 19, 32], ["260 NUTS2 regions", "DNA", 113, 130], ["HNV", "SPECIES", 178, 181], ["GHG emission rates", "TEST", 154, 172]]], ["For farm income, we used a measure of income per person per year engaged in full-time farm labor (agricultural factor income [AFI] per annual work unit [AWU]), adjusted to PPS to reflect equal ability to buy goods and services in different countries.", [["person", "SPECIES", 49, 55], ["PPS", "TREATMENT", 172, 175]]], ["We took the average AFI and AWU from 2010 to 2017 to fill annual gaps in Eurostat data and to account for inter-annual variability.", [["Eurostat data", "TEST", 73, 86], ["inter-annual variability", "PROBLEM", 106, 130]]], ["We then grouped regions into deciles by per hectare rates of GHG emissions from agriculture and fraction of HNV farmland, and again analyzed CAP payments by these groups (please see Supplemental Experimental Procedures for full details of how these indicators were processed).and the list of EU SDG indicators used by Eurostat to translate the global SDGs into an EU context.", [["HNV", "SPECIES", 108, 111], ["HNV farmland", "TREATMENT", 108, 120], ["GHG emissions", "OBSERVATION", 61, 74], ["HNV farmland", "OBSERVATION", 108, 120]]], ["60The results of decile analyses are visualized as bar charts and maps in Figures 2 and 3 .", [["decile analyses", "TEST", 17, 32], ["bar charts", "TEST", 51, 61], ["maps", "TEST", 66, 70], ["Figures", "TEST", 74, 81]]], ["NUTS2 regions grouped into deciles are mapped for Europe (excluding outlying EU territories).", [["NUTS2", "GENE_OR_GENE_PRODUCT", 0, 5], ["NUTS2 regions", "DNA", 0, 13]]], ["For farm income and HNV farmland, red regions in Figure 2 indicate NUTS2 regions in the lowest deciles (i.e., low income or low fraction of HNV farmland) and blue regions are those in the highest deciles (i.e., high income or high fraction of HNV farmland).", [["HNV", "SPECIES", 20, 23], ["red regions", "PROBLEM", 34, 45], ["blue regions", "PROBLEM", 158, 170]]], ["For GHG emissions, the highest per hectare emitting regions are mapped red and the lowest are blue.", [["GHG emissions", "TEST", 4, 17], ["GHG emissions", "OBSERVATION", 4, 17], ["blue", "OBSERVATION", 94, 98]]], ["To qualify as an environmental payment, we applied the following definition to the description of every measure available under both Pillars, thereby capturing measures other than those designated agri-environmental schemes or agri-environment-ll OPEN ACCESSArticleOne Earth 3, 237-250, August 21, 2020 247 climate measures under Pillar II that also have a main objective of benefiting the environment.ArticleDefinition: We define an environmental payment to include all CAP measures that state the intention to principally benefit nature, the environment, climate, or promote sustainable farming in the wording of the measure itself, and that involve more than the application of usual good farming practice or directly support production.", [["capturing measures", "TREATMENT", 150, 168], ["an environmental payment", "TREATMENT", 431, 455], ["all CAP measures", "TREATMENT", 467, 483], ["main", "OBSERVATION_MODIFIER", 357, 361]]], ["We checked the correspondence between measures from different payment periods (2007-2013 and 2014-2020) assessed the measure wording independently for each period.ArticleNUTS2 regions summarized in each of the bars of each chart are the NUTS2 regions in those particular deciles (i.e., income deciles, GHG emission deciles, and HNV farmland deciles).", [["ArticleNUTS2 regions", "DNA", 163, 183], ["NUTS2 regions", "DNA", 237, 250]]], ["Also shown on the bar charts in Figure 2 are the total number of full-time agricultural workers in each income decile, the total GHG emissions from each GHG decile, and the maximum fraction of HNV farmland in each HNV farmland decile.", [["HNV", "SPECIES", 193, 196], ["HNV farmland", "OBSERVATION", 193, 205]]], ["In addition to the exclusion of Finland, four NUTS2 regions were excluded from each of these analyses (UKI3, UKI4, ES64, and ES65) because of zeros or no data in either AWU (labor force), UAA (agricultural area), or GHG emissions.", [["NUTS2 regions", "DNA", 46, 59], ["ES65", "DNA", 125, 129], ["these analyses", "TEST", 87, 101], ["UKI3", "TEST", 103, 107], ["UKI4", "TEST", 109, 113], ["ES64", "TEST", 115, 119], ["zeros", "PROBLEM", 142, 147], ["UAA", "PROBLEM", 188, 191], ["GHG emissions", "PROBLEM", 216, 229], ["GHG emissions", "OBSERVATION", 216, 229]]], ["All of Greece was excluded from the HNV farmland analysis because of no available HNV data.ArticleNext, we identified and isolated all income support payments that were made in NUTS2 regions with an average farm income at or above the 2015 EU median equivalized net income of V16,163 (adjusted for PPS).", [["HNV", "SPECIES", 36, 39], ["HNV", "SPECIES", 82, 85], ["the HNV farmland analysis", "TEST", 32, 57], ["ArticleNext", "TREATMENT", 91, 102], ["support payments", "TREATMENT", 142, 158], ["PPS", "TREATMENT", 298, 301]]], ["This total amount of income support distributed to regions above the EU median income is visualized as orange bars in Figure 3 .ArticleFinally, we analyzed the distribution of CAP payments under Pillar I and Pillar II (designated for rural development) against the Eurostat urban-rural typologies.", [["income support", "TREATMENT", 21, 35], ["CAP payments", "TREATMENT", 176, 188], ["Pillar I and Pillar II", "TREATMENT", 195, 217], ["total", "OBSERVATION_MODIFIER", 5, 10], ["amount", "OBSERVATION_MODIFIER", 11, 17], ["CAP", "OBSERVATION_MODIFIER", 176, 179]]], ["64 We used NUTS3 as the spatial unit here, as opposed to NUTS2, because the Eurostat urban-rural typologies are applied at the NUTS3 level (please see Eurostat for details on NUTS regions 63 and urban-rural typologies 64 ).", [["NUTS3", "DNA", 11, 16], ["NUTS2", "DNA", 57, 62], ["NUTS3", "DNA", 127, 132], ["NUTS3", "TREATMENT", 11, 16], ["the Eurostat urban", "TEST", 72, 90]]], ["CAP payments that could not be allocated to a NUTS3 unit (due to missing spatial information in the original data) or to a particular CAP Pillar were kept separate from this analysis.SUPPLEMENTAL INFORMATIONSupplemental Information can be found online at https://doi.org/10.1016/j. oneear.2020.07.011.Brief history of CAP reformIn its first three decades, the CAP primarily supported farmers through guaranteed minimum prices for products, which ultimately resulted in extreme levels of overproduction described as \"lakes of milk and beef mountains\" 1 in the 1970s and 80s.", [["milk", "ANATOMY", 525, 529], ["milk", "ORGANISM_SUBSTANCE", 525, 529], ["NUTS3 unit", "DNA", 46, 56], ["CAP Pillar", "DNA", 134, 144], ["CAP payments", "TREATMENT", 0, 12], ["a particular CAP Pillar", "TREATMENT", 121, 144], ["this analysis", "TEST", 169, 182], ["CAP reformIn", "TREATMENT", 318, 330], ["the CAP", "PROBLEM", 356, 363], ["extreme levels of overproduction", "PROBLEM", 469, 501], ["CAP", "OBSERVATION_MODIFIER", 318, 321]]], ["This problem led to the MacSharry reform in 1992 when indirect price or market support was replaced by producer support, so-called direct payments to farmers, based on areas of eligible crops and numbers of eligible livestock.", [["market support", "TREATMENT", 72, 86]]], ["Direct payments reduced production surpluses to some extent, but not sufficiently in the eyes of the World Trade Organization, primarily because farmers still needed to produce commodities to receive support, and hence the amount of support they received was still linked to production, i.e., these were coupled direct payments.Brief history of CAP reformAs a result, reforms in 2003 (called the Mid-Term Review) decoupled-cut the link between-direct payments from production 2 .", [["eyes", "ANATOMY", 89, 93], ["eyes", "ORGAN", 89, 93], ["support", "TREATMENT", 200, 207], ["support", "TREATMENT", 233, 240], ["some extent", "OBSERVATION_MODIFIER", 48, 59]]], ["Since 2005, farmers receive the majority of their support as decoupled direct payments based on their agricultural area, and contingent on meeting two conditions.", [["their support", "TREATMENT", 44, 57]]], ["The second condition is that farmers must comply with legislation relating to the Statutory Management Requirements including meeting minimum standards for protection of the environment, animal health and welfare, and food safety; failure to do so can result in reductions of payments, in addition to prosecution under national legislation.", [["the Statutory Management", "TREATMENT", 78, 102]]], ["Together, these two strands of conditions for receiving direct payments are referred to as cross-compliance.", [["direct payments", "TREATMENT", 56, 71], ["strands", "OBSERVATION_MODIFIER", 20, 27]]], ["Overall, agricultural output in the EU today is more or less driven by market demand; decoupling has generally eliminated the contribution of the CAP to overproduction 3 .", [["CAP", "DISEASE", 146, 149], ["agricultural output", "TEST", 9, 28], ["the CAP to overproduction", "PROBLEM", 142, 167], ["agricultural output", "OBSERVATION", 9, 28]]], ["Moreover, cross-compliance implies that decoupled direct payments help prevent abandonment of agricultural land in areas where production is not profitable.", [["direct payments", "TREATMENT", 50, 65]]], ["Thereby, it is argued, cross-compliance and decoupled direct payments indirectly contribute to food security, biodiversity conservation, and cultural heritage through preservation of agricultural landscapes in marginal areas, which often use more traditional, extensive management with lower industrial input intensity 4 .Brief history of CAP reformThree remaining problems with direct payments after the 2003 reforms, however, were that i) rates of decoupled payments varied substantially both within and among the Member States 5 , ii) payments were concentrated among few farmers, and iii) the CAP still failed to adequately address citizens' concerns regarding the sustainability of farming, the environment, and climate change 6 .", [["CAP", "DISEASE", 339, 342], ["biodiversity conservation", "TREATMENT", 110, 135], ["cultural heritage", "TREATMENT", 141, 158], ["agricultural landscapes in marginal areas", "PROBLEM", 183, 224], ["extensive management", "TREATMENT", 260, 280], ["CAP", "PROBLEM", 339, 342], ["agricultural landscapes", "OBSERVATION", 183, 206], ["marginal", "OBSERVATION_MODIFIER", 210, 218]]], ["Reforms undertaken to date to address each of these problems have so far proven ineffective.Brief history of CAP reformTo address the first problem, the 2013 reform intended to even out payments within and among the Member States through internal and external convergence, respectively; to eventually result in a uniform decoupled payment per hectare of farmland throughout the EU 7 .", [["these problems", "PROBLEM", 46, 60], ["CAP", "PROBLEM", 109, 112]]], ["To offset the potentially negative effects of the redistribution of payments on agricultural sub-sectors \"undergoing difficulties\", the possibility to re-introduce voluntary coupled support up to 13% of national Pillar I budgets was also introduced, and indeed implemented by Member States.", [["voluntary coupled support", "TREATMENT", 164, 189], ["negative effects", "OBSERVATION_MODIFIER", 26, 42], ["redistribution", "OBSERVATION_MODIFIER", 50, 64]]], ["Hence CAP now has more even payments per hectare across the EU, but also a substantial level of Pillar I support once again coupled to production, thereby risking overproduction and associated environmental damage.Brief history of CAP reformTo redress the second problem, the inequity of the concentration of payments to large farms, the Commission introduced two new measures in 2013: capping and redistribution of payments.", [["Pillar I support", "TREATMENT", 96, 112], ["risking overproduction", "PROBLEM", 155, 177], ["environmental damage", "PROBLEM", 193, 213], ["CAP", "PROBLEM", 231, 234], ["capping and redistribution of payments", "TREATMENT", 386, 424], ["CAP", "OBSERVATION_MODIFIER", 6, 9], ["Pillar", "OBSERVATION", 96, 102], ["environmental damage", "OBSERVATION", 193, 213], ["CAP", "OBSERVATION_MODIFIER", 231, 234], ["large", "OBSERVATION_MODIFIER", 321, 326], ["farms", "OBSERVATION", 327, 332], ["redistribution", "OBSERVATION_MODIFIER", 398, 412]]], ["The first measure, capping, implies that farms receiving more than \u20ac150,000 in annual Pillar I payments would have their future payments over this level reduced by, at most, 5%, and be limited to receiving a maximum of \u20ac300,000 in annual Pillar I payments.Brief history of CAP reformDespite the relatively low capping rate and generous maximum payment, the calculation of total farm payments above which capping would apply must first be reduced by the costs of hired labour and imputed family labour, which naturally will be higher the larger the farm.Brief history of CAP reformThus, the intended redistribution of payments towards smaller farms essentially failed.", [["capping", "TREATMENT", 19, 26], ["CAP", "PROBLEM", 273, 276], ["the relatively low capping rate", "TREATMENT", 291, 322], ["generous maximum payment", "TREATMENT", 327, 351], ["total farm payments", "TREATMENT", 372, 391], ["CAP reformThus", "PROBLEM", 570, 584], ["CAP", "OBSERVATION_MODIFIER", 273, 276], ["larger", "OBSERVATION_MODIFIER", 537, 543], ["CAP", "OBSERVATION_MODIFIER", 570, 573], ["redistribution", "OBSERVATION_MODIFIER", 599, 613]]], ["The second measure, redistribution, provided Member States with a mechanism to increase perhectare decoupled payments to small farms (i.e., those less than 30 hectares).", [["redistribution", "OBSERVATION", 20, 34]]], ["However, since small farms have by definition a small area, the total potential redistribution of payments to them via this mechanism is relatively low.", [["small farms", "PROBLEM", 15, 26], ["a small area", "PROBLEM", 46, 58], ["small", "OBSERVATION_MODIFIER", 15, 20], ["farms", "OBSERVATION", 21, 26], ["small", "OBSERVATION_MODIFIER", 48, 53], ["area", "OBSERVATION_MODIFIER", 54, 58], ["total", "OBSERVATION_MODIFIER", 64, 69], ["potential", "OBSERVATION_MODIFIER", 70, 79], ["redistribution", "OBSERVATION_MODIFIER", 80, 94], ["relatively", "OBSERVATION_MODIFIER", 137, 147], ["low", "OBSERVATION_MODIFIER", 148, 151]]], ["Consequently, capping and redistribution have not meaningfully reduced the inequitable distribution of income support among farms 3, 8 .", [["capping", "TREATMENT", 14, 21], ["capping", "OBSERVATION_MODIFIER", 14, 21], ["redistribution", "OBSERVATION_MODIFIER", 26, 40], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["inequitable", "OBSERVATION_MODIFIER", 75, 86], ["distribution", "OBSERVATION_MODIFIER", 87, 99]]], ["Even after these two reforms, in 2018 the top 20% of beneficiaries, comprising the largest farms, received 82% of direct payments as a whole (ranging from 48% in Luxembourg to 94% in Slovakia), while the majority of CAP beneficiaries (76%, nearly all small farms) received less than \u20ac5,000 per year (15% of total direct payments) 9 .Brief history of CAP reformThe 2013 reform intended to address the third problem by attaching specific environmental obligations to 30% of direct payments farmers receive, so-called green direct payments, hence its designation as the \"greening\" reform.", [["CAP", "DISEASE", 350, 353], ["beneficiaries", "TREATMENT", 53, 66], ["CAP beneficiaries", "TREATMENT", 216, 233], ["total direct payments", "TREATMENT", 307, 328], ["CAP reform", "TREATMENT", 350, 360], ["the third problem", "PROBLEM", 396, 413], ["largest", "OBSERVATION_MODIFIER", 83, 90]]], ["In order to receive full decoupled direct payments in the form of the Basic Payment Scheme, farmers since 2015 are obligated, in addition to cross-compliance, to fulfil greening measures related to two conditions: i) encouraging crop diversification to primarily improve soil quality; and ii) having some of their agricultural land as semi-natural habitat, called Ecological Focus Areas, primarily to safeguard and improve biodiversity on farms.", [["semi-natural habitat", "OBSERVATION", 335, 355]]], ["Further, there is a requirement applicable at the national level that Member States must maintain the area of permanent grassland relative to arable land calculated as a ratio at the national level, and protect the most environmentally sensitive grasslands from ploughing to support carbon sequestration, and preserve biodiversity and soils 7 .", [["carbon", "CHEMICAL", 283, 289], ["carbon", "SIMPLE_CHEMICAL", 283, 289], ["permanent grassland", "PROBLEM", 110, 129], ["carbon sequestration", "PROBLEM", 283, 303], ["carbon sequestration", "OBSERVATION", 283, 303]]], ["However, the greening measures do not apply to all farms, due to broad exemptions based on farm and regional characteristics, and suffer from low environmental requirements 10 ; consequently, they have failed to deliver substantial environmental benefits 11 .Alignment of CAP spending, objectives, indicators, and SDGsTo evaluate how well the CAP aligns with SDGs in terms of 1) current spending, 2) modern CAP objectives, and 3) monitoring and evaluation indicators, we used a combination of previously published analyses and our own alignment based on keywords in officially stated CAP objectives and SDG targets.", [["SDG", "SIMPLE_CHEMICAL", 603, 606], ["the greening measures", "TREATMENT", 9, 30], ["low environmental requirements", "PROBLEM", 142, 172], ["modern CAP objectives", "TEST", 400, 421], ["monitoring and evaluation indicators", "TEST", 430, 466], ["previously published analyses", "TEST", 493, 522], ["CAP", "OBSERVATION_MODIFIER", 272, 275]]], ["The results were visualised in a Sankey diagram Table S2 .3 of Pe'er et al. 12 .", [["Pe", "OBSERVATION", 63, 65]]], ["Second, the number of SDG targets aligned with new CAP objectives was determined by analysing the official wording of CAP objectives 14 and SDG targets 15 .", [["SDG", "CHEMICAL", 22, 25], ["CAP objectives", "TEST", 118, 132], ["SDG targets", "TEST", 140, 151]]], ["Following the method of Scown and Nicholas 13 , we used keywords, shown in Table S1 , to count the number of SDG targets that could potentially be achieved in Europe through action towards stated CAP objectives (i.e., co-benefits for SDGs through CAP objectives).Alignment of CAP spending, objectives, indicators, and SDGsWe assumed that if similar themes (reflected in the keywords) appeared in an SDG target and a CAP objective, that target was aligned with that objective.", [["SDG", "SIMPLE_CHEMICAL", 109, 112], ["SDG targets", "TREATMENT", 109, 120], ["SDGs through CAP objectives", "TREATMENT", 234, 261], ["CAP", "OBSERVATION_MODIFIER", 276, 279], ["SDG", "OBSERVATION", 399, 402]]], ["Finally, the relative number of CAP indicators aligned with each SDG was taken from the analysis of Scown and Nicholas 13 , who aligned the CAP monitoring and evaluation indicators (Context, Output, Target, Result, and Impact indicator sets) 16 , the Agri-Environmental Indicators used by the European Environment Agency to incorporate environmental concerns into the CAP 17 , and the list of EU SDG indicators used by Eurostat to translate the global SDGs into an EU context 18 .", [["the CAP monitoring", "TEST", 136, 154], ["evaluation", "TEST", 159, 169], ["Output", "TEST", 191, 197], ["the CAP", "TEST", 364, 371], ["CAP", "OBSERVATION_MODIFIER", 32, 35]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["Alignment of CAP objectives and SDG targets.", [["SDG", "SIMPLE_CHEMICAL", 32, 35], ["CAP objectives", "TEST", 13, 27], ["CAP", "OBSERVATION_MODIFIER", 13, 16]]], ["Number of targets within each SDG aligned with each CAP objective is listed (simply a count of the targets aligned) and this is used to create the Sankey diagram in Figure 1 of the main text. (e) foster sustainable development and efficient management of natural resources such as water, soil and air 2.4 By 2030, ensure sustainable food production systems and implement resilient agricultural practices that increase productivity and production, that help maintain ecosystems, that strengthen capacity for adaptation to climate change, extreme weather, drought, flooding and other disasters and that progressively improve land and soil quality 3.9 By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contamination 6.3 By 2030, improve water quality by reducing pollution, eliminating dumping and minimizing release of hazardous chemicals and materials, halving the proportion of untreated wastewater and substantially increasing recycling and safe reuse globally 6.4 By 2030, substantially increase water-use efficiency across all sectors and ensure sustainable withdrawals and supply of freshwater to address water scarcity and substantially reduce the number of people suffering from water scarcity 6.5 By 2030, implement integrated water resources management at all levels, including through transboundary cooperation as appropriate 12.4 By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment 15.1 By 2020, ensure the conservation, restoration and sustainable use of terrestrial and inland freshwater ecosystems and their services, in SDG2: 1 SDG3: 1 SDG6: 3 SDG12: 1 SDG15: 2 particular forests, wetlands, mountains and drylands, in line with obligations under international agreements 15.3 By 2030, combat desertification, restore degraded land and soil, including land affected by desertification, drought and floods, and strive to achieve a land degradation-neutral world (f) contribute to the protection of biodiversity, enhance ecosystem services and preserve habitats and landscapes 2.4 By 2030, ensure sustainable food production systems and implement resilient agricultural practices that increase productivity and production, that help maintain ecosystems, that strengthen capacity for adaptation to climate change, extreme weather, drought, flooding and other disasters and that progressively improve land and soil quality 6.6 By 2020, protect and restore water-related ecosystems, including mountains, forests, wetlands, rivers, aquifers and lakes Table S2 shows which payments were included in each of the categories shown in bar charts in Figures 2 and 3 of the main document.", [["flooding", "DISEASE", 563, 571], ["deaths", "DISEASE", 693, 699], ["flooding", "DISEASE", 2581, 2589], ["people", "ORGANISM", 1241, 1247], ["human", "ORGANISM", 1689, 1694], ["people", "SPECIES", 1241, 1247], ["human", "SPECIES", 1689, 1694], ["human", "SPECIES", 1689, 1694], ["natural resources", "TREATMENT", 255, 272], ["illnesses", "PROBLEM", 704, 713], ["dumping", "PROBLEM", 861, 868], ["hazardous chemicals", "TREATMENT", 895, 914], ["untreated wastewater", "PROBLEM", 956, 976], ["integrated water resources management", "TREATMENT", 1301, 1338], ["all wastes", "TREATMENT", 1489, 1499], ["mountains and drylands", "TREATMENT", 1936, 1958], ["main", "OBSERVATION_MODIFIER", 181, 185]]], ["We grouped only income support payments from Pillar I, although some instruments under Pillar II are also aimed at supporting income.Categorisation of CAP payment instrumentsWe define an environmental payment to include all CAP measures that state the intention to principally benefit nature, the environment, climate, or promote sustainable farming in the wording of the measure itself, and that involve more than the application of usual good farming practice or directly support production.", [["CAP payment instruments", "TREATMENT", 151, 174], ["an environmental payment", "TREATMENT", 184, 208], ["all CAP measures", "TREATMENT", 220, 236], ["CAP", "OBSERVATION_MODIFIER", 151, 154]]], ["We checked the correspondence between measures from different payment All other payments are grouped together as \"other payments\".Background to NUTS regionsThe system of spatial units we base our analyses upon is the Nomenclature of TerritorialValidation of NUTS0 to NUTS2 CAP payment allocationIn order to analyse CAP payments against social and environmental outcomes of For these 18 countries, we only included payments that were spatially-explicit (i.e., we excluded those payments recorded within these 18 countries but without a NUTS3 location; excluding \u20ac1.2 billion or 2% of the total payments).", [["NUTS regions", "DNA", 144, 156], ["Background to NUTS regions", "PROBLEM", 130, 156], ["the total payments", "TREATMENT", 583, 601]]], ["For four of the Member States with country-level (NUTS0) data, the single NUTS2 region for these Member States is identical to the NUTS0 region, so the aggregation was also straightforward.", [["NUTS2 region", "DNA", 74, 86], ["NUTS0 region", "DNA", 131, 143]]], ["No CAP payment data was available for Finland, so it was excluded from all analyses.", [["CAP payment data", "TEST", 3, 19], ["CAP", "OBSERVATION_MODIFIER", 3, 6], ["payment", "OBSERVATION", 7, 14]]], ["We also exclude \"\"National\" schemes from the data of Nicholas et al. (co-submitted).Validation of NUTS0 to NUTS2 CAP payment allocationCAP payment data for six countries (Bulgaria, Czech Republic, Greece, Ireland, Romania, Slovenia) was manually allocated from the NUTS0 (country) to NUTS2 level, which was done based on the share of national utilised agricultural area (UAA) within each NUTS2.", [["NUTS0", "DNA", 98, 103], ["NUTS2", "DNA", 388, 393]]], ["The method of manual allocation of CAP payments to NUTS2 was validated by performing the same allocation from NUTS0 to NUTS2 for all other countries that did have reliable data at the NUTS2 level, then comparing the results between original and manually-allocated NUTS2 data.", [["NUTS2", "DNA", 51, 56], ["NUTS2", "DNA", 119, 124], ["NUTS2", "DNA", 184, 189], ["NUTS2", "DNA", 264, 269], ["manual allocation of CAP payments", "TREATMENT", 14, 47]]], ["Figure S1 shows the observed vs. predicted payments in each NUTS2 region using this approach.", [["NUTS2 region", "DNA", 60, 72], ["this approach", "TREATMENT", 79, 92]]], ["Manual allocation based on UAA had a mean absolute error of \u20ac43 million (less than 0.1% of the total payments), which was inflated 40% by only 8 outliers with an absolute error over \u20ac200 million.", [["UAA", "DNA", 27, 30], ["UAA", "TEST", 27, 30], ["absolute error", "OBSERVATION", 162, 176]]], ["Overall, more than 79% of NUTS2 regions had a manually allocated value within 30% of the true value.", [["NUTS2", "GENE_OR_GENE_PRODUCT", 26, 31], ["NUTS2 regions", "DNA", 26, 39]]], ["The NUTS0 to NUTS2 manual allocation using UAA was only performed on six countries, representing less than 12% of the total payments.", [["NUTS0", "DNA", 4, 9], ["NUTS2", "DNA", 13, 18], ["UAA", "DNA", 43, 46], ["UAA", "TEST", 43, 46], ["the total payments", "TREATMENT", 114, 132]]], ["Thus, we consider this to be a reliable estimate of total payments made to each NUTS2 region within the six countries allocated manually.", [["NUTS2 region", "DNA", 80, 92], ["total payments", "TREATMENT", 52, 66]]], ["Validation of NUTS0 to NUTS2 manually allocation of payments based on utilised agricultural area for countries reporting both levels.", [["NUTS0", "TREATMENT", 14, 19], ["payments", "TREATMENT", 52, 60]]], ["Solid diagonal shows 1:1 line and dashed diagonals show an over-and underestimate of \u20ac200 million in predicted compared to observed payments.Analyses of CAP payments against social and environmental indicatorsWe analysed CAP payments against Agricultural Factor Income (AFI) per Annual Work Unit (AWU), greenhouse gas emissions from agriculture, and areas of High Nature Value (HNV) farmland.", [["HNV", "SPECIES", 378, 381], ["1:1 line", "TREATMENT", 21, 29], ["CAP payments", "TREATMENT", 153, 165], ["greenhouse gas emissions", "TEST", 303, 327], ["diagonal", "ANATOMY_MODIFIER", 6, 14], ["1:1 line", "OBSERVATION", 21, 29], ["areas", "OBSERVATION_MODIFIER", 350, 355], ["High Nature", "OBSERVATION_MODIFIER", 359, 370]]], ["These analyses were performed at the NUTS2 level because this is the spatial unit at which many CAP indicators are reported and curated by Eurostat.Analyses of CAP payments against social and environmental indicatorsAFI is a measure of agricultural income (including subsidies) after input costs, depreciation, and total taxes paid 21 .", [["NUTS2", "DNA", 37, 42], ["These analyses", "TEST", 0, 14], ["CAP payments", "TREATMENT", 160, 172], ["total taxes paid", "TREATMENT", 315, 331], ["CAP", "OBSERVATION_MODIFIER", 96, 99], ["CAP", "OBSERVATION_MODIFIER", 160, 163]]], ["AFI and AWU were taken from Eurostat tables agr_r_accts and ef_olfreg, respectively, and we calculated the average of each indicator for the latest five years in order to fill gaps in the data.", [["AFI", "TEST", 0, 3]]], ["Additionally, where data were only available at the NUTS0 level, this national AFI/AWU value was applied to all NUTS2 within that country.", [["NUTS2", "DNA", 112, 117], ["this national AFI/AWU value", "TEST", 65, 92]]], ["Because subsidies are already accounted for in the calculation of AFI, we separated the fraction of total AFI in each region that is made up of CAP payment data from the income that would be received without support.", [["AFI", "TEST", 66, 69], ["support", "TREATMENT", 208, 215]]], ["All financial calculations were done on euros adjusted to Purchasing Power", [["All financial calculations", "TEST", 0, 26]]]], "PMC7462661": [["Speculative Hyperinflations and Partial Backing: RepriseWe begin by reprising our argument that by backing currency, a government can foreclose the possibility of hyperinflationary equilibria.", [["Speculative Hyperinflations", "PROBLEM", 0, 27], ["hyperinflationary equilibria", "PROBLEM", 163, 191], ["Partial", "OBSERVATION_MODIFIER", 32, 39], ["Backing", "OBSERVATION_MODIFIER", 40, 47], ["hyperinflationary equilibria", "OBSERVATION", 163, 191]]], ["Importantly, in this setup the government can always make good any commitment to redeem money partially by levying lump-sum taxes.Speculative Hyperinflations and Partial Backing: RepriseIndividuals receive y units of the perishable consumption good each period.", [["Hyperinflations", "DISEASE", 142, 157], ["Speculative Hyperinflations", "PROBLEM", 130, 157], ["the perishable consumption", "TREATMENT", 217, 243], ["Hyperinflations", "OBSERVATION", 142, 157], ["Partial", "OBSERVATION_MODIFIER", 162, 169], ["Backing", "OBSERVATION_MODIFIER", 170, 177]]], ["Let ct denote an individual's consumption rate at time t, Mt her nominal money holdings, and \u03b2\u2208(0,1) her subjective discount factor.", [["Let ct", "GENE_OR_GENE_PRODUCT", 0, 6], ["Let ct", "TEST", 0, 6]]], ["The infinitely lived representative consumer maximizes(1)U0=\u2211t=0\u221e\u03b2t[u(ct)+\u03c5(Mt/Pt)],where Pt is the price level at time t, subject toMt\u2212Mt\u22121=Pt(y\u2212ct)+Ht,M\u22121 given,with Ht denoting transfers from the government that the individual takes to be exogenous.", [["Pt", "CHEMICAL", 90, 92], ["Pt", "CHEMICAL", 79, 81], ["Pt", "CHEMICAL", 90, 92], ["Pt(y\u2212ct)", "CHEMICAL", 141, 149], ["Mt/Pt)", "SIMPLE_CHEMICAL", 76, 82], ["U0", "TEST", 57, 59], ["\u2211t", "TEST", 60, 62], ["u(ct", "TEST", 68, 72], ["Mt/Pt)", "TEST", 76, 82], ["Mt", "TEST", 136, 138], ["Pt", "TEST", 141, 143], ["y\u2212ct", "TEST", 144, 148], ["Ht", "TEST", 150, 152], ["M\u2212", "TEST", 153, 155], ["Ht", "PROBLEM", 168, 170], ["exogenous", "OBSERVATION", 242, 251]]], ["We assume that u(.) and v(.) are increasing and strictly concave, with the usual smoothness and Inada properties.", [["increasing", "OBSERVATION_MODIFIER", 33, 43], ["strictly concave", "OBSERVATION_MODIFIER", 48, 64]]], ["The above assumption of separability between the utility from consumption and the derived utility from holding cash balances is quite important, as Obstfeld and Rogoff (1983, 1986) emphasize: otherwise, even though there may not exist divergent speculative paths, there can still be multiple stable equilibrium paths converging to the same monetary equilibrium (as shown in Obstfeld, 1984), a fundamental point to which we return later.", [["multiple stable equilibrium paths", "PROBLEM", 283, 316], ["multiple", "OBSERVATION_MODIFIER", 283, 291], ["stable", "OBSERVATION", 292, 298]]], ["The consumer's first-order necessary conditions imply(2)u\u2032(ct)Pt=\u03c5\u2032(Mt/Pt)Pt+\u03b2u\u2032(ct+1)Pt+1for t\u22650.Speculative Hyperinflations and Partial Backing: RepriseDefining real balances as mt=Mt/Pt, and assuming purely for simplicity that the money supply is constant at M, the last equation above can be rewritten as the simple difference equation(3)\u03b2u\u2032(y)mt+1=mt[u\u2032(y)\u2212v\u2032(mt)],where we have imposed the equilibrium condition ct=y.", [["Pt", "CHEMICAL", 62, 64], ["Pt", "CHEMICAL", 71, 73], ["Pt", "CHEMICAL", 74, 76], ["\u03b2u\u2032(ct+1)Pt", "CHEMICAL", 77, 88], ["Pt", "CHEMICAL", 186, 188], ["Mt/Pt)Pt+\u03b2u\u2032", "SIMPLE_CHEMICAL", 68, 80], ["ct", "TEST", 59, 61], ["Pt", "TEST", 62, 64], ["Pt", "TEST", 71, 73], ["Pt", "TEST", 74, 76], ["\u03b2u\u2032", "TEST", 77, 80], ["ct", "TEST", 81, 83], ["Pt", "TEST", 86, 88], ["Speculative Hyperinflations", "PROBLEM", 98, 125], ["Partial", "OBSERVATION_MODIFIER", 130, 137], ["Backing", "OBSERVATION_MODIFIER", 138, 145]]]]}